ABOUT ISHLT

2017-2018 BOARD OF DIRECTORS

ISHLT STAFF

2018 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

2018 ABSTRACT REVIEWERS

ISHLT COMMITTEES ROSTERS

Corporate Development Committee
Education Committee
Governance Committee
Grants and Awards Committee
International and Inter-Society Coordination Committee (I2C2)
ISHLT Mechanically Assisted Circulatory Support (IMACS®) Registry Steering Committee
International DCD Registry Steering Committee
International Pediatric Heart Failure Registry (IPHFR) Steering Committee
International Thoracic Transplant Registry Steering Committee
Journal of Heart and Lung Transplantation (JHLT) Editorial Board
Registries and Databases Committee
Standards and Guidelines Committee
Links Newsletter Editorial Staff

ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

Basic Science and Translational Research
Chronic Thromboembolic Pulmonary Hypertension
Heart Failure and Transplantation
Infectious Diseases
Junior Faculty and Trainee
Mechanical Circulatory Support
Nursing, Health Sciences and Allied Health
Pathology
Pediatric Thoracic Transplantation and Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension
Pulmonary Transplantation

PAST PRESIDENTS

PAST PROGRAM CHAIRS

JOURNAL AND LINKS NEWSLETTER EDITORS

REGISTRY MEDICAL DIRECTORS

ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

ISHLT Pioneer Award
ISHLT Lifetime Achievement Award
ISHLT Lifetime Service Award
Emeritus Membership

GRANTS AND SCHOLARSHIPS:

ISHLT Norman E. Shumway Career Development Award
ISHLT Joel D. Cooper Career Development Award
ISHLT Nursing Research Grant Award
ISHLT Research Fellowship Award
ISHLT Transplant Registry Early Career Award
ISHLT/Bayer Pulmonary Hypertension Research Grant Award
ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic
ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)
ISHLT International Traveling Scholarship Award
ISHLT Leach-Abramson-Imhoff Links Travel Awards

ABSTRACT AWARDS:
Philip K. Caves Award
Nursing, Health Sciences & Allied Health Excellence in Research Award
Early Career Scientist Award
JFTC Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award
ISHLT Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)

ACCREDITATION INFORMATION / CONTINUING MEDICAL EDUCATION INFORMATION

UNRESTRICTED EDUCATIONAL GRANTS

COMMERCIAL SUPPORT

ANNUAL MEETING HIGHLIGHTS

Basic Science and Translational Research
Heart Failure and Transplantation
Infectious Diseases
Lung Transplantation
Mechanical Circulatory Support
Nursing, Health Sciences and Allied Health
Pathology
Pediatric Thoracic Transplantation and Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension

CONVENTION CENTER FLOOR PLANS

First Floor
Second Floor
Third Floor

ACRONYMS

SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS

SCHEDULE AT A GLANCE

Monday, April 9, 2018
Tuesday, April 10, 2018
Wednesday, April 11, 2018
Thursday, April 12, 2018
Friday, April 13, 2018
Saturday, April 14, 2018

WEDNESDAY, APRIL 11, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS
ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion
ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation
ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned
ORAL SESSION 05: Don’t Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors
ORAL SESSION 06: Building a Better Transplant
ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique
OPENING PLENARY SESSION
SYMPOSIUM 01: The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs
SYMPOSIUM 02: Adult Congenital Heart Disease: Reaching the Summit
SYMPOSIUM 03: Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now?
SYMPOSIUM 04: Cardio-Oncology: A Tale of Two Problems
SYMPOSIUM 05: The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults
SYMPOSIUM 06: Novel Tools in Transplant Research (Say You Want a Revolution...)
SYMPOSIUM 07: The Devil is in the Details - Nuances in CTEPH
ORAL SESSION 08: Four Liters and Fingers Crossed: ECMO - Management and Outcomes
ORAL SESSION 09: The Pressure is On! Assessment and Role of Blood Pressure in MCS
ORAL SESSION 10: Mechanisms of Allograft Injury after Lung Transplantation
ORAL SESSION 11: Predictable or Inevitable? Complications of Heart Transplantation
ORAL SESSION 12: The Leading Edge: Novel Practices in Patient Care Pathways
ORAL SESSION 13: Early Career Scientist Award in Transplantation
ORAL SESSION 14: Reading Tea Leaves - Heart Failure Prediction Risks
MINI ORAL 01: Mechanical Circulatory Support: ECMO
MINI ORAL 02: Heart Transplantation: Outcomes
MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH
MINI ORAL 04: Mechanical Circulatory Support: Thrombosis
MINI ORAL 05: Pediatric Thoracic Transplantation
MINI ORAL 06: Heart Failure & Transplantation: Outcomes and Antibodies

THURSDAY, APRIL 12, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support
SYMPOSIUM 09: "The Heat Is On" - Great Debates in Heart Transplantation
SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die
SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics
SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making
SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team
SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology
ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS
SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation
ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses
SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule
ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection
ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science
SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished
SYMPOSIUM 18: It's Electric! Electrophysiologic Management of the LVAD Patient
SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation – 2018
SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?
SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy
SYMPOSIUM 22: Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape
SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation
ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS
ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD
ORAL SESSION 22: Trials and Treatments in Lung Transplantation
ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant
ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population
ORAL SESSION 25: Philip K. Caves Award Candidate Presentations
ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes
MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques
MINI ORAL 08: Heart Transplantation: PGD and CAV
MINI ORAL 09: Lung Transplantation: Allograft Function
MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology
MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics
MINI ORAL 12: Basic Science & Translational Research

FRIDAY, APRIL 13, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs
ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support
ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status
ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support
ORAL SESSION 31: Spotlight on a Heart Transplant Donor
ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best
SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself?
PLENARY SESSION: Moving Cardiothoracic Transplantation Forward
SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS
SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure
SYMPOSIUM 27: DCD Lungs - Expanding Utilization
SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant
SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT
SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads
SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction
ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS
ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure
ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP
ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies
ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension
ORAL SESSION 38: Hot Topics in Infectious Diseases
MINI ORAL 13: Mechanical Circulatory Support: Bleeding
MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection
MINI ORAL 15: Heart Transplantation: Donor Issues
MINI ORAL 16: Basic Science and Infectious Disease Issues

SATURDAY, APRIL 14, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS
ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation
ORAL SESSION 42: Lung Allocation: New Rules and Old Age
ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure
ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money
ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant
PLENARY SESSION
ORAL SESSION 46: Flight Plan: Planning the LVAD Implant
ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation
ORAL SESSION 48: Procedures and Standards in Lung Transplantation
ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation
ORAL SESSION 50: What is Really Going On in The Lung Transplant
ORAL SESSION 51: I'm at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension

WEDNESDAY, APRIL 11, 2018 – POSTER SESSION 1

Basic Science and Translational Research
Economics, Ethics, Public Policy
Junior Faculty Clinical Case Reports
Lung Transplantation
Mechanical Circulatory Support
Nursing, Health Sciences, Allied Health
Pathology
Pharmacy and Pharmacology

THURSDAY, APRIL 12, 2018 – POSTER SESSION 2

Heart Failure
Heart Transplantation
Infectious Diseases
Junior Faculty Clinical Case Reports
Mechanical Circulatory Support
Pediatric Transplantation
FRIDAY, APRIL 13, 2018 – POSTER SESSION 3

Heart Transplantation
Lung Transplantation
Mechanical Circulatory Support
Pulmonary Hypertension and CTEPH

POSTER MAPS

POSTER SESSION 1, WEDNESDAY
Gallieni 1-2
Agora 2
Agora 3
Muses/Euterpe

POSTER SESSION 2, THURSDAY
Gallieni 1-2
Agora 3
Muses/Euterpe

POSTER SESSION 3, FRIDAY
Gallieni 1-2
Agora 3
Muses/Euterpe

ISHLT ACADEMY: CORE COMPETENCIES IN HEART FAILURE AND CARDIAC TRANSPLANTATION

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION

ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT

ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

ISHLT ACADEMY: MASTER CLASS IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

AFFILIATE EVENTS

CORPORATE EVENTS AND INDUSTRY THEATER LISTINGS

EXHIBIT HALL FLOOR PLAN

2018 EXHIBITORS AND BOOTH NUMBERS

2018 EXHIBITOR PRODUCT DESCRIPTIONS

FUTURE ANNUAL MEETINGS
ISHLT Mission

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

The purposes of the Society are:

1. Promoting the association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences;
2. Encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung disease, and promoting new therapeutic strategies;
3. Holding scientific meetings featuring presentations and discussions relevant to heart and lung transplantation and the treatment of end-stage heart and lung disease;
4. Sponsoring a scientific journal for the publication of manuscripts related to these disciplines;
5. Maintaining an international registry for heart and lung transplantation;
6. Awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung disease, when funds are available and without jeopardizing the financial well-being of the organization; and
7. Sponsoring and conducting educational activities and providing educational resources, which promote expert development and improve standards of care in advance heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.

Society Origins and Description

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.
2017-2018 BOARD OF DIRECTORS

Andrew J. Fisher, FRCP, PhD, President, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Jeffrey J. Teuteberg, MD, President-Elect, Stanford University School of Medicine, Stanford, CA, United States
Maryl R. Johnson, MD, Past President, University of Wisconsin, Madison, WI, United States
Joseph Rogers, MD, Treasurer, Duke University Medical Center, Durham, NC, United States
Lara Danziger-Isakov, MD, MPH, Secretary, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
Kevin Chan, MD, Director, University of Michigan Health System, Ann Arbor, MI, United States
Jason D. Christie, MD, Director, University of Pennsylvania, Philadelphia, PA, United States
Jennifer Cowger, MD, MS, Director, Henry Ford Hospitals, Detroit, MI, United States
Teresa De Marco, MD, FACC, Director, University of California San Francisco, San Francisco, CA, United States
Tobias Deuse, MD, PhD, Director, University of California at San Francisco, San Francisco, CA, United States
Howard J. Eisen, MD, Director, Drexel University College of Medicine, Philadelphia, PA, United States
Stephan M. Ensminger, MD, DPhil, Director, Ruhr-University Bochum, Bad Oeynhausen, Germany
Daniel J. Goldstein, MD, Director, Montefiore Medical Center, Bronx, NY, United States
Peter M. Hopkins, FRACP, Director, The Prince Charles Hospital, Brisbane, Australia
Michael G. Petty, PhD, RN, CNS, Director, University of Minnesota Medical Center, Minneapolis, MN, United States
Dirk Van Raemdonck, MD, PhD, Director, University Hospital Gasthuisberg, Leuven, Belgium

Ex Officio Board Members
Amanda W. Rowe, ISHLT Executive Director
ISHLT STAFF

Amanda W. Rowe
Executive Director

Jennifer Coy
Deputy Executive Director of Professional Education and Meetings

Lisa Edwards
Director of Meetings

Lee Ann Mills
Director of Finance and Operations

Susie Newton
Programs and Services Manager

Megan Barrett
Programs and Services Assistant

Justin Hickman
Finance and Operations Assistant

Phyllis Glenn
Administrative Assistant

14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.isHLT.org
ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

◆ Symposium Planning Committee
★ Abstract Selection Committee

Christian Benden, MD FCCP, University Hospital Zurich, Zurich, Switzerland, 2018 Scientific Program Chair ◆◆
Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK, ISHLT President ◆◆
Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, United States, 2019 Scientific Program Chair ◆◆
Jeffrey J. Teuteberg, MD, Stanford University, Palo Alto, CA, United States, 2017 Scientific Program Chair ◆◆
Francisco Arabia, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States ★
Saima Aslam, MD, UCSD, San Diego, United States ◆◆
Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA, United States ◆◆
Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany ◆◆
Nancy Blumenthal, CRNP, University of Pennsylvania, Philadelphia, PA, United States ★
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada ★
Agnieszka Ciarka, MD, KU Leuven, Leuven, Belgium ★
Stephen Clark, FRCS, Freeman Hospital, Newcastle Upon Tyne, UK ★
Rachel Crickett, MSc, Freeman Hospital, Newcastle Upon Tyne, UK ◆◆
Marcelo Cypel, MD, University of Toronto, Toronto, ON, Canada ★
Kyle Dawson, PharmD, MBA, BCPS, University of Kentucky, Lexington, KY, United States ★
Teresa De Marco, MD, UCSF, San Francisco, CA, United States ◆◆
Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, United States ◆◆
Sitaramesh Emani, MD, The Ohio State University, Columbus, OH, United States ★
Melanie Everitt, MD, Children's Hospital Colorado, Aurora, CO, United States ◆◆
Savithri Fedson, MD, Baylor College of Medicine, Houston, TX, United States ★
Rochelle Gellatly, PharmD, The Alfred Hospital, Melbourne, Australia ◆◆
Ranny Goldwasser, MD, University Children's Hospital Heidelberg, Heidelberg, Germany ◆◆
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany ★
Matthew Hartwig, MD, Duke University, Durham, NC, United States ◆◆
Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway ◆◆
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, United States ◆◆
Jason Katz, MD, MHS, University of North Carolina, Chapel Hill, NC, United States ★
Mary Keebler, MD, Vanderbilt University, Nashville, TN, United States ★
Ahmet Kilic, MD, The Ohio State University, Columbus, OH, United States ★
Ivan Knezevic, MD, University Clinical Center, Ljubljana, Slovenia ★
Antonio Loforte, MD, PhD, University of Bologna, Bologna, Italy ★
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia ◆◆
Marco Masetti, MD, University of Bologna, Bologna, Italy ★
Mandeep Mehra, MD, MBBS, FACC, FACP, Brigham & Women's Hospital, Boston, MA, United States ◆◆
Joshua Mooney, MD, Stanford University, Palo Alto, CA, United States ★
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia ◆◆
Sanem Nalbantgil, MD, Ege University Tip Hospital, Izmir, Turkey ◆◆
Alexandra Rice, FRCPath, Royal Brompton Hospital, London, UK ◆◆
Mace Schuurmans, MD, University of Zurich, Zurich, Switzerland ★
Ashish Shah, MD, Vanderbilt University, Nashville, TN, United States ★
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States ◆◆
Jorge Silva Enciso, MD, UCSD, San Diego, CA, United States ◆◆
Marc Simon, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States ◆◆
Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada ★

Annual Meeting Program Committee
Carmela Tan, MD, Cleveland Clinic, Cleveland, OH, United States ★★
Mitesh Thakrar, MD, University of Calgary, Calgary, AB, Canada ★★
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, United States ★
Marian Urban, MD, Freeman Hospital, Newcastle Upon Tyne, UK ★★
Stijn Verleden, PhD, KU Leuven, Leuven, Belgium ★★
Christopher Wigfield, MD, FRCS, Advocate Christ Medical Center, Chicago, IL, United States ★★
Keith Wille, MD, MSPH, University of Alabama, Birmingham, AL, United States ★★
Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada ★★
Sirtaz Adatya, MD, University of Chicago, Chicago, IL, United States
Clemens Aigner, MD, Ruhrlandklinik, Essen, Germany
Peta Alexander, MBBS, Boston Children's Hospital, Boston, MA, United States
Hakim Ali, MD, Duke University, Durham, NC, United States
Amal Alotaibi, MBBS, University of Texas Medical Branch, Galveston, TX, United States
Cristiano Amarelli, MD, Monaldi Hospital, Napoli, Italy
Amrut Ambadekar, MD, University of Colorado, Aurora, CO, United States
Antonio Amodeo, MD, Banbino Gesu Pediatric Hospital, Rome, Italy
Samantha Anthony, PhD, Hospital for Sick Children, Toronto, ON, Canada
Christina Aquilante, PharmD, University of Colorado, Aurora, CO, United States
Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, United States
John-David Aubert, MD, Lausanne University Hospital, Lausanne, Switzerland
William Auger, MD, UCSD Medical Center, San Diego, CA, United States
Sanjeet Singh Avtaar Singh, MSc, Golden Jubilee National Hospital, Glasgow, United Kingdom
Estela Azeka, MD, InCor/University of Sao Paulo, Sao Paulo, Brazil
Roberto Badagliacca, MD, PhD, Sapienza University of Rome, Rome, Italy
Dipanjan Banerjee, MD, Stanford University, Palo Alto, CA, United States
Aditya Bansal, MD, Ochsner Clinic Foundation, New Orleans, LA, United States
David Baran, MD, Sentara Heart Hospital, Norfolk, VA, United States
Jay Baumwol, FRACP, Fiona Stanley Hospital, Murdoch, Australia
Jennifer Beckman, ARNP, University of Washington, Seattle, WA, United States
Jürgen Behr, MD, Hospital of the University of Munich, Munich, Germany
Lavanya Bellumkonda, MD, Yale University, New Haven, CT, United States
Alberto Benazzo, MD, Medical University of Vienna, Vienna, Austria
Mark Benzimra, FRACP, St. Vincent's Hospital, Sydney, Australia
Christian Bermudez, MD, University of Pennsylvania, Philadelphia, PA, United States
Alejandro Bertolotti, MD, Favaloro Foundation, Buenos Aires, Argentina
Pramod Bonde, MD, FACS, Yale University, New Haven, CT, United States
Karen Booth, MBChB, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Gerard Boyle, MD, Cleveland Clinic Children's, Cleveland, OH, United States
Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, United States
Olivier Brugiere, MD, PhD, Hopital Bichat, Paris, France
Patrick Bruneval, MD, University Paris Descartes, Paris, France
Fay Burrows, BPharm, St. Vincent's Hospital, Sydney, Australia
Ryan Butts, MD, UT Southwestern, Dallas, TX, United States
Marco Caccamo, DO, West Virginia University, Morgantown, WV, United States
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Silvia Campos, MD, InCor/University of Sao Paulo, Sao Paulo, Brazil
Edward Cantu, MD, University of Pennsylvania, Philadelphia, PA, United States
Adrian Carlson, PharmD, University of Utah, Salt Lake City, UT, United States
Kevin Carney, MSN, CRNP, CCTC, Temple University, Philadelphia, PA, United States
Chesney Castleberry, MD, Washington University, St. Louis, MO, United States
Sandra Chaparro, MD, University of Miami, Miami, FL, United States
Richard Cheng, MD, University of Washington Medical Center, Seattle, WA, United States
Laveena Chhatwani, MD, Stanford University, Palo Alto, CA, United States
Dawn Christensen, MS, CRNP, Innovative Program Solutions, Pine Grove, PA, United States
Jose Cifrian, PhD, Hospital University Marques Valdecilla, Santander, Spain
Adam Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, United States
Erin Coglianoese, MD, Massachusetts General Hospital, Boston, MA, United States
Robert Cole, MD, Emory University, Atlanta, GA, United States
Monica Colvin, MD, MS, FAHA, University of Michigan, Ann Arbor, MI, United States
Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, United States
Carol Conrad, MD, Lucile Packard Children's Hospital, Palo Alto, CA, United States
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada
Jennifer Cook, MD, University of Arizona, Tucson, AZ, United States
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, United States
William Cornwell, MD, University of Colorado, Aurora, CO, United States
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, United States
Maria Crespo, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
Sourbha Dani, MD, Eastern Maine Medical Center, Bangor, ME, United States
Todd Dardas, MD, University of Washington, Seattle, WA, United States
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Nicolaas de Jonge, MD, PhD, University Medical Center, Utrecht, Netherlands
Michel De Pauw, PhD, Ghent University Hospital, Ghent, Belgium
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, United States
Tobias Deuse, MD, UCSF Medical Center, San Francisco, CA, United States
Ravi Dhingra, MD, MPH, University of Wisconsin, Madison, WI, United States
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, United States
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada
Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, United States
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada
Karen Doucette, MD, University of Alberta, Edmonton, AB, Canada
Stavros Drakos, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT, United States
Hilary DuBrock, MD, Mayo Clinic, Rochester, MN, United States
Anique Ducharme, MD, Montreal Heart Institute, Montreal, QC, Canada
Ignacio Echenique, MD, Cleveland Clinic, Weston, FL, United States
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, United States
Thomas Egan, MD, MSc, University of North Carolina, Chapel Hill, NC, United States
Frank Enseleit, MD, University Hospital, Zurich, Switzerland
Stephan Ensminger, MD, DPhil, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany
Christopher Ensor, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
John Entwistle, MD, PhD, Thomas Jefferson University, Philadelphia, PA, United States
Eric Epailly, MD, University Hospital, Strasbourg, France
Michele Estabrook, MD, Washington University, St. Louis, MO, United States
Gregory Ewald, MD, Washington University, St. Louis, MO, United States
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France
Christine Falk, MD, Hannover Medical School, Hannover, Germany
Maryjane Farr, MD, Columbia University Medical Center, New York, NY, United States
Marta Farrero, MD, PhD, Hospital Clinic, Barcelona, Spain
Carol Farver, MD, Cleveland Clinic, Cleveland, OH, United States
Marny Fedrigo, PhD, University of Padua, Padua, Italy
Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States
Veronica Franco, MD, The Ohio State University, Columbus, OH, United States
Meg Fregoso, MSN, Inova Fairfax Hospital, Falls Church, VA, United States
Maria Frigerio, MD, A. O. Niguarda Ca’ Granda, Milan, Italy
Norihide Fukushima, PhD, National Cerebral and Cardiovascular Center, Osaka, Japan
Erik Fung, MB ChB PhD, Prince of Wales Hospital, Shatin, Hong Kong
Sonia Garg, MD, UT Southwestern, Dallas, TX, United States
Patricia Ging, MSc, Mater Misericordiae, Dublin, Ireland
Michael Givertz, MD, Brigham & Women's Hospital, Boston, MA, United States
Allan Glanville, MD, St. Vincent's Hospital, Sydney, Australia
Martin Goddard, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Lee Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, United States
Samuel Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, United States
Livia Goldraich, MD, MSc, Hospital de Clinicas, Porto Alegre, Brazil
Daniel Goldstein, MD, Montefiore Medical Center, Bronx, NY, United States
Mardi Gomberg-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, United States
José González-Costello, MD, Hospital University de Bellvitge, Barcelona, Spain
Jeffrey Gossett, MD, UCSF Medical Center, San Francisco, CA, United States
Umesh Goswami, MD, University of Minnesota, Minneapolis, MN, United States
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
Kate Gould, FRCPath, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Kathleen Grady, PhD, Northwestern University, Chicago, IL, United States
Aric Gregson, MD, UCLA Medical Center, Los Angeles, CA, United States
Cynthia Gries, MD, Florida Hospital, Orlando, FL, United States
Paolo Antonio Grossi, MD, PhD, University of Insubria, Varese, Italy
Maya Guglin, MD, PhD, University of Kentucky, Lexington, KY, United States
Dipankar Gupta, MD, UF College of Medicine, Gainesville, FL, United States
Ramsey Hachem, MD, Washington University, St. Louis, MO, United States
Denis Hadjiliadis, MD, University of Pennsylvania, Philadelphia, PA, United States
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, United States
Elizabeth Hammond, MD, University of Utah School of Medicine, Salt Lake City, UT, United States
Ayesha Hasan, MD, The Ohio State University, Columbus, OH, United States
Chris Hayward, MD, St. Vincent's Hospital, Sydney, Australia
Christian Heim, MD, PhD, University of Erlangen-Nuremberg, Nuremberg, Germany
Jaime Hernandez Montfort, MD, MPH, Baystate Medical Center, Northampton, MA, United States
Brian Houston, MD, Medical University of South Carolina, Charleston, SC, United States
Eileen Hsich, MD, Cleveland Clinic, Cleveland, OH, United States
Chih-Hsin Hsu, MD, PhD, National Cheng Kung University Hospital, Tainan, Taiwan
Howard Huang, MD, Baylor University Medical Center, Dallas, TX, United States
Charles Huddleston, MD, St. Louis School of Medicine, St. Louis, MO, United States
Christine Hui, PharmD, UCSF Medical Center, San Francisco, CA, United States
Sharon Hunt, MD, Stanford University, Palo Alto, CA, United States
Ilhan Inci, MD, University Hospital, Zurich, Switzerland
Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, United States
Claire Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, Australia
Debra Isaac, MD, University of Calgary, Calgary, AB, Canada
Miriam Jacob, MD, Cleveland Clinic, Cleveland, OH, United States
Jama Jahanyar, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jeffrey Javidfar, MD, Emory University School of Medicine, Atlanta, GA, United States
George Javorsky, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia
Christine Jensen, RN, MSN, St. Joseph Medical Center, Lynden, WA, United States
Ranjit John, MD, University of Minnesota, Minneapolis, MN, United States
Maryl Johnson, MD, University of Wisconsin, Madison, WI, United States
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN, United States
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, United States
Sung-Ho Jung, MD, PhD, Asan Medical Center, Seoul, South Korea
Colleen Juricek, University of Chicago Medical Center, Chicago, IL, United States
Stephen Juvet, MD, PhD, University Health Network, Toronto, ON, Canada
Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, BC, Canada
Forum Kamdar, MD, PhD, University of Minnesota, Minneapolis, MN, United States
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, United States
Nandkishore Kapadia, MCH, PhD, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
Shalika Katugaha, MD, Inova Fairfax Hospital, Falls Church, VA, United States
Jamie Kennedy, MD, University of Virginia, Charlottesville, VA, United States
Ron Kerman, PhD, Baylor College of Medicine, Houston, TX, United States
Umit Kervan, MD, University of Health Science, Ankara, Turkey
Feras Khaliel, MD, PhD, King Faisal Hospital and Research Center, Riyadh, Saudi Arabia
Sanjeev Khulbey, MCH, CVTS, Apollo Hospital, Hyderabad, India
Kiran Khush, MD, Stanford University, Palo Alto, CA, United States
Michael Kiernan, MD, Tufts Medical Center, Boston, MA, United States
Kyung-Hee Kim, PhD, Sejong General Hospital, Seoul, South Korea
Miae Kim, PharmD, MS, Brigham & Women's Hospital, Boston, MA, United States
Richard Kirk, FRCP, FRCPC, UT Southwestern, Dallas, TX, United States
Charles Kiolled, MD, University of Florida, Gainesville, FL, United States
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States
Takushi Kohmoto, MD, PhD, MBA, University of Wisconsin, Madison, WI, United States
Robert Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Evan Kransdorf, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States
A. Sasha Krupnick, MD, University of Virginia, Charlottesville, VA, United States
Jasleen Kukreja, MD, UCSF Medical Center, San Francisco, CA, United States
Johanna Kwakkel-van Erp, PhD, University Medical Center, Utrecht, Netherlands
Jose Luis Lambert Rodriguez, PhD, Hospital University Central de Asturias, Oviedo, Spain
Brandon Larsen, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jacob Lavee, MD, Sheba Medical Center, Tel Hashomer, Israel
Adrian C Lawrence, MD, University of Minnesota, Minneapolis, MN, United States
Jerome Le Pavec, MD, Hopital Marie Lannelongue, Le Plessis Robinson, France
Erika Lease, MD, University of Washington Medical Center, Seattle, WA, United States
Sangjin Lee, MD, Spectrum Health, Grand Rapids, MI, United States
Amanda Leech, RN, BSN, CPTC, University of Pennsylvania Medical Center, Philadelphia, PA, United States
Anthony Lemaire, MD, Robert Wood Johnson Medical Center, Princeton, NJ, United States
Karl Lemstrom, MD, PhD, University of Helsinki, Helsinki, Finland
Clive Lewis, MD, PhD, Papworth Hospital, Cambridge, United Kingdom
Brian Lima, MD, North Shore University Hospital, Roslyn, NY, United States
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, United States
Me-Linh Luong, MD, Hopital St. Luc-Montreal University, Montreal, QC, Canada
Haifa Lyster, MSc, Royal Brompton & Harefield NHS Trust, Middlesex, United Kingdom
Guy MacGowan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
George Mallory, MD, Baylor College of Medicine, Houston, TX, United States
Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jiri Maly, MD, PhD, IKEM, Prague, Czech Republic
Pradeep Mammen, MD, UT Southwestern, Dallas, TX, United States
Charles Marboe, MD, Columbia University Medical Center, New York, NY, United States
Fabiana Marcondes-Braga, PhD, Heart Institute, Sao Jose dos Campos, Brazil
Sofia Masri, MD, University of Washington Medical Center, Seattle, WA, United States
H. Todd Massey, MD, Thomas Jefferson University, Philadelphia, PA, United States
Leann Matura, PhD, RN, University of Pennsylvania Medical Center, Philadelphia, PA, United States
Jeremy Mazurek, MD, University of Pennsylvania Medical Center, Philadelphia, PA, United States
David McGiffin, FRACS, The Alfred Hospital, Melbourne, Australia
Dana McGoohan, MD, Kaiser Permanente, San Francisco, CA, United States
Colleen McIlvennan, University of Colorado, Denver, CO, United States
Scott McKenzie, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia
Bruno Meiser, MD, University Munich/Grosshadern, Munich, Germany
Vojtech Melenovsky, MD, PhD, IKEM, Prague, Czech Republic
Olaf Mercier, MD, Hopital Marie Lannelongue, Le Plessis Robinson, France
Anna Meyer, MD, Leipzig Heart Center, Leipzig, Germany
ISHLT COMMITTEES

CORPORATE DEVELOPMENT COMMITTEE
Joseph Rogers, MD, Chair
Andrew J. Fiser, FRCP, PhD, ISHLT President
Jeffrey J. Teuteberg, MD, President-Elect
Amanda Rowe, ISHLT Executive Director

EDUCATION COMMITTEE
Christopher H. Wigfield, MD, FRCS(C/TH), Director of Educational Affairs
Mardi Gomberg-Maitland, MD, MSc, Committee Vice Chair
Jennifer Cowger, MD, MS, Board of Directors Liaison
Amanda Rowe, ISHLT Executive Director

Additional Committee Members
David Baran, MD
Goran Dellgren, MD, PhD
Howard J. Eisen, MD
Lorriana Leard, MD
Donna M. Mancini, MD
Anna Reed, MD

GOVERNANCE COMMITTEE
Maryl R. Johnson, MD, Chair
Andrew J. Fisher, FRCP, PhD, ISHLT President
Jeffrey J. Teuteberg, MD, President-Elect
Joseph Rogers, MD, Treasurer

At Large Members
Duane Davis, MD, MBA, Past President
David O. Taylor, MD, Past President
Stuart C. Sweet, MD, PhD, Past Secretary/Treasurer

GRANTS AND AWARDS COMMITTEE
Stephan M. Ensminger, MD, DPhil, Co-Chair & Board of Directors Liaison
Kathleen Grady, PhD, APN, FAAN, Co-Chair
Daniel Kreisel, MD, PhD, Co-Chair
Louise M. Fuller, PT, Nursing, Health Sciences & Allied Health Research Grant Awards
Josef Stehlik, MD, MPH, Transplant Registry Early Career Awards

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)
Howard J. Eisen, MD, FAHA, FACC, FACP, Chair
Maryl R. Johnson, MD, Board of Directors Liaison
David O. Taylor, MD, Standards & Guidelines Committee Chair
Christopher H. Wigfield, MD, FRCS(C/Th), Director of Educational Affairs
Joseph Rogers, MD, Finance Committee Chair
Josef Stehlik, MD, MPH, Thoracic Registry Medical Director

Councils
Ciara Shaver, MD, PhD, Basic Science & Translational Research Council
Alejandro Bertolotti, Heart Failure & Transplantation Council
Fernanda Silveira, Infectious Disease Council
Hirsch S. Mehta, Junior Faculty & Trainee Council
Rasha Adams, RN, Nursing, Health Sciences & Allied Health Council
Annalisa Angelini, MD, Pathology Council
James D. St. Louis, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Douglas L. Jennings, PharmD, Pharmacy & Pharmacology Council
Manreet Kanwar, MD, Pulmonary Hypertension Council
Denis Hadjiliadis, MD, Pulmonary Transplantation Council

Ad Hoc Members
Jacob Lavee, MD
Lori J. West, MD, DPhil

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®) REGISTRY INTERIM STEERING COMMITTEE
Daniel J. Goldstein, Chair
Jennifer Cowger, MD, MS, Vice Chair for Data Studies
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Bart Meyns, MD, EUROMACS Representative
Takeshi Nakatani, MD, PhD, JMACS Representative
Steven Shaw, MBChB, MRCP, PhD, UK Representative
Amanda W. Rowe, ISHLT Executive Director
Rongbing Xie, MPH, Statistician

INTERNATIONAL DCD REGISTRY STEERING COMMITTEE
Dirk Van Raemdonck, MD, PhD, Chair
Wida S. Cherikh, PhD, Biostatistician
Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Active Participating Centers (LUNG)
Allan R. Glanville, MBBS, MD, FRACP
Michael T. Musk, MBBS
Peter M. Hopkins, FRACP
Gregory I. Snell, MD
Marcelo Cypel, MD
Shaf Keshavjee, MD, FRCSC
Michiel E. Erasmus, MD, PhD
Marshall I. Hertz, MD
Roger D. Yusen, MD, MPH
Kenneth R. McCurry, MD, FACS
Frank D’Ovidio, MD, PhD

Starting Up Centers (Heart)
Stephen R. Large, FRCS
Steven SL Tsui, MD, FRCS
Kumud K. Dhital, MD, PhD
Peter MacDonald, MD, PhD

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (IPHFR) STEERING COMMITTEE
Anne I. Dipchand, MD, Chair
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Scott Auerbach, MD
Estela Azeka, MD
Wida S. Cherikh, PhD
Richard Kirk, FRCP, FRCPCH
Beth Kaufman, MD
Aliessa Barnes, MD
David Peng, MD
Philip Thrush, MD
Jennifer Conway, MD
Warren Zuckerman, MD
INTERNATIONAL THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE
Josef Stehlik, MD, MPH, Medical Director & Chair
Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Associate Medical Directors
Kiran K. Khush, MD, Adult Heart (Sept 2021)
Daniel C. Chambers, MBBS, MRCP, FRACP, MD, Adult Lung/Heart-Lung (Sept 2021)
Joseph W. Rossano, MD, Pediatric Heart (Sept 2019)
Samuel B. Goldfarb, MD, Pediatric Lung/Heart-Lung (Sept 2018)

Additional Members
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes (Sept 2018)
Bruno M. Meiser, MD, OEO Relations (Sept 2018)
Wida S. Cherikh, PhD, Biostatistics
Anna Kucheryavaya, MD, Assistant Biostatistician

JOURNAL FOR HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Hilary Campbell, Journal Office Coordinator
Maria Rosa Costanzo, MD, Consulting Editor (Editor Emeritus 1995-1999)
James K. Kirklin, MD, Consulting Editor (Editor Emeritus 2000-2009)

Editorial Board Consultants
Annalisa Angelini, MD (Italy)
William R. Auger, MD (USA)
David A. Baran, MD (USA)
Christian Benden, MD (Switzerland)
Christian A. Bermudez, MD (USA)
Charles E. Canter, MD (USA)
Pablo Castro, MD (Chile)
Jean Connors (USA)
Paul A. Corris, MB, FRCP (UK)
Kevin P. Daly, MD (USA)
John Dark, MB, FRCS (UK)
Kyle L. Dawson, PharmD, MBA, BCPS (USA)
S.W. Denfield, MD (USA)
Mary Amanda Dew, PhD (USA)
Fabienne Dobbels, MSc, PhD (Belgium)
Thomas M. Egan, MD, MSC (USA)
Howard Eisen, MD (USA)
Roger W. Evans, PhD (USA)
Andrew J. Fisher, FRCP, PhD (UK)
Robert Frantz, MD (USA)
Allan R. Glenville, MBBS, MD, FRACP (Australia)
Daniel J. Goldstein, MD (USA)
Paolo Grossi, MD, PhD (Italy)
Margaret Hannan, MD (Ireland)
Marius M. Hoeper (Germany)
Peter M. Hopkins, FRACP (Australia)
Valluvan Jeevanandam, MD (USA)
Mary R. Johnson, MD (USA)
Shaf Keshavjee, MD, FRCSC (Canada)
Kiran Kaur Khush, MD (USA)
Richard Kirk, FRCP, FRCPCH (UK)
Jon Kobashigawa, MD (USA)
Neal K. Lakdawala, MD (USA)
Lorriana Leard, MD (USA)
JoAnn Lindenfeld, MD (USA)
Peter MacDonald, MD, PhD (Australia)
Stanley I. Martin, MD (USA)
Tereza Martinu, MD (Canada)
Bruno Meiser, MD (Germany)
Thalachallour Mohanakumar, PhD (USA)
David Morales, MD (USA)
Ivan Netuka, MD, PhD (Czech Republic)
Francis Pagani, MD, PhD (USA)
Sean P. Pinney, MD (USA)
Jeffery L. Platt, MD (USA)
Evgenij V. Potapov, MD, PhD (Germany)
Luciano Potena, MD, PhD (Italy)
Joseph G. Rogers, MD (USA)
Heather J. Ross, MD, MHSc, FRCPC (Canada)
Lewis Rubin, MD (USA)
Stephan Schueler, MD, PhD, FRCS (UK)
Martin Schweiger, MD (Switzerland)
Keyur B. Shah, MD (USA)
Jacqueline M. Smits, MD, PhD (The Netherlands)
Josef Stehlik, MD, MPH (USA)
Jeffrey J. Teuteberg, MD (USA)
Jean Luc Vachiery, MD (Belgium)
Hector O. Ventura, MD (USA)
Geert Verleden, MD, PhD (Belgium)
Robin Vos, MD, PhD (Belgium)
Aaron Waxman, MD, PhD (USA)
Lori J. West, MD, DPhil (Canada)
Roger D. Yusen, MD, MPH (USA)
Michael Zakliczynski, MD (Poland)

REGISTRIES AND DATABASES COMMITTEE
Josef Stehlik, MD, MPH, Chair (July 2022)
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Wida S. Cherikh, PhD, Biostatistician for the International Thoracic, International Pediatric Heart Failure, and Donation After Cardiac Death (DCD) Registries
Daniel J. Goldstein, MD, IMACS Registry Committee Chair
Rongbing Xie, MPH, IMACS Registry Biostatistician
Anne I. Dipchand, MD, International Pediatric Heart Failure Registry Committee Chair
Dirk Van Raemdonck, MD, PhD, International Donation after Cardiac Death (DCD) Registry Committee Chair
Roger D. Yusen, MD, MPH, Additional Member

STANDARDS AND GUIDELINES COMMITTEE
David O. Taylor, MD, Chair
Peter Hopkins, FRACP, Vice Chair
Teresa De Marco, MD, FACC, Board of Directors Liaison
Megan Barrett, ISHLT Staff Liaison

Council Workforce Leaders
Keshava Rajagopal, MD, PhD, Basic Science & Translational Research Council
Hannah Copeland, MD, Heart Failure & Transplantation Council
Valentina Stosor, MD, Infectious Disease Council
Agnieszka Ciarka, MD, Junior Faculty & Trainee Council
David A. D’Alessandro, MD, Mechanical Circulatory Support Council
Colleen Juricek, Nursing, Health Sciences & Allied Health Council
Anja C. Roden, MD, Pathology Council
Steven Kindel, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Kevin Daly, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Robert L. Page, II, Pharm D, MS, Pharmacy & Pharmacology Council
Oksana Shlobin, MD, Pulmonary Hypertension Council
Erika D. Lease, MD, Pulmonary Transplantation Council

ISHLT Committees
LINKS NEWSLETTER EDITORIAL STAFF
Vincent Valentine, MD, Editor
Megan Barrett, Managing Editor

Senior Associate Editors
Pamela Combs, PhD, RN
Paul Corris, MB, FRCP
John Dark, MB, FRCS
Roger Evans, PhD
Allan Glanville, MBBS, MD, FRACP
Maryl Johnson, MD

Associate Editors
Manreet Kanwar, MD, Cardiology
Claudius Mahr, DO, Cardiology
Joshua Mooney, MD, Junior Faculty & Trainee
Stephanie Pouch, MD, Infectious Disease
Emily Stimpson, MSN, FN, CCTC, Nursing, Health Sciences & Allied Health
Maryanne R. Chrisant, MD, Pediatrics
Daniel F. Dilling, MD, Pulmonary Transplantation

International Correspondents Board
Zargham Ahmadi, MD (Iran)
Javier Carbone, MD, PhD (Spain)
Marco Masetti, MD, PhD (Italy)
Andreas Zuckermann, MD (Austria)

Council Communications Liaisons
Howard J. Eisen, MD, Basic Science & Translational Research Council
David P. Nelson, MD, Heart Failure & Transplantation Council
Saima Aslam, MD, MS, Infectious Diseases Council
Jorge Silva Enciso, MD, Junior Faculty & Trainee Council
Evgenij Potapov, MD, PhD, Mechanical Circulatory Support Council
Kirsten Diegel, RD, LDN, Nursing, Health Sciences & Allied Health Council
Jill Giordano, MA, MSW, LCSW, Nursing, Health Sciences & Allied Health Council
Brandon Larsen, MD, PhD, Pathology Council
Martin Schweiger, Pediatric Thoracic Transplantation and Heart Failure Council
Ed Horn, PharmD, BCPS, Pharmacy & Pharmacology Council
Amresh Raina, MD, Pulmonary Hypertension Council
Jussi Tikkanen, MD, PhD, Pulmonary Transplantation Council
ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

BASIC SCIENCE AND TRANSLATIONAL RESEARCH
Edward Cantu, III, MD, Chair
Joshua M. Diamond, MD, Vice Chair
Sonja Schreperf, MD, PhD, Past Chair
Stephan M. Ensminger, MD, DPhil, Board of Directors Liaison
Mary Porteous, MD, Education Committee Workforce Leader
Ciara M. Shaver, MD, PhD, I2C2 Workforce Leader
Doris A. Taylor, PhD, Senior Advisor
Jeffrey L. Platt, MD, Senior Advisor
Howard J. Eisen, MD, FAHA, FACC, FACP, ISHLT Links Newsletter Liaison
Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplantation Council Liaison
Aric Gregson, MD, Infectious Diseases Council Liaison
Simone Pecher, MD, Junior Faculty & Trainee Council Liaison
J. Michael DiMaio, MD, Mechanical Circulatory Support Council Liaison
Monica Horn, RN, CCRN, CCTC, Nursing, Health Sciences & Allied Health Council Liaison
Annalisa Angelini, MD, Pathology Council Liaison
Aaron B. Waxman, MD, PhD, Pulmonary Hypertension Council Liaison
Pablo G. Sanchez, MD, PhD, Pulmonary Transplantation Council Liaison

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
William R. Auger, MD, Chair
Marc De Perrot, MD, Vice Chair-Elect
Jason D. Christie, MD, Board of Directors Liaison
Manreet Kanwar, MD, Education Workforce Leader

HEART FAILURE AND TRANSPLANTATION
Michael Pham, MD, MPH, Chair
Jignesh K. Patel, MD, PhD, Vice Chair
Marta Farerro, MD, PhD, Vice Chair-Elect
Monica M. Colvin, MD, Past Chair
Howard J. Eisen, MD, FAHA, FACC, FACP, Board of Directors Liaison
Daniel H. Kim, MD, Education Committee Workforce Leader
Alejandro Bertolotti, MD, I2C2 Workforce Leader
Hannah Copeland, MD, Standards & Guidelines Committee Workforce Leader
David P. Nelson, MD, ISHLT Links Newsletter Liaison
Pradeep P. A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Liaison
Natasha Altman, MD, Junior Faculty & Trainee Council Liaison
Marco Masetti, MD, PhD, Junior Faculty & Trainee Council Liaison
Edith Boyes, MSN, FNP-BC, CHFN, Nursing, Health Sciences & Allied Health Council Liaison

INFECTIOUS DISEASES
Me-Linh Luong, MD, Chair
Saima Aslam, MD, MS, Vice Chair-Elect
Paolo A. Grossi, MD, PhD, Past Chair
Joseph Rogers, MD, Board of Directors Liaison
Joanna Schaenman, MD, PhD, Education Committee Workforce Leader
Fernanda Silveira, MD, I2C2 Workforce Leader
Valentina Stosor, MD, Standards & Guidelines Committee Workforce Leader
Saima Aslam, MD, MS, ISHLT Links Newsletter Liaison
Aric Gregson, MD, Basic Science & Translational Research Council Liaison
Ignacio A. Echenique, MD, Junior Faculty & Trainee Council Liaison
JUNIOR FACULTY AND TRAINEE
Keyur B. Shah, MD, Chair
Evan P. Kransdorf, MD, PhD, Vice Chair
Martin Schweiger, MD, Vice Chair-Elect
Eugene C. DePasquale, MD, Past Chair
Maryl Johnson, MD, Board of Directors Liaison
Martin Schweiger, MD, Education Workforce Leader
Hirsch S. Mehta, MD, I2C2 Workforce Leader
Agneszka Ciarka, MD, Standards & Guidelines Committee Workforce Leader
Jorge Silva Enciso, MD, ISHLT Links Newsletter Liaison
Simon Pecha, MD, Basic Science & Translational Research Council Liaison
Natasha Altman, MD, Heart Failure & Transplantation Council Liaison
Marco Masetti, MD, PhD, Heart Failure & Transplantation Council Liaison
Ignacio Echenique, MD, Infectious Diseases Council Liaison
Jaime Hernandez Montfort, MD, MPH, Mechanical Circulatory Support Liaison
Feras Khalied, MD, PhD, Mechanical Circulatory Support Council Liaison
Colleen K. Mcllvennan, Nursing, Health Sciences & Allied Health Council Liaison
Claire A. Irving, MBChB, MRCPCH, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Ann Punnoose, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Marco A. Caccamo, MD, Pulmonary Hypertension Council Liaison
Darko Vucicevic, MD, International Liaison

MECHANICAL CIRCULATORY SUPPORT
Nir Uriel, MD, Chair
Simon Maltais, MD, PhD, Vice Chair
Stephan Schueler, MD, PhD, FRCS, Past Chair
Tobias Deuse, MD, PhD, Board of Directors Liaison
Diyar Saeed, MD, PhD, Education Committee Workforce Leader
David A. D’Alessandro, MD, Standards & Guidelines Committee Workforce Leader
Evgenij V. Potapov, MD, ISHLT Links Newsletter Liaison
Dawn M. Christensen, MS, CRNP, VAD Coordinator Liaison
J. Michael DiMaio, MD, Basic Science & Translational Research Council Liaison
Jaime Hernandez Montfort, MD, MPH, Junior Faculty & Trainee Council Liaison
Feras Khalied, MD, PhD, Junior Faculty & Trainee Council Liaison
Jennifer A. Beckman, MSN-FNP, RN, CHFN, Nursing, Health Sciences & Allied Health Council Liaison
Angela Lorts, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH
Kevin Carney, MSN, CRNP, CCTC, Chair
Pamela S. Combs, PhD, RN, Vice Chair
Caron Burch, RN, MSN, FNP, CCTC, Vice Chair-Elect
Samantha J. Anthony, PhD, MSW, Past Chair
Michael G. Petty, PhD, RN, CCNS, CNS, Board of Directors Liaison
Caron Burch, RN, MSN, FNP, CCTC, Education Workforce Leader
Rasha Adam, RN, I2C2 Workforce Leader
Colleen Juricek, Standards & Guidelines Committee Workforce Leader
Louise M. Fuller, PT, Grants & Award Committee Workforce Leader
Kirsten Diegel, RD, LDN, ISHLT Links Newsletter Liaison
Jill Giordano, MA, MSW, LCSW, Links Newsletter Liaison
Monica Horn, RN, CCRN, CCTC, Basic Science & Translational Research Council Liaison
Edith Boyes, MSN, FNP-BC, CHFN, Heart Failure & Transplantation Council Liaison
Colleen Mcllvennan, Junior Faculty & Trainee Council Liaison
Jennifer A. Beckman, MSN-FNP, RN, CHFN, Mechanical Circulatory Support Council Liaison
Jodie Lantz, CNS, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Rachel M. Crackett, MSc, Pulmonary Hypertension Council Liaison
Nicole Davis, BSN, MPH, CCTC, Pulmonary Transplantation Council Liaison

ISHLT Council Operating Boards
PATHOLOGY
Robert F. Padera, MD, PhD, Chair
Fiorella Calabrese, MD, Vice Chair
Martin J. Goddard, FRCS, MRCPa, Past Chair
Dirk Van Raemdonck, MD, PhD, Board of Directors Liaison
Annalisa Angelini, MD, I2C2 Workforce Leader
Anja C. Roden, MD, Standards & Guidelines Committee Workforce Leader
Brandon T. Larsen, MD, PhD, ISHLT Links Newsletter Liaison
Annalisa Angelini, MD, Basic Science & Translational Research Council Liaison

PEDIATRIC THORACIC TRANSPLANTATION AND HEART FAILURE
Brian Feingold, MD, MS, Chair
Carol K. Conrad, MD, Vice Chair
Tajinder P. Singh, MD, MSc, Past Chair
Kevin Chan, MD, Board of Directors Liaison
Beth Kaufman, MD, Education Committee Workforce Leader
James D. St. Louis, MD, I2C2 Workforce Leader
Steven Kindel, MD, Standards & Guidelines Committee Workforce Leader
Kevin Daly, MD, Standards & Guidelines Committee Workforce Leader
Ryan Butts, MD, Pediatric Heart Failure Workforce Leader
Marc Schecter, MD, Pediatric Lung Transplant Workforce Leader
Martin Schweiger, MD, ISHLT Links Newsletter Liaison
Claire Irving, MBChB, MRCPCH, Junior Faculty & Trainee Council Liaison
Ann Punnoose, MD, Junior Faculty & Trainee Council Liaison
Angela Lorts, MD, Mechanical Circulatory Support Council Liaison
Jodie Lantz, CNS, Nursing, Health Sciences & Allied Health Council Liaison

PHARMACY AND PHARMACOLOGY
Adam B. Cochrane, PharmD, MPH, Chair
Haifa Lyster, MSc, Vice Chair
Walter Uber, PharmD, Past Chair
Daniel J. Goldstein, MD, Board of Directors Liaison
Tam Khuu, PharmD, BCPS, Education Committee Workforce Leader
Douglas L. Jennings, PharmD, I2C2 Workforce Leader
Robert L. Page, II, PharmD, MS, Standards & Guidelines Committee Workforce Leader
Edward Horn, PharmD, BCPS, ISHLT Links Newsletter Liaison

PULMONARY HYPERTENSION
Dana P. McGlothlin, MD, Chair
Jean-Luc Vachiery, MD, Vice Chair
Ioana Preston, MD, Vice Chair-Elect
Mardi Gomberg-Maitland, MD, MSc, Past Chair
Teresa De Marco, MD, FACC, Board of Directors Liaison
Ioana Preston, MD, Education Workforce Leader
Manreet Kanwar, MD, I2C2 Workforce Leader
Oksana A. Shlobin, MD, FACC, Standards & Guidelines Committee Workforce Leader
Amresh Raina, MD, ISHLT Links Newsletter Liaison
Aaron B. Waxman, MD, PhD, Basic Science & Translational Research Council Liaison
Marco A. Caccamo, MD, Junior Faculty & Trainee Council Liaison
Rachel M. Crackett, MSc, Nursing, Health Sciences & Allied Health Council Liaison

PULMONARY TRANSPLANTATION
Cynthia J. Gries, MD, MSc, Chair
Ramsey R. Hachem, MD, Vice Chair
Glen P. Westall, FRACP, PhD, Vice Chair-Elect
Michael Mulligan, MD, Past Chair
Peter M. Hopkins, FRACP, Board of Directors Liaison
Lorriana E. Leard, MD, Education Committee Workforce Leader
Denis Hadjiliadis, MD, I2C2 Workforce Leader
Erika D. Lease, MD, Standards & Guidelines Committee Workforce Leader
Jonathan P. Singer, MD, MS, Quality of Life Workforce Leader
Jussi Tikkanen, MD, PhD, ISHLT Links Newsletter Liaison
Pablo G. Sanchez, MD, PhD, Basic Science & Translational Research Council Liaison
Joshua J. Mooney, MD, Junior Faculty & Trainee Council Liaison
Nicole Davis, BSN, MPH, CCTC, Nursing, Health Sciences & Allied Health Council Liaison
<table>
<thead>
<tr>
<th>Year</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981-82</td>
<td>Michael Hess, MD</td>
</tr>
<tr>
<td>1982-84</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1984-86</td>
<td>Terence English, FRCS</td>
</tr>
<tr>
<td>1986-88</td>
<td>Stuart Jamieson, MD</td>
</tr>
<tr>
<td>1988-90</td>
<td>Bruno Reichart, MD</td>
</tr>
<tr>
<td>1990-91</td>
<td>Margaret Billingham, MD</td>
</tr>
<tr>
<td>1991-92</td>
<td>Christian Cabrol, MD</td>
</tr>
<tr>
<td>1992-93</td>
<td>John O’Connell, MD</td>
</tr>
<tr>
<td>1993-94</td>
<td>Eric Rose, MD</td>
</tr>
<tr>
<td>1994-95</td>
<td>John Wallwork, FRCS</td>
</tr>
<tr>
<td>1995-96</td>
<td>Sharon Hunt, MD</td>
</tr>
<tr>
<td>1996-97</td>
<td>William Baumgartner, MD</td>
</tr>
<tr>
<td>1997-98</td>
<td>Leslie Miller, MD</td>
</tr>
<tr>
<td>1998-99</td>
<td>Alan Menkis, MD, FRCS(C)</td>
</tr>
<tr>
<td>1999-00</td>
<td>Robert L. Kormos, MD</td>
</tr>
<tr>
<td>2000-01</td>
<td>Anne Keogh, MBBS, MD</td>
</tr>
<tr>
<td>2001-02</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>2002-03</td>
<td>Stephan Schueler, MD</td>
</tr>
<tr>
<td>2003-04</td>
<td>Jon Kobashigawa, MD</td>
</tr>
<tr>
<td>2004-05</td>
<td>Alec Patterson, MD</td>
</tr>
<tr>
<td>2005-06</td>
<td>Mark L. Barr, MD</td>
</tr>
<tr>
<td>2006-07</td>
<td>Robert C. Robbins, MD</td>
</tr>
<tr>
<td>2007-08</td>
<td>Paul A. Corris, MB FRCP</td>
</tr>
<tr>
<td>2008-09</td>
<td>Mandeep R. Mehra, MD</td>
</tr>
<tr>
<td>2009-10</td>
<td>James K. Kirklin, MD</td>
</tr>
<tr>
<td>2010-11</td>
<td>John Dark, MB, FRCS</td>
</tr>
<tr>
<td>2011-12</td>
<td>Lori J. West, MD, DPhil</td>
</tr>
<tr>
<td>2012-13</td>
<td>David O. Taylor, MD</td>
</tr>
<tr>
<td>2013-14</td>
<td>Allan R. Glanville, MBBS, MD, FRACP</td>
</tr>
<tr>
<td>2014-15</td>
<td>Hermann Reichenspurner, MD, PhD</td>
</tr>
<tr>
<td>2015-16</td>
<td>Duane Davis, MD, MBA</td>
</tr>
<tr>
<td>2016-17</td>
<td>Maryl Johnson, MD</td>
</tr>
<tr>
<td>Year</td>
<td>Location, Country</td>
</tr>
<tr>
<td>------</td>
<td>-------------------</td>
</tr>
<tr>
<td>1981</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>1982</td>
<td>Phoenix, AZ</td>
</tr>
<tr>
<td>1983</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>1984</td>
<td>New York, NY</td>
</tr>
<tr>
<td>1985</td>
<td>Anaheim, CA</td>
</tr>
<tr>
<td>1986</td>
<td>New York, NY</td>
</tr>
<tr>
<td>1987</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>1988</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>1989</td>
<td>Munich, Germany</td>
</tr>
<tr>
<td>1990</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>1991</td>
<td>Paris, France</td>
</tr>
<tr>
<td>1992</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>1993</td>
<td>Boca Raton, FL</td>
</tr>
<tr>
<td>1994</td>
<td>Venice, Italy</td>
</tr>
<tr>
<td>1995</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>1996</td>
<td>New York, NY</td>
</tr>
<tr>
<td>1997</td>
<td>London, England</td>
</tr>
<tr>
<td>1998</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>1999</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>2000</td>
<td>Osaka, Japan</td>
</tr>
<tr>
<td>2001</td>
<td>Vancouver, Canada</td>
</tr>
<tr>
<td>2002</td>
<td>Washington, DC</td>
</tr>
<tr>
<td>2003</td>
<td>Vienna, Austria</td>
</tr>
<tr>
<td>2004</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>2005</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>2006</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>2007</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>2008</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>2009</td>
<td>Paris, France</td>
</tr>
<tr>
<td>2010</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>2011</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>2012</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>2013</td>
<td>Montreal, Canada</td>
</tr>
<tr>
<td>2014</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>2015</td>
<td>Nice, France</td>
</tr>
<tr>
<td>2016</td>
<td>Washington, DC</td>
</tr>
<tr>
<td>2017</td>
<td>San Diego, CA</td>
</tr>
</tbody>
</table>
EDITORS

JOURNAL OF HEART AND LUNG TRANSPLANTATION
1981-1985  Jacques G. Losman, MD
1986-1994  Michael P. Kaye, MD
1995-1999  Maria Rosa Costanzo, MD
2000-2009  James K. Kirklin, MD
2010-Present  Mandeep R. Mehra, MD

LINKS NEWSLETTER
2008-2011  David S. Feldman, MD, PhD
2011-Present  Vincent G. Valentine, MD

MEDICAL DIRECTORS

INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION
1987-1993  Michael P. Kaye, MD
1993-2001  Jeffrey D. Hosenpud, MD
2001-2012  Marshall I. Hertz, MD
2012-Present  Josef Stehlik, MD, PhD
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

ISHLT PIONEER AWARD
2000 Christiaan Barnard, MD
    Joel D. Cooper, MD
    Norman E. Shumway, MD
2002 Michael DeBakey, MD
    Bruce A. Reitz, MD
2006 Leonard L. Bailey, MD
2008 Richard E. Lower, MD
2009 Christian E. A. Cabrol, MD
2011 Elizabeth Hammond, MD
2013 Jack G. Copeland, MD
2015 Bruno Reichart, MD
2016 Sir Roy Calne, FRCP, FRCS, FRS

ISHLT LIFETIME ACHIEVEMENT AWARD
1996 Norman Shumway, MD
1999 Keith Reemtsma, MD
2004 Sir Magdi Yacoub, MD
2010 Margaret Billingham, MD
2012 Sharon Hunt, MD
2014 Sir Terence English, KBE, FRCS
2016 Adrian Kantrowitz, MD
    Jean Kantrowitz, MPH
2018 O. Howard Frazier, MD

ISHLT LIFETIME SERVICE AWARD
1996 Michael P. Kaye, MD
1997 Jacques G. Losman, MD

EMERITUS MEMBERSHIP
Margaret D. Allen, MD
Christian Cabrol, MD
Sir Terence English, KBE, FRCS
Albert J. Guerraty, MD
Sharon A. Hunt, MD
Carl V. Leier, MD
Bruno Reichart, MD
Marlene Rose, PhD
John Wallwork, FRCS
Elaine M. Winkel, MD
Prof. Magdi Yacoub, MD

GRANTS AND SCHOLARSHIPS:

ISHLT NORMAN E. SHUMWAY CAREER DEVELOPMENT AWARD
2000 Gordon D. Wu, MD (supported by Roche)
2002 Anthony Azakie, MD (supported by Roche)
2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
2008 Glen Westall, MD, PhD (supported by Roche)
2010 Sonja Schrepfer, MD, PhD (supported by Astellas)
2012 Tereza Martinu, MD, PhD
2014  Keshava Rajagopal, MD, PhD
2015  Xingan Wang, MD, PhD
2016  Stephen Juvet, MD, PhD, FRCPC
2017  Nicole Valenzuela, PhD, D(ABHI)
2018  David Schibilsky, MD

**ISHLT JOEL D. COOPER CAREER DEVELOPMENT AWARD**
2017  Keki Blasara, MD
2018  Brian Wong, PhD

**ISHLT NURSING RESEARCH GRANT AWARD**
1997  Eileen Collins, RN, PhD
1998  Katherine St. Clair, RN, MSN
1999  Jeanne Salyer, PhD
2000  Nancy M. Albert, MSN, RN
2001  Lynn Doering, RN, DNSc
2002  Annette J. De Vito Dabbs, RN, MN, PhD
2003  Diane H. Leloudis, RN, MSN
   Janet E. Madill, PhD
2004  Deidre E. Logan, PhD
2005  Annemarie F. Kaan, MCN
2006  Thierry Troosters, PhD
2007  Mi-Kyung Song, PhD
2008  Stacey M. Pollock-BarZiv, PhD
2009  Jane Maclver, RN, MSc
2010  Heike Spaderna, PhD
   Gerdi Weidner, PhD
2011  Christiane Kugler, PhD (supported by CSL Behring)
   Hilde Bollen, RN
2012  Lut Berben, PhD, RN (supported by CSL Behring)
   Connie White-Williams, PhD, RN, FAAN
2013  Jo Wray, PhD
   Jane Haines, DNP, RN, CMSRN
2014  Lea Ann Matura, PhD, RN
2015  JiYeon Choi, PhD, RN
2016  Mohammad Alrawashdeh, BSN, MSN
2016  Melissa Cousino, PhD (Jointly Funded by Enduring Hearts)
2017  Samantha Anthony, PhD, MSW
2018  Martha Abshire, PhD, RN
   Mary Amanda Dew, PhD

**ISHLT RESEARCH FELLOWSHIP AWARD**
1995  Frances L. Johnson, MD (supported by Ortho-Biotech)
1996  Tuija S. Ikonen, MD (supported by Roche)
   Andrew F. Pierre, MD (supported by Ortho-Biotech)
1997  Jonathan Chen, MD (supported by Roche)
   Alyssa M. Krasinskas, MD (supported by Astellas)
   Owen T. Lawrence, MD (supported by Ortho-Biotech)
   Anne K. Raisanen-Sokolowski, MD (supported by Roche)
1998  Kelly S.A. Blair, MD (supported by Roche)
   A.M. El Gamel, MD (supported by Roche)
   Christine L. Lau, MD (supported by Wyeth-Ayerst)
   Scott D. Ross, MD
   Margaret L. Schwarze, MD (supported by Novartis)
1999  George Juang, MD (supported by Novartis)
   Sivasai Krovvidi, PhD (supported by Roche)
   Satoshi Saito, MD (supported by Novartis)
   Donald Wong, PhD (supported by Roche)
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Institution</th>
<th>Supporting Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>Richard S. Lee, MD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Christopher H. Wigfield, FRCS</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2001</td>
<td>Arnar Geirsson, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Matteo Vatta, PhD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2002</td>
<td>Ruediger Hoebelt, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2003</td>
<td>Ewout J. van den Bos, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Felix Fernandez, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2004</td>
<td>Christian A. Gleissner, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Tsuyoshi Shoji, MD, PhD</td>
<td></td>
<td>Actelion</td>
</tr>
<tr>
<td></td>
<td>Kendra N. Taylor, PhD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Monica Zwierzchonieuska, MD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td>2005</td>
<td>Ryan C. Fields, MD</td>
<td></td>
<td>Chiron</td>
</tr>
<tr>
<td></td>
<td>Arne Neyrinck, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Ahmad Saad, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2006</td>
<td>Rachel L. Anderson, MBBS</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Zhaoohui Li, PhD</td>
<td></td>
<td>Transmedics</td>
</tr>
<tr>
<td></td>
<td>Heather E. Merry, MD</td>
<td></td>
<td>Encysive</td>
</tr>
<tr>
<td></td>
<td>Edward N. Seung, PhD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Matthew J. Weiss, MD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td>2007</td>
<td>J. Raymond Fitzpatrick, III, MD</td>
<td></td>
<td>Encysive</td>
</tr>
<tr>
<td></td>
<td>Howard J. Huang, MD</td>
<td></td>
<td>Transmedics</td>
</tr>
<tr>
<td></td>
<td>Mylvganam Jeyakanthan, MD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Timothy M. Millington, MD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Satish N. Nadig, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Takeshi Oyaizu, MD</td>
<td></td>
<td>Actelion</td>
</tr>
<tr>
<td></td>
<td>Sonja Schrepfer, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td>2008</td>
<td>Jonathan Choy, PhD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Satoshi Itoh, MD</td>
<td></td>
<td>Transmedics</td>
</tr>
<tr>
<td></td>
<td>Tereza Martinu, MD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Deepti Saini, PhD</td>
<td></td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td>Atsushi Shiozaki, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Seiichiro Sugimoto, MD, PhD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2009</td>
<td>Hua Shen, MD, PhD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Tobias Deuse, MD, PhD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Masahiro Miyajima, MD, PhD</td>
<td></td>
<td>XDX</td>
</tr>
<tr>
<td></td>
<td>Shin Hirayama, MD, PhD</td>
<td></td>
<td>Gilead</td>
</tr>
<tr>
<td>2010</td>
<td>Esme Dijke, PhD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Smita Sihag, MD</td>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td></td>
<td>Sumiharu Yamamoto, MD</td>
<td></td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td>Khurram Shahzad, MD</td>
<td></td>
<td>United Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Nina Pilat, MSc, PhD</td>
<td></td>
<td>XDX</td>
</tr>
<tr>
<td>2011</td>
<td>Alejandro Bribiesco, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Alexey Dashkevich, MD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Patricia E. de Almeida, DVM, MS, PhD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Tiago Machuca, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2012</td>
<td>Stephen C. Juvet, MD, FRCPC</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Maria Lucia L. Madariga, MD</td>
<td></td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Jessica H. Spahn, PhD</td>
<td></td>
<td>Gilead</td>
</tr>
<tr>
<td></td>
<td>Konstantinos Malliaras, PhD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td>2013</td>
<td>Nikolaos Diakos, MD</td>
<td></td>
<td>United Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Raymond Givens, MD, PhD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Pablo Sanchez, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td>2014</td>
<td>Charles Evans, MD</td>
<td></td>
<td>United Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Christine Lin, MD</td>
<td></td>
<td>XDx</td>
</tr>
<tr>
<td></td>
<td>Stijn Verleden, PhD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2015</td>
<td>Jonathan Merola, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2016</td>
<td>Hsi-Min Hsaio, PhD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Nikolas Skartsis, MD</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>Corey Tabit, MD, MBA, MPH</td>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td>2017</td>
<td>Ramiro Fernandez, MD</td>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td>2018</td>
<td>Ei Miyamoto, MD</td>
<td></td>
<td>Roche</td>
</tr>
</tbody>
</table>
ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD
(formerly Junior Faculty Award)
2007 Beth D. Kaufman, MD
2008 Cynthia Gries, MD, MSc
    Scott Halpern, MD, PhD
    Josef Stehlik, MD, MPH
2010 Jennifer Conway, MD, FRCPC
    Kiran K. Khush, MD, MAS
2011 Jose Nativi, MD
2012 Erin M. Lowery, MD
    Omar E. Wever-Pinzon, MD
2013 Chesney Castleberry, MD
    Eugene DePasquale, MD
    Aaron Healy, MD
2014 Marian Urban, MD
    Miranda Paraskeva, MBBS
    Hrishikesh Kulkarni, MD
    Agnieszka Ciarka, MD, PhD
2015 Livia Goldraich, MD, MSc
    Deipanjan Nandi, MD, MSc
    Evan Kransdorf, MD, PhD
    Manreet Kanwar, MD
    Natasha Loghmanpour, PhD
    Alexander Bernhardt, MD
    Jong-Chan Youn, MD, PhD
2016 Sai Bhagra, MBBS, MRCP
    Forum Kamdar, MD
    Marco Masetti, MD, PhD
    Joshua Mooney, MD
    Edit Nagy, MD, PhD
2017 Laith Alshawabkeh, MD, MSc
    Yuka Furuya, MD
    Christian Heim, MD
    Monique Robinson, MBBS, MRCP, DPhil
    Lorenzo Zaffiri, MD, PhD
2018 Hakim Ali, MD
    Daniel Reichart, MD
    Lanesha Tague, MD, MSCI
    Amanda Vest, MBBS, MPH
    Michael Yaoyao Yin, MD

ISHLT/BAYER PULMONARY HYPERTENSION RESEARCH GRANT AWARD
2014 Benjamin Freed, MD

ISHLT/HEARTWARE AWARD FOR TRANSLATIONAL RESEARCH IN MCS
2014 Leigh Reardon, MD
2015 Alexander Bernhardt, MD

ISHLT/O.H. FRAZIER AWARD IN MCS TRANSLATIONAL RESEARCH Sponsored by Medtronic
2016 Todd Dardas, MD, MS
2017 Yasuhiro Shudo, MD, PhD
2018 Kavitha Muthiah, MBChB, PhD, FRACP

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT (supported by Thoratec)
2009 Sasa D. Borovic, MD
2010 Iki Adachi, MD
2012 Antigone Koliopoulou, MD
2014 Masahiro Ono, MD, PhD
ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP AWARD

2011  Stephanie T. Yerkovich, PhD
       Sarah E. Gilpin, PhD
       Kimberly M. Derkatz, BNSc
       Jennifer Conway, MD, FRCPC

2012  Ramin E. Beygui, MD
       Kevin C. Carney, MSN
       Alexandre Souza Cauduro, MD
       Esme Dijke, PhD
       Ana Belen Mendez, MD
       David Schibilsky, MD
       Aleem Siddique, MBBS
       Amparo Solé, MD, PhD
       Manon Huibers, MSc
       Daniel R. Goldstein, MD
       Laveena Munshi, MD, FRCPC
       Marco Masetti, MD
       Rochelle M. Gellatly, PScPharm, ACPR, PharmD

2013  Alison Gareau, MSc
       Erin Schumer, MD, MS
       Bojan Vrtovec, MD, PhD
       Marsha Renikunta, PhD (student)
       Katie Morley, BA(Hons), RCN, MA
       Ali Yeginsu, MD
       Fabrizio Gandolfo, MD
       Marian Urban, MD
       Alexander Bernhardt, MD
       Victor Rossel, MD
       Mohammed Quader, MD

2014  Marny Fedrigo, MD, PhD
       Zachary Kon, MD
       Evgenios Neofytou, MD
       Dong, Wang, MD
       Stephen Clark, DM, FRCS
       Caroline Patterson, BMBS, BMedSci, MRCP
       Tahaunty Pena, MD

2015  Oisin O’Connell, MD, MRCPI
       Lucas Van Aelst, MD, PhD
       Arezu Aliabadi, MD
       Timothy Sladden, MBBS, BVSc
       Bao Tran, MD
       L G Saptharishi, MD, DM
       Allison Carroll, MD
       Akshay Pendyal, MD
       Stefania Paolillo, MD, PhD
       Soumitra Sinha Roy, MD

2016  Lucas Van Aelst, MD, PhD
       Espeed Khoshin, MB ChB, MD, FRCS

2017  Amit Adlakha, MBChB, MRCP, FFICM
       In-Cheol Kim, MD, PhD
       Sanjeev Kumar Khulbey, MBBS, MS, MCH
       Antonios Kourliouros, PhD, FRCS (CTh)
       Mrinalini Krishnan, MD
       Simon Pecha, MD
       Kuruswamy Prasad, MD, DM
       Ann Punnoose, MD
       Adam Putschoegl, DO
       Jong-Chan Young, MD, PhD
ISHLT LEACH-ABRAMSON-IMHOFF LINKS TRAVEL AWARDS

2012
- Tereza Martinu, MD, Writer of the Year
- Stanley I. Martin, MD, First Runner-Up
- Luciano Potena, MD, PhD, First Runner-Up
- Nancy P. Blumenthal, CRNP, Honorable Mention
- Bronwyn J. Levvey, RN, Honorable Mention
- Javier Carbone, MD, PhD, Honorable Mention
- Stavros G. Drakos, MD, Honorable Mention
- Daniel F. Dilling, MD, Honorable Mention

2013
- Michele Estabrook, MD, Writer of the Year
- Melanie Everitt, MD, First Runner-Up
- Christina Migliore, MD, First Runner-Up
- Veronica Franco, MD, Honorable Mention
- Manreet Kanwar, MD, Honorable Mention
- Luciano Potena, MD, PhD, Honorable Mention
- Macé Schuurmans, MD, Honorable Mention
- Jeffrey J. Teuteberg, MD, Honorable Mention

2014
- Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year
- Amanda Ingemi, PharmD, First Runner-Up
- Simon Urschel, MD, Honorable Mention

2015
- Pamela S. Combs, PhD, RN, Writer of the Year
- Manreet Kanwar, MD, First Runner-Up
- Oveimar De la Cruz, MD, Honorable Mention
- Heather T. Henderson, MD, Honorable Mention
- Simon Urschel, MD, Honorable Mention
- Erin Wells, RN, BSN, CPN, Honorable Mention

2016
- Kyle Dawson, PharmD, MBA, BCPS, Writer of the Year
- Adam Cochrane, PharmD, BCPS, First Runner-Up
- Christa Kirk, PharmD, First Runner-Up
- Angela Velleca, RN, BSN, CCTC, Honorable Mention
- Erin Wells, RN, BSN, CPN, Honorable Mention

2017
- Quincy Young, PhD, RPsych, Writer of the Year
- Monica Horn, RN, First Runner-Up
- Melissa Cousino, PhD, Honorable Mention
- Erin Wells, RN, BSN, CPN, Honorable Mention

2018
- Erin Wells, RN, BSN, Writer of the Year
- Martin Schweiger, MD, First Runner-Up
- Adam Cochrane, Honorable Mention
- Pamela S. Combs, Honorable Mention
- Kyle Dawson, PharmD, MBA, BCPS, Honorable Mention
- Joshua Mooney, MD, Honorable Mention

ABSTRACT AWARDS:

PHILIP K. CAVES AWARD
1983  Robbin G. Cohen, MD
1984  Hermann Reichenspurner, MD
1985  Michael A. Breda, MD
1986  Stuart J. Knechtle, MD
1987  Wim Van Der Bij, MD
1988  Charles D. Fraser, Jr., MD
1989  A.M. Wood, MD
1990  Andres J. Duncan, MD
1991  A. Jiminez, MD
1992  David P. Kapelanski, MD
1993  David Marshman, MD
1994  Jobst Winter, MD
1995  Elizabeth A. Davis, MD
1996  Moninder S. Bhobra, MD
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>Simon D. Eiref, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>1998</td>
<td>Carla C. Baan, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>1999</td>
<td>Joerg Koglin, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2000</td>
<td>Michael P. Fischbein, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2001</td>
<td>Alexander S. Krupnick, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2002</td>
<td>Peter Blaha, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2003</td>
<td>Sigrid Sandner, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2004</td>
<td>M.D. Peterson, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2005</td>
<td>Sigrid Sandner, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td></td>
<td>Frank D'Ovidio, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2006</td>
<td>Gregor Warnecke, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2007</td>
<td>Heather E. Merry, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2008</td>
<td>Satish N. Nadig, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2009</td>
<td>Howard Huang, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2010</td>
<td>Tobias Deuse, MD, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2011</td>
<td>Ankit Bharat, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2012</td>
<td>Simo Syrjälä, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2013</td>
<td>Alexey Dashkevich, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2014</td>
<td>Jessica Spahn</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2015</td>
<td>Simon Pecha, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2016</td>
<td>Corey E. Tabit, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2017</td>
<td>Stephen Chiu, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
</tbody>
</table>

**NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Mary Amanda Dew, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2006</td>
<td>Kathleen L. Grady, PhD, RN</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2007</td>
<td>Christiane Kugler, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2008</td>
<td>Annette DeVito Dabbs, RN, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2009</td>
<td>Connie White-Williams, MSN</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2010</td>
<td>Bronwyn Levvey, RN</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2011</td>
<td>Samantha J. Anthony, PhD, MSW</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2012</td>
<td>Kate Hayes, MPhysio (Cardio)</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2013</td>
<td>Jane Haines, DNP, RN, CMSRN</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2014</td>
<td>Louise Fuller, PT</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2015</td>
<td>Catherine Murks, PhD, APN</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2016</td>
<td>Fabienne Dobbels, MSc, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2017</td>
<td>Maral Bakir, RN, PHN</td>
<td>ISHLT Award Recipients</td>
</tr>
</tbody>
</table>

**EARLY CAREER SCIENTIST AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>His-Min Hsiao, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
</tbody>
</table>

**JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION BEST PRESENTATION AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Michelle M. Kittleson, MD, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2012</td>
<td>Erin Albers, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2013</td>
<td>Mustafa Ahmed, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2014</td>
<td>Lauren Sacha</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2015</td>
<td>Ankit Bharat, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2016</td>
<td>Yasufumi Goda, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2017</td>
<td>Robert Gottlieb, MD, PhD</td>
<td>ISHLT Award Recipients</td>
</tr>
</tbody>
</table>

**ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS ABSTRACT AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>Nishant Shah, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2010</td>
<td>Jose N. Nativi, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2012</td>
<td>Arun Raghav Mahankali Sridhar, MD, MPH</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2013</td>
<td>Claire Watkins, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
<tr>
<td>2014</td>
<td>Jason O. Robertson, MD</td>
<td>ISHLT Award Recipients</td>
</tr>
</tbody>
</table>
CONTINUING MEDICAL EDUCATION INFORMATION

ACCME Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement
ISHLT designates this live activity for a maximum of 29 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation
The ABTC Board of Governors has granted a total of 29 Category 1 Continuing Education Points for Transplant Certification (CEPTC) to the International Society for Heart & Lung Transplantation's ISHLT 38th Annual Meeting and Scientific Sessions.

Nurses and Pharmacists
Accreditation Statement – In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco designates this live activity for a maximum of 29 contact hours for nurses and 17 contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives
Because of the rapid advances in patient health care in general and end-stage heart and lung disease management in particular, professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in the field. This meeting is designed to address their needs.

Educational Goals
The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

Target Audience
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in the care and treatment of patients with end-stage heart and lung disease. The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators, and other allied health and social science professionals engaged in the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.
Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end-stage heart and lung disease.

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with end-stage heart and lung failure.

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.
UNRESTRICTED EDUCATIONAL GRANTS

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in the support of the Thirty-Eighth Annual Meeting and Scientific Sessions.

Actelion
Medtronic
Abbott

COMMERCIAL SUPPORT

The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2018:

**Tier 1**
Medtronic

**Tier 2**
Abbott
Actelion

**Tier 3**
Gilead Sciences
Bayer/Merck

**Tier 4**
Transmedics
XVIVO
CareDx
One Lambda (Thermo Fisher)
Basic Science and Translational Research
The ISHLT returns to Nice in 2018. As the French say, “c'est si bon” (that is so good). So taking French in high school and college has some utility after all. Come to Nice for the beautiful vistas, the fine beaches, excellent museums, great food (it is France after all) and the ISHLT Annual Meeting. The crème de la crème of the meeting will be the BSTR Symposia. Participants will be provided with sound and selective updates in applied science and novel research methods relevant for scientists and specialists in heart and lung transplantation as well as allied professionals. This year’s foci will appraise the “evolution” of our understanding of cell population subsets in immune processes and their interactions. Amaze your friends with the knowledge you acquire in OLD CELLS NEW TRICKS: Updates in Transplant Immunology. The second emphasis will be on the emerging tools currently tackling research challenges to produce a “revolution” in translational science. You will learn about these in Novel Tools in Transplant Research (Say You Want a Revolution...). So come one, come all to the ISHLT in Nice and be amazed. After all, why do you think they call it nice?

Heart Failure and Transplantation
This year’s heart symposia will feature a diverse range of topics appealing to a broad audience of cardiologists, surgeons, nurses and allied healthcare professionals, focusing on practical aspects surrounding heart transplantation and providing perspectives to hotly debated controversies in our daily clinical practice. We Never Stop Learning: 50th Anniversary of Heart Transplantation will wind back the clock to the early days of heart transplantation with its surgical challenges, changes in patient selection, evolution of immunosuppression, developing and refining the definition of rejection, as well as the role ISHLT played in its advancement. The session will also include the unique experience of the longest surviving heart transplant recipient in the world. Adult Congenital Heart Disease: Reaching the Summit will bring an exciting set of lectures dedicated to the growing population of patients with congenital diseases surviving to adulthood. Cardio-Oncology: A Tale of Two Problems will discuss the challenging problem of concurrent heart failure and oncological disease. Too Frail to Rock and Roll, Too Young to Die will delve into the role of frailty in heart transplantation. The very clinically oriented symposium, First Days of a New Life: Management After Heart Transplantation, will focus on practical issues relative to pre-transplant optimization, ICU post-transplant haemodynamic and rhythm management, and optimal management of early graft failure. Our program highlight will be “The Heat Is On” - Great Debates in Heart Transplantation, where brief case presentations by junior faculty will set the stage for each debate by expert faculty with the audience declaring a winner. Controversial debate topics include utilization of donors with low ejection fraction, Hepatitis C positive status, and the value of desensitization strategies in the highly allo sensitized heart transplant candidate. This session will further engage the audience with a final panel discussion. We hope the lessons learned during this year’s meeting will have a lasting positive impact on your clinical practice.

Infectious Diseases
We have an exciting meeting in store for our Infectious Diseases (ID) colleagues and ID “wannabes”. For the first time, we have partnered with the Transplant Infectious Diseases section of The Transplantation Society to bring you the ISHLT/TTS-TID Joint Symposium: Infectious Challenges Around the World - Common Threads. This unique symposium will assemble internationally renowned transplant ID physicians to discuss a diverse range of issues including arboviral infections, cryptococcosis, CMV guidelines, multi-drug resistant pathogens, donor screening and parasitic infections. The multidisciplinary symposium Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape will tackle different aspects of CMV including the continuum between viremia and disease, use of immunoglobulins, duration of prophylaxis, immunoassays, management strategies for difficult cases and pharmacology/toxicity of the drugs used to treat CMV. The program includes a smattering of ID in other symposia - hepatitis C organ debate, overview of mechanical circulatory support infections, Aspergillus in cystic fibrosis patients, and talks on microbiome/virome in lung transplant recipients.

Lung Failure and Transplantation
This year at the ISHLT conference, five symposia will address hot topics in lung transplantation. The scarcity of organs available for transplant remains a challenge in lung transplantation and using organs procured by donation after circulatory death (DCD) may be a way to increase the number of available organs. DCD Lungs – Expanding Utilization will address some of the challenges and controversies related to establishing a DCD program. The impact of novel antifibrotic drugs and drugs for patients with CF on the perioperative care and postoperative follow-up of lung transplant recipients will be discussed in Can My Lung Transplant Recipient Take This Medication and, in separate talks, traditional drugs such as neurotropic drugs and the use of anticoagulation will be addressed. Cystic Fibrosis in Lung Transplantation: Controversial Topics, will address clinical, pharmacological, surgical and other challenges specific to CF patients. Antibody-Mediated Rejection After Lung Transplantation – 2018 will discuss some of the uncertainties...
and controversies of AMR as a cause of allograft rejection. How are HLA-antibodies detected? What are the pathological findings in AMR? How should AMR be treated? Finally, the greatest challenge to long term success after lung transplantation is the development of chronic lung allograft dysfunction (CLAD). There are still many unknowns regarding the diagnosis, risk factors, phenotypes and treatment of this condition. These issues will be examined in *Chronic Lung Allograft Dysfunction (CLAD): Where Are We?* In summary, these five LUNG symposia at the ISHLT 2018 will present scientific data and expert opinions of high clinical relevance to everyone who works in the field of lung transplantation.

**Mechanical Circulatory Support**

If you are interested in MCS, you are in for a terrific experience at the Nice 2018 meeting with five dedicated symposia offering a wide range of MCS topics. *A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support* will feature a primer on the vascular physiology and the impact of low pulsatility on angiogenesis, renal function, and cerebral autoregulation. The right ventricle continues to vex our field and we will delve into the impact of RV dysfunction on exercise physiology and end-organ function, define the best modalities to characterize RV function and discuss novel medical and surgical approaches to its treatment in *The Role of the RV in Advanced Heart Failure and LVADs*. One of the hottest topics in MCS is the interface of pacing technologies and LVADs and this will be discussed in detail in *It’s Electric! Electrophysiologic Management of the LVAD Patient* where we will debate the merits of intra-operative VT ablation and the benefits of resynchronization therapy after LVAD. The emerging role of short term MCS in cardiogenic shock, decision making in patients with shock and the transition to durable support will be the centerpiece of the *Crashing and Burning: Cardiogenic Shock and Short-Term MCS*. Lastly, don’t miss the cutting-edge talks on MCS complications in *Rapid Update on MCS Complications and Management: The Unpublished* which will offer the latest twists on anticoagulation and pump optimization in addition to the most recent insights into the management of common problems such as stroke, infection and hemolysis. In this rapidly expanding field, we are excited to bring you the latest insights into non-pulsatile physiology as well as many expert tips on how to optimize results with current MCS technology. See you in Nice!

**Nursing and Allied Health**

Nursing and Allied Health sessions will kick off the annual conference on Wednesday in Nice so plan to arrive early! Transplant teams are faced daily with complex, ethically-loaded decisions. Such decisions are even more challenging and distressing when the patient at hand is a young person. *The Young and the Restless: Unique Issues in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults* will highlight common challenging decisions faced by providers, and review the evidence base related to such decisions. Novel patient-reported data on end-of-life care preferences and clinically derived tools for improving practice will be shared. The symposium will conclude with a complex case presentation of a young adult presenting for re-transplantation which highlights the issues uncovered in previous presentations. Audience participation will be encouraged during a question and answer period with the panel of presenters. The multi-disciplinary symposium, *Too Frail to Rock and Roll, Too Young to Die*, will examine frailty in cardiothoracic transplantation and mechanical support. With health care becoming ever more complex, the issue of frailty needs to be addressed and more fully understood. Presentations of the assessment of frailty and pharmacological issues in the frail will be included, rounded out by an exploration of shared decision making and multidisciplinary considerations for the older candidate and recipient, including a focus on cognition and mood.

**Pathology**

The pathologist plays a key role in the thoracic transplant team. Through case discussions, *A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team* will focus on the contribution of the pathologist to patient care, quality assurance and research. Lectures will explore some of the diagnostic difficulties faced by pathologists in the assessment of native and transplanted organs, and how these may be resolved by multidisciplinary teamwork and new advances including molecular pathology.

**Pediatrics**

Pediatric thoracic transplantation requires expertise in acute and chronic multi-organ failure and mechanical support both before and after transplantation. In Nice, attendees will find an array of topics that span the continuum of care for pediatric patients. *Pediatric Heart Failure: MCS, ICU Care and Early Graft Failure* will cover the evaluation and treatment of the failing heart before and after heart transplant. Topics will include the treatment of acute heart failure while awaiting heart transplant and care in the ICU after transplantation. Short-term circulatory support, management of the positive crossmatch patient, and early graft failure are a few of the highly-anticipated talks. *Retransplantation in the Child to Young Adult - History Repeating Itself?* will address the challenges of decision-making in the pediatric heart or lung transplant recipient with graft failure. When is the right time and who is the right patient for re-transplantation? And don’t meander on the Riviera while missing *Too Little or Too Much: Controversies in Monitoring After Pediatric*
**Thoracic Transplantation.** These great debates will interrogate the questions around routine invasive monitoring in pediatric heart recipients and lung recipients. Be sure to schedule time for The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults which will include discussions of adherence, transition and communication tools. These topics will be distinctly applicable to our patient population and will be tackled by leading experts in the field. In addition to these pediatric symposia, don’t overlook the many other symposia of interest to pediatric thoracic transplant attendees throughout the program.

**Pharmacy and Pharmacology**
Malignancy has significant effects in thoracic transplant, both limiting listing options and causing morbidity and mortality after transplantation. As such, management questions exist in post-transplant malignancy. What are the risk factors for developing malignancy post-transplant and how do we modify them? What is the role of anti-CMV prophylaxis with respect to EBV reactivation? Is there a period during and after chemotherapy where risk of rejection fluctuates? What immunosuppressants have heightened roles after successful treatment? These questions will be tackled in Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late? We will discuss the approach to the thoracic transplant recipient who has risk factors for developing cancer post transplant or who has already developed cancer after transplantation. This session will appeal to all members of ISHLT who work with thoracic transplant recipients.

**Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)**
Pulmonary hypertension and the grand début of the CTEPH Council is sure to be a show stopper with 4 symposia at the ISHLT Scientific Sessions in Nice! The ISHLT is partnering with the European Society of Cardiology (ESC) this year for a joint symposium in which experts in the field from both Societies will take a unique and hard look at Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT. In Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy, experts will go head to head on provocative questions at the cutting edge of care through a series of three pro-con debates. Debaters will take on genomics vs. proteomics to guide therapy, the use of ECLS vs. atrial septostomy, and a sure to be lively debate of the REVEAL scoring system vs. the ESC goal-directed therapy approach in PAH. And for CTEPH, thought leaders will be discussing risk factors and disease evolution, along with the latest developments in diagnosis and therapies available to patients in The Devil is in the Details - Nuances in CTEPH. More controversial topics will be addressed in CTEPH: Challenges in Intervention Decision Making. Case presentations will provide the stimulus for debates focused on distal vessel CTEPH, on what to do for patients with symptomatic chronic thromboembolic disease without pulmonary hypertension at rest, and on the emerging role of balloon pulmonary angioplasty vis-à-vis pulmonary endarterectomy.
**ACRONYMS**

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSTR</td>
<td>Basic Science and Translational Research</td>
</tr>
<tr>
<td>EEP</td>
<td>Economics, Ethics, Public Policy</td>
</tr>
<tr>
<td>HF</td>
<td>Heart Failure (Adult)</td>
</tr>
<tr>
<td>HTX</td>
<td>Heart Transplantation (Adult)</td>
</tr>
<tr>
<td>ID</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>LBCS</td>
<td>Late Breaking Clinical Science</td>
</tr>
<tr>
<td>LTX</td>
<td>Lung Transplantation (Adult)</td>
</tr>
<tr>
<td>MCS</td>
<td>Mechanical Circulatory Support (Adult)</td>
</tr>
<tr>
<td>NHSAH</td>
<td>Nursing, Health Science, and Allied Health</td>
</tr>
<tr>
<td>PATH</td>
<td>Pathology</td>
</tr>
<tr>
<td>PEDS</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>PHARM</td>
<td>Pharmacy and Pharmacology</td>
</tr>
<tr>
<td>PH</td>
<td>Pulmonary Hypertension</td>
</tr>
</tbody>
</table>
### SCIENTIFIC COUNCIL MEETINGS

<table>
<thead>
<tr>
<th>Council</th>
<th>Meeting Date and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science and Translational Research</td>
<td>Wed, Apr 11, 7:15 – 8:15 AM (Clio/Thalie/Erato)</td>
</tr>
<tr>
<td>Chronic Thromboembolic Pulmonary Hypertension</td>
<td>Wed, Apr 11, 7:15 - 8:15 AM (Athena)</td>
</tr>
<tr>
<td>Heart Failure &amp; Transplantation</td>
<td>Fri, Apr 13, 7:15 - 8:15 AM (Clio/Thalie/Erato)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Fri, Apr 13, 7:15 - 8:15 AM (Gallieni 5)</td>
</tr>
<tr>
<td>Junior Faculty and Trainees</td>
<td>Fri, Apr 13, 7:15 - 8:15 AM (Gallieni 1-2/Mykonos)</td>
</tr>
<tr>
<td>Mechanical Circulatory Support</td>
<td>Thurs, Apr 12, 7:15 - 8:15 AM (Athena)</td>
</tr>
<tr>
<td>Nursing, Health Science, and Allied Health</td>
<td>Thurs, Apr 12, 7:15 - 8:15 AM (Agora 2)</td>
</tr>
<tr>
<td>Pathology</td>
<td>Thurs, Apr 12, 7:15 - 8:15 AM (Muses)</td>
</tr>
<tr>
<td>Pediatric Thoracic Transplantation &amp; Heart Failure</td>
<td>Thurs, Apr 12, 7:15 - 8:15 AM (Muses)</td>
</tr>
<tr>
<td>Pharmacy and Pharmacology</td>
<td>Thurs, Apr 12, 7:15 - 8:15 AM (Euterpe)</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Fri, Apr 13, 7:15 - 8:15 PM (Euterpe)</td>
</tr>
<tr>
<td>Pulmonary Transplantation</td>
<td></td>
</tr>
</tbody>
</table>

### COUNCIL NETWORKING RECEIPTIONS

In response to feedback from Council members requesting more opportunities for networking at the ISHLT Annual Meetings, we are excited to announce the following Council receptions planned in association with respective evening poster sessions:

<table>
<thead>
<tr>
<th>Council</th>
<th>Reception Date and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science and Translational Research</td>
<td>Wed, Apr 11, 6:15 PM – 7:15 PM (Agora 2)</td>
</tr>
<tr>
<td>Chronic Thromboembolic Pulmonary Hypertension</td>
<td>Fri, Apr 13, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)</td>
</tr>
<tr>
<td>Heart Failure &amp; Transplantation</td>
<td>Thurs, Apr 12, 6:15 - 7:15 PM (Muses)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Thurs, Apr 12, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)</td>
</tr>
<tr>
<td>Junior Faculty and Trainees</td>
<td>Wed, Apr 11, 6:15 - 7:15 PM (Agora 3)</td>
</tr>
<tr>
<td>Mechanical Circulatory Support</td>
<td>Wed, Apr 11, 6:15 - 7:15 PM (Muses)</td>
</tr>
<tr>
<td>Nursing, Health Science, and Allied Health</td>
<td>Wed, Apr 11, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)</td>
</tr>
<tr>
<td>Pathology</td>
<td>Wed, Apr 11, 6:15 - 7:15 PM (Agora 2)</td>
</tr>
<tr>
<td>Pediatric Thoracic Transplantation &amp; Heart Failure</td>
<td>Thurs, Apr 12, 6:15 - 7:15 PM (Agora 3)</td>
</tr>
<tr>
<td>Pharmacy and Pharmacology</td>
<td>Wed, Apr 11, 6:15 - 7:15 PM (Agora 2)</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Fri, Apr 13, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)</td>
</tr>
<tr>
<td>Pulmonary Transplantation</td>
<td>Fri, Apr 13, 6:15 - 7:15 PM (Euterpe)</td>
</tr>
</tbody>
</table>
All meetings and activities will take place at The Acropolis Congress Centre, Nice, France, unless otherwise specified. All papers will be presented in English. Please check the ISHLT website (www.ishlt.org) for updates. This Final Program reflects the latest session schedule and room assignments.

MONDAY, APRIL 9, 2018

4:00 PM - 7:00 PM
Academy Registration Open (Agora 1)
Speaker Ready Room Open (Academy Faculty Only) (Hermes Lounge)

TUESDAY, APRIL 10, 2018

7:00 AM - 3:00 PM
Academy Registration Open (Agora 1)

7:00 AM - 7:00 PM
Speaker Ready Room Open (Hermes Lounge)
Exhibitor Registration Open (Agora 1)

7:55 AM - 5:30 PM
ISHLT ACADEMY: Core Competencies in Heart Failure and Cardiac Transplantation (Mediterranee ABC)

7:55 AM - 5:45 PM
ISHLT ACADEMY: Core Competencies in Lung Transplantation (Hermes)

8:00 AM - 5:30 PM
ISHLT ACADEMY: Core Competencies in Mechanical Circulatory Support (Athena)

8:00 AM - 1:00 PM
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Clio, Thalie)

8:00 AM - 2:00 PM
ISHLT Board of Directors Meeting (Gallieni 4)

2:00 PM - 5:00 PM
ISHLT Board/Committee/Council Leadership Orientation (Gallieni 5)

2:00 PM - 7:00 PM
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Clio, Thalie)
ISHLT ACADEMY: Master Class in Chronic Thromboembolic Pulmonary Hypertension (Erato, Uranie)

4:00 PM - 7:00 PM
Annual Meeting Registration Open (Agora 1)

5:00 PM - 6:00 PM
I2C2 Committee Meeting (Gallieni 5)
Standards & Guidelines Committee Meeting (Gallieni 7)

5:00 PM - 7:00 PM
Press Office Open (Gallieni 6)
International Thoracic Organ Transplant Registry Steering Committee Meeting (Gallieni 4)
WEDNESDAY, APRIL 11, 2018

7:00 AM - 10:00 AM
Poster Session 1 Mount (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)

7:00 AM - 7:00 PM
Annual Meeting Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)

7:15 AM - 8:15 AM
Chronic Thromboembolic Pulmonary Hypertension Scientific Council Meeting (Athena)
Basic Science and Translational Research Scientific Council Meeting (Clio/Thalie/Erato)
Nursing, Health Science and Allied Health Scientific Council Meeting (Uranie/Caliope)
Pharmacy and Pharmacology Scientific Council Meeting (Hermes)
DCD Registry Steering Committee Meeting (Gallieni 7)
IMAC Registry Committee Meeting (Gallieni 4)

7:15 AM - 8:30 AM
International Engagement Committee Meeting (Gallieni Conference Office 5)

8:00 AM - 8:30 AM
Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 7:15 PM
Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM
ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS (Apollon)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion (Athena)
(HTX, BSTR, EEP, HF, MCS, NHSAH, PATH)

ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation (Mediterranee ABC)
(LTX, BSTR, PATH)

ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned (Clio/Thalie/Erato)
(HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM)

ORAL SESSION 05: Don’t Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors (Uranie/Caliope)
(NHSAH, HF, HTX, MCS)

ORAL SESSION 06: Building a Better Transplant (Hermes)
(BSTR, HTX, MCS, PATH)

ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique (Mediterranee 6)
(CTEPH, BSTR, MCS, PH)

9:00 AM - 7:00 PM
Press Office Open (Gallieni 6)

10:00 AM - 10:30 AM
Coffee Break (Rhodes Exhibit Hall)

10:00 AM - 7:15 PM
Poster Hall Open (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)

10:30 AM - 12:30 PM
Opening Plenary Session (Apollon)
(ALL)
12:30 PM - 2:00 PM
Lunch Break
Junior Faculty Mentor Lunch Meeting (Gallieni)

12:45 PM - 1:45 PM
Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM
**SYMPOSIUM 01:** The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs (Apollon)
(MCS, HF/HTX, NHSAH, PEDS, PH, PHARM)

**SYMPOSIUM 02:** Adult Congenital Heart Disease: Reaching the Summit (Athena)
(HF/HTX, PEDS)

**SYMPOSIUM 03:** Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now? (Mediterranee ABC)
(LF/LTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM)

**SYMPOSIUM 04:** Cardio-Oncology: A Tale of Two Problems (Clio/Thalie/Erato)
(HF/HTX, MCS, NHSAH, PEDS, PHARM)

**SYMPOSIUM 05:** The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults (Uranie/Caliop)
(NHSAH, HF/HTX, LF/LTX, MCS, PEDS)

**SYMPOSIUM 06:** Novel Tools in Transplant Research (Say You Want a Revolution...) (Hermes)
(BSTR, HF/HTX, LF/LTX, PATH, PHARM)

**SYMPOSIUM 07:** The Devil is in the Details - Nuances in CTEPH (Mediterranee 6)
(CTEPH, LF/LTX, PH)

4:00 PM - 4:30 PM
Coffee Break (Rhodes Exhibit Hall)

4:30 PM - 6:00 PM
**ORAL SESSION 08:** Four Liters and Fingers Crossed: ECMO - Management and Outcomes (Apollon)
(MCS)

**ORAL SESSION 09:** The Pressure is On! Assessment and Role of Blood Pressure in MCS (Athena)
(MCS, NHSAH, PHARM, PH)

**ORAL SESSION 10:** Mechanisms of Allograft Injury after Lung Transplantation (Mediterranee ABC)
(LTX, BSTR, PATH)

**ORAL SESSION 11:** Predictable or Inevitable? Complications of Heart Transplantation (Clio/Thalie/Erato)
(HTX, BSTR, HF, NHSAH, PATH)

**ORAL SESSION 12:** The Leading Edge: Novel Practices in Patient Care Pathways (Uranie/Caliop)
(NHSAH, HF, HTX, LTX, MCS)

**ORAL SESSION 13:** Early Career Scientist Award in Transplantation (Hermes)
(BSTR, HTX, LTX, PATH)

**ORAL SESSION 14:** Reading Tea Leaves - Heart Failure Prediction Risks (Mediterranee 6)
(HF, HTX, MCS, PHARM)

6:00 PM - 7:15 PM
Exhibit Hall Opening Reception (Rhodes Exhibit Hall)
6:15 PM - 7:15 PM
MINI ORAL 01: Mechanical Circulatory Support: ECMO (Athena)
(MCS, HTX, PHARM)

MINI ORAL 02: Heart Transplantation: Outcomes (Mediterranee ABC)
(HTX, BSTR, EEP, HF, MCS, PHARM)
MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH (Clio/Thalie/Erato)
(LTX, CTEPH, HF, PH)

MINI ORAL 04: Mechanical Circulatory Support: Thrombosis (Uranie/Caliope)
(MCS, PHARM)

MINI ORAL 05: Pediatric Thoracic Transplantation (Hermes)
(PEDS, HF, HTX, ID, MCS, NHSAH, PHARM)

MINI ORAL 06: Heart Failure & Transplantation: Outcomes and Antibodies (Mediterranee 6)
(HF, BSTR, EEP, HTX, MCS, NHSAH, PATH)

COUNCIL NETWORKING RECEPTIONS:
Mechanical Circulatory Support (Muses)
Nursing, Health Science and Allied Health (Gallieni 1-2/Mykonos)
Basic Science and Translational Research (Agora 2)
Pathology (Agora 2)
Pharmacy and Pharmacology (Agora 2)
Junior Faculty and Trainee (Agora 3)

POSTER SESSION 1:
Basic Science and Translational Research (Agora 2)
(BSTR, HF, HTX, ID, LTX, MCS, PATH, PEDS, PH)

Economics, Ethics, Public Policy (Muses)
EEP, HF, HTX, LTX, MCS, NHSAH)

Junior Faculty Clinical Case Reports (Agora 3)
(ALL)

Lung Transplantation (Euterpe)
(LTX, BSTR, LTX, PHARM)

Mechanical Circulatory Support (Muses)
(MCS)

Nursing, Health Sciences, Allied Health (Gallieni 1-2)
(NHSAH, HF, HTX, LTX, MCS)

Pathology (Agora 2)
(PATH, BSTR, HTX, LTX)

Pharmacy and Pharmacology (Agora 2)
(PHARM, BSTR, HF, HTX, LTX, MCS, NHSAH)

7:15 PM - 8:00 PM
Poster Session 1 Removal (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)
THURSDAY, APRIL 12, 2018

7:00 AM - 7:00 PM
Annual Meeting Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)

7:15 AM - 8:15 AM
Mechanical Circulatory Support Scientific Council Meeting (Athena)
Pulmonary Transplantation Scientific Council Meeting (Clio/Thalie/Erato)
Pulmonary Hypertension Scientific Council Meeting (Uranie/Caliope)
Pathology Scientific Council Meeting (Hermes)
International Pediatric Heart Failure Registry Steering Committee Meeting (Gallieni 4)

8:00 AM - 8:30 AM
Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 7:15 PM
Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM
Poster Session 2 Mount (Muses Nord, Euterpe, Agora 3, Gallieni 1-2)

8:30 AM - 10:30 AM
SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support (Apollon)
(MCS, HF/HTX)

SYMPOSIUM 09: "The Heat Is On" - Great Debates in Heart Transplantation (Athena)
(HF/HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM)

SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die (Mediterranean ABC)
(HF/HTX, EEP, LTX, NHSAH, PEDS, PHARM)

SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics (Clio/Thalie/Erato)
(LF/LTX, ID, NHSAH, PATH, PHARM)

SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making (Uranie/Caliope)
(CTEPH, LF/LTX, PH)

SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team (Hermes)
(PATH, EEP, HF/HTX, LF/LTX, MCS, NHSAH, PEDS, PHARM)

SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology (Mediterranean 6)
(BSTR, HF/HTX, LF/LTX, PATH)

9:00 AM - 7:00 PM
Press Office Open (Gallieni 6)

10:30 AM - 11:00 AM
Coffee Break (Rhodes Exhibit Hall)

10:30 AM - 7:15 PM
Poster Hall Open (Muses, Euterpe, Agora 3, Gallieni 1-2)

11:00 AM - 12:30 PM
ORAL SESSION 15: The Final Frontier? Bleeding in MCS (Apollon)
(MCS, NHSAH, PHARM)

ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS (Athena)
(MCS, HF, NHSAH, PATH)
SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation (Mediterranee ABC)  
(HF/HTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM)

ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses (Clio/Thalie/Erato)  
(ID, HTX, LTX, MCS, PHARM,)

SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule (Uranie/Caliopoe)  
(ALL)

ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection (Hermes)  
(PATH, BSTR, HTX, LTX)

ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science (Mediterranee 6)  
(BSTR, LTX, PATH)

12:30 PM - 2:00 PM  
Lunch Break  
JHLT Editorial Board Lunch Meeting (Gallieni 5)

12:45 PM - 1:45 PM  
Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM  
SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished (Apollon)  
(MCS, HF/HTX, ID, NHSAH, PHARM)

SYMPOSIUM 18: It's Electric! Electrophysiologic Management of the LVAD Patient (Athena)  
(MCS, HF/HTX, NHSAH, PEDS)

SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation - 2018 (Mediterranee ABC)  
(LF/LTX, BSTR, PATH, PEDS)

SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late? (Hermes)  
(PHARM, BSTR, HF/HTX, ID, LF/LTX, NHSAH, PATH, PEDS)

SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy (Uranie/Caliopoe)  
(PH, HF/HTX, LF/LTX, MCS, PEDS, PHARM)

SYMPOSIUM 22: Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape  
(Clio/Thalie/Erato)  
(ID, BSTR, HF/HTX, LF/LTX, NHSAH, PATH, PEDS, PHARM)

SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation (Mediterranee 6)  
(PEDS, ID, LF/LTX)

4:00 PM - 4:30 PM  
Coffee Break (Rhodes Exhibit Hall)  
2019 Symposium Planning Committee Meeting (Gallieni 5)

4:30 PM - 6:00 PM  
ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS (Apollon)  
(MCS, NHSAH, PEDS)

ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD (Athena)  
(MCS, NHSAH, PH)
ORAL SESSION 22: Trials and Treatments in Lung Transplantation (Mediterrane ABC)  
(LTX, PHARM)

ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant (Clio/Thalie/Erato)  
(PHARM, HTX, ID, LTX, NHSAH)

ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population  
(Uranie/Caliope)  
(HTX, BSTR, EEP, HF, MCS, NHSAH, PATH, PEDS)

ORAL SESSION 25: Philip K. Caves Award Candidate Presentations (Hermes)  
(BSTR, HTX, LTX, PATH)

ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes  
(Mediterrane 6)  
(PEDS, EEP, HTX, LTX, NHSAH)

6:00 PM - 7:00 PM  
Past President’s Meeting (Gallieni 4)

6:00 PM - 7:15 PM  
Wine and Cheese Reception (Rhodes Exhibit Hall)

6:15 PM - 7:00 PM  
MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques (Athena)  
(MCS, NHSAH)

MINI ORAL 08: Heart Transplantation: PGD and CAV (Mediterrane ABC)  
(HTX, BSTR, EEP, HF, NHSAH, PATH)

MINI ORAL 09: Lung Transplantation: Allograft Function (Clio/Thalie/Erato)  
(LTX, PATH)

MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology (Uranie/Caliope)  
(PHARM, BSTR, HTX, LTX, MCS, PEDS)

MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics (Hermes)  
(NHSAH, HF, HTX, LTX, MCS, PEDS)

MINI ORAL 12: Basic Science & Translational Research (Mediterrane 350)  
(BSTR, HTX, LTX, MCS, PATH)

COUNCIL NETWORKING RECEPTIONS:  
Heart Failure and Transplantation (Muses)  
Infectious Diseases (Gallieni 1-2/Mykonos)  
Pediatric Thoracic Transplantation and Heart Failure (Agora 3)

POSTER SESSION 2:  
Heart Failure (Muses)  
(HF, HTX, MCS, PHARM, PH)

Heart Transplantation (Muses)  
(HTX, BSTR, EEP, HF, ID, MCS, NHSAH, PATH, PHARM, PH)

Infectious Diseases (Gallieni 1-2)  
(ID, HTX, LTX, MCS, PEDS)

Junior Faculty Clinical Case Reports (Agora 3)  
(ALL)
Mechanical Circulatory Support (Euterpe)
(MCS)

Pediatric Transplantation (Agora 3)
(PEDS, HF, HTX, ID, LTX, MCS, PHARM)

7:00 PM - 8:00 PM
Poster Session 2 Removal (Muses, Euterpe, Agora 3, Gallieni 1-2)

FRIDAY, APRIL 13, 2018

7:00 AM - 7:00 PM
Annual Meeting Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)

7:15 AM - 8:15 AM
Heart Failure and Transplantation Scientific Council Meeting (Clio/Thalie/Erato)
Junior Faculty and Trainee Scientific Council Meeting (Uranie/Caliope)
Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting (Hermes)
Infectious Diseases Scientific Council Meeting (Gallieni 7)
Grants and Awards Committee Meeting (Gallieni Conference Office 5)

8:00 AM - 8:30 AM
Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 6:30 PM
Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM
ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs (Apollon)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support (Athena)
(MCS, BSTR, HF, NHSAH, PHARM)

ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status (Mediterranee ABC)
(LTX, EEP)

ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support (Clio/Thalie/Erato)
(ID, HTX, MCS)

ORAL SESSION 31: Spotlight on a Heart Transplant Donor (Uranie/Caliope)
(HTX)

ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best
(Hermes)
(ALL)

SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself? (Mediterranee 6)
(PEDS, EEP, HF/HTX, LF/LTX, MCS, NHSAH, PHARM)

Poster Session 3 Mount (Muses, Euterpe, Agora 3, Gallieni 1-2)

9:00 AM - 7:00 PM
Press Office Open (Gallieni 6)

10:00 AM - 10:30 AM
Coffee Break (Rhodes Exhibit Hall)
Annual Business Meeting (Apollon)
10:30 AM - 7:15 PM
Poster Hall Open (Muses Nord, Euterpe, Agora 3, Gallieni 1-2)

10:30 AM - 12:30 PM
Plenary Session: Moving Cardiothoracic Transplantation Forward (Apollon)
(ALL)

12:30 PM - 2:00 PM
Lunch Break

12:45 PM - 1:45 PM
Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM
SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS (Apollon)
(MCS, HF/HTX, NHSAH, PEDS, PHARM)

SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure (Athena)
(LF/LTX, BSTR, ID, NHSAH, PEDS, PHARM)

SYMPOSIUM 27: DCD Lungs- Expanding Utilization (Mediterranee ABC)
(LF/LTX, NHSAH)

SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant (Clio/Thalie/Erato)
(HF/HTX, MCS, PHARM, PH)

SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT (Uranie/Caliope)
(PH, BSTR, HF/HTX, NHSAH, PATH, PEDS, PHARM)

SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads (Hermes)
(ID, EEP, HF/HTX, LF/LTX, NHSAH, PEDS, PHARM)

SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction (Mediterranee 6)
(PEDS, HF/HTX, MCS)

4:00 PM - 4:30 PM
Coffee Break (Rhodes Exhibit Hall)

4:30 PM - 6:00 PM
ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS (Apollon)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure (Athena)
(MCS)

ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP (Mediterranee ABC)
(LTX)

ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies (Clio/Thalie/Erato)
(HTX, BSTR, EEP, HF, NHSAH, PATH)

ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension (Uranie/Caliope)
(PH, HF, MCS, PHARM)
ORAL SESSION 38: Hot Topics in Infectious Diseases (Hermes)
(ID, HTX, LTX, MCS)

ORAL SESSION 39: All Is Not Lost: Improving Outcomes in Children with a Failing Heart (Mediterranee 6)
(PEDS, HF, HTX, MCS, NHSAH)

6:00 PM - 6:30 PM
Wine and Cheese Reception (Rhodes Exhibit Hall)

6:15 PM - 7:15 PM
MINI ORAL 13: Mechanical Circulatory Support: Bleeding (Athena)
(MCS, PHARM)

MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection (Clio/Thalie/Erato)
(LTX)

MINI ORAL 15: Heart Transplantation: Donor Issues (Uranie/Caliope)
(HTX, BSTR, EEP, NHSAH, PATH)

MINI ORAL 16: Basic Science and Infectious Disease Issues (Hermes)
(ID, BSTR, HTX, LTX, MCS)

COUNCIL NETWORKING RECEPTIONS:
Pulmonary Hypertension (Gallieni 1-2/Mykonos)
Chronic Thromboembolic Pulmonary Hypertension (Gallieni 1-2/Mykonos)
Pulmonary Transplantation (Euterpe)

POSTER SESSION 3:
Heart Transplantation (Muses Foyer/Corridor)
(HTX)

Lung Transplantation (Euterpe)
(LTX)

Mechanical Circulatory Support (Agora 3)
(MCS)

Pulmonary Hypertension and CTEPH (Gallieni 1-2)
(PH, BSTR, CTEPH, HF, LTX, MCS, NHSAH, PATH, PHARM)

7:00 PM - 8:00 PM
Poster Session 3 Removal (Muses, Euterpe, Agora 3, Gallieni 1-2)

8:00 PM - 9:30 PM
ISHLT President’s Cocktail Reception (Le Negresco Palace)

SATURDAY, APRIL 14, 2018

7:30 AM - 12:15 PM
Annual Meeting Registration Open (Agora 1)

7:30 AM - 2:00 PM
Speaker Ready Room Open (Hermes Lounge)

8:00 AM - 8:15 AM
Morning Coffee (Hermes Foyer/Mykonos Lounge)
8:15 AM - 9:45 AM
ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS (Athena)
(MCS, HTX)

ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation (Mediterranee ABC)
(HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM)

ORAL SESSION 42: Lung Allocation: New Rules and Old Age (Clio/Thalie/Erato)
(LTX, EEP)

ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure
(Uranie/Caliope)
(HF, BSTR, HTX, MCS, PHARM)

ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money (Hermes)
(EEP, HF, HTX, LTX, MCS, NHSAH)

ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant (Mediterranee 6)
(PEDS, HTX, NHSAH, PHARM)

9:45 AM - 10:00 AM
Coffee Break (Hermes Foyer/Mykonos Lounge)

10:00 AM - 12:00 PM
Plenary Session (Athena)
(ALL)

12:00 PM - 12:15 PM
Coffee Break (Hermes Foyer/Mykonos Lounge)

12:15 PM - 1:45 PM
ORAL SESSION 46: Flight Plan: Planning the LVAD Implant (Athena)
(MCS, NHSAH, PHARM, PH)

ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation (Mediterranee ABC)
(HTX, BSTR, EEP, HF, MCS, NHSAH, PATH)

ORAL SESSION 48: Procedures and Standards in Lung Transplantation (Clio/Thalie/Erato)
(LTX, BSTR, PATH)

ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation (Uranie/Caliope)
(HF, HTX, PHARM)

ORAL SESSION 50: What is Really Going On in The Lung Transplant (Hermes)
(BSTR, LTX, PATH)

ORAL SESSION 51: I’m at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension (Mediterranee 6)
(PH, HF)

2:00 PM - 7:30 PM
ISHLT Board of Directors Meeting (Gallieni 1-2)
WEDNESDAY, APRIL 11, 2018

8:30 AM - 10:00 AM
ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS

Location: Apollon
Target Audience: MCS, HF, NHSAH, PHARM

Chairs: Andre R Simon, MD, PhD, and Sangjin Lee, MD

8:30 AM (1) **Blood Pressure Management Ameliorates the Severity of Neurological Events;** J. J. Teuteberg¹, J. G. Rogers², C. A. Milano², M. S. Kiernan³, G. S. Couper⁴, S. W. Boyce⁴, C. Mahr⁵, N. A. Mokadam⁶, T. A. Vassiliades⁷, F. D. Pagani⁷. ¹Stanford University, Stanford, CA, ²Duke University, Durham, NC, ³Tufts Medical Center, Boston, MA, ⁴Medstar Health, Washington, DC, ⁵University of Washington, Seattle, WA, ⁶Medtronic, Framingham, MA, ⁷University of Michigan, Ann Arbor, MI

8:45 AM (2) **Quantifying the Devastation From Stroke During Support With Continuous Flow Pumps: An Intermacs Analysis;** J. K. Kirklin¹, D. C. Naftel¹, S. L. Myers¹, F. D. Pagani², L. W. Stevenson³, R. L. Kormos⁴, P. C. Colombo⁵. ¹Kirklin Institute for Research in Surgical Outcomes (KIRSO), University of Alabama at Birmingham, Birmingham, AL, ²University of Michigan, Ann Arbor, MI, ³Vanderbilt University, Nashville, TN, ⁴University of Pittsburgh Medical Center, Heart and Vascular Institute, Pittsburgh, PA, ⁵Columbia University Medical Center, New York, NY

9:00 AM (3) **Neurocognitive Deficits are Prevalent in Ambulatory Patients Living with Left Ventricular Assist Devices;** M. R. Robinson¹, H. Khalid¹, L. Meece¹, S. Al-Kindi¹, M. Zacharias¹, C. El Amm¹, M. Ginwalla¹, M. Moghbelli¹, R. Benatti¹, G. H. Oliveira¹. ¹Cardiology, University Hospitals Cleveland Medical Center, Cleveland, OH

9:15 AM (4) **Risk of Thromboembolic Events Among Heart Transplant Recipients Bridged with Durable Mechanical Circulatory Support Devices Receiving Anticoagulation Reversal Agents at Time of Transplant;** J. D. Moretz¹, J. Lindenfeld¹, A. S. Shah², M. A. Wigger¹, K. H. Schンドr1, M. E. Keebler¹, M. R. Danter², S. B. Sacks¹, H. Ooi¹, D. M. Brinkley¹, S. K. Zalawadiya¹. ¹Advanced Heart Failure and Transplant, Vanderbilt University Medical Center, Nashville, TN, ²Dept of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN

9:30 AM (5) **Development of New Algorithms for Early Detection of Pump Thrombosis by Analysis of HeartWare LVAD Log Files;** N. Reiss¹, F. Mueller-von Aschwege², T. Schmidt¹, C. Feldmann², J. Schmitto², A. Hein², J. Glitza². ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²OFFIS Institute, Oldenburg, Germany, ³Hannover Medical School, Hannover, Germany

9:45 AM (6) **Stroke After LVAD: Does Age Matter? A Sex-based Analysis;** V. Blumer¹, G. A. Hernandez², M. Ortiz³, V. Mehta¹, S. Chaparro¹. ¹University of Miami, Miami, FL, ²Vanderbilt University, Nashville, TN, ³Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of
8:30 AM - 10:00 AM
ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion

Location: Athena
Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAH, PATH

Chairs: Stephen R. Large, MB MA MS F, and Kumud K Dhital, BM.BCh, FRCS-CTh, FRACS, PhD

8:30 AM (7) Non Ischemic Heart Preservation; J. Nilsson, V. Jernryd, G. Qin, S. Nozohoor, D. C. Goncalves, S. Ragnarsson, A. Paskevicus, M. Johansson, J. Warheim, P. Höglund, T. Sjöberg, S. Steen. 1Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane University Hospital, Lund, Sweden, 2Clinical Sciences Lund, Anesthesiology, Lund University, Skane University Hospital, Lund, Sweden, 3Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund University, Skane University Hospital, Lund, Sweden


9:30 AM (11) Prolonged Donation Withdrawal Ischaemic Time (DWIT) Does Not Impact on DCD Heart Transplant Outcomes; S. Messer, A. Page, M. Berman, S. Tsui, S. Large. Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom

8:30 AM - 10:00 AM
ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation

Location: Mediterranea ABC
Target Audience: LTX, BSTR, PATH

Chairs: Amparo Sole, MD, PhD, and Christophe Pison, MD, PhD

8:30 AM (13) **Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?**; S. Agbor-Enoh1, A. Cochrane2, A. Jackson3, I. Tunc4, P. Shah5, Z. Cao6, A. Brown7, I. Timofte8, A. Marishta9, M. Jang10, S. Gorham11, Y. Yang12, U. Fidel13, A. Iacono14, S. Nathan15, J. Orens16, H. Valantine17. 1Nat'l Inst. of Health, Bethesda, MD, 2Pharmacy Dept, Inova FairFax Hospital, Falls Church, VA, 3Immunogenetic Laboratory, Johns Hopkins Hospital, Baltimore, MD, 4Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, 5Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, 6Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, 7Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, 8Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, 9Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, 10Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD

8:45 AM (14) **Risk Factors for the Development of Donor-specific Antibodies and Their Impact on Outcomes After Lung Transplantation**; K. Tsui1, P. Aguilar1, D. Byers1, R. Yusen1, Y. Furuya1, L. Tague1, A. Gelman2, V. Puri2, D. Kreisel2, E. Trulock1, R. Hachem1. 1Pulmonary/Critical Care, Washington University, St Louis, MO, 2Cardiothoracic Surgery, Washington University, St Louis, MO

9:00 AM (15) **Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?**; S. Agbor-Enoh1, A. Jackson2, G. Berry3, A. Cochrane4, I. Tunc5, M. Jang1, K. Bhatti1, A. Marishta5, S. Gorham1, Y. Yang1, U. Fidel1, J. Zhu1, M. Pirooznia8, D. Grimm9, H. Luikart10, P. Shah1, I. Timofte8, A. Iacono8, Z. Cao8, A. W. Brown10, P. Shah11, J. Orens7, C. Marboe12, S. Nathan10, K. Khush9, H. Valantine1. 1Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, 2Immunogenetic Laboratory, Johns Hopkins Hospital, Baltimore, MD, 3Dept of Pathology, Stanford University School of Medicine, Palo Alto, CA, 4Pharmacy Dept, Inova FairFax Hospital, Falls Church, VA, 5Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, 6Division of Cardiology, Stanford School of Medicine, Palo Alto, CA, 7Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, 8Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, 9Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Bethesda, MD, 10Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, 11Division of Cardiology, Inova Fairfax Hospital, Falls Church, VA, 12Dept of Pathology, New York Presbyterian Hospital, New York, NY

9:15 AM (16) **Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an Early Risk Factor for the Development and Persistence of De Novo Donor Specific HLA Antibody**; A. M. Jackson1, A. B. Cochrane2, S. Nathan3, A. W. Brown2, P. Shah1, J. Orens1, A. Iacono4, I. Timofte4, S. Agbor-Enoh5, H. Valantine6. 1Medicine, Johns Hopkins University, Baltimore, MD, 2Medicine, Inova Fairfax Hospital, Fairfax, VA, 3Medicine, Inova Fairfax Hospital, Fairfax, MD, 4Medicine, University of Maryland Medical Center, Baltimore, MD, 5Medicine, National Heart, Lung and Blood Institute, Baltimore, MD, 6Medicine, National Heart, Lung and Blood Institute, Baltimore, VA

9:30 AM (17) **Important HLA and Non-HLA Pre-Transplant Determinantes Associated with the Development of De Novo Donor Specific Antibody After Lung Transplantation**; A. Zhang1, R. Pei2, D. Thomas1, Y. Sun3, M. Budev4. 1Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, 2R&D Dept, Thermo Fisher Scientific, Woodland Hills, CA, 3Avalon Medical University, Curaçao, Netherlands Antilles, 4Pulmonary Medicine, Cleveland Clinic, Cleveland, OH

9:45 AM (18) **Feasibility of Avoiding Higher Risk Epitope and Allele HLA Mismatch to Reduce de novo Donor Specific Antibody (dnDSA) in Lung Transplantation**; R. Zamel1, J. McCaughan2, A. Hirji3, M. Cypel4, L. G. Singer4, S. Keshavjee4, K. Tinkam2, J. Tikkkanen4. 1Latner Thoracic Research Laboratories, University Health Network, Toronto, ON, Canada, 2Dept of Medicine - Nephrology, University Health Network, Toronto, ON, Canada, 3Respirology, University of Alberta, Edmonton, AB, Canada, 4Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
8:30 AM - 10:00 AM
ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned

**Location:** Clio/Thalie/Erato  
**Target Audience:** HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM  
**Chairs:** Jon A Kobashigawa, MD, and Sanjeet Singh Avtaar Singh, MRCS, MSc

8:30 AM (19) *Multicenter Study to Determine Up to 5 Year Clinical Outcome of Heart Transplant Recipient Receiving Rituximab Versus Placebo Outcomes in Subjects Previously Randomized in the CTOT-11 Study;* R. C. Starling1, B. Armstrong2, Y. R. Morrison3, M. H. Sayegh4, A. Chandraker5. 1Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 2Rho Federal Systems Division, Rho Federal Systems Division, Chapel Hill, NC, 3Transplantation Branch, NIH, Rockville, MD, 4Internal Medicine, American University of Beirut, Beirut, Lebanon, 5Nephrology, Brigham and Womens Hospital, Boston, MA

8:30 AM (20) *Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance (Schedule): Results After 6 Years of Follow-up;* A. K. Andreassen. Oslo University Hospital, Oslo, Norway

9:00 AM (21) *TICTAC 10: Ten Year Follow-up of the Tacrolimus in Combination Tacrolimus Alone Compared Trial;* D. A. Baran1, S. Kapoor2, S. Vijaykumar2, C. Gidea2, M. Camacho2, M. J. Zucker2. 1Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, 2Newark Beth Israel Medical Center, Newark, NJ

9:15 AM (22) *Clinical Outcomes Associated With mTORi Initiation in Adult Heart Transplant: An ISHLT Registry Analysis;* J. G. Duero Posada1, Y. Moayedi2, M. Alhussein1, S. Bhagra3, S. Fan4, C. Manlhiot5, J. Stehlik6, A. I. Dipchand4, H. J. Ross5. 1Cardiology, University Health Network, Toronto, ON, Canada, 2Cardiology, Stanford University, Palo Alto, CA, 3Cardiothoracic Transplantation, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom, 4Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, 5Cardiology, Ted Rogers Centre for Heart Research, Toronto, ON, Canada, 6Cardiology, University of Utah School of Medicine, Salt Lake City, UT

9:30 AM (23) *Quantiferon Monitor Assay Identifies Over-Immunosuppressed Patients with Adverse Outcomes After Heart Transplantation: Towards the Definition of a Phenotype of Immune Frailty;* L. Potena1, A. Gaudenzi1, A. Chiereghin2, L. Borgese1, A. Brighenti1, G. Piccirilli2, M. Masetti1, L. Giovannini1, S. Boschi1, T. Lazzarotto2, F. Grigioni1. 1Cardiology, University of Bologna, Bologna, Italy, 2Microbiology, University of Bologna, Bologna, Italy

8:30 AM - 10:00 AM
ORAL SESSION 05: Don't Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors

Location: Uranie/Calliope
Target Audience: NHSAH, HF, HTX, MCS
Chairs: Annemarie Kaan, MCN, RN, and Christiane Kugler, PhD

8:30 AM (25) Variability in Depressive Symptoms and Its Multilevel Correlates in Heart Transplant Recipients: Results From the International Cross-sectional BRIGHT Study; N. Duerinckx1, S. De Geest2, K. Denhaerynckx2, L. Berben2, J. Vanhaecke3, C. Russell4, R. Helmy2, M. Crespo-Leiro5, F. Dobbels5. 1KU Leuven, UZ Leuven, Leuven, Belgium, 2University of Basel, Basel, Switzerland, 3University Hospitals of Leuven, Leuven, Belgium, 4University of Missouri, Kansas City, MO, 5Hospital Universitario A Coruña, Coruña, Spain

8:45 AM (26) Pre-transplant Distress and Risk of Early Death in UK Cardiothoracic Transplant Recipients; Z. G. Malpus, A. Diallo, Z. Lawrence, E. Karimi, R. Venkateswaran, M. AlAloul. Cardiothoracic Transplant Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom

9:00 AM (27) Psychosocial Assessment for LVAD Candidates: A National Survey; M. J. Clancy1, A. B. Jessop1, H. J. Eisen2. 1Mayes College of Health Policy, University of the Sciences, Philadelphia, PA, 2Division of Cardiology, Drexel University, Philadelphia, PA

9:15 AM (28) Psychosocial Risk in LVAD Candidates: Preliminary Evaluation of Validity and Reliability of mPACT; M. C. Maltby1, M. P. Flattery1, J. Salyer2, S. R. Weinland1, K. B. Shah1. 1Pauley Heart Center, VCU Health System, Richmond, VA, 2Adult Health & Nursing Systems, VCU School of Nursing, Richmond, VA

9:30 AM (29) Predictors of Posttraumatic Growth Post Lung Transplant; S. Airdrie1, L. Stopa1, A. Reed2, M. Sanchez3. 1Psychology, University of Southampton, Southampton, United Kingdom, 2Faculty of Medicine, National Heart Lung Institute, Imperial College, London, United Kingdom, 3Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

9:45 AM (30) PTSD Following Heart and Lung Transplant: Outcome of Those Receiving Trauma-Focused Cognitive Behavioral Therapy; L. Painter, I. S. Fontanilla. Transplant Psychology, Auckland City Hospital, Auckland, New Zealand
8:30 AM - 10:00 AM
ORAL SESSION 06: Building a Better Transplant

Location: Hermes
Target Audience: BSTR, HTX, MCS, PATH

Chairs: Kyung-Hee Kim, and Tobias Deuse, MD, PhD

8:30 AM (31) Mitochondrial Transplantation Prolongs Cold Preservation Time in Murine Cardiac Transplantation; K. Moskowitzova1, K. Liu2, B. Shin1, G. F. Ramirez-Barbieri1, A. Guariento1, D. Blitzer1, D. B. Cowan3, J. K. Thedsanamooorthy3, R. Yao3, A. Orfany1, G. Visner2, P. J. del Nido1, J. D. McCully1. 1Cardiac Surgery, Boston Children’s Hospital and Harvard Medical School, Boston, MA, 2Pulmonary and Respiratory diseases, Boston Children’s Hospital and Harvard Medical School, Boston, MA, 3Anesthesiology, Boston Children’s Hospital and Harvard Medical School, Boston, MA


9:00 AM (33) Knockout of the M33 Receptor Gene in Murine Cytomegalovirus is Associated With Decreased Levels of Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model; C. Heim1, N. Fritz1, T. Stamminger2, A. Gocht1, M. Ramsperger-Gleixner1, S. M. Ensminger3, M. Weyand1. 1Dept of Cardiac Surgery, University of Erlangen, Erlangen, Germany, 2Dept of Virology, University of Erlangen, Erlangen, Germany, 3Dept of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany


9:30 AM (36) Pre-Transplant Serum Exosome Proteomics Differentiates Right and Left Ventricular Primary Graft Dysfunction; B. Fine1, E. Chen2, G. Lebreton3, S. Restaino4, J. Taupin4, E. Zorn5, M. Farr1, P. C. Colombo1, P. Leprince6. 1Cardiology, Columbia University, New York, NY, 2Proteomics, Columbia University, New York, NY, 3Thoracic And Cardiovascular Surgery, Pitie-Salpeïtre University Hospital, Paris, France, 4Immunology, Hôpital Saint-Louis, Paris, France, 5Immunology, Columbia University, New York, NY

9:45 AM (220) Variable Cell-free DNA Characteristics With Different Acute Rejection Phenotypes; S. Agbor-Enoh1, i. Tunc2, M. Jang1, S. Gorhan1, A. Marishta1, U. Fideli1, Y. Yang1, K. Bhatti1, H. Luikart3, M. Pirooznia2, J. Zhu2, K. Khush3, H. Valantine1. 1Laboratory of Transplant Genomics, Nat’l Inst. of Health, Bethesda, MD, 2Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat’l Inst. of Health, Bethesda, MD, 3Division of Cardiology, Stanford University School of Medicine, Palo Alto, CA
8:30 AM - 10:00 AM
ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique

Location: Mediterranee 6
Target Audience: CTEPH, BSTR, MCS, PH
Chairs: Robert J. Moraca, MD, and David P. Jenkins, FRCS

8:30 AM (37) Pre-PTE Pulmonary Artery Elastance, Right Ventricular Elastance, and RV-PA Coupling Predict Post-Operative Length of Stay and Hemodynamics; F. Contijoch¹, D. Wong², S. Igata², A. McDivit Mizzell², W. Auger², A. DeMaria², D. Blanchard², A. Waheed³, T. Bachman³, M. Simon³, M. Pinsky⁴. ¹Bioengineering, UC San Diego, La Jolla, CA, ²Medicine, UC San Diego, La Jolla, CA, ³Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

8:45 AM (38) Metabolomics Analysis in Chronic Thromboembolic Pulmonary Hypertension; G. A. Heresi¹, I. Haddadin², J. R. Bartholomew³, M. Gomes³, R. Renapurkar², N. G. Smedira⁴, R. A. Dweik¹. ¹Respiratory Institute, Cleveland Clinic, Cleveland, OH, ²Imaging Institute, Cleveland Clinic, Cleveland, OH, ³Vascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH

9:00 AM (39) A Comparison of Short Term Outcomes of Minimally Invasive versus Sternotomy Pulmonary Thromboendarterectomy; J. R. Higgins¹, N. H. Kim², K. Kerr², T. Fernandez², D. Poch², M. Madani¹. ¹Cardiothoracic Surgery, UCSD Medical Center, La Jolla, CA, ²Pulmonary Medicine, UCSD Medical Center, La Jolla, CA

9:15 AM (40) Impact on Outcomes with Extra-Corporeal Life Support (ECLS) After Complicated Pulmonary Thrombo-Endarterectomy; H. Nair. Anesthesiology, Narayana Institute of Cardiac Sciences, Bangalore, India

9:30 AM (41) Pulmonary Endarterectomy: Relationship Between Total Reopened Branches and Outcomes; M. Pin, B. Vanini, A. Sciortino, V. Grazioi, V. Merli, A. Celentano, I. Parisi, C. Klersy, G. Silvaggio, C. Monterosso, M. Salati, C. Pellegrini, B. Cattadori, A. D'Armini. Policlinico San Matteo, Policlinico San Matteo, Pavia, Italy

9:45 AM (42) The Incidence and Identification of Chronic Thromboembolic Disease in Patients Presenting with Acute Pulmonary Embolism; L. DiChiacchio, C. Pasrija, F. Boulos, J. Jeudy, Z. Kon. University of Maryland Medical Center, Baltimore, MD
10:30 AM - 12:30 PM
PLENARY 1: Opening Plenary Session

Location: Apollon
Target Audience: ALL

Chairs: Christian Benden, MD, FCCP, and Andrew J Fisher, PhD, FRCP

10:30 AM Welcome/Program Chair Report
Christian Benden, MD, FCCP, University Hospital Zurich, Zurich, Switzerland

10:40 AM Thoracic Registry Report
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

10:55 AM MCSD Registry Reports
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

11:05 AM JHLT Editor's Report
Mandeep R Mehra, MD, MBBS, FACC, FACP, Brigham and Women's Hospital, Boston, MA, USA

11:15 AM Presidential Address
Andrew J Fisher, PhD FRCP, Newcastle University, Newcastle Upon Tyne, United Kingdom

11:30 AM Molecular Diagnosis of Rejection Phenotypes in 889 Heart Transplant Biopsies: The INTERHEART Study
1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, 4Cedars-Sinai Heart Institute, Beverly Hills, CA, 5University of Bologna, Bologna, Italy, 6Ronald Reagan UCLA Medical Center, Los Angeles, CA, 7Hôpital Européen Georges Pompidou, Paris, France, 8Hôpital Necker, Paris, France, 9The Victor Chang Cardiac Research Institute, Sydney, Australia, 10Medical University of Vienna, Vienna, Austria

11:45 AM Interactive Discussant for Presentation 43
Lori J West, MD, D.Phil, University of Alberta, Edmonton, AB, Canada

12:05 PM Interactive Discussant for Presentation 44
Roger D. Yusen, MD, MPH, Washington Univ Sch Med, St. Louis, MO, USA

12:10 PM Lifetime Achievement Award Laudation
Robert L Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

12:25 PM Lifetime Achievement Award Acceptance
O. Howard Frazier, MD, Texas Heart Institute, Houston, TX, USA
2:00 PM - 4:00 PM
SYMPOSIUM 01: The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs

Location: Apollon
Target Audience: MCS, HF/HTX, NHSAH, PEDS, PH, PHARM
Chairs: Sanem Nalbantgil, MD, and Francis D Pagani, MD, PhD

Session Summary: The rise of MCS has brought a lot of attention to the usually “forgotten” RV. This close scrutiny is driven by lack of options for durable RVAD support and worse outcome associated with RV failure. As MCS technology advances and complications decline, less sick patients will be offered therapy. The following question arises: Should we shift our focus from LV-centric approach to RV-centric one, pulling surgical trigger early on, to prevent major short and long-term consequences for our patients? A panel discussion with all speakers will conclude this session.

2:00 PM Pathogenesis of RV Failure Due to Left Heart Disease
Ryan Tedford, MD, FACC, FAHA, Medical University of South Carolina, Charleston, SC, USA

2:12 PM The Importance of Exercise Physiology in the Assessment of RV Function in Heart Failure Patients
Marco Guazzi, MD, University of Milano, Milano, Italy

2:24 PM Defining Biventricular Failure: What is the Best Modality?
Maria G Crespo-Leiro, MD, Hospital Univ A Coruna, La Coruna, Spain

2:36 PM Systemic Venous Congestion From RV Failure as a Fundamental Stimulus for Dysfunction and Damage of Vital Organs
Paolo C Colombo, MD, Columbia University, New York, NY, USA

2:48 PM Non-Surgical Treatment of RV Failure Post LVAD
Sandra Eifert, MD, LMU University clinic Munich, Dept. of cardiac surgery  Germany, Munich, Germany

3:00 PM CASE PRESENTATION: Unexpected RV Failure with Persistent Pulmonary Hypertension Following LVAD: What Now?
Steven Hsu, MD, Johns Hopkins University, Baltimore, MD, USA

3:05 PM Drug Therapies for Pulmonary Hypertension are Needed to Target the Right Ventricle
Marc A Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

3:17 PM Surgical Treatment of RV Failure Post LVAD
Francis D Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

3:29 PM Pulsatile BiVAD: Reality or Fantasy?
Arjang Ruhparwar, MD, PhD, University of Heidelberg, Heidelberg, Germany

3:41 PM Panel Discussion
2:00 PM - 4:00 PM
SYMPOSIUM 02: Adult Congenital Heart Disease: Reaching the Summit

Location: Athena
Target Audience: HF/HTX, PEDS

Chairs: Michael Burch, MD, and Monica M Colvin, MD

Session Summary: The aim of this session is to discuss assessment, management and outcome of ACHD patients from the time of referral for cardiac transplantation, as opposed to the well described time points of listing and transplant. Speakers will describe the population and address specific considerations required when managing these patients particularly those which are different from acquired heart disease. Options for those not suitable for transplant and alternatives to transplant will also be discussed.

2:00 PM Transplant Assessment of Adult Congenital Heart Disease Patients: Who, When and By Whom
David S Crossland, MRCPCH, Freeman Hospital, Newcastle upon Tyne, United Kingdom

2:20 PM Q&A

2:24 PM Presentation and Management of Cardiogenic Shock in the Single Ventricle
Joseph W. Rossano, MD, The Children's Hospital, Philadelphia, PA, USA

2:44 PM Q&A

2:48 PM Pain for How Much Gain? Non-transplant Strategies and Bridging to Candidacy in Adult Congenital Heart Disease Patients
Lucy S Roche, MD, University of Toronto, Toronto, ON, Canada

3:08 PM Q&A

3:12 PM The Liver, the Kidneys and Everything Else! Assessing Non-Thoracic Organs for Suitability for Heart Transplant
Stephan Schubert, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

3:32 PM Q&A

3:36 PM Planning the Plumbing: Anatomical Limitations and How to Address Them
Antonio Amodeo, MD, Pediatric Hospital Bambino Gesù, Rome, Italy

3:56 PM Q&A
2:00 PM - 4:00 PM
SYMPOSIUM 03: Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now?

Location: Mediterranee ABC
Target Audience: LF/LTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM
Chairs: Cynthia J Gries, MD, MSc, and Are Martin Holm, MD, PhD

Session Summary: The pathogenesis of CLAD involves both alloimmune and non-alloimmune pathways. This multi-council forum will present up-to-date knowledge about the pathobiology of CLAD phenotypes including new paradigms of pathophysiology, host-pathogen interactions, the impact of lung microbiome and pulmonary infections upon innate immunity and their impact on CLAD development, diagnosis using more sensitive pulmonary function parameters, radiographic and pathological correlates, and therapeutic strategies.

2:00 PM Is It CLAD or Is It Something Else: Why Does Lung Function Decline After Transplant?
Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

2:15 PM Q&A

2:20 PM Non-Infectious Risk Factors for CLAD
Adrian C Lawrence, MD, MACM, University of Minnesota, Minneapolis, MN, USA

2:35 PM Q&A

2:40 PM Biomarkers for CLAD: Are Cellular and Molecular Analyses Useful for the Clinician?
Johanna Kwakkel-van Erp, MD, PhD, University Medical Center, Utrecht, Netherlands

2:55 PM Q&A

3:00 PM The Impact of the Lung Microbiome and Pulmonary Infections Upon the Development of CLAD
Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom

3:15 PM Q&A

3:20 PM Subtypes of CLAD: Where Are We Now?
Jamie L Todd, MD, Duke University Medical Center, Durham, NC, USA

3:35 PM Q&A

3:40 PM Treatment Options in CLAD: A Story of Hope or Evidence?
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

3:55 PM Q&A
2:00 PM - 4:00 PM
SYMPOSIUM 04: Cardio-Oncology: A Tale of Two Problems

Location: Clio/Thalie/Erato
Target Audience: HF/HTX, MCS, NHSAH, PEDS, PHARM

Chairs: Jennifer N. Gray, PharmD, and Sofia C Masri, MD

Session Summary: This session will focus on cardiac risk in cancer patients, including: (1) Risks of the newer agents (including fulminant myocarditis with checkpoint inhibitors), (2) Balancing risk of cardiac complications when treating cancer, (3) Use of temporary and durable MCS in setting of increased risk of infection and bleeding, (4) Timing of heart transplant and post-transplant outcomes in cancer, and (5) Role of heart transplant in AL (light chain) amyloid.

2:00 PM Cardio Toxicity in Cancer: The Frontier Beyond Anthracyclines
Douglas L. Jennings, PharmD, Columbia University Medical Center, New York, NY, USA

2:20 PM Treating Heart Failure in Cancer Patients: How Do We Balance Cardio Toxicity with Cancer Risk?
Guilherme H Oliveira, MD, University Hospitals Case Medical Center, Cleveland, OH, USA

2:40 PM Medical and Mechanical Heart Failure Therapies in Cancer Therapeutics Related Cardiomyopathies
Meike Rybczynski, MD, University Heart Centre Hamburg, Hamburg, Germany

3:00 PM Survivors of Cancer: Is This a Contraindication to Transplant?
Charles E. Canter, MD, St Louis Children’s Hospital, St. Louis, MO, USA

3:20 PM Advanced Therapies in AL Amyloidosis: Is This a Good Idea?
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

3:40 PM Panel Discussion
2:00 PM - 4:00 PM
SYMPOSIUM 05: The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults

Location: Uranie/Calliope
Target Audience: NHSAH, HF/HTX, LF/LTX, MCS, PEDS
Chairs: Liz Painter, MA, MSc, and Quincy Young, PhD, RPpsych

Session Summary: This session will address: 1) challenges in transitioning from pediatrics to the adult setting, 2) how to manage non-adherence in youth and young adults, 3) best practices in managing frailty, 4) data on youth preferences regarding end of life discussions and review tips on how to best approach those conversations. The challenging issues discussed by presenters will be highlighted in a complex clinical case presentation of a young adult presenting for re-transplantation. Audience participation and panel discussion will be encouraged in the last 15 minutes of the symposium.

2:00 PM It's So Hard to Say Goodbye: Transitioning from the Pediatric to the Adult Setting
Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom

2:15 PM Prehabbing and Rehabbing: What Can We Do for the Frail Patient at Any Age?
Louise M Fuller, PT, Alfred Hospital, Melbourne, Australia

2:30 PM You are Not the Boss of Me! Managing Non-Adherence in Adolescents and Young Adults in Cardiothoracic Transplantation and Mechanical Support
Samantha J Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

2:45 PM Dying to Talk about Death? Adolescent and Young Adult Preferences for Advance Care Planning and End of Life Discussions
Melissa Cousino, PhD, CS Mott Children’s Hospital, Ann Arbor, MI, USA

3:00 PM Communication Tools for Goals of Care Conversations
Elizabeth Blume, MD, Boston Children’s Hospital, Boston, MA, USA

3:15 PM Education and Employment After Cardiothoracic Transplantation or Mechanical Support
Michael Petty, PhD, RN, CNS, University of Minnesota, Minneapolis, MN, USA

3:30 PM So, Should We Do This Again? Re-Transplantation of the Medically and Psychosocially Complex Young Adult
Mustafa Toma, MD, University of British Columbia, Vancouver, BC, Canada

3:45 PM Panel Discussion
2:00 PM - 4:00 PM
SYMPOSIUM 06: Novel Tools in Transplant Research (Say You Want a Revolution...)

**Location:** Hermes

**Target Audience:** BSTR, HF/HTX, ID, LF/LTX, PATH, PHARM

**Chairs:** Sonja Schrepfer, MD, PhD, and Christopher H Wigfield, MD

**Session Summary:** New tools and techniques in clinical immunology are redefining what is possible. We will explore some of the cutting-edge research tools that are fueling research into heart and lung transplantation, including advanced microscopy, cytometry, immune monitoring, RNA sequencing, proteomics, microbiome profiling, and genome-wide association studies. Exciting possibilities will be tempered with practical considerations on how to use these techniques to advance your research career.

2:00 PM *If Tissue is the Issue...*
Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

2:15 PM **Q&A**

2:20 PM *Scrutinizing the Immune System*
Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI, USA

2:35 PM **Q&A**

2:40 PM *What’s in the DNA?*
Bart Vanaudenaerde, MD, Katholieke Universiteit, Leuven, Belgium

2:55 PM **Q&A**

3:00 PM *Should We Act Based on the DNA?*
Nancy Reinsmoen, PhD, Cedars-Sinai Health System, Los Angeles, CA, USA

3:15 PM **Q&A**

3:20 PM *Epigenetics, MicroRNA, Transcriptome*
Thalachallour Mohanakumar, PhD, St. Joseph's Hospital and MC, Phoenix, AZ, USA

3:35 PM **Q&A**

3:40 PM *Microbiome and Virome*
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

3:55 PM **Q&A**
2:00 PM - 4:00 PM
SYMPOSIUM 07: The Devil is in the Details - Nuances in CTEPH

Location: Mediterranee 6
Target Audience: CTEPH, LF/LTX, PH

Chairs: Marc De Perrot, MD, and Irene Lang, MD

Session Summary: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is one of the commonest subsets of PH, and potentially curable. It is of utmost importance to familiarize the audience with key characteristics of the condition, including risk factors and details of diagnostic imaging. With a rising number of providers focusing on managing patients with CTEPH, patient selection and appropriateness of diagnosis remains key in predicting clinical outcomes post interventions.

2:00 PM Acute Pulmonary Embolism to CTEPH - Understanding the Pathway
Frederikus A Klok, MD, Leiden University Medical Center, Leiden, Netherlands

2:15 PM Q&A

2:20 PM Diagnostic Imaging to Adequately Assess Thrombus Burden in CTEPH
Nicholas Screaton, MD, Papworth Hospital, London, United Kingdom

2:35 PM Q&A

2:40 PM CTEPH Outcomes - Insights from Registries
Kim Kerr, MD, UCSD Medical Center, San Diego, CA, USA

2:55 PM Q&A

3:00 PM Medical Management in CTEPH
Manreet V Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

3:15 PM Q&A

3:20 PM Evolving Approach to Pulmonary Endarterectomy: Unraveling the Distal Vessels
Andrea M D'Armini, MD, Foundation IRCCS Policlinico San Matteo, Pavia, Italy

3:35 PM Q&A

3:40 PM CTEPH - The Great Mimic
Gustavo Heresi, MD, Cleveland Clinic foundation, Cleveland, OH, USA

3:55 PM Q&A
4:30 PM - 6:00 PM
ORAL SESSION 08: Four Liters and Fingers Crossed: ECMO - Management and Outcomes

**Location:** Apollon  
**Target Audience:** MCS

**Chairs:** Jose Gonzalez-Costello, MD, and Ranjit John, MD

**4:30 PM (45)** Percutaneous Unloading of the Left Ventricle During Extracorporeal Membrane Oxygenation in Cardiogenic Shock - Ongoing Experience from a High-Volume Centre; B. Schrage¹, M. Becher¹, M. Schwarzl¹, H. Grahn¹, G. Söffker², E. Lubos³, A. Bernhardt³, H. Reichensperner³, S. Blankenberg¹, D. Westermann¹. ¹Dept of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, ²Dept of Intensive Care Medicine, University Heart Center Hamburg, Hamburg, Germany, ³Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

**4:45 PM (46)** Extracorporeal Membrane Oxygenation as a Bridge to Heart Transplant versus Left Ventricular Assist Device: Analysis of a Multicenter, Nationwide Database; Z. Shah¹, V. Vuddanda², M. Yin¹, O. Wever-Pinzon¹, J. Nativi-Nicolau¹, S. Drakos¹, A. Kfoury, J. Fang¹, J. Stehlik¹. ¹University of Utah Medical Center, Salt Lake City, UT, ²Department of Public Health, Harvard Medical School, Boston, MA, ³Intermountain Medical Center, Salt Lake City, UT

**5:00 PM (47)** Long-term Outcome of Patients Bridged to Recovery After Short-term Mechanical Circulatory Support for Cardiogenic Shock; Y. Cheng¹, A. R. Garan², H. Takayama¹, M. Ando¹, J. Han¹, P. A. Kurlansky, M. Yuzefpolskaya², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Division of Cardiothoracic Surgery, Dept of Surgery, New York Presbyterian Hospital, New York, NY, ²Division of Cardiology, New York Presbyterian Hospital, New York, NY


**5:30 PM (49)** Early Elevated Plasma Free Hemoglobin Predicts Occurrence of Thromboembolic Stroke during Venoarterial Extracorporeal Membrane Oxygenation Support; O. Saeed¹, W. Jackobleff², T. Chinnadurai¹, S. Forest³, S. Rangasamy¹, S. Madan¹, M. Aljoudi¹, Y. Xia², S. R. Patel¹, S. Vukelic¹, D. B. Sims¹, J. Shin¹, H. H. Billett¹, D. J. Goldstein², U. P. Jorde³. ¹Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, ²Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, ³Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

4:30 PM - 6:00 PM
ORAL SESSION 09: The Pressure is On! Assessment and Role of Blood Pressure in MCS

Location: Athena
Target Audience: MCS, NHSAH, PHARM, PH

Chairs: Brent C Lampert, DO, and Jason N Katz, MD, MHS

4:30 PM (51) Estimation of Mean Arterial Pressure in HeartMate II Patients Using Doppler Blood Pressure and Pump Speed; A. Pinsino¹, F. Castagna², E. J. Stöhr³, B. J. McDonnell⁴, J. R. Cockcroft⁴, M. Tiburcio¹, L. Effner¹, A. R. Garan¹, V. K. Topkara¹, K. Takeda¹, H. Takayama¹, Y. Naka¹, R. T. Demmer³, M. Yuzefpolskaya¹, P. C. Colombo¹. ¹Columbia University, New York, NY, ²Columbia University, Yale Bridgeport Hospital, New York, Bridgeport, NY, ³Columbia University, Cardiff Metropolitan University, New York, NY, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵University of Minnesota, Columbia University, New York, NY

4:45 PM (52) Systolic Blood Pressure and Outcomes in Patients on Continuous Flow LVAD Support: An INTERMACS Analysis; J. A. Cowger¹, T. Chamogeorgakis², J. Borgi², G. Grafton³, Y. Selektor³, H. Nemeh², C. Williams³, C. Tita³, D. Lanfear³. ¹Henry Ford Health System, Detroit, MI, ²Cardiothoracic Surgery, Henry Ford Health System, Detroit, MI, ³Cardiology, Henry Ford Health System, Detroit, MI

5:00 PM (53) Blood Pressure Control as a Risk Factor for Stroke in LVAD Patients- Single Center Experience; N. S. Clarke¹, R. Vela¹, J. Pruszynski¹, M. Drazner², L. C. Huffman¹, M. Peltz¹. ¹Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, ²Internal Medicine, University of Texas Southwestern, Dallas, TX

5:15 PM (54) Risk Predictors for Ischemic Stroke in CF-LVAD Patients by Pump Flow Type; M. Kanwar¹, L. Lohmueller², R. Kormos³, S. Bailey¹, C. Mcilvennan⁴, S. Murali¹, J. Antaki². ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Colorado, Denver, CO

5:30 PM (55) Predictive Value of Mean Arterial Pressure Versus Systolic Blood Pressure and Visit-To-Visit Blood Pressure Variability for Stroke and Pump Thrombosis in HeartMate II Patients; A. Pinsino¹, F. Castagna¹, J. Z. Willey¹, A. M. Zuver¹, M. A. Flannery¹, B. Cagliostrò¹, J. R. Cockcroft², A. R. Garan¹, V. K. Topkara¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, R. T. Demmer³, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia University, New York, NY, ²Cardiff Metropolitan University, Cardiff, United Kingdom, ³University of Minnesota, Columbia University, New York, NY

5:45 PM (56) Increased Aortic Stiffness is Associated with Higher Rates of Stroke, GI-bleeding and Pump Thrombosis in Continuous-Flow Left Ventricular Assist Device Patients; H. Rosenblum¹, A. Pinsino¹, R. T. Demmer¹, P. C. Colombo¹, M. Yuzefpolskaya¹, A. R. Garan¹, V. K. Topkara¹, A. Gaudig¹, M. T. Pineda¹, Y. Naka¹, H. Takayama¹, K. Takeda¹, F. Castagna², J. Z. Willey¹, B. J. McDonnell¹, J. R. Cockcroft¹, E. J. Stöhr¹. ¹Columbia University, New York, NY, ²Columbia University/Yale New Haven Bridgeport, New York, NY
4:30 PM - 6:00 PM
ORAL SESSION 10: Mechanisms of Allograft Injury after Lung Transplantation

Location: Mediterranee ABC
Target Audience: LTX, BSTR, PATH

Chairs: Angela Koutsokera, MD, PhD, and Jonathan D'Cunha, MD

4:30 PM (57) Clinically-unrecognized Allograft Injury is Common After Lung Transplantation; S. Agbor-Enoh1, L. Tunc2, S. Gorham1, M. Jang1, U. Fideli1, A. Marishta1, J. Zhu2, M. Pirooznia2, Y. Yang1, A. Davis1, D. Grimm3, Z. Cao4, H. Luikart5, P. Shah6, I. Timofte7, A. W. Brown8, A. Iacono4, S. Nathan7, J. Orens5, K. Khush3, H. Valantine1. 1Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, 2Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, 3Division of Cardiology, Stanford School of Medicine, Palo Alto, CA, 4Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, 5Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, 6Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, 7Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA

4:45 PM (58) Impact of Carbon Dioxide Tension on Survival After Lung Transplantation for Pulmonary Fibrosis; M. A. Villavicencio1, A. L. Axtell1, A. G. Fiedler1, E. Heng1, Y. Raz2, I. P. Neuringer2, S. I. Melnitchouk1, G. Tolis1, D. A. D’Alessandro1, T. A. Astor2. 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA

5:00 PM (59) Neutrophil Extracellular Traps in Human Ex Vivo Lung Perfusion as a Biomarker of Lung Injury; L. Caldarone1, A. Mariscal1, A. Sage1, S. Juvet1, T. Martinu1, M. Khan2, M. Cypel1, M. Liu1, N. Palaniyar2, S. Keshavjee1. 1University Health Network, Toronto, ON, Canada, 2SickKids Research Institute, Toronto, ON, Canada


5:30 PM (61) Increasing Frequency of CD127low Regulatory Cells Early After Lung Transplantation Improves Freedom From Chronic Lung Allograft Rejection and Graft Survival in 673 Patients; F. Lus1, A. Knoefel1, J. Salman1, W. Sommer1, T. Nakagiri1, T. Siemeni2, C. Kuehn1, M. Avsar1, D. Bobylev1, R. Poyamehr1, D. Boethig1, T. Welte2, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Respiratory Medicine, Hannover Medical School, Hannover, Germany

5:45 PM (62) Exosomes With Lung Self-antigens, Ka1Tubulin and Collagen V, as Biomarker for Bronchiolitis Obliterans Syndrome Following Human Lung Transplantation; T. Mohanakumar1, M. Gunasekaran1, M. Sharma1, S. Elnahas1, S. Biswas Roy1, R. Hachem2, R. Bremmer1, M. Smith1. 1Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 2Washington University School of Medicine, St. Louis, MO
4:30 PM - 6:00 PM
ORAL SESSION 11: Predictable or Inevitable? Complications of Heart Transplantation

**Location:** Clio/Thalie/Erato

**Target Audience:** HTX, BSTR, HF, NHSAH, PATH

**Chairs:** Debra L Isaac, MD, and David A Baran, MD

4:30 PM (63) **Assessing the Predictive Validity of ISHLT’s Primary Graft Dysfunction Classification Instrument;** F. Foroutan¹, C. Alba¹, J. Krakovsky¹, S. Chih², G. H. Guyatt³, H. Ross¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada, ²Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada, ³Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

4:45 PM (64) **Association Between Common Measures of Graft Function and Mortality Post Heart Transplant (HT);** F. Foroutan¹, H. J. Ross¹, A. Malik¹, G. H. Guyatt², C. Alba¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada, ²Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

5:00 PM (65) **ST2 as a Marker of Primary Graft Dysfunction;** A. Galeone¹, S. Varnous¹, J. Salem², G. Lebreton¹, G. Coutance¹, J. Hulot², P. Leprince¹. ¹Dept of Thoracic and Cardiovascular Surgery, La Pitié-Salpêtrière Hospital, Paris, France, ²Dept of Pharmacology, CIC Paris-Est 1421, Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, Paris, France

5:15 PM (66) **Pre-transplant Macrophage Cholesterol Efflux Capacity is Associated With Angiographic Cardiac Allograft Vasculopathy in a Multi-center Observational Study;** A. Javaheri¹, E. Novak¹, K. Lavine¹, D. J. Rader², R. Starling³, A. K. Chandraker⁴, D. Baran⁵, P. S. Heeger⁶, J. Stehlik on behalf of CTOT18 investigators. ¹Medicine, Washington University of Saint Louis, Saint Louis, MO, ²Medicine, University of Pennsylvania, Philadelphia, PA, ³Medicine, Cleveland Clinic, Cleveland, OH, ⁴Medicine, Harvard Medical School, Boston, MA, ⁵Medicine, Sentara Advanced Heart Failure Center, Norfolk, VA, ⁶Medicine, Mount Sinai School of Medicine, New York, NY, ⁷Medicine, University of Utah, Salt Lake City, UT

5:30 PM (67) **The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the Schedule Trial after 6 Years;** S. Arora¹, K. Karason², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, L. Aaberge¹, E. Gude¹, D. Solbu⁶, G. Dellgren⁷, A. K. Andreassen¹, L. Gullestad¹. ¹Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Cardiology, Aarhus University Hospital, Aarhus, Denmark, ⁵Cardiology, Skåne University Hospital, Lund, Sweden, ⁶Novartis Norge, Oslo, Norway

5:45 PM (68) **A Novel Risk Prediction Model for PTLD in the Post Cardiac Transplantation Population: A UNOS Database Analysis;** N. Nair¹, S. Yang², E. Gongora³. ¹Division of Cardiology, Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ²Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ³Cardiothoracic Surgery, Memorial Cardiac and Vascular Institute, Hollywood, FL
4:30 PM - 6:00 PM
ORAL SESSION 12: The Leading Edge: Novel Practices in Patient Care Pathways

**Location:** Uranie/Calliope
**Target Audience:** NHSAH, HF, HTX, LTX, MCS
**Chairs:** Nicola Robinson Smith, RN, and Kevin C. Carney, MSN, CRNP, CCTC

4:30 PM (69) **Assessing the Need for Palliative Care in LVAD and HTX Patients;** F. Strangl¹, A. Ullrich², A. Bernhardt³, M. Barten³, C. Bokemeyer², S. Blankenberg¹, H. Reichenspurner³, K. Oechsle², M. Rybczynski¹. ¹Dept of Cardiology, University Heart Center Hamburg-Eppendorf, Hamburg, Germany, ²Dept of Oncology, Hematology and Bone Marrow Transplantation, Palliative Care Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³Dept of Cardiac Surgery, University Heart Center Hamburg-Eppendorf, Hamburg, Germany


5:00 PM (71) **Clinicians’ Acceptance of Interactive Health Technologies for Self-Management among Patients with Chronic Cardiopulmonary Disorders;** M. Alrawashdeh¹, R. Zomak², S. Al-Zaiti¹, S. Sereika¹, B. Parmanto³, A. DeVito Dabbs¹. ¹School of Nursing, University of Pittsburgh, Pittsburgh, PA, ²Cardiothoracic Transplant Program, University of Pittsburgh Medical Center, Pittsburgh, PA, ³School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, PA

5:15 PM (72) **Pilot Experience with a Novel Bluetooth Tablet-Based Technology for Home Monitoring and Education After Lung Transplantation;** F. A. Schenkel, S. Ganesh, J. O’Conner, R. Sadeghi, M. Bembi, M. Duong, M. L. Barr, A. E. Hackmann. Keck Medical Center of USC, Los Angeles, CA

5:30 PM (73) **Outcomes of Telehealth Assessment of Lung Transplant Candidates;** A. Sidhu, R. Colman, J. Tikkanen, M. Binnie, C. Chaparro, S. Keshavjee, L. G. Singer. Toronto Lung Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada

5:45 PM (74) **Impact of a Mobile Health Intervention on Long-term Nonadherence in Lung Transplantation;** E. M. Rosenberger¹, M. Dew¹, A. F. DiMartini¹, J. M. Pilewski¹, A. J. DeVito Dabbs². ¹School of Medicine, University of Pittsburgh UPMC, Pittsburgh, PA, ²School of Nursing, University of Pittsburgh UPMC, Pittsburgh, PA
4:30 PM - 6:00 PM
ORAL SESSION 13: Early Career Scientist Award Candidate Presentations

Location: Hermes
Target Audience: BSTR, HTX, LTX, PATH

Chairs: Edward Cantu, MD, and Karl B Lemstrom, MD, PhD

4:30 PM (75) Dynamics of Transient Populations of the Human Respiratory Virome After Lung Transplantation; A. B. Mitchell¹, B. Mourad¹, L. Morgan², B. Oliver³, A. R. Glanville⁴. ¹Molecular Biology, University of Technology, Sydney, Naremburn, Australia, ²Thoracic Medicine, Concord Clinical School, University of Sydney, Concord, Australia, ³Cellular and Molecular Biology, Woolcock Institute of Medical Research, Glebe, Australia, ⁴Lung Transplantation, St Vincent's Hospital, Sydney, Darlinghurst, Australia

4:30 PM (76) MicroRNAs Signature in Heart Transplant Enhances Diagnosis of Different Types of Acute Rejection; A. Di Francesco¹, M. Fedrigo¹, D. Santovito², F. De Pascale³, C. Castellani¹, G. Toscano¹, G. Feltrin¹, A. Fraiese¹, A. Nocco², E. Benazzi², G. Thiene¹, G. Valle³, A. Schober², G. Gerosa¹, A. Angelini¹. ¹Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ²Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) Munich, Muenchen, Germany, ³CRIBI Biotechnology Centre, University of Padova, Padova, Italy, ⁴Organ and Tissue Transplantation Immunology, Fondazione IRCSS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy

5:06 PM (77) CD4 T Cells, Foreign Protein and CD22 Control Antibody Response to Non-Self Blood Group A-Antigen in A-Transgenic Mice; I. Adam¹, B. Motyka², J. Pearcey², K. Tao², L. West³. ¹Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada, ²Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology & Immunology, Pediatrics, surgery, University of Alberta, Edmonton, AB, Canada

5:24 PM (78) Time and Perfusate Dependent Molecular Repair Response During Ex Vivo Lung Perfusion; N. S. Aboelnazar¹, P. Dromparis², S. Wagner², S. Himmat¹, C. W. White³, S. Hatami¹, B. Adam², M. Mengel⁴, D. H. Freed⁵, J. Nagendran⁵. ¹Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada, ²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, ³Cardiac Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, ⁵Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada

5:42 PM (79) Lysophosphatidic Acid Drives Recruitment and Fibroblastic Differentiation of Mesenchymal Stromal Cells in Chronic Lung Allograft Dysfunction; K. A. Sinclair, M. E. Tan, T. M. Sladden, P. M. Hopkins, B. J. O'Sullivan, D. C. Chambers. School of Medicine, University of Queensland, Brisbane, Australia
4:30 PM - 6:00 PM
ORAL SESSION 14: Reading Tea Leaves - Heart Failure Prediction Risks

Location: Mediterranee 6
Target Audience: HF, HTX, MCS, PHARM

Chairs: Sharon Chih, MD, and Savitri Fedson, MD

4:30 PM (80) Natriuretic Doses of Mineralocorticoid Receptor Antagonists in Outpatients With Acute Decompensated Heart Failure: H. Rosenblum1, R. Aponte Medina1, P. Trinh1, J. Fried1, R. T. Demmer2, J. Radhakrishnan1, M. Yuzefpolskaya1, R. Bijou1, V. K. Topkara1, P. C. Colombo1, A. Masoumi1. 1Columbia University, New York, NY, 2University of Minnesota, Columbia University, New York, NY

4:45 PM (81) Discordance Between Clinical and Invasive Assessment of Hemodynamics in Patients with Decompensated Heart Failure: N. Narang1, R. Kalathiyi2, L. Laffin2, B. Chung2, A. Nguyen2, M. R. Costanzo3, T. Imamura4, G. Kim2, J. Raikhelkar2, N. Sarswat2, S. Kalantari2, V. Jeevanandam4, G. T. Sayer4, N. Uriel2. 1University of Chicago Medical Center, Chicago, IL, 2Cardiology, University of Chicago Medical Center, Chicago, IL, 3Cardiology, Edwards Hospital Center, Naperville, IL, 4Cardiac Surgery, University of Chicago Medical Center, Chicago, IL

4:50 PM (82) Pulmonary Artery Catheterization is Associated with Mortality Decline over Time in Cardiogenic Shock Compared to Patients with Acute Decompensated Heart Failure: G. A. Hernandez1, A. Lemo2, V. Blumer3, C. Rueda1, S. Zalawadiya1, L. W. Stevenson1, J. Lindenfeld1. 1Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN, 2Dept of Internal Medicine, Icahn School of Medicine at Mount Sinai St Luke’s – Mount Sinai West Hospital, New York, NY, 3Depart, University of Miami - Jackson Memorial Hospital, Miami, FL


5:00 PM (82) A Novel Readmission Risk Score is Highly Predictive of Mortality after Heart Failure Admission: R. Cogswell1, A. Rhodes2, T. Alexy1, J. Shultz1, C. Martin1, T. Freitag1, L. Wick1, R. John3. 1Medicine, University of Minnesota, Minneapolis, MN, 2Fairview Health Services, University of Minnesota, Minneapolis, MN, 3Surgery, University of Minnesota, Minneapolis, MN

5:05 PM (83) Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support (SUSTAIN-IT): Baseline Findings: K. L. Grady1, A. Andrei2, L. Pollan2, H. Shi2, H. Adam2, A. Kao3, D. Pham1, M. Dew4, R. Kormos5, E. Hsich6, W. Cotts7, S. LaRue8, S. V. Pamboukian8, F. Pagan10, M. Petty11, B. Lampert12, M. Johnson13, M. Murray14, J. Spertus15, J. K. Kirklin16, S. C. Collum1, C. Yancy17. 1Surgery / Division of Cardiac Surgery, Northwestern University, Chicago, IL, 2Surgery / BCVI Clinical Trials Unit, Northwestern University, Chicago, IL, 3Medicine, University of Missouri-Kansas City, Kansas City, MO, 4Psychiatry, University of Pittsburgh, Pittsburgh, PA, 5Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, 6Medicine, Cleveland Clinic, Cleveland, OH, 7Medicine, Advocate Christ Medical Center, Oak Lawn, IL, 8Medicine, Washington University, St. Louis, MO, 9Medicine, University of Alabama at Birmingham, Birmingham, AL, 10Cardiac Surgery, University of Michigan, Ann Arbor, MI, 11Surgery, University of Minnesota Medical Center, Minneapolis, MN, 12Medicine, Ohio State University, Columbus, OH, 13Medicine, University of Wisconsin, Madison, WI, 14Cardiothoracic Surgery, University of Wisconsin, Madison, WI, 15Medicine, University of Missouri Kansas City, Kansas City, MO, 16Surgery, University of Alabama Birmingham, Birmingham, AL, 17Medicine / Division of Cardiology, Northwestern University, Chicago, IL

5:15 PM (84) Discordance Between Clinical and Invasive Assessment of Hemodynamics in Patients with Decompensated Heart Failure: N. Narang1, R. Kalathiyi2, L. Laffin2, B. Chung2, A. Nguyen2, M. R. Costanzo3, T. Imamura4, G. Kim2, J. Raikhelkar2, N. Sarswat2, S. Kalantari2, V. Jeevanandam4, G. T. Sayer4, N. Uriel2. 1University of Chicago Medical Center, Chicago, IL, 2Cardiology, University of Chicago Medical Center, Chicago, IL, 3Cardiology, Edwards Hospital Center, Naperville, IL, 4Cardiac Surgery, University of Chicago Medical Center, Chicago, IL
6:15 PM - 7:15 PM
MINI ORAL 01: Mechanical Circulatory Support: ECMO

Location: Athena
Target Audience: MCS, HTX, PHARM

Chairs: Pavan Atluri, MD, and Susan Joseph, MD


6:20 PM (87) Optimal Hemodynamics During LVAD Support Are Associated with Reduced Hemocompatibility-related Adverse Events; T. Imamura1, J. Raikhelkar1, N. Sarswat1, S. Kalantari1, C. Murks1, D. Rodgers1, C. Juricsek1, G. Kim1, M. Costanzo1, T. Ota1, T. Song1, V. Jeevanandam1, U. Jorde2, D. Burkhoff3, G. Sayer1, N. Uriel1. University of Chicago, Chicago, IL, 2Montefiore Medical Center, New York, NY, 3Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

6:25 PM (88) Highly Accurate Continuous Blood Pressure Measurement in LVAD Patients with a Non-Invasive, Non-Oscillometric Wearable Device: A Pilot Study; G. Sayer1, G. H. Kim2, D. Rodgers2, B. Chung2, A. Nguyen1, N. Narang1, J. Raikhelkar1, S. Kalantari1, N. Sarswat1, V. Jeevanandam1, N. Uriel2. University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL, 3Cardiac Surgery, University of Chicago, Chicago, IL

6:30 PM (89) Novel Minimally Invasive Surgical Approach for Refractory Cardiogenic Shock: A Hemodynamic Comparison With Current Percutaneous Strategies; O. Akanni1, A. R. Garan2, H. Takayama3, J. Han1, P. A. Kurlansky1, D. H. Burkhoff3, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1, K. Takeda1. 1Dept of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Dept of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY


6:40 PM (91) Higher Age and Lower BMI Are Stronger Predictors of Mortality For Females Than Males on VA ECMO; M. Leacche1, N. K. Manandhar Shresta2, S. V. Jovinge3, T. Boeve1. 1Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, 2Fredrik Meijer Heart and Vascular Institute, Fredrik Meijer Heart and Vascular INstitute, Grand Rapids, MI

6:45 PM (92) Identifying Appropriate Durable VAD Candidates in Patients with Veno-Arterial Extracorporeal Membrane Oxygenation: Can We Identify the “Point of No Return”?; D. Saeed1, A. Loforte2, F. Pappalardo3, M. Attisani4, M. Morshuis5, D. Zimpfer6, F. Ramjankhan7, U. Jorde8, R. Wieloch1, A. Albert1, A. Lichtenberg1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Cardiovascular Surgery, Bologna University, Bologna, Italy, 3Cardiovascular Surgery, San Raffaele Hospital, Milan, Italy, 4Cardiovascular Surgery, University of Turin, Turin, Italy, 5Cardiothoracic and Vascular Surgery, Herz und Diabetes Zentrum NRW, Bad Oenyhausen, Germany, 6Cardiovascular Surgery, Medical University Vienna, Vienna, Austria, 7Dept of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands, 8Dept of Cardiology, Albert Einstein College of Medicine, New York, NY

6:50 PM (93) The Impact of Age on In-hospital Mortality With Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock; M. Chung1, Y. Zhao2, J. B. Strom3, C. Shen2, R. Yeh2. 1Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, 2Dept of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

6:55 PM (94) Effects of Percutaneous LVAD Support on Right Ventricular Load and Adaptation Acutely and Over Time; J. P. Yourshaw1, C. Armstrong2, P. Mishra2, D. Steinberg1, B. Ramu1, M. Craig1, A. Van Bakel1, R. J. Tedford1, B. A. Houston1. 1Cardiology, Medical University of South Carolina, Charleston, SC, 2Internal Medicine, Medical University of South Carolina, Charleston, SC

7:00 PM (95) Impact of Ongoing CPR on VA ECMO Outcomes; K. J. Fujita, A. P. Rabenstein, R. Chiu, F. Seifert, A. J. McLarty. Stony Brook University, Stony Brook, NY
7:05 PM (96) Neuron-Specific-Enolase as a Predictor of Overall and Neurological Outcome After Cardiopulmonary Resuscitation in Patients with VA-ECMO; B. Schrage¹, N. Rübsamen¹, M. Becher¹, M. Schwarzl¹, H. Grahn¹, G. Söffker², E. Lubos¹, A. Bernhardt³, H. Reichenspurner³, S. Blankenberg¹, D. Westermann¹. ¹Dept of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, ²Dept of Intensive Care Medicine, University Heart Center Hamburg, Hamburg, Germany, ³Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

6:15 PM - 7:15 PM
MINI ORAL 02: Heart Transplantation: Outcomes

Location: Mediterrane ABC
Target Audience: HTX, BSTR, EEP, HF, MCS, PHARM

Chairs: Fabiana G Marcondes-Braga, MD, PhD, and Robert T Cole, MD

6:15 PM (98) Pulmonary Artery Decoupling Further Enhances Discriminatory Power of Pulmonary Vascular Resistance in Patients Bridged to Transplant with Left Ventricular Assist Devices; L. K. Truby1, A. R. Garan1, R. Givens1, H. Takayama1, M. Yuzefpolskaya1, K. Takeda1, F. Latif1, S. Restaino1, Y. Naka1, P. C. Colombo1, M. Farr1, N. Uriel2, V. K. Topkara1. 1Columbia University, New York, NY, 2University of Chicago, Chicago, IL

6:20 PM (99) Patterns of Gene Expression in High GEP Score Samples Correlated with Clinical Factors in the Outcomes AlloMap Registry; S. P. Pinney1, R. N. Woodward2, J. Sinsky2, M. Machrus2, J. A. Kobashigawa3. 1Cardiology, Mount Sinai Health System, New York, NY, 2CareDx, Brisbane, CA, 3Cedars-Sinai Heart Institute, Los Angeles, CA

6:25 PM (100) Frailty Predicts Mortality After Heart Transplantation; S. Offen, S. Jha, M. Connell, K. Dhital, E. Granger, M. Harkness, C. Hayward, A. Jabbour, P. Jansz, E. Kotlyar, E. Montgomery, K. Muthiah, P. Newton, A. Smith, P. Spratt, P. Macdonald. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia

6:30 PM (101) Center Effect on Long-term Post-transplant Survival Among Currently Active United States Heart Transplant Centers; T. P. Singh1, K. Gauvreau2. 1Boston Children's Hospital, Boston, MA, 2Cardiology, Boston Children's Hospital, Boston, MA

(102) WITHDRAWN

6:35 PM (863) Outcomes of the Cardiac Transplantation with Opioid Overdose Donors; K. Oh1, J. Fertel1, D. B. Sims1, J. J. Shin1, O. Saeed1, S. Murthy1, S. Vukelic1, S. Forest1, D. Goldstein1, U. P. Jorde1, S. R. Patel1. 1Dept of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

6:40 PM (103) Heart Transplantation in Patients with Active Prostate Cancer; Are We Denying a Life Saving Therapy Due to an Indolent Tumor?; J. Raikhelkar1, M. Pham2, T. Riley1, C. Murks1, J. Powers1, M. Reilly1, L. Lourenco3, B. Chung1, A. Nguyen1, N. Narang1, S. Kalantari1, N. Sarswat1, G. Kim1, G. Zagaja4, G. Sayer6, N. Uriel1. 1Cardiology, University of Chicago, Chicago, IL, 2Cardiology, California Pacific Medical Center, San Francisco, CA, 3Pharmacy Services, University of Chicago, Chicago, IL, 4Surgery, University of Chicago, Chicago, IL

6:45 PM (104) Gender Mismatch in NonVAD Patients Doesn't Negatively Affect Heart Transplant Survival; Y. Itoda, T. Okamoto, H. Niikawa, K. S. Ayyat, K. R. McCurry. Dept of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH


6:55 PM (106) Increase in DCD Donation in the United States May Adversely Impact DBD Heart Transplantation: Retrospective Analysis of a Limited UNOS Dataset; M. Farr1, J. Lindower2, S. Taylor2, U. Jorde2, L. Chen4, A. Gass5, L. Truby1, S. DeLair2, S. Pinney6. 1Columbia University Medical Center, New York, NY, 2New York Cardiothoracic Transplant Consortium, Albany, NY, 3Montefiore Medical Center, Bronx, NY, 4University of Rochester Medical Center, Rochester, NY, 5Westchester Medical Center, Valhalla, NY, 6Mount Sinai Medical Center, New York, NY

7:00 PM (107) DCD Heart Retrieval Does Not Compromise Other Donor Organs: The UK Experience; A. Page1, S. Messer1, J. Bunnett2, J. Mehew2, E. Wong2, M. Berman1, A. Simon3, R. Venkateswaran4, P. Catarino1, G. Oniscu5, S. Tsui1, S. Large1. 1Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, 2NHS Blood and Transplant, Bristol, United Kingdom, 3Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, 4University Hospital South Manchester NHS Foundation Trust, Manchester, United Kingdom, 5Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
7:05 PM (108) Variability of Both Raw and Transformed Gene Expression Profile Scores Predict Adverse Events Post Heart Transplant: The Mid America Experience: S. R. Beauchamp¹, K. R. Carl¹, K. F. Kennedy², B. A. Austin³, M. P. Everley³, T. M. Khumri³, S. L. Lawhorn³, A. Magalski³, B. W. Sperry³, D. Vodnala³, A. M. Borkon⁴, G. Dryton¹, A. Kao³, ¹Surgery, Saint Luke's Hospital, Kansas City, MO, ²Cardiology, Saint Luke's Hospital, Kansas City, MO, ³Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO, ⁴Surgery, Mid America Heart & Lung Surgeons, Kansas City, MO

6:15 PM - 7:15 PM
MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH

Location: Clio/Thalie/Erato
Target Audience: LTX, CTEPH, HF, PH

Chairs: Veronica Franco, MD, and Wiebke Sommer, MD

6:15 PM (110) **Endothelial to Mesenchymal Transition (EndMT) Occurs in Lungs Secondary to Heart Failure in a Non Ischemic Cardiomyopathy Mouse Model**; F. Hussain, A. S. Solbas, A. Guha, R. Barrios, K. A. Youker, A. Bhimaraj. Heart Failure Division, Houston Methodist Hospital, Houston, TX

6:20 PM (111) **Mitochondrial Respiratory Function is Impaired in the Setting of Right Ventricular Remodeling Induced by Pressure Overload**; P. Noly1, J. Piquereau2, J. arthur-Ataam3, M. Coblen3, J. Guihaire3, E. Fadel3, O. Mercier3. 1Montreal Heart Institute, Montreal, QC, Canada, 2UMR-S 1180 INSERM, Chatenay-Malabry, France, 3Research and Innovation Unit, ISERM U999, Le Plessis Robinson, France

6:25 PM (112) **Endothelin-1 Derived from the Pulmonary Endarterectomy Specimen Could Play a Major Role in Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension**; Y. Zhao, M. Ding, L. Dong, Y. Yao, I. Wu, J. Granton, M. de Perrot. University Health Network, University Health Network, Toronto, ON, Canada

6:30 PM (113) **Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study**; M. V. Thakrar, J. C. Weatherald, R. A. Varughese, D. S. Helmens, C. Lydell, N. Fine, N. Hirani. University of Calgary, Calgary, AB, Canada

6:35 PM (114) **Right Ventricular Dysfunction in Group 3 PH: Male Gender is Associated With RV-PA Uncoupling**; L. Rose1, K. W. Prins1, S. L. Archer2, M. Pritzker1, E. K. Weir1, T. Thenappan1. 1Cardiovascular Division, University of Minnesota, Minneapolis, MN, 2Dept of Medicine, Queen’s University, Kingston, ON, Canada

6:40 PM (115) **Abnormal Invasive Pulmonary Hemodynamics Predict Outcomes in Exercising Patients**; A. Jose1, C. King2, E. Welt3, O. A. Shlobin2, A. Brown2, S. Arya2, N. Wei2, S. D. Nathan2. 1George Washington Hospital, Washington, DC, 2Inova Fairfax Hospital, Falls Church, VA, 3Georgetown University Hospital, Washington, DC

6:45 PM (116) **Portable Normothermic Perfusion for Critical Marginal Graft Use: A Clinical-Pathological Comparison with Standard Marginal Donors Stored with Cold Preservation**; M. Schiavon1, G. Faggi2, G. Marulli1, P. Feltracco3, A. Rebusso1, D. Azzolina4, F. Lunnardi5, E. Faccioli1, E. Verder1, E. Cozzi1, F. Calabrese5, F. Rea1. 1Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, 2Istitution of Anaesthesia, University of Padua, Padova, Italy, 3Istitution of Anaesthesia, University of Padua, Padova, Italy, 4Statistics Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, 5Pathologic Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, 6Immunology Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy

6:50 PM (117) **Modified Surgical Technique of Normothermic Ex-Vivo Perfusion Reduces Cold Ischemic Time in Lung Transplantation During the EXPAND Trial**; M. A. Villavicencio1, A. L. Axtell1, A. G. Fiedler1, E. E. Heng1, S. E. Kilmux1, N. Roy1, M. Funamoto1, T. Astor2, S. Melnitchouk2, D. A. D’Alejandro1, G. Tolis1, T. M. Sundt1. 1Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

6:55 PM (118) **The Intent or Performance of EVLP in Donor Lungs in the United States: National Trends and OPO Variability**; K. M. Chan1, R. R. Lehman2, T. P. Whelan3, K. Uccellini4, R. J. Carrico2. 1Division of Pulmonary and Critical Care Medicine, Michigan Medicine, Ann Arbor, MI, 2Research, United Network for Organ Sharing, Richmond, VA, 3Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, 4Policy, United Network for Organ Sharing, Richmond, VA

7:00 PM (119) **A Near Point of Care Test for Interleukin 1B During Human Ex-Vivo Lung Perfusion**; A. S. Andreasson1, W. Laroo2, J. H. Dark1, A. J. Fisher1. 1Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2MyCartis NV, Gent, Belgium

7:05 PM (120) **Predictors of Donor Utilization in Lung Transplantation**; E. Singh1, F. Zafar2, C. Towe2, D. L. Morales2, R. Bryant2, J. K. Steger2, J. Tweddell2, M. G. Schecter2. 1University of Cincinnati, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, OH
7:10 PM (121) ISHLT Consensus on Standardization of Bronchoalveolar Lavage in Lung Transplantation; T. Martinu1, A. Koutsokera1, C. Benden2, E. Cantu3, D. Chambers4, M. Cypel1, J. Edelman5, A. Emtiazjoo6, A. Fisher7, J. Greenland8, D. Hayes, Jr.9, D. Hwang10, B. C. Keller11, E. D. Lease12, M. Perch13, M. Sato14, J. Todd15, S. Verleden16, J. von der Thüsen17, S. Weight18, S. Keshavjee1, .. On behalf of the BAL Standardization Workgroup1, 1Lung Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada, 2Lung Transplant Program, University Hospital Zurich, Zurich, Switzerland, 3Dept of Surgery, University Hospital of Pennsylvania, Philadelphia, PA, 4Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia, 5Lung Transplant Program, Puget Sound VAMC, Seattle, WA, 6Lung Transplant Program, University of Florida, Gainesville, FL, 7Lung Transplant Program, Freeman Hospital, Newcastle, United Kingdom, 8Lung Transplant Program, University of California, San Francisco, CA, 9Lung Transplant Program, Nationwide Children's Hospital, Columbus, OH, 10Dept of Pathology, Toronto General Hospital, UHN, Toronto, ON, Canada, 11Lung Transplant Program, Wexner Medical Center, The Ohio State University, Columbus, OH, 12Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Washington, WA, 13Lung Transplant Program, Rigshospitalet, Copenhagen, Denmark, 14Dept of Surgery, University of Tokyo, Tokyo, Japan, 15Lung Transplant Program, Durham University Medical Center, Durham, NC, 16Laboratory of Pulmonology, Katholieke Universiteit, Leuven, Belgium, 17Dept of Pathology, Erasmus Medical Center, Rotterdam, Netherlands, 18Lung Transplant Program, UCLA, Los Angeles, CA
6:15 PM - 7:15 PM
MINI ORAL 04: Mechanical Circulatory Support: Thrombosis

Location: Uranie/Calliope
Target Audience: MCS, PHARM

Chairs: Andrew J Boyle, MD, and Mustafa Toma, MD


6:20 PM (123) An Analysis of Preceding Signals and Treatment Strategies of VAD Thrombus in the ENDURANCE and ENDURANCE SUPPLEMENTAL Trials; F. D. Pagani¹, S. S. Naijar², U. P. Jorde³, J. J. Teuteberg⁴, R. L. Kormos⁵, R. Starling⁶, J. D. Rich⁷, T. A. Vassiliades⁸, S. W. Boyce², ¹University of Michigan, Ann Arbor, MI, ²MedStar Health, Washington, DC, ³Montefiore Medical Center, Bronx, NY, ⁴Stanford University, Stanford, CA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Cleveland Clinic, Cleveland, OH, ⁷Northwestern, Chicago, IL, ⁸Medtronic, Framingham, MA

6:25 PM (124) Increased Pump Speed is Associated with Reduced Rates of Stroke on HeartMate II LVAD Support; J. N. Schultz¹, R. Cogswell², M. Pritzker², E. Misso², K. Liao², J. Misiuk², R. John³. ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Cardiology, University of Minnesota, Minneapolis, MN, ³Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

6:30 PM (125) Hemocompatibility of an Ambulatory Counterpulsation Circulatory Assist System; V. Jeevanandam, D. Onsager, T. Song, T. Ota, C. Juricek LaBuhn, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, S. Kalantari, N. Uriel. University of Chicago Medicine, Chicago, IL


6:40 PM (127) Validity of a Novel Institutional Method to Analyze and Display HeartWare HVAD Log Files; Y. Lin¹, A. Ambardekar², L. A. Allen², C. Pierce³, A. Brieke², E. Benton², J. C. Cleveland¹, J. D. Pal¹. ¹Surgery, University of Colorado, Aurora, CO, ²Medicine, University of Colorado, Aurora, CO, ³University of Colorado Hospital, Aurora, CO

6:45 PM (128) High Thromboembolic Event Rate in Patients Supported With an Impella CP Device With an Anti-Xa Level of Less Than 0.1 u/mL; S. Batra¹, H. Kamran², T. Lech¹, J. Montgomery³, D. Venes³, R. Patten¹, S. Shah¹. ¹Cardiology, Lahey Hospital & Med Ctr, Burlington, MA, ²Internal Medicine, Lahey Hospital & Med Ctr, Burlington, MA

6:50 PM (129) 4D Flow MRI in 3D Printed Models of Aorta Grafted With a Ventricular Assist Device Allows Detailed Embolic Trajectory Analysis; O. Amili¹, F. Coletti², R. Maclver². ¹Aerospace Engineering and Mechanics, University of Minnesota, Minneapolis, MN, ²Cardiac Surgery, Childrens Hospitals and Clinics of Minnesota, Minneapolis, MN

6:55 PM (130) Mobilization of ECMO Patients with Various Cannulation Configurations; E. Colclough¹, S. Ramsey², P. Barrett², E. Sheffield², J. Webster², D. Dean². ¹CT Surgery, Cardiovascular Critical Care, Piedmont Heart, Atlanta, GA, ²Advanced Heart Failure, Piedmont Heart, Atlanta, GA

7:00 PM (131) Time Spent Out of Mean Arterial Blood Pressure (MAP) Goal Correlates With Adverse Events in Patients on Left Ventricular Assist Device; A. Khan, E. Sultanik, M. Racherla, E. Sorensen, H. Voorhees, L. Dees, E. Feller, D. Kaczorowski, Z. Kon, V. Ton. University of Maryland School of Medicine, Baltimore, MD

7:05 PM (132) Treatment of Pump Thrombosis With Low Dose Thrombolytic Therapy in Heartware HVAD Left Ventricular Assist Devices: Single Center Experience; E. Demir¹, S. Nalbantgil¹, P. Öztürk², C. Sahutoglu³, Ç. Engin², T. Yagci¹, M. Özbaran¹. ¹Cardiology, Ege University Medicine Faculty, Izmir, Turkey, ²Cardiovascular surgery, Ege University Medicine Faculty, Izmir, Turkey, ³Anesthesiology, Ege University Medicine Faculty, Izmir, Turkey

7:10 PM (133) Clinical Profile of Patients with Late Stroke after Left Ventricular Assist Device Implantation; J. Nnanabu, D. Rodgers, N. Sarswat, J. Raikhelkar, G. Kim, S. Kalantari, T. Ota, T. Song, C. Juricek, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
6:15 PM - 7:15 PM
MINI ORAL 05: Pediatric Thoracic Transplantation

Location: Hermes
Target Audience: PEDS, HF, HTX, ID, MCS, NHSAH, PHARM

Chairs: Bart L. Rottier, MD, and Jacqueline M. Lamour, MD

6:15 PM (134) Increasing Use of Exceptions After Changes to Pediatric Heart Allocation; A. M. Robinson1, W. T. Mahle2, R. R. Davies3. 1United Network for Organ Sharing, Richmond, VA; 2Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA; 3Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX

6:20 PM (135) Poor Outcomes on the Waiting List for Pediatric Lung Retransplant Patients Listed in Low Volume Centers; B. B. Scully1, J. S. Heinle1, M. L. Kueht1, E. D. McKenzie2, G. B. Mallory3, E. Melicoff3, A. Rana3. 1Surgery, Baylor College of Medicine, Houston, TX; 2Surgery, Emory College of Medicine, Atlanta, GA; 3Pulmonology and Pediatrics, Baylor College of Medicine, Houston, TX

6:25 PM (136) Worse Survival After Heart Transplantation in Children With Heterotaxy Syndrome; A. M. Khan1, E. Pahl1, E. Pruitt2, J. K. Kirkin3, E. Azeka4, P. G. Rusconi5, S. Guan6, A. P. Barnes7, S. Blensdorf1, M. D. Everitt8. 1Cardiology, Ann and Robert H. Lurie Children's Hospital, Chicago, IL; 2University of Alabama at Birmingham, Birmingham, AL; 3Surgery, University of Alabama at Birmingham, Birmingham, AL; 4Cardiology, University of Sao Paulo Medical School, Sao Paulo, Brazil; 5Miller School of Medicine, University of Miami, Miami, FL; 6Division of Cardiovascular and Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; 7University of Missouri-Kansas City School of Medicine, Kansas City, MO; 8Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO

6:30 PM (137) Prolonged Management in Donors with Reduced Ejection Fraction is a Risk Factor for Graft Loss in Pediatric Heart Transplantation; N. Singh1, C. Grosshuesch2, W. Johnson2, N. DeVogel2, Z. Yin2, T. Wang2, S. Kindel1, R. Woods1. 1Herma Heart Institute, Children's Hospital of Wisconsin, Milwaukee, WI; 2Medical College of Wisconsin, Milwaukee, WI

6:35 PM (138) Mycophenolic Acid Trough Levels Underestimate Drug Exposure in Pediatric Heart Transplant Patients; J. Pak1, T. Herzog2, T. Nemeth3, N. Jorgensen4, J. Friedland-Little5, B. Hong6, E. Albers6, M. Kemna7, Y. Law8. 1Pharmacy, Seattle Children’s Hospital, Seattle, WA; 2Pediatrics, Seattle Children's Hospital, Seattle, WA; 3Dept of Biostatistics, University of Washington, Seattle, WA; 4Pediatric Cardiology, Seattle Children’s Hospital, Seattle, WA

6:40 PM (139) What is the Risk of Rejection Following Subtherapeutic CNI Levels After Heart Transplantation?; S. Kerr1, N. Jorgensen2, B. Hong3, J. Friedland-Little3, E. Albers3, Y. Law3, M. Kemna3. 1Univ of Washington, School of Medicine, Seattle, WA; 2Univ of Washington, Dept of Biostatistics, Seattle, WA; 3Seattle Children’s Hospital, Seattle, WA

6:45 PM (140) Poor Out-patient Clinic Appointment Compliance is a Predictor of Post-Heart Transplant Mortality in Children; J. Dentel, B. Keeshan, J. Grijalva, Y. Law, J. Chen, D. M. McMullan. Seattle Children's Hospital, Seattle, WA

6:50 PM (141) Alteration of the Intestinal Microbiome in Pediatric Heart Transplant Patients is Associated with Diarrhea; J. A. Spinner1, S. W. Denfield1, R. Luna2, M. Balderas3, W. J. Dreyer1, S. Devaraj2. 1Pediatrics, Baylor College of Medicine, Houston, TX; 2Pathology & Immunology, Baylor College of Medicine, Houston, TX; 3Pathology, Baylor College of Medicine, Houston, TX

6:55 PM (142) The Effect of Infectious Complications During Ventricular Assist Device Use on Outcomes of Pediatric Heart Transplantation; S. R. Auerbach1, E. Pruitt2, T. T. Bradford3, M. J. Bock4, E. R. Skipper5, R. S. Cantor2, D. A. Koehl2, K. Butler6, J. C. Alejos7, R. E. Edens8, J. K. Kirkin6. 1Pediatrics, Div of Cardiology, Univ of Colorado Anschutz Medical Campus, Aurora, CO; 2Dept of Cardiovascular Surgery, Univ of Alabama at Birmingham, Birmingham, AL; 3Pediatrics, Div of Cardiology, Univ of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR; 4Pediatrics, Div of Cardiology, Loma Linda Univ Children's Hosp, Loma Linda, CA; 5Dept of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, NC; 6Children's Hosp Colorado, Heart Institute, Aurora, CO; 7Pediatrics, Div of Cardiology, UCLA, Mattel Children's Hosp, Los Angeles, CA; 8Pediatrics, Div of Cardiology, Univ of Iowa, Iowa City, IA

7:00 PM (143) Nutritional Rehabilitation of Pediatric Patients on Ventricular Assist Device Support; S. A. Hollander1, L. Schultz2, K. Dennis3, A. M. Hollander3, S. Rizzuto3, J. E. Murray4, D. N. Rosenthal1, C. S. Almond1. 1Pediatrics (Cardiology), Stanford University, Palo Alto, CA; 2Nutrition Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA; 3Rehabilitation Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA; 4Solid Organ Transplant Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA
7:05 PM (144) Using HeartWare Device in Paediatric Patients with Left Ventricular Heart Failure as Bridge to Transplantation Provides Improved Outcomes and Better Quality of Life: UK Based Experience; A. Khushnood1, A. R. Armada2, Z. Reinhardt2, T. Chila2, F. De Rita2, T. Hsia1, A. Karimova1, M. Fenton1, M. Burch1. 1Heart Transplantation, Great Ormond Street Hospital, London, United Kingdom, 2Heart Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

7:10 PM (145) Novel Virtual Reality Techniques Improve Virtual Implantation of Total Artificial Heart in the Pediatric Population; R. A. Moore, N. Szugye, F. Zafar, C. Villa, R. Bryant III, M. Taylor, A. Lorts, D. Morales. The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
6:15 PM - 7:15 PM
MINI ORAL 06: Heart Failure and Transplantation: Outcomes and Antibodies

Location: Mediterranea 6
Target Audience: HF, BSTR, EEP, HTX, MCS, NHSAH, PATH

Chairs: Eugenia Raichlin, MD, and Javier Segovia, MD, PhD

6:15 PM (146) Elevated Panel Reactive Antibodies in Patients Bridged to Heart Transplantation with Ventricular Assist Devices: A. Iyengar, M. Caceres Polo, O. Kwon, E. Adams, L. Reardon, J. Schaeneman, M. Kwon, A. Ardehalii, E. DePasquale. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2University of California - Los Angeles, Los Angeles, CA


6:25 PM (148) Trends of Admission and Hospital Outcomes of Acute Myocarditis. Insight from the U.S. Nationwide Inpatient Sample 2010-2014: V. Blumer, G. A. Hernandez, M. Ortiz, C. Rueda, J. Lindenfeld, S. V. Chaparro. 1Dept of Internal Medicine, University of Miami - Jackson Memorial Hospital, Miami, FL, 2Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN, 3Universidad Central de Venezuela, Caracas, Venezuela, 4Bolivarian Republic of, 5Division of Cardiology, University of Miami, Miller School of Medicine, Miami, FL

6:30 PM (149) Normal Serum Lactic Acid is Discordant with Shock in Advanced Heart Failure Patients: N. Narang, L. Lafim, R. Kalathiya, B. Chung, A. Nguyen, M. R. Costanzo, T. Imamura, S. Kalantari, G. H. Kim, J. Raikhelkar, N. Sarswat, V. Jeevanandam, G. Sayer, N. Uriel. 1Cardiology, University of Chicago Medical Center, Chicago, IL, 2Cardiology, Edwards Hospital Center, Naperville, IL, 3Cardiac Surgery, University of Chicago Medical Center, Chicago, IL


6:45 PM (152) Effect of Cardiac Rehabilitation on Muscle Mass, Muscle Strength, and Exercise Tolerance in Patients with Heart Failure: K. Kim, S. Kim, S. Lee, S. Hong. 1Sejong General Hospital, Seoul, Korea, Republic of, 2Dept of Rehabilitaition, Sejong General Hospital, Seoul, Korea, Republic of


6:55 PM (154) Profiles of Ambulatory Advanced Heart Failure: A Report from the REVIVAL Registry: M. Kittleson, J. D. Estep, M. Palardy, N. Gilotra, P. Shah, A. V. Ambardekar, J. Thibodeau, G. A. Ewald, M. M. Mountis, S. W. Robinson, K. Shah, S. Khalatbiri, C. A. Spino, J. Baldwin, N. Jeffries, D. L. Mann, L. W. Stevenson, K. D. Aaronson, G. C. Stewart. 1Cedars Sinai Heart Institute, Los Angeles, CA, 2Houston Methodist Research Institute, Houston, TX, 3Univ of Michigan, Ann Arbor, MI, 4Johns Hopkins Hospital, Baltimore, MD, 5Inova Heart and Vascular Institute, Falls Church, VA, 6Univ of Colorado, Aurora, CO, 7Univ of Texas Southwestern Medical Center, Dallas, TX, 8Washington Univ, St. Louis, MO, 9Cleveland Clinic Foundation, Cleveland, OH, 10Univ of Maryland, Baltimore, MD, 11Virginia Commonwealth University, Richmond, VA, 12National Heart, Lung, and Blood Institute, Bethesda, MD, 13Vanderbilt Univ, Nashville, TN, 14B Brigham and Women's Hospital, Boston, MA
7:00 PM (155) Frailty Screening in Advanced Heart Failure Patients Provided Multidimensional Prognostic Information and Disease Management Strategies; K. Fan, M. Wong, K. Cheng, C. Chow, K. Au. Cardiac Medical Unit, Grantham Hospital, Aberdeen, Hong Kong

7:05 PM (156) Highly Sensitized Heart Transplant Recipients Have Similar Outcomes Irrespective of Pre-transplant Ventricular Assist Device Implantation; C. D. Fraser, X. Zhou, J. T. Magruder, A. Suarez Pierre, C. Lui, R. S. Higgins, R. S. Higgins, A. Kilic. Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD

7:10 PM (157) The Role of Non-HLA Antibody to Angiotensin-II Type 1 Receptor in Patients Bridged to Heart Transplant Using Continuous Flow Ventricular Assist Device; V. Q. Chau, M. Flattery, K. Desai, P. Uber, P. M. Kimball, K. B. Shah. 1Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, 2Transplant Surgery, Virginia Commonwealth University, Richmond, VA
THURSDAY, APRIL 12, 2018

8:30 AM - 10:30 AM
SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support

**Location:** Apollon  
**Target Audience:** MCS, HF/HTX  
**Chairs:** James Antaki, PhD, and Anna L Meyer, MD  

**Session Summary:** The purpose of this symposium is to review the impact of Continuous Flow (CF) LVAD physiology on the vascular system. The symposium will start with a primer on vascular physiology. It will follow with sessions on new data regarding larger artery stiffness and cerebral autoregulation during CF LVAD. The fourth session will offer a fresh perspective on bleeding with a focus on AVM development. The last session will explore changes in the peripheral vasculature and endothelial dysfunction during CF LVAD.

8:30 AM *The ABCs of Low Pulsatile Flow - A Primer on Vascular Physiology*  
Karen May-Newman, PhD, San Diego State University, San Diego, CA, USA

8:42 AM Q&A

8:47 AM *Is Aortic Stiffness the Missing Link Between Large Vessel Vascular Disease and Continuous Flow LVAD support?*  
Amrut V Ambardekar, M.D., University of Colorado, Aurora, CO, USA

8:59 AM Q&A

9:04 AM *Carotid Mechanoreceptors, Sympathetic Neural Activity and Cerebral Autoregulation*  
David W Markham, MD, Emory St. Joseph Hospital, Atlanta, GA, USA

9:16 AM Q&A

9:21 AM *Differential Effects of Pulsatile vs Non-Pulsatile Flow on the Renal Vasculature*  
Meredith A Brisco-Bacik, MD, MSCE, FACC, Temple University, Philadelphia, PA, USA

9:33 AM Q&A

9:38 AM *Maladaptation of the Peripheral Vasculature During Continuous Flow LVAD - Restoration of Cardiac Output Does Not Equal Normal Exercise Capacity*  
Finn Gustafsson, MD, Rigshospitalet, Copenhagen, Denmark

9:50 AM Q&A

9:55 AM *An Acquired Vasculopathy - A New Paradigm in Continuous Flow LVAD Related Arteriovenous Malformation Bleeding*  
Snehal R Patel, MD, Montefiore Medical Center, Bronx, NY, USA

10:07 AM Q&A

10:12 AM *Mechanisms of Angiogenesis During Continuous Flow LVAD Support*  
Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

10:24 AM Q&A
8:30 AM - 10:30 AM
SYMPOSIUM 09: “The Heat Is On” - Great Debates in Heart Transplantation

Location: Athena
Target Audience: HF/HTX, ID, MCS, NHSAH, PATH, Peds, PHARM

Chairs: Jon A Kobashigawa, MD, and Teresa De Marco, MD

Session Summary: This session will provide a forum for debate and discussion on controversial questions in heart transplantation, including selection of donors and management of allosensitized patients. Each debate will start with 5-minute case presented by a junior faculty member. The chairs will then poll the audience with a simple yes, no, or maybe question with a show of hands. This will be followed by 15 minutes PRO and 15 minutes CON debate by senior faculty members. The Chairs will subsequently poll the audience again, and declare the winner. A panel discussion with all speakers will conclude this session.

8:30 AM CASE PRESENTATION: A Young Donor with Brain Injury and Low Ejection Fraction
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

8:35 AM QUICK AUDIENCE POLL led by session co-chairs

8:36 AM DEBATE (Pro): “Come As You Are” – Low Ejection Fraction Donors Should Be Used for Heart Transplantation
Ulrich Jorde, MD, Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, USA

8:51 AM DEBATE (Con): “Come As You Are” – Low Ejection Fraction Donors Should Be Used for Heart Transplantation
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

9:06 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs

9:10 AM CASE PRESENTATION: A Young Hep C Positive Donor
Karen L Booth, MBChB, Freeman Hospital, Newcastle upon Tyne, United Kingdom

9:15 AM QUICK AUDIENCE POLL led by session co-chairs

9:16 AM DEBATE (Pro): “You Can’t Always Get What You Want” – Hep C Donors Should Be Used in Heart Transplantation
JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

9:31 AM DEBATE (Con): “You Can’t Always Get What You Want” – Hep C Donors Should Be Used in Heart Transplantation
Michael G Ison, MD, MS, Northwestern University Feinberg SoM, Chicago, IL, USA

9:46 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs

9:50 AM CASE PRESENTATION: A Diabetic, Allosensitized Patient on LVAD Awaiting Heart and Kidney Transplantation
Van N Selby, MD, UCSF Medical Center, San Francisco, CA, USA

9:55 AM QUICK AUDIENCE POLL by the session co-chairs

9:56 AM DEBATE (Pro): “Living on a Prayer” – Highly Allosensitized Patients on LVAD as Bridge to Transplantation Should Undergo Desensitization
Jignesh K. Patel, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, CA, USA

10:11 AM DEBATE (Con): “Living on a Prayer” – Highly Allosensitized Patients on LVAD as Bridge to Transplantation Should Undergo Desensitization
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

10:26 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs
8:30 AM - 10:30 AM  
**SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die**

**Location:** Mediterranee ABC  
**Target Audience:** HF/HTX, EEP, LTX, NHSAH, PEDS, PHARM  
**Chairs:** Maria G Crespo-Leiro, MD, and Margaret Fregoso, NP

**Session Summary:** Selection criteria for advanced heart & lung failure therapies have continued to evolve. Most centers have strict age limits. Despite this, there are more than 2000 heart & lung transplants in adults = 70 years of age. As the population ages, criteria for transplant may need to be reconsidered. This symposium serves to more closely examine the older population & considerations for advanced therapies including immunologic considerations, frailty, multiorgan dysfunction, ethical considerations.

**8:30 AM** *Definition of Frailty and Adapting Frailty Measures for Solid Organ Transplant*  
Geetha Bhat, MD, Advocate Christ Medical Center, Oak Lawn, IL, USA

**8:45 AM** *Pathophysiology and Risk Factors of Frailty*  
Peter MacDonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

**9:00 AM** *Reversing Frailty*  
Savitri Fedson, MD, Baylor College of Medicine, Houston, TX, USA

**9:15 AM** *Pharmacology in the Frail Patient*  
Steven P Ivulich, BPharm, Alfred Hospital, Melbourne, Australia

**9:30 AM** *The Right Stuff: Shared Decision Making in End-Stage Illness*  
Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**9:45 AM** *Multidisciplinary Considerations for the Frail Candidate and Recipient: Cognition and Mood*  
Rose DeRosa, PA-C, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

**10:00 AM** *Panel Discussion*
8:30 AM - 10:30 AM
SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics

Location: Clio/Thalie/Erato
Target Audience: LF/LTX, ID, NHSAH, PEDS, PHARM
Chairs: Cecilia Chaparro, MD, and Monique Malouf, FRACP

Session Summary: This session will discuss important issues surrounding the care of cystic fibrosis patients before and after lung transplantation such as nutritional optimization strategies, colon cancer screening and indication for liver-lung transplantation; CF transplantation outcome, timing for transplantation referral and re-listing; Surgical and perioperative issues specific to CF; Management of important infectious pathogens; Strategies to improve efficacy/ minimize toxicity of antimicrobial drugs

8:30 AM When Is It Time for Transplant in Cystic Fibrosis?
Jasvir S. Parmar, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom

8:45 AM Q&A

8:50 AM Keep Calm and Call the Surgeon: Surgical Perspective of Lung Transplant in Cystic Fibrosis
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

9:05 AM Q&A

9:10 AM The Cystic Fibrosis Gut
Denis Hadjiliadis, MD, University of Pennsylvania, Philadelphia, PA, USA

9:25 AM Q&A

9:30 AM What Comes Around Stays Around: Dealing with Pre- and Post-Transplant Aspergillus
Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

9:45 AM Q&A

Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

10:05 AM Q&A

10:10 AM Lung Transplantation in Cystic Fibrosis Patients: Who Should not be Transplanted?
Walter Weder, MD, University Hospital Zurich, Zurich, Switzerland

10:25 AM Q&A
8:30 AM - 10:30 AM
SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making

**Location:** Uranie/Calliope
**Target Audience:** CTEPH, LF/LTX, PH
**Chairs:** Elie Fadel, MD, and William Auger, MD

**Session Summary:** This symposium will focus on the key challenges in decision making that physicians face in managing a rising number of patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – especially those with 'early' disease and those with severe, distal disease. Presented in a debate format, this symposium highlights the advantages and disadvantages of each approach in a case based discussion.

8:30 AM **CASE PRESENTATION: A Male Patient with Distal CTEPH**
Mark Toshner, MD, Papworth Hospital, Cambridge, United Kingdom

8:35 AM **DEBATE (Pro): Distal Vessel CTEPH: "The Scalpel is Mightier than the Balloon"**
Michael M Madani, MD, UCSD Medical Center, San Diego, CA, USA

8:50 AM **DEBATE (Con): Distal Vessel CTEPH: "The Scalpel is Mightier than the Balloon"**
Irene Lang, MD, Medical University of Vienna, Vienna, Austria

9:05 AM **Debate Rebuttal (Pro)**
Michael M Madani, MD, UCSD Medical Center, San Diego, CA, USA

9:10 AM **Debate Rebuttal (Con)**
Irene Lang, MD, Medical University of Vienna, Vienna, Austria

9:15 AM **CASE PRESENTATION: Female Patient with Chronic Thromboembolic Disease (CTED)**
Mithun Chakravarthy, MD, Allegheny General Hospital, Pittsburgh, PA, USA

9:20 AM **DEBATE (Pro): Early Intervention in CTED: A Stitch in Time Saves Nine**
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland

9:35 AM **DEBATE (Con): Early Intervention in CTED: A Stitch in Time Saves Nine**
Joanna Pepke-Zaba, MD, Papworth Hospital, Cambridge, United Kingdom

9:50 AM **Debate Rebuttal (Pro)**
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland

9:55 AM **Debate Rebuttal (Con)**
Joanna Pepke-Zaba, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom

10:00 AM **Balloon Pulmonary Angioplasty: Is It Complementary or an Alternative to Pulmonary Thrombo-Endarterectomy?**
Olaf Mercier, MD, Centre Chirurgical Marie Lannelongue, Fontenay aux roses, France

10:15 AM **Should Balloon Pulmonary Angioplasty be Combined with Pulmonary Thrombo-Endarterectomy?**
Hiromi Matsubara, MD, PhD, Okayama Medical Center, Okayama, Japan
8:30 AM - 10:30 AM
SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team

Location: Hermes
Target Audience: PATH, EEP, HF/HTX, LF/LTX, MCS, NHSAH, PEDS, PHARM

Chairs: Martin J Goddard, FRCS, MRCPa, and Charles C Marboe, MD

Session Summary: The pathologist plays an important clinical role in the care of a thoracic transplant patient. The session will follow two patients (one heart and one lung) through the stages of pre-transplant diagnosis, the transplant itself, post-transplant follow-up and ultimately re-transplantation or death. The role of the pathologist in his/her clinical and scientific role will be emphasized at each stage of the process.

8:30 AM Evaluating the Native Heart and Mechanical Support Device (MCS: What's Gone Wrong?)
Robert Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

8:42 AM Q&A

8:47 AM Call the Pathologist: The Diagnostic Dilemma in the Failing Cardiac Allograft
Katharina Wassilew, MD, University of Copenhagen, Copenhagen, Denmark

8:59 AM Q&A

9:04 AM Cardiologist's Perspective
Mazen Hanna, MD, Cleveland Clinic, Cleveland, OH, USA

9:16 AM Q&A

9:21 AM Evaluating the Explanted Lungs: The Unexpected Diagnosis
Doris Rassl, MD, Papworth Hospital, Cambridge, United Kingdom

9:33 AM Q&A

9:38 AM Call the Pathologist: The Diagnostic Dilemma in the Failing Lung Allograft
Fiorella Calabrese, MD, University of Padua, Padua, Italy

9:50 AM Q&A

9:55 AM Pulmonologist's Perspective
Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

10:07 AM Q&A

10:12 AM Closing the Loop: What the Post-Mortem Offers the Clinician and the Family
Gregory Fishbein, MD, UCLA Medical Center, Los Angeles, CA, USA

10:24 AM Q&A
8:30 AM - 10:30 AM
SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology

Location: Mediterranee 6
Target Audience: BSTR, HF/HTX, LF/LTX, PATH

Chairs: Stijn Verleden, PhD, and Tereza Martinu, MD, PhD

Session Summary: Graft-specific responses involve a coordinated effort between multiple immune cell types. Exciting advances in transplant immunology are providing insights into these complex interactions that will affect both present and future care for heart and lung allograft recipients. This session will highlight cutting edge transplant immunology research into T, B, and NK lymphocytes and neutrophils, and describe how available therapies affect the cells.

8:30 AM **Immunosuppression Strategies and Innate Immunity**
Daniel R Goldstein, MD, University of Michigan, Ann Arbor, MI, USA

8:45 AM Q&A

8:50 AM **Coming Soon to an Allograft Near You: Regulatory T Cell Immunotherapy**
Gregor Warnecke, PhD, Hannover Medical School, Hannover, Germany

9:05 AM Q&A

9:10 AM **Natural Killer (NK) Cells: Friend or Foe?**
John R Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

9:25 AM Q&A

9:30 AM **Macrophages and Dendritic Cells: Inside the Control Center**
Carla C Baan, PhD, Erasmus Medical Center, Rotterdam, Netherlands

9:45 AM Q&A

9:50 AM **Targeting Rejection by Targeting B Cells**
Lori J West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

10:05 AM Q&A

10:10 AM **Alloimmunity: And Don’t Forget the Neutrophils!**
Andrew Gelman, PhD, Washington University, St. Louis, MO, USA

10:25 AM Q&A
11:00 AM - 12:30 PM
ORAL SESSION 15: The Final Frontier? Bleeding in MCS

Location: Apollon
Target Audience: MCS, NHSAH, PHARM

Chairs: Ulrich Jorde, MD, and Thomas Schlöglhofer, BSc

11:00 AM (158) Increased Bleeding Risk in LVAD Patients with Elevated Angiopoietin-2 and TNF-α: Analysis of the PREVENT Multicenter Study; G. H. Kim¹, G. Sayer¹, J. Ransom², M. Keebler³, J. Katz⁴, A. Kilic⁵, J. Lindenfeld⁶, G. Egnaczyk⁶, P. Shah⁶, A. Brieke⁶, J. Walenga⁶, D. Crandall¹⁰, D. Farrar¹⁰, K. Sundareswaran¹⁰, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Baptist Health Heart and Transplant Institute, Little Rock, AR, ³Vanderbilt University, Nashville, TN, ⁴University of North Carolina, Chapel Hill, NC, ⁵Ohio State University, Columbus, OH, ⁶Christ Hospital, Cincinnati, OH, ⁷Inova Heart and Vascular Institute, Falls Church, VA, ⁸University of Colorado, Aurora, CO, ⁹Loyola University Medical Center, Maywood, IL, ¹⁰Abbott (Formerly St. Jude Medical), Chicago, IL


11:30 AM (160) Discontinuation of Aspirin in Heartmate 3 Left Ventricular Assist Device; S. Lim, A. Ranasinghe, N. Howell. University Hospital Birmingham, Birmingham, United Kingdom

11:45 AM (161) Minimal AnticoaGulation Evaluation To aUgment heMocompatibility - The MAGENTUM 1 Study; I. Netuka¹, P. Ivák², Z. Tučanová³, S. Gregor¹, O. Szárszoi², P. Sood⁴, J. Rimsans⁴, J. M. Connors⁵, M. R. Mehra⁶. ¹Institute for Clinical & Experimental Medicine, Prague, Czech Republic, ²Dept of Cardiovascular Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, ³Global Clinical Affairs, Heart Failure, Abbott, Burlington, MA, ⁴Dept of Pharmacy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Heart and Vascular Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

12:00 PM (162) Pre-Operative Pectoralis Muscle Quantity and Attenuation by Computed Tomography are Predictive of Recurrent Gastrointestinal Bleeding on Left Ventricular Assist Device Support; R. Cogswell¹, R. John², J. Shultz³, C. Martin₁, T. Thenappan¹, F. Kamdar¹, C. P. Earthman², L. M. Teigen³. ¹Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ²Dept of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁴Food Science and Nutrition, University of Minnesota, St. Paul, MN

12:15 PM (163) Pre-Operative Tricuspid Regurgitation and Right Ventricular Enlargement are Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices; M. Liebo¹, Z. Hussain¹, S. Malik², R. Zolty², H. Ilias Basha¹, A. Heroux¹, B. Lowes², E. Raichlin¹. ¹Medicine, Loyola University Medical Center, Maywood, IL, ²Medicine, University of Nebraska Medical Center, Omaha, NE
11:00 AM - 12:30 PM
ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS

Location: Athena
Target Audience: MCS, HF, NHSAH, PATH
Chairs: Pascal N Leprince, MD, PhD, and Shelley Hall, MD

11:00 AM (164) Valvular Regurgitation Affects Hemodynamic Predictors of Right Ventricular Failure After Left Ventricular Assist Device Implantation; R. M. Wehbe¹, A. Tibrewala¹, J. E. Wilcox¹, K. Ghafourian¹, A. S. Anderson¹, R. Harap², J. Tomasko², J. Nakano², A. Churyla², D. T. Pham², J. D. Rich¹, E. Vorovich¹. ¹Division of Cardiology, Dept of Medicine, Northwestern University, Chicago, IL, ²Division of Cardiac Surgery, Dept of Surgery, Northwestern University, Chicago, IL


11:30 AM (166) Impact of Concomitant Mitral Valve Surgery for Mitral Regurgitation During LVAD Implantation: Systematic Review and Meta-Analysis; J. Choi¹, J. G. Luc², E. Moncho Escrivá³, K. Phan⁴, S. A. Rizvi¹, S. Patel¹, J. W. Entwistle¹, R. J. Morris¹, H. T. Massey¹, V. Tchantchaleishvili¹. ¹Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, ²University of Alberta, Edmonton, AB, Canada, ³University of Granada, Granada, Spain, ⁴University of New South Wales, Sydney, Australia

11:45 AM (167) Natural History of Mild Aortic Insufficiency at the Time of Left Ventricular Assist Device Implantation for Heartmate II and HVAD; M. Kawabori, C. Kurihara, R. T. Conyer, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. Texas Heart Institute/Baylor College of Medicine, Texas Heart Institute/Baylor College of Medicine, Houston, TX


12:15 PM (169) TAVR is an Effective and Durable Treatment Modality for Symptomatic Aortic Insufficiency in LVAD Patients; A. Yehya¹, V. Rajagopal¹, C. Meduri¹, J. Kauten², M. Brown², L. Dean¹, J. Webster¹, A. Krishnamoorthy¹, T. Hrobowski¹, D. Dean¹. ¹Advanced Heart Failure, Piedmont Heart, Atlanta, GA, ²Cardiac Surgery, Piedmont Heart, Atlanta, GA
11:00 AM - 12:30 PM  
**ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses**

**Location:** Clio/Thalie/Erato  
**Target Audience:** ID, HTX, LTX, MCS, PHARM  
**Chairs:** Paolo A Grossi, MD, PhD, and Robin K. Avery, MD

11:00 AM (170) **Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV-Negative Recipients;** S. Aslam, M. Mariski, G. Pretorius, E. Adler. *University of California, San Diego, San Diego, CA*


11:30 AM (172) **Early Experience With the Use of Hepatitis C Antibody-positive, Nucleic Acid Testing-negative Donors in Lung Transplantation;** M. S. Mulvihill¹, M. L. Cox¹, J. Watson¹, L. Eilaisi², C. R. Wolfe³, A. Gray³, M. G. Hartwig¹. ¹Dept of Surgery, Duke University, Durham, NC, ²Duke Transplant Center, Duke University, Durham, NC, ³Dept of Medicine, Duke University, Durham, NC

11:45 AM (173) **Unexplained Persistent Hepatitis C Seropositivity (Hepc Ab+Ve) in the Absence of Viremia in Lung Transplant LTX Recipients from Hepc Ab+Ve/Nucleic Acid Test Negative (NAT-Ve) Donors Associated with Excellent Clinical Outcomes and Implications for Future Practice;** O. C. Smibert¹, J. S. Doyle¹, D. Pilcher², M. A. Paraskeva³, G. I. Snell³. ¹Infectious Diseases, Alfred Hospital, Melbourne, Australia, ²Intensive Care, Alfred Hospital, Melbourne, Australia, ³Lung transplant service, Alfred Hospital, Melbourne, Australia

12:00 PM (174) **Hepatitis E Virus Infection in Lung Transplant Recipients;** G. Ambrocio¹, M. Aguilar Perez², R. Laporta², M. Lázaro², A. Avellón³, G. Arán-Tohá⁴, N. Martos Gisbert², M. Ussetti Gil². ¹Section of Pulmonary Medicine, Philippine General Hospital-University of Philippines, Manila, Philippines, ²Section of Pulmonary Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³Section of Microbiology, Instituto de Salud Carlos III, Madrid, Spain, ⁴Section of Microbiology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

12:15 PM (175) **The Prevalence of Hepatitis E Virus Infections and Ribavirin Therapy in Heart Transplant Recipients;** K. Okamura¹, K. Nawata¹, M. Kimura¹, O. Kinoshita¹, A. Masuzawa¹, H. Yamauchi¹, Y. Hirata¹, Y. Owada², Y. Oshiro³, H. Okamoto⁴, N. Ohkohchi³, M. Ono¹. ¹Cardiac Surgery, The University of Tokyo Hospital, Bunkyo-ku Tokyo, Japan, ²Cardiac Surgery, University of Tsukuba, Tsukuba, Ibaraki, Japan, ³University of Tsukuba, Tsukuba, Japan, ⁴Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan
11:00 AM - 12:30 PM
ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection

Location: Hermes
Target Audience: PATH, BSTR, HTX, LTX

Chairs: E Rene Rodriguez, MD, and Alexandra Rice, FRCPath

11:00 AM (176) Validation of Donor-derived Cell-free DNA to Detect Heart-transplant Rejection; H. Valantine, P. Shah, S. Shah, S. Hsu, E. Feller, M. Rodrigo, S. Najjar, U. Fidelì, S. Gorham, A. Marishta, Y. Yang, M. Jang, I. Tunc, S. Agbor-Enoh. Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, 2Division of Cardiology, Inova Fairfax Hospital, Falls Church, VA, 3Division of Cardiology, Virginia Commonwealth University, Richmond, VA, 4Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD, 5Division of Cardiology, University of Maryland Medical Center, Baltimore, MD, 6Division of Cardiology, Medstar Washington Hospital Center, Washington, DC


11:30 AM (178) By Molecular Analysis, Many ISHLT Histologic Rejection Diagnoses Are Associated With Molecular Injury, Not Molecular Rejection; J. Reeve, D. H. Kim, M. G. Crespo-Leiro, J. Kobashigawa, L. Potena, M. Deng, M. Cadeiras, E. C. Depasquale, P. Bruneval, A. Loupy, P. Macdonald, A. Zuckermann, A. Z. Aliabadi, J. Goekler, P. F. Halloran. 1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, 4Cedars-Sinai Heart Institute, Beverly Hills, CA, 5University of Bologna, Bologna, Italy, 6Ronald Reagan UCLA Medical Center, Los Angeles, CA, 7Hôpital Européen Georges Pompidou, Paris, France, 8Hôpital Necker, Paris, France, 9The Victor Chang Cardiac Research Institute, Sydney, Australia, 10Medical University of Vienna, Vienna, Austria

11:45 AM (179) Phosphorylated P70 S6 Kinase and S6 Ribosomal Protein Value as Diagnostic Marker of Antibody-mediated Rejection in Lung Allografts: A Multicenter Study; F. Calabrese, F. Lunardi, J. Le Pavec, P. Dorfmuller, M. Ivanovic, T. Pena, K. Wassilew, M. Perch, S. Hirsch, M. Chenard, D. Neil, A. Montero-Fernandez, A. Rice, E. Cozzi, P. Tellaroli, F. Rea, D. J. Levine, M. Goddard. 1Univ of Padova Medical School, Padova, Italy, 2Marie Lannelongue Hospital, Le Plessis Robinson, France, 3Univ of Iowa, Iowa City, IA, 4Univ Hospital of Copenhagen, Copenhagen, Denmark, 5Univ Hospital of Strasbourg, Strasbourg, France, 6Queen Elizabeth Hospital, Birmingham, United Kingdom, 7Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, 8Univ of Texas Health Science Center, San Antonio, TX, 9Papworth Hospital NHS Trust, Cambridge, United Kingdom

12:00 PM (180) Molecular Diagnosis of Rejection Phenotypes in Lung Transplant Biopsies: Initial Findings of the INTERLUNG Study; K. Halloran, M. D. Parkes, J. Chang, K. Famulski, J. Reeve, R. Hachem, P. Jaksch, S. Juvet, S. Keshavjee, W. Klepetko, D. Kreisel, A. Loupy, A. Roux, E. P. Trulock, G. Snell, I. Timofte, G. Westall, P. Halloran. 1Univ of Alberta, Edmonton, AB, Canada, 2Washington Univ School of Medicine in St. Louis, St. Louis, MO, 3Medical Univ of Vienna, Vienna, Austria, 4Univ of Toronto, Toronto, ON, Canada, 5Necker Hospital, Paris, France, 6Foch Hospital, Paris, France, 7Alfred Hospital, Melbourne, Australia, 8Univ of Maryland, Baltimore, MD

12:15 PM (181) Molecular Detection of Rejection-like Changes in Proximal Bronchial Mucosal Lung Transplant Biopsies: Initial Findings of the INTERLUNG Study; K. Halloran, M. D. Parkes, J. Chang, K. Famulski, J. Reeve, R. Hachem, S. Juvet, S. Keshavjee, D. Kreisel, G. Snell, E. P. Trulock, I. Timofte, G. Westall, P. Halloran. 1Univ of Alberta, Edmonton, AB, Canada, 2Washington Univ School of Medicine in St. Louis, St. Louis, MO, 3Univ of Toronto, Toronto, ON, Canada, 4Alfred Hospital, Melbourne, Australia, 5Univ of Maryland, Baltimore, MD
11:00 AM - 12:30 PM
ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science

**Location:** Mediterranee 6
**Target Audience:** BSTR, LTX, PATH

**Chairs:** Daniel Chambers, MBBS, MRCP, FRACP, MD, and Arne Neyrinck, MD, PhD

**11:00 AM (182) Alpha 1 Antitrypsin to Prevent Ischemia Repercusión Injury in a Pig Lung Transplant Survival Model;** A. Mariscal1, L. Caldaronése, M. Chen2, M. Cypel2, J. Tikkanen2, M. Liu2, S. Keshavjee2. 1UHN, Toronto Lung Transplant Program, Toronto, ON, Canada, 2UHN, Toronto Lung Transplant Program, Toronto, ON, Canada

**11:15 AM (183) Repeated Episodes of Airway Inflammation Augment Acute Rejection and Fibrosis in a Mouse Lung Transplant Model;** T. Watanabe1, K. Boonstra1, M. Horie2, C. Konoeda3, Z. Guan1, M. Maxim1, D. Hwang3, M. Liu1, S. Keshavjee1, S. Juvet1, T. Martinu1. 1Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada, 2Joint Dept of Medical Imaging, University Health Network, Toronto, ON, Canada, 3Dept of Pathology, University Health Network, Toronto, ON, Canada

**11:30 AM (184) Impact of Primary Graft Dysfunction on Allograft T Cell Chimerism Following Lung Transplantation;** M. E. Snyder1, T. Connors2, L. Benvenuto1, L. Shah1, H. Robbins1, J. Hook1, F. D’Ovidio3, M. Bacchetta1, J. R. Sonett1, S. Arcasoy3, D. L. Farber3. 1Medicine, Columbia University Medical Center, New York, NY, 2Pediatrics, Columbia University Medical Center, New York, NY, 3Surgery, Columbia University Medical Center, New York, NY

**11:45 AM (185) Linking Early Humoral Sensitization in Lung Transplant Recipients with Even Earlier Cellular Alloreactivity in Humanized Mice;** T. Siemeni1, A. Knöfel1, F. Ius1, J. Salman1, N. Madrahimov1, W. Sommer1, M. Avsar1, K. Jansson1, C. Kühn1, C. Falk2, I. Tudorache1, A. Haverich1, G. Warnecke1. 1Hannover HTTG, Hannover, Germany, 2Institute of transplant immunology, Hannover, Germany

**12:00 PM (186) Emphysema Induces Lung-Specific Autoantibodies that Exacerbate Ischemia Reperfusion Injury Post-Lung Transplantation;** K. J. Patel1, Q. Cheng2, D. P. Allen1, S. Stephenson2, M. Goddard3, S. N. Nadig1, C. Atkinson2. 1Surgery, Medical University of South Carolina, Charleston, SC, 2Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 3Transplantation, Papworth Hospital NHS Foundation Trust, Cambridgeshire, United Kingdom

11:00 AM – 12:30 PM
SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation

Location: Mediterranee ABC
Target Audience: HF/HTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM
Chairs: Maryl R Johnson, MD, and Hermann Reichenspurner, MD, PhD
Session Summary: Heart transplantation has evolved from a highly specialized procedure performed at only a handful of centers to a routine treatment option for end-stage heart failure. This session will highlight the historical milestones in surgical techniques, immunosuppression, pathology interpretation, and recipient management that have helped to define the field over the past 50 years.

11:00 AM Second Chances: How I Spent the Past 38 Years with My New Heart
Brent Evje, Fairdale, ND, USA

11:15 AM Replacing the Heart: The Early Days of Heart Transplantation
Sir Terence English, KBE, FRCS, Oxford, United Kingdom

11:30 AM Heart-to-Heart: Patient Selection for Heart Transplantation
Marco Masetti, MD, Malpighi University Hospital, Bologna, Italy

11:45 AM Protect My Heart: The Evolution of Immunosuppression
Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

12:00 PM A Piece of My Heart: Developing and Refining Pathologic Grading of Rejection
Elizabeth H Hammond, MD, Intermountain Healthcare/University of Utah, Salt Lake City, UT, USA

12:15 PM Our Community: The Role of ISHLT in Advancing Heart Transplant Knowledge
Sharon A. Hunt, MD, Stanford University, Stanford, CA, USA
11:00 AM - 12:30 PM
SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule

Location: Uranie/Calliope
Target Audience: ALL

Chairs: Evan P Kransdorf, MD, PhD, and Fabienne Dobbels, MSc, PhD

Session Summary: This session will highlight the most exciting publications in JHLT over the past year, each paper followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field. Due to time limits the presented papers for each talk will STRICTLY be limited to FOUR selected papers.

11:00 AM JHLT Best Papers of the Year
Patricia A Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

11:10 AM Highlights of Heart Transplantation and Mechanical Circulatory Support
Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA

11:25 AM Expert Senior Discussant in Heart Transplantation and MCS
Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA

11:30 AM Highlights of Lung Transplantation
Gustavo Parrilla, MD, Hospital University Fundación Favaloro, Favaloro, Argentina

11:45 AM Expert Senior Discussant in Lung Transplantation
Tereza Martinu, MD, Toronto General Hospital, Toronto, Canada

11:50 AM Highlights of Pediatric Heart and Lung Transplantation
Claire Irving, MD, Children’s Hospital Westmead, Westmead, Australia

12:05 PM Expert Senior Discussant in Pediatric Heart and Lung Transplantation
Richard Kirk, FRCP, FRCPCH, UT Southwestern Medical Center, Dallas, TX, USA

12:10 PM Highlights of Pulmonary Hypertension
Mitesh V Thakrar, MD, University of Calgary, Calgary, AB, Canada

12:25 PM Expert Senior Discussant in Pulmonary Hypertension
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
2:00 PM - 4:00 PM
SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished

Location: Apollon
Target Audience: MCS, HF/HTX, ID, NHSAH, PHARM
Chairs: Bastian Schmack, MD, and Aly El Banayosy, MD

Session Summary: Mechanical Circulatory Support management is constantly evolving. While serious adverse events such as bleeding, thrombosis, stroke and RV failure are now recognized, comprehensive prevention and treatment strategies have either not been developed or are in constant flux.

2:00 PM Anticoagulation Approaches in MCS - New Developments?
Andre Vincentelli, MD, PhD, CHU de Lille, Lille, France

2:10 PM Q&A

2:15 PM Hemolysis in Continuous Flow LVAD Patients: When Is It Clinically Relevant?
Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, USA

2:25 PM Q&A

2:30 PM Pathophysiology and Management of Stroke in Continuous Flow LVAD Patients
Joshua Z Willey, MD, MAS, Columbia University, New York, NY, USA

2:40 PM Q&A

2:45 PM How to Assess Aortic Insufficiency and Its Clinical Relevance During Continuous Flow LVAD Support? Implications for Management
Jennifer A Cowger, MD, MS, St. Vincent Heart Center, Indianapolis, IN, USA

2:55 PM Q&A

3:00 PM Dealing with the Bugs - Chronic LVAD Infections During Destination Therapy Support
Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

3:10 PM Q&A

3:15 PM Device Optimization - Invasive or Noninvasive
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

3:25 PM Q&A

3:30 PM Pulmonary Artery Sensors and LVAD: First Step to a SmartPump
Nir Uriel, MD, University of Chicago, Chicago, IL, USA

3:40 PM Q&A

3:45 PM Ancillary Procedures During LVAD Placement Prevent Long-Term Complications: Myth or Reality?
Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

3:55 PM Q&A
2:00 PM - 4:00 PM
SYMPOSIUM 18: It’s Electric! Electrophysiologic Management of the LVAD Patient

Location: Athena
Target Audience: MCS, HF/HTX, NHSAH, PEDS

Chairs: Jan Schmitto, MD, PhD, and Brian Houston, MD

Session Summary: As the population of LVAD patients grows (largely due to increased use of destination therapy devices), the management of the accompanying electrophysiologic complications and devices becomes increasingly important. In this session, the speakers will tackle topics including the prevention and treatment of ventricular tachyarrhythmias, the implications and treatment of atrial fibrillation, and a pro/con debate regarding the utility of cardiac resynchronization therapy (CRT) in VAD patients.

2:00 PM An Ounce of Prevention: Intra-Operative Approach to Ventricular Tachycardia in LVAD
James D Bergin, MD, University of Virginia Health Science Center, Charlottesville, VA, USA

2:15 PM Q&A

2:20 PM Approach to Ventricular Tachycardia in LVAD Patients - A Pound of Cure: Invasive Management of Ventricular Tachycardia After VAD Implantation
Joshua D Moss, MD, UCSF Medical Center, San Francisco, CA, USA

2:35 PM Q&A

2:40 PM Atrial Fibrillation in the LVAD Patient: Pest or Problem?
Kavitha Muthiah, MBchB, PhD, St. Vincent's Hospital, Sydney, Australia

2:55 PM Q&A

3:00 PM The Shocking Truth: Utility Of and Programming For the Implantable Cardioverter Defibrillator After LVAD
Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany

3:15 PM Q&A

3:20 PM DEBATE (Pro): Cardiac Resynchronization Therapy is Beneficial in LVAD Patients
Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

3:35 PM DEBATE (Con): Cardiac Resynchronization Therapy is Beneficial in LVAD Patients
Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA

3:50 PM Debate Rebuttal (Pro)
Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

3:55 PM Debate Rebuttal (Con)
Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA
2:00 PM - 4:00 PM
SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation - 2018

Location: Mediterranee ABC
Target Audience: LF/LTX, BSTR, PATH, PEDS

Chairs: Deborah Levine, MD, and Christian Benden, MD, FCCP

Session Summary: AMR after lung transplantation is an increasingly recognized form of rejection that often results in allograft failure. Since the Society developed a standardized definition in 2016, the community has had increasing experience in AMR, however numerous questions regarding the diagnosis and management persist. The purpose of this session is to provide clinicians and researchers with the latest update on HLA antibody testing, pathology, clinical management, and future diagnostics.

2:00 PM HLA Antibody Testing - 2018
Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA, USA

2:20 PM Pathology of Pulmonary AMR
Desley Neil, FRCPath, Queen Elizabeth Hospital, Birmingham, United Kingdom

2:40 PM Treatment of AMR in Lung Transplantation
Olivier Brugière, MD, PhD, Hôpital Bichat, Paris, France

3:00 PM DEBATE: We Should Treat De Novo DSA (Pro)
Ramsey Hachem, MD, Washington University, St. Louis, MO, USA

3:15 PM DEBATE: We Should Treat De Novo DSA (Con)
Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

3:30 PM Debate Rebuttal (Pro)
Ramsey Hachem, MD, Washington University, St. Louis, MO, USA

3:35 PM Debate Rebuttal (Con)
Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

3:40 PM Panel Discussion
2:00 PM - 4:00 PM
SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?

**Location:** Hermes
**Target Audience:** PHARM, BSTR, HF/HTX, ID, LF/LTX, NHSAH, PATH, PEDS
**Chairs:** Haifa Lyster, MSc, and Andreas Zuckermann, MD

**Session Summary:** The session will cover malignancy after transplantation focusing on causes, epidemiology, effective treatments, and risks associated with immunosuppression minimization.

2:00 PM *The Root of All Evil: Pathophysiology/Epidemiology of Malignancy in Transplant*
Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

2:20 PM *Q&A*

2:24 PM *The Bad Actor: the Role of Epstein-Barr Virus (EBV) Reactivation in the Development of Post-Transplant Lympho-Proliferative Disease*
Erik Verschuuren, MD, PhD, University Medical Center, Groningen, Netherlands

2:44 PM *Q&A*

2:48 PM *Treatment of Malignancy - More Than Just CHOPping Away at Cancer*
Nicole Kaiser, PharmD, BCOP, Children's Hospital Colorado, Aurora, CO, USA

3:08 PM *Q&A*

3:12 PM *Lurking in the Shadows: Risk of Rejection or Graft Failure Before, During, and After Chemotherapy*
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia

3:32 PM *Q&A*

3:36 PM *Looking Back and Moving Forward - Immunosuppression Before and After Cancer*
Edward Horn, PharmD, Allegheny General Hospital, Pittsburgh, PA, USA

3:56 PM *Q&A*
2:00 PM - 4:00 PM
SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy

Location: Uranie/Calliope
Target Audience: PH, HF/HTX, LF/LTX, MCS, PEDS, PHARM
Chairs: Ioana Preston, MD, and Oksana A Shlobin, MD

Session Summary: This symposium focuses on current challenges in decision making that physicians face in managing PAH patients in the setting of increased genetic/proteomic awareness, bridge to lung transplant, and management algorithms through a series of pro-con debates and didactic lectures.

2:00 PM DEBATE (Pro): Gene vs. Product: Genetic Testing and Not Proteomics is the Path Forward to Realize Personalized Management of PAH
Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

2:15 PM DEBATE (Con): Gene vs. Product: Genetic Testing and Not Proteomics is the Path Forward to Realize Personalized Management of PAH
Evelyn M Horn, MD, Weill Cornell Medical Center, New York, NY, USA

2:30 PM Debate Rebuttal (Pro)
Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

2:35 PM Debate Rebuttal (Con)
Evelyn M Horn, MD, Weill Cornell Medical Center, New York, NY, USA

2:40 PM DEBATE (Pro): Early Application of ECLS is the Preferred Bridge to Lung Transplantation for PAH
Clemens Aigner, MD, Ruhrlandklinik - University Essen, Essen, Germany

2:55 PM DEBATE (Con): Early Application of ECLS is the Preferred Bridge to Lung Transplantation for PAH
Erika Berman-Rosenzweig, MD, Columbia University, New York, NY, USA

3:10 PM Debate Rebuttal (Pro)
Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

3:15 PM Debate Rebuttal (Con)
Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

3:20 PM DEBATE (Pro): The ERS/ESC Risk Profiles are Superior to the REVEAL Calculator for Providing Goal Directed Therapy in PAH
C. Dario Vizza, MD, University of Rome, Rome, Italy

3:35 PM DEBATE (Con): The ERS/ESC Risk Profiles are Superior to the REVEAL Calculator for Providing Goal Directed Therapy in PAH
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

3:50 PM Debate Rebuttal (Pro)
C. Dario Vizza, MD, University of Rome, Rome, Italy

3:55 PM Debate Rebuttal (Con)
Raymond L Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
2:00 PM - 4:00 PM
SYMPOSIUM 22: Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape

Location: Clio/Thalie/Erato
Target Audience: ID, BSTR, HF/HTX, LF/LTX, NHSAH, PATH, PEDS, PHARM

Chairs: Aric Gregson, MD, and Macé M Schuurmans, MD

Session Summary: Cytomegalovirus (CMV) continues to present diagnostic and therapeutic challenges for clinicians caring for thoracic organ transplant recipients. Advances in CMV detection, such as quantitative PCR, have introduced uncertainties about when to initiate and cease therapy. Newer CMV immunoassays may change how we manage CMV. Prolonged prophylactic strategies with valganciclovir have reduced disease incidence, but present new challenges, including resistant and potentially untreatable CMV disease.

2:00 PM How Many Copies Do We Need? Viremia, Disease, and Everything In Between
Jutta K Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada

2:15 PM Q&A

2:20 PM Counting Spots: The Use of CMV Immunoassays
Kovi Levin, MD, The Alfred Hospital, Melbourne, Australia

2:35 PM Q&A

2:40 PM CMV Immunoglobulins: When, Where and Why?
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

2:55 PM Q&A

3:00 PM Prophylaxis Duration: Are We There Yet?
Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital, Cincinnati, OH, USA

3:15 PM Q&A

3:20 PM Resistance and Challenging Infections: Time to Get Creative
Robin Avery, MD, Johns Hopkins University, Baltimore, MD, USA

3:35 PM Q&A

3:40 PM Skirting the Abyss: Drug Toxicities
Kyle Dawson, MBA, BCPS, University of Kentucky, Lexington, KY, USA

3:55 PM Q&A
SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation

Location: Mediterranee 6
Target Audience: PEDS, ID, LF/LTX
Chairs: Ranny Goldwasser, MD, and Melinda P. Solomon, MD, FRCPC

Session Summary: Due to the small number of thoracic transplants in children, interventions and monitoring are extrapolated from adult and other solid organ transplant protocols. How imaging studies, biopsy, and routine cardiac catheterization or bronchoscopy examinations affect long term morbidities and mortality in children is unclear. In this session, experts in the field of pediatric thoracic transplantation will debate the impact of routine post-transplant care on long term morbidities and outcome.

2:00 PM Emerging Biomarkers in Pediatric Thoracic Transplantation
Kevin P Daly, MD, Boston Children's Hospital, Boston, MA, USA

2:20 PM DEBATE (Pro): Bronchoscopy is the Gold Standard
Brigitte Willemse, MD, University Medical Center, Groningen, Netherlands

2:35 PM DEBATE (Con): Bronchoscopy is the Gold Standard
Marc Schecter, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

2:50 PM Debate Rebuttal (Pro)
Brigitte W Willemse, MD, PhD, University Medical Center, Groningen, Netherlands

2:55 PM Debate Rebuttal (Con)
Marc G Schecter, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

3:15 PM DEBATE (Pro): Cardiac Catheterization is the Gold Standard
Daphne T. Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA

3:00 PM DEBATE (Con): Cardiac Catheterization is the Gold Standard
Brian Feingold, MD, MS, Children ’s Hospital of Pittsburgh, Pittsburgh, PA, USA

3:30 PM Debate Rebuttal (Pro)
Daphne T Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA

3:35 PM Debate Rebuttal (Con)
Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

3:40 PM Panel Discussion
4:30 PM - 6:00 PM
ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS

Location: Apollon
Target Audience: MCS, NHSAH, PEDS

Chairs: Antonio Loforte, MD, and Joshua Z Willey, MD, MAS

(188) WITHDRAWN

4:30 PM (1246) Less Invasive Left Ventricular Assist Device Implantation - 5-Year Survival and Post Transplant Outcomes; J. Riebandt1, R. Moayedifar1, D. Wiedemann1, T. Schlöglhofer2, K. Dimitrov1, A. Rajek3, G. Laufer1, D. Zimpfer1. 1Cardiac Surgery, Medical Univ Vienna, Vienna, Austria, 2Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria, 3Anesthesiology, General Intensive Care and Pain Management, Medical Univ Vienna, Vienna, Austria

4:45 PM (189) The Impact of VAD Clinical Course on Post-Transplant Survival: A Merged Intermacs and OPTN Data Project; J. A. Tallaj1, S. V. Pamboukian1, D. C. Naftel2, S. L. Myers2, W. S. Cherikh3, J. K. Kirklin2. 1Cardiovascular Disease, Univ of Alabama at Birmingham, Birmingham, AL, 2Univ of Alabama at Birmingham, Birmingham, AL, 3Research Dept, United Network for Organ Sharing, Richmond, VA

5:00 PM (190) Impact of the Thoracotomy Implant Approach on Average Length of Stay and Rehospitalizations in the HVAD LATERAL Trial; M. Strueber1, A. Cheung2, N. A. Mokadam3, G. Weisethaler4, S. Lee5, T. Boeve5, S. Maltais6, V. Pretorius7, M. Danter8, T. A. Vassiliades9, E. McGee10. 1Beth Israel Medical Center, Newark, NJ, 2University of British Columbia, Vancouver, BC, Canada, 3University of Washington, Seattle, WA, 4University of California San Francisco, San Francisco, CA, 5Spectrum Health, Grand Rapids, MI, 6Mayo Clinic, Rochester, NY, 7University of California San Diego, San Diego, CA, 8Vanderbilt University Medical Center, Nashville, TN, 9Medtronic, Framingham, MA, 10Loyola University Medical Center, Maywood, IL

5:15 PM (191) Clinical Outcomes with Heartmate 3™ Left Ventricular Assist Device as Treatment for Advanced Heart Failure: 12-Month Outcomes from the ELEVATE Registry; M. Morshuis1, J. Garbade2, D. Zimpfer3, S. Shaw4, J. Lavee5, F. Gustafsson6, S. Lim7, F. Beyersdorf8, L. Damme9, D. Saeed10. 1Cardiothoracic Surgery, Heart and Diabetic Center NRW, Bad Oeynhausen, Germany, 2Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, 3Division of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria, 4Transplant Center, University Hospital of South Manchester NHS Trust, Manchester, United Kingdom, 5Heart Transplantation Unit, Leviev Heart Center, Sheba Medical Center and sacks Faculty of medicine, tel Aviv University, Tel Aviv, Israel, 6Dept of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 7Dept of Cardiology, Queen Elisabeth Hospital, Birmingham, United Kingdom, 8Medical Faculty, University Heart Center Freiburg, Freiburg, Germany, 9Abbott, Abbott, Chicago, IL, 10Cardiovascular Surgery, University Hospital of Duesseldorf, Dusseldorf, Germany

5:30 PM (192) A Multidisciplinary Continuous Support Heart Team Approach Improves Survival in Continuous Flow LVAD Recipients; A. M. Shah1, D. Sims1, S. Madan1, N. Siddiqi1, A. Luke1, O. Saeed1, S. Patel1, S. Murthy1, J. Shin1, S. Watts1, W. Jakobleff3, S. Forest2, S. Vukelic1, D. Belov1, Y. Puius3, G. Minamoto3, V. Muggia3, A. Carlese4, S. Leung4, M. Rahmanian4, J. Leff5, D. Goldstein2, U. Jorde1. 1Division of Cardiology, Montefiore Medical Center, Bronx, NY, 2Division of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, 3Division of Infectious Disease, Montefiore Medical Center, Bronx, NY, 4Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, 5Division of Cardiothoracic Anesthesia, Montefiore Medical Center, Bronx, NY

5:45 PM (193) Ambulatory Counterpulsation with a Minimally Invasive Circulatory Assist Device - Expanding Indications and Extending Support; V. Jeewavanandam, T. Song, T. Ota, D. Onsager, C. Juricek LaBuhn, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, S. Kalantari, N. Urial. University of Chicago Medicine, Chicago, IL
4:30 PM - 6:00 PM
ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD

**Location:** Athena
**Target Audience:** MCS, NHSAH, PH

**Chairs:** Michael S Kiernan, MD, and Jeffrey J Teuteberg, MD

4:30 PM (194) **Outcomes After Isolated Durable Right Ventricular Assist Device**; E. Y. Birati, E. Grandin, M. Seigerman, A. Padegimas, F. Cabezas, J. A. Mazurek, M. S. Kiernan, N. K. Kapur, G. H. Oliveira, F. D. Pagani, D. C. Naftel, J. J. Teuteberg, R. L. Kormos, J. Kirklin, P. Atluri, M. A. Acker, J. Rame. 1Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, Boston, MA, 3Internal Medicine, University of Pennsylvania, Philadelphia, PA, 4Cardiology, Tufts Medical Center, Boston, MA, 5Cardiology, University Hospitals, Cleveland, OH, 6Cardiovascular Surgery, University of Michigan School of Medicine, Ann Arbor, MI, 7School of Public Health, University of Alabama Birmingham, Birmingham, AL, 8Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 9Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 10Cardiothoracic Surgery, University of Alabama Birmingham School of Medicine, Birmingham, PA, 11Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

4:45 PM (195) **Chemokine Receptor Regulation in Mechanical Circulatory Support to Predict RV Failure and Mortality is Dependent on Etiology**; A. Nayak, C. Neill, R. L. Kormos, L. Lagazzi, I. Halder, C. McTiernan, J. Larsen, J. Teuteberg, T. N. Bachman, K. Hanley-Yanez, D. M. McNamara, M. A. Simon. 1UPMC Presbyterian, Pittsburgh, PA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3UPMC Heart and Vascular Institute, Pittsburgh, PA, 4UPMC Vascular Medicine Institute, Pittsburgh, PA

5:00 PM (196) **Outcomes in Late Right Heart Failure after LVAD:A Contemporary Analysis of the New Intermacs 4.0 Definition**; J. E. Rame, E. Y. Birati, J. Teuteberg, E. W. Grandin, P. Atluri, M. Kiernan, G. H. Oliveira, S. L. Myers, D. C. Naftel, F. D. Pagani, R. L. Kormos, J. K. Kirklin. 1Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 2Cardiovascular Medicine, Stanford University, Palo Alto, CA, 3Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, 4Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 5Cardiovascular Center, Tufts Medical Center, Boston, MA, 6Division of Cardiology, University Hospital, Cleveland, OH, 7Dept of Surgery, University of Alabama at Birmingham, Birmingham, AL, 8Division of Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor, MI, 9Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA


5:30 PM (198) **The Global Experience With Biventricular Support Using Two HeartMate 3 Ventricular Assist Devices**; J. Lavee, J. Mulzer, T. Krabatsch, S. Marasco, D. McGiffin, J. Garbade, J. D. Schmitto, D. Zimpfer, E. V. Potapov. 1Leviev Heart Center, Sheba Medical Center Tel Aviv University, Tel Aviv, Israel, 2Cardiac, Thoracic and Vascular Surgery, German Heart Center, Berlin, Germany, 3Cardiothoracic Surgery & Transplantation, The Alfred, Melbourne, Australia, 4University of Leipzig Heart Center, Leipzig, Germany, 5Dept. of Cardio, Thoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 6Dept. of Cardiac Surgery, Medical University Vienna, Vienna, Austria

5:45 PM (199) **Minimally Invasive Left Ventricular Assist Device Implantation is Associated with Decreased Postoperative Right Ventricular Failure**; C. Pasjia, M. A. Sawan, E. Sorensen, H. Voorhees, L. Wang, F. M. Boulos, L. DiChiacchio, V. Ton, E. Feller, D. J. Kaczorowski, B. P. Griffith, S. M. Pham, Z. N. Kon. 1Division of Cardiac Surgery, University of Maryland, Baltimore, MD, 2Division of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD, 3Medicine, University of Maryland, Baltimore, MD, 4Cardiothoracic Surgery, Mayo Clinic, Jacksonsville, FL
4:30 PM - 6:00 PM
ORAL SESSION 22: Trials and Treatments in Lung Transplantation

Location: Mediterranee ABC
Target Audience: LTX, PHARM

Chairs: Geert M Verleden, MD, PhD, and Christian A Bermudez, MD

4:30 PM (200) A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation (NCT01915082); R. Vos, A. Van Herck, B. M. Vanaudenaerde, S. E. Verleden, D. E. Van Raemdonck, A. Frick, A. P. Neyrinck, G. M. Verleden. University Hospitals Leuven, Leuven, Belgium

4:45 PM (201) A Randomized Controlled Trial of Naloxone for Optimization of Hypoxemia in Lung Donors; R. Dhar¹, A. Paramesh², G. Marklin³. ¹Neurology, Washington University in St. Louis School of Medicine, St Louis, MO, ²Surgery, Tulane University, New Orleans, LA, ³Mid-America Transplant, St Louis, MO

5:00 PM (202) Improved Lung Preservation in the Organ Care System in a Porcine Transplantation Setting Modelled After the INSPIRE Trial Triggers a Preregulatory T Cell Phenotype; J. Salman, R. Sanz, T. Siemeni, K. Janssøn, A. Knoefel, F. Ius, W. Sommer, K. Hoeffer, A. Haverich, I. Tudorache, C. Falk, G. Warnecke. hannover medical school, Hannover, Germany

5:15 PM (203) Human Leukocyte Antigen Allosensitization in Patients Bridged to Lung Transplantation with Extracorporeal Membrane Oxygenation; A. Courtwright¹, M. Molina², L. Gardo¹, V. N. Ahya¹, J. D. Christie¹, J. M. Diamond¹, D. Hadjiliadis¹, J. Lee¹, N. Patel¹, M. Porteous¹, E. Cantu², M. Crespo¹, C. Bermudez². ¹Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ²Dept of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

5:30 PM (204) Influence of an IgM-enriched Intravenous Immunoglobulin-based Treatment on Regulatory T Cells in Patients with Donor Specific Antibodies After Lung Transplantation; F. Ius¹, W. Sommer¹, A. Knoefel¹, J. Salman¹, T. Nakagiri¹, T. Siemeni¹, C. Kuehn¹, M. Avsar¹, D. Bobylev¹, R. Poyanmehr¹, T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

5:45 PM (205) Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative; J. Mackintosh¹, M. Munsif², C. Thomson³, M. Musk⁴, G. Snell², A. Glanville⁴, D. Chambers¹, P. Hopkins¹. ¹Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, ²Lung Transplant Service, The Alfred, Melbourne, Australia, ³Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ⁴Lung Transplant Unit, Royal Perth Hospital, Perth, Australia
4:30 PM - 6:00 PM
ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant

Location: Clio/Thalie/Erato
Target Audience: PHARM, HTX, ID, LTX, NHSAH
Chairs: Michael Shullo, PharmD, and Fay S Burrows, BPharm

4:30 PM (206) Polymorphisms in the KCNJ11 Gene are Associated with New Onset Diabetes After Lung Transplantation; E. Henricksen¹, D. R. Calabrese², R. Florez¹, K. W. Dewey¹, C. Hui¹, L. Leard², J. Singer², S. Hays², J. Kukreja³, J. Golden², J. R. Greenland⁴. ¹University of California San Francisco, San Francisco, CA, ²Division of Pulmonology, University of California San Francisco, San Francisco, CA, ³Dept of Surgery, University of California San Francisco, San Francisco, CA, ⁴VA Health Care System, San Francisco, CA

4:30 PM (207) Effect of Marijuana Exposure on Calcineruin Inhibitor Dose to Trough Ratios in Heart Transplant Recipients; C. Shakowski¹, S. Freedman², K. Schwarz¹, R. L. Page II³. ¹Dept of Pharmacy, University of Colorado Hospital, Aurora, CO, ²Dept of Pharmacy, University of Maryland Medical Center, Baltimore, MD, ³Dept of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, CO

5:00 PM (208) Outcomes Associated With Mammalian Target of Rapamycin (mTOR) Inhibitors in Heart Transplant Recipients: A Meta-analysis; N. Lange¹, W. L. Baker², M. Shullo³, F. Latif¹, S. Restaino¹, K. Takeda¹, H. Takayama¹, Y. Naka¹, M. Farr¹, P. Colombo¹, D. L. Jennings¹. ¹Columbia University Medical Center, New York, NY, ²University of Connecticut, Storrs, CT, ³University of Pittsburgh Medical Center, Pittsburgh, PA


5:30 PM (210) Effect of Everolimus and CNI Reduction on Rejection, CLAD, and Death in Thoracic Transplant Recipients; R. A. Cartus¹, C. J. Iasella¹, C. A. Moore¹, M. R. Morrell¹, J. Hayanga², N. Shigemura³, A. Zeevi¹, J. F. McDyer¹, C. R. Ensor¹. ¹University of Pittsburgh, Pittsburgh, PA, ²West Virginia University, Morgantown, WV, ³Temple University, Philadelphia, PA

5:45 PM (211) Stabilization of Lung Function and Survival Improvement By Aerosolized Liposomal Cyclosporine A (L-CsA) for Bronchiolitis Obliterans Syndrome; A. Iacono¹, M. Wijesinha², K. Rajagopal³, N. Murdock¹, T. Hughes¹, S. McGee¹, I. Timofte⁴, J. Kim⁴, J. Rinaldi¹, M. Terrin². ¹Shock Trauma and Transplantation, University of Maryland, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Cardiac Surgery, Memorial Hermann Hospital, Houston, TX, ⁴Medicine, Division of Pulmonary & Critical Care Medicine, University of Maryland, Baltimore, MD
4:30 PM - 6:00 PM
ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population

Location: Uranie/Calliope
Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAH, PATH, PEDS
Chairs: Joseph Rogers, MD, and Eulalia Roig, MD

4:30 PM (212) Optimizing Outcomes after Heart Transplantation in Patients with Cardiac Amyloidosis - A Single Center Analysis of 48 Patients in 2 Eras; M. M. Kreusser1, A. V. Kristen1, S. O. Schönland2, P. Blum1, B. Schmack3, A. Ruhparwar3, U. Hegenbart2, H. A. Katus1, P. W. Raake1. 1Cardiology, University of Heidelberg, Heidelberg, Germany, 2Hematology, University of Heidelberg, Heidelberg, Germany, 3Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

4:45 PM (213) Cardiac Transplantation with Delayed Autologous Stem Cell Transplant in Patients with Cardiac Amyloidosis; B. H. Trachtenberg1, R. Araujo-Gutierrez1, K. Rammurti2, L. Rice2, A. Bhimaraj1, A. Guha1, M. H. Park1, I. Hussain1, E. E. Suarez1, B. Bruckner1, J. D. Estep1. 1DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, 2Hematology, Houston Methodist Hospital, Houston, TX


5:15 PM (215) Outcomes in Heart Transplantation for Adults with Congenital Heart Disease - Contemporary Analysis and Development of a Risk Model - ReDoT Score; M. R. Robinson1, J. Rossano2, W. Cherikh3, A. Kucheryavaya3, G. H. Oliveira1, J. Stehlik4. 1Cardiology, University Hospitals Cleveland Medical Center, Cleveland, OH, 2Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 3United Network of Organ Sharing, Richmond, VA, 4Cardiology, University of Utah Health, Salt Lake, UT

5:30 PM (216) Pregnancy Outcomes in 91 Female Heart Transplant Recipients; L. R. Punnoose1, L. A. Coscia2, D. P. Armenti2, S. Costantinescu2, M. J. Moritz2. 1Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 2Transplant Pregnancy Registry International, Gift of Life Institute, Philadelphia, PA

4:30 PM - 6:00 PM
ORAL SESSION 25: Philip K. Caves Award Candidate Presentations

Location: Hermes
Target Audience: BSTR, HTX, LTX, PATH

Chairs: Stephan M Ensminger, MD, DPhil, and Kathleen L Grady, PhD, APN, FAAN

4:30 PM (32) Human Thrombomodulin Expression Confers Prolonged Graft Survival over Costimulation Blockade Alone in a Pig-to-Baboon Heterotopic Cardiac Xenotransplant Model; L. DiChiacchio¹, A. Singh¹, J. Chan², P. Corcoran², B. Lewis¹, M. Thomas², D. Ayares³, K. Horvath², K. Horvath², M. Mohiuddin¹. ¹University of Maryland Medical Center, Baltimore, MD, ²Cardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, ³Re vivicor, Inc, Blacksburg, VA

4:45 PM (219) Donor HLA-G Single Nucleotide Polymorphisms Predict Post-lung Transplant Mortality; J. Lazarte¹, J. Ma², T. Martinu², L. Levy², W. Klement², M. White², J. Pelling², Z. Guan², S. Azad², J. Tikkanen², V. Rao³, G. Tomlinson², D. Delgado³, S. Keshavjee², S. Juvet². ¹Medicine, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

5:00 PM (34) Heart En Bloc Thymus Cotransplantation in NHPs Controls Cellular but not Humoral Alloreactivity; J. O, W. Sommer, K. Pruner, I. T. Paster, I. M. Hanekamp, I. Dehnadi, I. Rosales, R. N. Smith, R. B. Colvin, G. Benichou, J. S. Allan, J. C. Madsen. Center for Transplantation Sciences, MGH, Boston, MA

5:15 PM (221) Dectin-1 Genotypes are Associated with Decreased CLAD-Free Survival in Lung Transplant Recipients; D. R. Calabrese¹, T. Chong², J. Singer¹, D. Torgerson², S. Hays¹, J. Golden¹, J. Kukreja¹, J. R. Greenland⁴. ¹Division of Pulmonology, University of California San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Dept of Surgery, University of California San Francisco, San Francisco, CA, ⁴VA Health Care System, San Francisco, CA


5:45 PM (223) Tolerance to A-Antigen After Treatment of Infant or Adult Mice with MHC-Matched A-Expressing Blood Cells; J. Fersovich¹, B. Motyka², B. Lamarche¹, M. Sosniuk¹, I. Adam², J. Pearcey², K. Tao², C. W. Cairo³, P. J. Cowan⁴, L. J. West². ¹Dept Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, ²Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ³Dept Chemistry, University of Alberta, Edmonton, AB, Canada, ⁴Immunology Research Centre, University of Alberta, Melbourne, Australia
4:30 PM - 6:00 PM
ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes

Location: Mediterranee 6
Target Audience: PEDS, EEP, HTX, LTX, NHSAH

Chairs: Carol K Conrad, MD, and Brian Feingold, MD, MS

4:30 PM (224) Incidence, Predictors and Outcomes of Severe Primary Graft Dysfunction in Pediatric Heart Transplant Recipients; E. L. Profita¹, K. Gauvreau¹, P. Rycus², R. Thiagarajan¹, T. P. Singh¹. ¹Dept of Cardiology, Boston Children’s Hospital, Boston, MA, ²ELSO Registry, University of Michigan, Ann Arbor, MI

4:45 PM (225) Number of Refusals Due to Donor Quality Does Not Impact Lung Transplantation Outcomes; E. Singh¹, M. G. Schecter², C. Towe², R. Rizwan², R. Bryant III², J. Tweddell², J. K. Steger², D. L. Morales², F. Zafar². ¹University of Cincinnati, Cincinnati, OH, ²Cincinnati Children’s Hospital, Cincinnati, OH

5:00 PM (226) Donor to Recipient Predicted Total Lung Capacity Ratio Matching Predicts Survival after Lung Transplantation in Pre-Adolescent Patients; C. D. Fraser¹, X. Zhou¹, J. C. Grimm¹, A. Suarez Pierre¹, J. T. Magruder¹, C. Lui¹, E. L. Bush¹, N. Hibino¹, L. A. Vricella¹, C. Merlo². ¹Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD, ²Dept of Medicine, The Johns Hopkins Hospital, Baltimore, MD


5:30 PM (228) Non-standard Donor Organs in Pediatric Lung Transplantation Have No Negative Impact on Recipients Outcome; W. Sommer¹, F. Ius¹, N. Schwerk², C. Müller², D. Bobylev¹, C. Kühn¹, M. Avsar¹, J. Salman¹, T. Siemeni¹, A. Horke¹, A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, ²Pediatric Pneumology, Hannover Medical School, Hannover, Germany

5:45 PM (229) A New Combined Model for End-Stage Liver Disease Excluding INR (CMELD-XI) Score Better Predicts Pediatric Heart Transplant Outcomes; S. Choudhry¹, K. E. Hosek¹, S. W. Denfield¹, J. F. Price¹, A. G. Cabrera¹, H. P. Tunuguntla¹, V. R. Dharnidharka², C. E. Canter², W. J. Dreyer¹. ¹Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, ²Washington University School of Medicine, Saint Louis, MO
6:15 PM - 7:15 PM
MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques

Location: Athena
Target Audience: MCS, NHSAH

Chairs: Mustafa Ozbaran, MD, and Vivek Rao, MD, PhD

6:15 PM (230) Minimally-invasive Implantation of a Centrifugal Continuous-flow Left Ventricular Assist Device is Associated With Decreased Early Right Ventricular Failure; M. Psopta1, V. Selby2, M. Janmohamed2, T. De Marco2, L. Klein2, G. Wiesethaler3, 1Advanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, 2Cardiology, UCSF, San Francisco, CA, 3Cardiothoracic Surgery, UCSF, San Francisco, CA

(231) WITHDRAWN

6:20 PM (1231) Changes in Metabolic Profiles Following Left Ventricular Assist Device Implantation: A. Nguyen1, T. Imamura1, B. Chung1, N. Narang1, L. Holzhauser1, C. LaBuhn1, D. Rodgers1, T. Ota1, T. Song1, M. Costanzo2, S. Kalantari1, N. Sarswat1, J. Raihelkar1, G. Kim1, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Advocate Medical Group, Chicago, IL

6:25 PM (232) Relation Between Intraventricular HVAD Position and Pump Thrombosis; P. Aigner1, T. Schloegelhofer2, L. Plunger2, D. Beitze4, A. Wielandner4, H. Schima2, D. Wiedemann5, D. Zimpler5, F. Moscato1. 1Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria, 2Center for Medical Physics and Biomedical Engineering, Dept of Cardiac Surgery, Medical Univ of Vienna, Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria, 3Center for Medical Physics and Biomedical Engineering, Medical Univ of Vienna, Vienna, Austria, 4Dept of Radiology and Nuclear Medicine, Medical Univ of Vienna, Vienna, Austria, 5Dept of Cardiac Surgery, Medical Univ of Vienna, Vienna, Austria

6:30 PM (233) Early and Late Outcomes of Subcostal Exchange of HeartMate II Left Ventricular Assist Device: A Word of Caution; S. N. Yu, H. Takayama, J. Han, A. R. Garan, V. K. Topkara, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY

6:35 PM (234) A Comparison of Surgical Outcomes for LVAD Implantation by Minimally Invasive Surgery and Conventional Sternotomy; S. D. Miller1, A. W. Cheung2, J. Hong2, J. G. Bashir2, M. J. Kearns1. 1Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, 2Dept of Surgery, University of British Columbia, Vancouver, BC, Canada

6:40 PM (235) Simplified, Less-Invasive LVAD Implantation in Redo Patients; M. O. Zembala, R. Antonczyk, J. Waszak, T. Niklewski, T. Wolny, M. Zembala. Cardiac Surgery and Transplantology, Silesian Center For Heart Disease, Zabrze, Poland


6:50 PM (237) Inflow Cannula Position is Associated with Improvement in Mitral Regurgitation After Left Ventricular Assist Device Implantation; C. Pasrja1, E. Sorensen2, M. A. Sawan3, H. Voorhees2, D. Tran1, L. Wang3, L. DiChiachio1, V. Ton3, E. Feller2, B. P. Griffith3, Z. N. Kon4, D. J. Kaczorowski3. 1Division of Cardiac Surgery, University of Maryland, Baltimore, MD, 2Division of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD, 3Medicine, University of Maryland, Baltimore, MD

6:55 PM (238) Survival Factors for Patients With Biventricular Failure on CentriMag Biventricular Support as Bridge to Decision or Transplant; R. Yanagida1, M. Camacho1, A. Okoh2, C. Gidea2, M. Strueber1, M. J. Zucker3. 1Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ, 2Surgery, Newark Beth Israel Medical Center, Newark, NJ, 3Medicine, Newark Beth Israel Medical Center, Newark, NJ

7:00 PM (239) Use of Protek Duo Cannula (RVAD) for Percutaneous Support in Various Clinical Settings. A Safe and Effective Option; J. A. Gomez-Abraham1, S. Brann1, V. Aggarwal2, B. O'Neill2, R. Alvarez2, E. Hamad2, Y. Toyoda1. 1Cardiothoracic Surgery, Temple University School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA, 2Cardiology, Temple University School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA
7:05 PM (240) **Berlin Heart Outcomes in Single Ventricle Patients: Where are we Now?**; J. C. Dykes¹, M. S. Bleiweis², K. Maeda³, S. Chen¹, D. N. Rosenthal¹, C. Tjossem⁴, J. Murray⁵, C. S. Almond¹. ¹Pediatrics, Stanford University, Palo Alto, CA, ²Cardiothoracic Surgery, University of Florida, Gainsville, FL, ³Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ⁴Berlin Heart, Woodlands, TX, ⁵Pediatrics, Lucile Packard Children’s Hospital, Palo Alto, CA

6:15 PM - 7:15 PM
MINI ORAL 08: Heart Transplantation: PGD and CAV

Location: Mediterranea ABC
Target Audience: HTX, BSTR, EEP, HF, NHSAH, PATH

Chairs: Bruno M. Meiser, MD, and Livia Goldraich, MD

6:15 PM (242) Donor Plasma VEGF as a Biomarker for Early Graft Failure After Heart Transplantation: E. Holmström1, R. Tuuminen1, R. Krebs1, E. Rouvinen1, A. Nykänen2, K. Lemström2. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2Transplantation Laboratory, Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland

6:20 PM (243) Validation of a Model to Predict Primary Graft Dysfunction (PGD) after Adult Heart Transplantation in the United Kingdom: S. Avtaar Singh1, N. Banner2, S. Rushton3, C. Berry4, N. Al-Attar1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Cardiology and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, 3Cardiothoracic Advisory Group Statistician, National Health Service Blood and Transplant, Bristol, United Kingdom, 4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

6:25 PM (244) Impact of ISHLT Left Ventricular Primary Graft Dysfunction on Survival After Heart Transplant: J. J. Martinez, M. Peltz, J. E. Pruszynski, L. C. Huffman, P. Bajona, M. A. Wait, J. S. Murala, M. E. Jessen, W. S. Ring. Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX

6:30 PM (245) Proinflammatory Cytokines as Biomarkers for Severe Primary Graft Dysfunction After Heart Transplantation: E. Holmström1, R. Tuuminen1, S. Syrijälä1, R. Krebs1, E. Rouvinen1, A. Nykänen2, K. Lemström2. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland

6:40 PM (247) Comparison of Predictors and Outcomes of Severe LV and RV Primary Graft Dysfunction in Heart Transplant Recipients: J. A. Fried1, L. Truby1, S. Restaino1, G. Rubin1, K. Clerkin1, K. Takeda2, H. Takayama2, M. Farr1, Y. Naka2, P. C. Colombo3, B. Fine1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

6:45 PM (248) Intracoronary Intimal Thickness in Recipients of Hepatitis C-Positive Donor Hearts: S. Zalawadiya1, J. Lindenfeld1, E. Haddad2, M. Wigger1, M. Danter3, M. Keebler1, M. Brinkley1, J. Menachem1, S. B. Sacks1, H. Ooi1, R. Perri4, C. Chung4, J. Awad4, S. Smith1, R. Hayes1, H. O’Dell4, C. Darragh5, S. Ruzevich-Scholl1, K. Schindorf1. 1Heart failure and transplantation, Vanderbilt University Medical Center, Nashville, TN, 2Cardiovascular medicine, Vanderbilt University Medical Center, Nashville, TN, 3Cardiothoracic surgery, Vanderbilt University Medical Center, Nashville, TN, 4Gastroenterology and hepatology, Vanderbilt University Medical Center, Nashville, TN, 5Vanderbilt University Medical Center, Nashville, TN

6:50 PM (249) Detecting Early Cardiac Allograft Vasculopathy Using Highly Automated 3D Coronary Optical Coherence Tomography Segmentation Analysis: M. Pazdern1, Z. Chen2, H. Bedanova3, J. Kautzner1, V. Melennykovsky1, V. Karmazin1, I. Malek1, A. Tomasek3, E. Ozabalova2, J. Krejci4, J. Franekova1, A. Wahle5, H. Zhang2, T. Kovarnik3, M. Sonka6. 1IKEM, Prague, Czech Republic, 2Dept of Biomedical Imaging, The University of Iowa, Iowa City, IA, 3Cardiovascular and Transplantation Surgery, Brno, Czech Republic, 4Dept of Cardiovascular Diseases, St. Anne’s University Hospital and Masaryk University, Brno, Czech Republic, 52nd Dept of Internal Medicine, Dept of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

6:55 PM (250) Human Immunodeficiency Virus (HIV), Heart Transplantation And Mechanical Circulatory Support (MCS: Where Do We Stand?): S. Madan1, S. R. Patel1, K. Patel2, D. B. Sims1, O. Saeed1, S. Forest1, W. Jakobleff1, S. Murthy1, J. J. Shin1, D. J. Goldstein5, U. P. Jorde1. 1Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
7:00 PM (251) Induction Immunosuppressive Therapy in Cardiac Transplantation: A Systematic Review and Meta-analysis; A. Briasoulis¹, C. Inampudi¹, P. Alvarez¹, D. C. Voruganti², T. Ando³, J. K. Bhama⁴. ¹Dept of Internal Medicine - Cardiology, University of Iowa Hospitals and Clinics, Iowa, IA, ²Dept of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa, IA, ³Dept of Internal Medicine - Cardiology, Wayne State University, Harper hospital/ Detroit Medical Center, Division of Cardiology, Detroit, MI, ⁴Dept of Surgery - Cardiothoracic surgery, University of Iowa Hospitals and Clinics, Iowa, IA

(252) PROMOTED TO ORAL

7:05 PM (886) Donor Simvastatin Treatment Alters the Gene Expression Profile of Human Cardiac Allografts During Ischemia and Reperfusion; R. Krebs¹, M. Kankainen², E. Holmström¹, J. Lukac¹, T. Ojala², P. Mattila², A. Nykänen¹, K. Lemström¹. ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland, ²Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

7:10 PM (253) Panel Reactive Antibodies and Outcomes Following Heart Transplantation in Adults with Congenital Heart Disease; L. Alshawabkeh¹, T. P. Singh², A. R. Opotowsky³, W. S. Cherikh⁴, A. Y. Kucheryavaya⁴, M. J. Landzberg⁵, M. A. Curry⁴, J. W. Rossano⁵, M. M. Givertz⁶. ¹Cardiovascular Medicine, University of California San Diego and Brigham & Women's Hospital, Harvard Medical School, La Jolla, CA, ²Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴United Network for Organ Sharing, Richmond, VA, ⁵Cardiology, Children's Hospital of Philadelphia, University of Pennsylvania, PA, ⁶Division of Cardiovascular Medicine, Dept of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
6:15 PM - 7:15 PM
MINI ORAL 09: Lung Transplantation: Allograft Function

Location: Clio/Thalie/Erato
Target Audience: LTX, PATH

Chairs: Michael Perch, MD, and Gundeep S Dhillon, MD

1Cardiothoracic Surgery, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH, 2Pulmonology, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH, 3Biostatistics and Epidemiology, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH

6:20 PM (255) CD8 T Effector Memory T Cells as Predictive Biomarker of Severe Acute Rejection in Lung Transplantation: J. Irure1, M. Á. Ballesteros2, D. Merino3, D. Iturbe4, V. Mora4, S. Fernández-Rozas4, R. Mons5, E. Asensio1, J. J. Gómez-Román6, J. Cifrián4, M. López-Hoyos1, D. San Segundo1. 1Immunology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, 2Intensive Care, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, 3Pneumology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, 4Surgery, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain

6:25 PM (256) Pitfalls in the Real-World Diagnosis and Management of Clinical Antibody Mediated Rejection of the Lung: D. Abelson1, A. Awford1, S. Garnett2, M. Plit3, A. Havyrk1, R. Pearson1, M. Benzimra3, M. A. Malouf1, A. Rigby1, A. R. Glanville1. 1Lung Transplantation Unit, St Vincent’s Hospital, Sydney, Australia, 2Integrative Biomedical Sciences, University of Capetown, Capetown, South Africa

6:30 PM (257) Treatment of Antibody Mediated Rejection in Lung Transplantation: Impact of Antibody Depletion Strategy: J. Le Pavec1, A. Hanna1, J. Taupin2, P. Pradère1, S. Feuillet1, A. Crut1, F. Leroy Ladurie1, D. Fabre1, O. Mercier1, S. Musso1, E. Fadel1, F. Lunardi3, P. Dorfmuller1, F. Calabrese3. 1Service de chirurgie thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, 2Service d’histocompatibilité, Hôpital Saint Louis, Paris, France, 3Dept of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy


6:40 PM (259) Long-term Results of an IgM-enriched Human Immunoglobulin-based Therapy for Early Donor Specific Antibodies After Lung Transplantation: F. Ius1, W. Sommer1, M. Verboom2, M. Hallensleben2, J. Salman1, T. Siemeni1, C. Kuehn1, M. Avsar3, D. Bobylev1, R. Poyanmehr1, N. Schwerk3, C. Mueller3, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Paediatrics, Hannover Medical School, Hannover, Germany

6:45 PM (260) Extracorporeal Photopheresis as Treatment Option of Chronic Lung Allograft Dysfunction. Is ECP the Therapy of the Future?: A. Benazzo1, M. Landi2, M. Mockenhuber1, S. Schwarz1, G. O. Murakoezy1, C. O. Lambers1, B. Moser1, K. Hoetzenecker1, J. O. Matilla Siguenza1, G. O. Lang2, S. Taghavi1, W. Klepetko1, P. Jaksch1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 3Thoracic Surgery, Medical University of Vienna, Vienna, Austria

6:50 PM (261) Impact of Neutropenia on Survival in Lung Transplant Recipients Receiving Mycophenolate for Immunosuppression: L. K. Tague1, D. Byers1, R. Hachem1, A. Krupnick2, D. Kreisel3, A. Gelman4. 1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO, 2Dept of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, 3Dept of Surgery, Division of Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO

6:55 PM (262) Eosinophils on Transbronchial Biopsies Are Predictive of Reduced Survival After Lung Transplantation: D. R. Darley1, J. Ma2, P. Fiset1, D. M. Hwang3, W. Klement1, R. Zamel4, S. Azad5, J. M. Tikkanen1, L. G. Singer1, G. Tomlinson1, T. Martinu1. 1Lung Transplant, Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, 2Lung Transplant, Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, 3Pathology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, 4Biostatistics Research Unit, Biostatistics Research Unit, University Health Network, Toronto, ON, Canada
7:00 PM (263) *A Prospective Study of Coagulation Profile in Lung Transplantation*; B. Saez-Gimenez¹, V. Cortina², M. Ramòn¹, H. Sintes¹, C. Berastegui¹, M. Lopez-Meseguer¹, V. Monforte¹, C. Bravo¹, A. Santamaria¹, A. Roman³. ¹Lung - Transplant Unit, Hospital Vall Hebron, Barcelona, Spain, ²Hemostasis and Thrombosis Unit, Hospital Vall Hebron, Barcelona, Spain, ³Lung - Transplant Unit, Hospital Vall Hebron. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES)., Barcelona, Spain

7:05 PM (264) *Donor Derived Cell Free DNA is Elevated With Pathogens That are Risk Factors For Chronic Lung Allograft Dysfunction*; P. Shah¹, M. Rohly², A. Brown³, I. Timotte⁴, M. Nayar³, A. Gandhi³, N. Kim³, A. Joshi⁷, A. Iacono⁴, S. Nathan⁵, R. Avery⁷, J. Orens⁷, S. Agbor-Enoh⁹, H. Valantine⁹. ¹Genomic Research Alliance for Transplantation (GRAFT), Johns Hopkins University, Baltimore, MD, ²Columbus State University, Athens, GA, ³GRAFT, Inova Fairfax Hospital, Fairfax, VA, ⁴GRAFT, University of Maryland, Baltimore, MD, ⁵University of Virginia, Charlottesville, VA, ⁶University of Maryland, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD, ⁸GRAFT, Johns Hopkins University, Baltimore, MD, ⁹GRAFT, National Institute of Health, Bethesda, MD

7:10 PM (265) *Sustained Reduction in FEV1 Decline After Cessation of Extracorporeal Photopheresis*; C. M. Shaver¹, A. Dunatchik², S. G. Norfolk¹, J. E. Loyd¹, M. P. Steele³, I. M. Robbins¹. ¹Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Veterans Affairs Administration, Salisbury, NC
6:15 PM - 7:15 PM
MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology

**Location:** Uranie/Calliope
**Target Audience:** PHARM, BSTR, HTX, LTX, MCS, PEDS

**Chairs:** Christina Aquilante, PharmD, and Peter J Bergin, MBBS, FRACP


6:25 PM (268) **Thrombotic Events With PSI Based Immunosuppression in Cardiac Transplantation;** O. Witkowsky, J. J. Teuteberg, A. Althouse, M. Shullo. 1Pharmacy, The Ohio State Univ Wexner Med Ctr, Columbus, OH, 2Stanford Univ, Stanford, CA, 3Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4West Virginia Univ Medicine, Morgantown, WV

6:30 PM (269) **Safety and Efficacy of Rabbit Anti-Thymocyte Globulin Induction in Pediatric Patients Undergoing Cardiac Transplantation;** M. L. Sell, A. L. Haney, K. Sprott, A. Burnette, H. Henderson, A. Savage. 1Pharmacy, Medical Univ of South Carolina, Charleston, SC, 2Pediatric Cardiology, Medical Univ of South Carolina, Charleston, SC


6:40 PM (271) **Effect of ABCC2 Polymorphisms on Tacrolimus Disposition in Heart Transplant Recipients;** K. Qreschak, K. M. Deininger, A. V. Ambardekar, R. L. Page, J. Lindenfeld, C. L. Aquilante. 1Univ of Colorado, Aurora, CO, 2Vanderbilt Univ, Nashville, TN


6:55 PM (274) **LVAD Patients with CKD: Are Two Organs Better than One?;** M. Y. Kamath, A. Salimbangon, A. Chang, E. Moreno, M. Cadeiras, M. Deng, T. Khuu, A. Nsair, A. Ardehali, M. Kwon, E. Depasquale. UCLA, Los Angeles, CA

7:00 PM (275) **Predictors of Dialysis Dependent Renal Failure in Patients Requiring Total Artificial Heart Support;** K. Desai, D. G. Tang, M. Quader, E. J. Sawey, I. Tchoukina, L. Thacker, V. Kasirajan, K. B. Shah. Virginia Commonwealth Univ Health System, Richmond, VA

7:05 PM (276) **Failure to Improve Renal Function Following VAD Placement Predicts Renal Injury and Chronic Kidney Disease Following Cardiac Transplant;** S. A. Hollander, E. Pruitt, S. M. Sutherland, R. S. Cantor, J. Kirklin, W. J. Ravekes, R. Ameduri, M. Chrisant, T. Hoffman, I. Lyitrivi, J. Conway. 1Pediatrics (Cardiology), Stanford Univ, Palo Alto, CA, 2Univ of Alabama at Birmingham, Birmingham, AL, 3Pediatrics (Nephrology), Stanford Univ, Palo Alto, CA, 4Johns Hopkins Univ School of Medicine (MDJH), Baltimore, MD, 5Univ of Minnesota Children's Hosp, Minneapolis, MN, 6Joe DiMaggio Children's Hosp, Hollywood, FL, 7Univ of North Carolina, Chapel Hill, NC, 8The Mount Sinai Medical Center, New York, NY, 9Univ of Alberta, Edmonton, AB, Canada
7:10 PM (277) Reduced Pulsatility During Continuous Flow Left Ventricular Assist Device Does Not Affect Kidney Function; M. Gallo, C. L. Valadon, J. R. Trivedi, M. S. Slaughter. Dept of Cardiovascular and Thoracic Surgery, Univ of Louisville, Louisville, KY
6:15 PM - 7:15 PM
MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics

Location: Hermes
Target Audience: NHSAH, HF, HTX, LTX, MCS, PEDS

Chairs: Annette J. Devito Dabbs, PhD, RN, and Melanie D Everitt, MD

6:15 PM (278) Reduced Body Weight, Improved Physical Activity and Healthier Eating with Fitness Intensive Therapy (Get FIT) vs. Get FIT+: A Feasibility Study; L. S. Evangelista1, M. Cacciata1, D. Lombardo2, A. Stromberg1. 1Sue & Bill Gross School of Nursing, Univ of California Irvine, Irvine, CA, 2School of Medicine, Univ of California Irvine, Irvine, CA


6:30 PM (281) A Single Centre UK Experience of Incorporating Urgently Listed Inotrope and Ventricular Assist Device Patients into a Cardiac Rehabilitation Programme Pre-Transplant; H. Probert, J. Copping, A. Bachtler, G. Donovan, C. O'Sullivan. Cardiac Rehab, Harefield Hosp, Harefield, United Kingdom

6:35 PM (282) Frailty Assessment in Lung Transplant Candidates: The Use of the Short Performance Physical Battery; A. L. Carswell1, C. L. Pereira1, A. M. Roberts1, M. A. Sanchez1, M. R. Carby2, A. R. Simon2, A. K. Reed2. 1Rehabilitation and Therapies, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, 2Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom

6:40 PM (283) Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring Extracorporeal Membrane Oxygenation (ECMO); K. Hayes1, A. E. Holland2, V. A. Pellegrino1, S. Mathur4, C. L. Hodgson5. 1Physiotherapy Dept, Alfred Hosp, Melbourne, Australia, 2Discipline of Physiotherapy, La Trobe Univ, Melbourne, Australia, 3Intensive Care Dept, Alfred Hosp, Melbourne, Australia, 4Dept of Physical Therapy, Univ of Toronto, Toronto, ON, Canada, 5Australian and New Zealand Intensive Care Research Ctr, Monash Univ, Melbourne, Australia

6:45 PM (284) Early and Continued Improvement in Cognition in Response to Left Ventricular Assist Device Implantation; C. S. Lee1, K. L. Grady2, J. M. Gelow3, C. V. Chien4, S. O. Hiatt1, J. O. Mudd3. 1School of Nursing, OHSU, Portland, OR, 2Feinberg School of Medicine, Northwestern Univ, Evanston, IL, 3Knight Cardiovascular Institute, OHSU, Portland, OR, 4REX Healthcare, Univ of North Carolina, Raleigh, NC

6:50 PM (285) Changes in Sexual Activity Among Patients Supported With an Implantable Left Ventricular Assist Device in Japan; N. P. Kato1, Y. Kagami2, M. Nemoto2, M. Endo2, M. Hatano1, M. Ono3, T. Jaarsma4, K. Kinugawa6. 1Therapeutic Strategy for Heart Failure, Univ of Tokyo, Tokyo, Japan, 2Organ Transplantation, Univ of Tokyo Hosp, Tokyo, Japan, 3Cardiovascular Surgery, Univ of Tokyo, Tokyo, Japan, 4Social and Welfare Studies, Linköping Univ, Linköping, Sweden, 5The Second Dept of Internal Medicine, Univ of Toyama, Toyama, Japan

6:55 PM (286) Frailty: Does it Predict Length of Stay in Hosp Post Lung Transplant; A. F. Jackson1, L. Painter2, I. S. Fontanilla2, C. A. Lewis3. 1Physiotherapy Dept, Green Lane Clinical Centre, Auckland, New Zealand, 2Transplant Psychology, Auckland City Hosp, Auckland, New Zealand, 3Lung Transplant, Auckland City Hosp, Auckland, New Zealand

7:00 PM (287) Impact of Genotype on Boys with Duchenne Muscular Dystrophy; K. Gambetta1, C. Wittlieb-Weber2, M. Bock3, C. Villa4, J. Johnson5, A. La6, K. Schumacher7, S. Law8, S. Deshpande9, S. West10, J. Friedland-Little11, I. Lytrivi12, R. Butts13, C. Cunningham14, K. R. Knecht15, M. McCullough16. 1Lurie Children's Hosp, Chicago, IL, 2Univ of Rochester Med Ctr, Rochester, NY, 3Loma Linda Univ, Loma Linda, CA, 4Cincinnati Children's Hosp, Cincinnati, OH, 5Mayo Clinic, Rochester, MN, 6Primary Children's Hosp Univ of Utah, Salt Lake City, UT, 7CS Mott Children's Hosp, Ann Arbor, MI, 8Columbia Univ, New York, NY, 9Emory Children's Hosp, Atlanta, GA, 10Children's Hosp of Pittsburgh, Pittsburgh, PA, 11Seattle Children's Hosp, Seattle, WA, 12Mount Sinai Med Ctr, New York, NY, 13UT Southwestern Dallas
Children’s Hosp, Dallas, TX, Univ of Alberta, Edmonton, AB, Arkansas Children’s Hosp, Little Rock, AR, Univ of Virginia, Charlottesville, VA

7:05 PM (288) **Utilization and Outcomes for BiVADs in Pedimacs Patients:** R. Butts¹, D. Sutcliffe¹, R. Davies¹, R. Jaquiss¹, T. Pirolli¹, M. Bano¹, R. Morrow², A. Gao¹, S. Zhang¹, R. Kirk¹. Univ of Texas Southwestern, Dallas, TX, Children’s Medical Center of Dallas, Dallas, TX

7:10 PM (289) **Incidence of Treatable Ventricular Arrhythmias After VAD Placement in Children:** S. J. Wilkens¹, C. S. Almond¹, S. Chen¹, S. R. Ceresnak¹, J. M. Murray¹, J. Dykes¹, K. S. Motonaga¹, D. N. Rosenthal¹, C. Tjossem², A. M. Dubin¹. Pediatric Cardiology, Stanford University, Lucile Packard Children’s Hosp, Palo Alto, CA, Berlin Heart Inc, The Woodlands, TX
6:15 PM - 7:15 PM
MINI ORAL 12: Basic Science & Translational Research

**Location:** Mediterranee 6
**Target Audience:** BSTR, HTX, LTX, MCS, PATH

**Chairs:** Pradeep P.A. Mammen, MD, FACC, FAHA, and Joshua Diamond, MD


6:20 PM (291) **Inhibition of Neutrophil Serine Proteases by Alpha 1 Antitrypsin During Storage Preserves Primary Graft Functions of Transplanted Murine Donor Lungs;** C. Morrone. Comprehensive Pulmonary Center, CPC/ILBD and Helmholtz Zentrum Munich, Munich, Germany


6:35 PM (294) **Regulatory T Cells Induce Persistent Acceptance by IL-2 Complexes after Mouse Lung Transplantation;** Y. Yamada, D. Impellizzeri, J. Jang, T. Nguyen, U. Karakus, I. Incl, I. Yoshino, C. Benden, W. Weder, W. Jungrathmayr, O. Boymann. 1Dept of Thoracic Surgery, Univ Hosp Zurich, Zurich, Switzerland, 2Dept of Immunology, Univ Hosp Zurich, Zurich, Switzerland, 3Dept of General Thoracic Surgery, Chiba Univ Graduate Sch of Med, Chiba, Japan, 4Dept of Pulmonology, Univ Hosp Zurich, Zurich, Switzerland, 5Dept of Thoracic Surgery, Brandenburg Med Sch, Neuruppin, Germany

6:40 PM (295) **Taci Polymorphisms Associated with Cardiac Allograft Rejection;** M. Barbosa, E. Farkash, J. Platt, M. Cascalho. 1Surgery, Microbiology and Immunology, Univ of Michigan Hosp, Ann Arbor, MI, 2Pathology, Univ of Michigan Hosp, Ann Arbor, MI

6:45 PM (296) **Targeting Glucose Metabolism During Ex vivo Lung Perfusion Improves Lung Preservation and Post Transplant Lung Function;** K. Noda, S. Tane, J. D’Cunha, J. D. Luketch, N. Shigemura. 1Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Cardiovascular Surgery, Temple University, Philadelphia, PA

6:50 PM (297) **Is Cold Storage Possible in DCD Heart Transplantation? A Pre-Clinical Study;** R. Ribeiro, J. Alvarez, F. Yu, M. Adamson, G. Rugeri, E. Paradiso, V. Bisoodath, C. Serrick, M. Meineri, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada


7:00 PM (299) **PDGF Receptor Blockade is Associated With Decreased Development of Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model;** C. Heim, A. Gocht, J. Distler, B. Spriewald, M. Ramsperger-Gleixner, M. Weyand, S. M. Ensminger. 1Dept of Cardiovascular Surgery, University of Erlangen, Erlangen, Germany, 2Dept of Medicine, University of Erlangen, Erlangen, Germany, 3Dept of Cardiovascular Surgery, HDZ NRW, Bad Oeynhausen, Germany

7:05 PM (300) **Heart Transplant Tolerance Induction in Mice: Understanding the Complex Interplay Between Tolerizing Cells and Host Immune System by Systematic Depletion of Effector Cells;** R. A. Bascom, K. Tao, L. J. West, University of Alberta, Edmonton, AB, Canada
7:10 PM (301) *Modification of Complement Activity in Donor Lungs with Cigarette Smoke Exposure History Improves Post-Lung Transplantation Outcomes*: K. J. Patel¹, Q. Cheng¹, D. P. Allen¹, S. Esckilsen¹, M. Goddard², S. N. Nadig¹, C. Atkinson³. ¹Surgery, Medical University of South Carolina, Charleston, SC, ²Transplantation, Papworth Hospital NHS Foundation Trust, Cambridgeshire, United Kingdom, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, SC
FRIDAY, APRIL 13, 2018

8:30 AM - 10:00 AM
ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs

Location: Apollon
Target Audience: MCS, HF, NHSAH, PHARM
Chairs: Mary E Keebler, MD, and Larry Allen, MD, MHS

8:30 AM (302) Ventricular Assist Device May Enhance Learning in End Stage Heart Failure; M. Karahan¹, S. Kocabeyoglu¹, U. Kervan¹, D. Sert¹, E. Aygun¹, M. Tola², B. Demirkan³, E. Bakar⁴, S. Mungan⁵, O. Kursun⁵, Z. Catav¹, M. Pac¹. ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Radiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ³Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ⁴Psychology, Ufuk University, Ankara, Turkey, ⁵Neurology, Ankara Numune Hospital, Ankara, Turkey

8:30 AM (302) Ventricular Assist Device May Enhance Learning in End Stage Heart Failure; M. Karahan¹, S. Kocabeyoglu¹, U. Kervan¹, D. Sert¹, E. Aygun¹, M. Tola², B. Demirkan³, E. Bakar⁴, S. Mungan⁵, O. Kursun⁵, Z. Catav¹, M. Pac¹. ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Radiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ³Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ⁴Psychology, Ufuk University, Ankara, Turkey, ⁵Neurology, Ankara Numune Hospital, Ankara, Turkey

8:45 AM (303) Predictors of Postoperative Vasoplegia in Patients Receiving Left Ventricular Assist Devices; J. Han¹, A. Pinsino², E. Royzman², A. Gaudig², M. Mabasa², H. Takayama¹, P. A. Kurlansky¹, A. R. Garan², V. Topkara², Y. Naka¹, K. Takeda¹, P. C. Colombo², M. Yuzefpolskaya². ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Columbia University Medical Center, New York, NY

9:00 AM (304) Survival in Intermacs 1 & 2 Patients After LVAD Therapy: Does Chronicity of Heart Failure Matter?; J. L. Guidi¹, G. Troutman², E. Y. Birati³, J. Wald³, A. Fox³, J. Ortega-Legaspi³, C. Bermudez⁴, J. Horak⁵, J. Gutsche⁵, C. Justice⁴, D. Guaraccino⁴, W. Shay⁴, P. A. Atluri⁴, M. A. Acker⁴, J. Rame⁵. ¹Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ³Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA

9:15 AM (305) Reversibility of Fried's Physical Frailty Domains Post- Ventricular-Assist Device Implantation Among Patients with Advanced Heart Failure; S. R. Jha¹, D. Robson¹, P. Jansz¹, P. Spratt¹, E. Granger¹, K. Dhital¹, M. Connellan¹, C. Hayward¹, K. Muthiah¹, A. Jabbour¹, E. Kotlyar¹, E. Montgomery¹, P. J. Newton², P. S. Macdonald¹. ¹Heart & Lung Transplant Clinic, St. Vincent's Hospital Sydney, Sydney, Australia, ²Nursing Research Center, Western Sydney University, Sydney, Australia

9:30 AM (306) The Impact of Frailty on Post-Bridge-to-Transplant Ventricular Assist Device (VAD) Outcomes; S. Jha¹, D. Robson¹, E. Montgomery¹, C. S. Hayward¹, P. Newton², P. C. Jansz¹, P. S. Macdonald¹. ¹Heart Transplant Unit, St. Vincent's Hospital, Sydney, Australia, ²Nursing, University of Western Sydney, Sydney, Australia, ³St. Vincent's Hospital, Sydney, Australia

9:45 AM (307) Further Improvement of Exercise Capacity One Year After Implantation of a Cf- Left Ventricular Assist Device; S. Felix¹, M. Oerlemans¹, F. Ramjankhan², M. Bujsrogge², H. Kirkels¹, N. de Jonge¹. ¹Cardiology, UMC Utrecht, Netherlands, Utrecht, Netherlands, ²Cardiothoracic surgery, UMC Utrecht, Netherlands, Utrecht, Netherlands
8:30 AM - 10:00 AM
ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support

Location: Athena
Target Audience: MCS, BSTR, HF, NHSAH, PHARM

Chairs: Jerry D Estep, MD, and Maria Frigerio, MD

8:30 AM (308) Atrial Fibrillation Burden in Patients with Left Ventricular Assist Devices: Analysis from ICDs; M. A. Brisco-Bacik, P. Eckman, B. Lima, A. Bansal, I. Gosev, R. Aggerwal, Y. Nabutovsky, S. M. Joseph. 1Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 2Minneapolis Heart Institute, Minneapolis, MN, 3North Shore University Hospital, Manhasset, NY, 4Ochsner, New Orleans, LA, 5University of Rochester, Rochester, NY, 6Abbott Medical, Sylmar, CA, 7Baylor University Medical Center in Dallas, Dallas, TX


9:00 AM (310) Implication of Appropriate ICD Shock on Mortality After Continuous Flow LVAD; B. Omery, R. Pedersen, N. Sulemanjee, T. E. Hastings, O. Cheema, E. Roberts, F. X. Downey, J. D. Crouch, V. Thohan. 1Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Center, Milwaukee, WI, 2Tendick Clinic for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, 3Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI

9:15 AM (311) Cardiac Resynchronization Therapy and Outcomes in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-analysis; D. C. Voruganti, A. Briasoulis, P. Alvarez, V. Cotorlan, J. K. Bhama, M. C. Giudici. 1Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Internal Medicine, Division of Cardiology, University of Iowa Hospitals and Clinics, Iowa City, IA, 3Internal Medicine, Division of Cardiology, University of Cincinnati, Cincinnati, OH, 4Division of Cardiothoracic Surgery, Dept of General Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA

9:30 AM (312) Improved Exercise Performance and Quality of Life with Right Ventricular Pacing Over Biventricular Pacing in LVAD Patients; B. Chung, J. Grinstein, G. Sayer, G. Kim, N. Sarswat, J. Raikhelkar, S. Kalantari, A. Nguyen, N. Narang, M. R. Costanzo, U. Jorde, D. Burkhoff, C. LaBuhn, V. Jeevanandam, R. Lang, N. Uriel. 1Cardiology, University of Chicago, Chicago, IL, 2Cardiology, MedStar Washington Hospital Center, Washington, DC, 3Cardiology, Edward-Elmhurst Health, Naperville, IL, 4Cardiology, Montefiore Medical Center, Bronx, NY, 5Columbia University Medical Center, New York, NY, 6Cardiac Surgery, University of Chicago, Chicago, IL

9:45 AM (313) Atrial Fibrillation is Associated With Early Right Ventricular Failure Post-LVAD; S. Koh, O. O. Braun, M. Brambatti, P. Kim, H. Tran, V. Pretorius, E. Adler, J. Silva Enciso. University of California San Diego, La Jolla, CA
8:30 AM - 10:00 AM
ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status

Location: Mediterranee ABC
Target Audience: LTX, EEP

Chairs: Inga Leuckfeld, MD, and Ilhan Inci, MD


1Thoracic Surgery, Univ Hosps Leuven, Leuven, Belgium, 2Thoracic Surgery, The Toronto General Hosp & Hosp for Sick Children, Toronto, ON, Canada, 3Nursing, Alfred Hosp, Melbourne, Australia, 4Pulmonology, Alfred Hosp, Melbourne, Australia, 5CardioThoracic Surgery, Universitair Medisch Centrum, Groningen, Netherlands, 6United Network for Organ Sharing, Richmond, VA, 7Cardiology, Univ of Utah, Salt Lake City, UT, 8CardioThoracic Surgery, Cleveland Clinic, Cleveland, OH, 9Pneumology, St Vincent's Hosp, Sydney, Australia, 10Thoracic Surgery, Columbia Univ Medical Center, New York, NY, 11Pulmonology, Univ of Minnesota Medical Center, Minneapolis, MN, 12Thoracic Surgery, Univ Hosp Zurich, Zurich, Switzerland, 13Thoracic Surgery, Prince Charles Hosp, Brisbane, Australia, 14Pulmonology, St. Joseph’s Hosp & Medical Center, Phoenix, AZ, 15CardioThoracic Surgery, Barnes Jewish Hosp Washington Univ, St Louis, MO, 16Pulmonology, Barnes Jewish Hosp Washington Univ, St Louis, MO, 17CardioThoracic Surgery, Baylor Univ Medical Center, Dallas, TX, 18Pulmonology, Fiona Stanley Hosp, Palmyra DC, Australia, 19Pulmonology, Loyola Univ Medical Centre, Maywood, IL, 20Thoracic Surgery, Brigham & Women’s Hosp, Boston, MA

8:45 AM (315) Chronic Lung Allograft Dysfunction (CLAD): Donation after Circulatory Death (DCD) vs Donation After Brain Death (DBD) - The First 10 Years: G. I. Snell, B. Levvey, H. Whitford, L. Kovi, T. Williams, S. Kotecha, D. McGiffin, G. Westall, M. Paraskeva. Lung Transplant Service, Alfred Hospital, Melbourne, Australia


9:15 AM (317) A Comparison of Inflammatory Profiles in Donor Lungs Following Donation After Brain-Death (DBD) and Donation After Circulatory Death (DCD): M. I. Morrison, A. S. Andreasson, W. E. Scott III, A. J. Fisher, J. H. Dark. Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom

9:30 AM (318) Low Partial Pressures of Oxygen in Circulatory Death Donors is Associated with Decreased Survival in Lung Transplant Recipients: A. G. Fiedler, A. L. Axtell, E. Heng, A. Osho, S. I. Melnitchouk, D. A. D'Alessandro, G. Tolis, T. Astor, Y. Raz, I. P. Neuringer, M. A. Villavicencio. 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA

9:45 AM (319) Prone Positioning Attenuates Lung Injury During Warm Ischemia in a Large Animal Controlled Donation after Cardiac Death Model: Y. Watanabe, M. Galasso, T. Watanabe, A. Ali, H. H. Chan, R. Qaqish, C. Summers, K. Ramadan, R. V. Ribeiro, Y. Zhang, A. Gazzalle, T. K. Waddell, M. Liu, S. Keshavjee, L. Del Sorbo, M. Cypel. 1Latner Thoracic Surgery Research Laboratories, Univ Health Network, Univ of Toronto, Toronto, ON, Canada, 2Guided Therapeutics, TECHNA Institute, Univ Health Network, Univ of Toronto, Toronto, ON, Canada, 3InterDeptal Division of Critical Care, Univ Health Network, Univ of Toronto, Toronto, ON, Canada
8:30 AM - 10:00 AM
ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support

Location: Clio/Thalie/Erato
Target Audience: ID, HTX, MCS

Chairs: Shahid Husain, MD, MS, and Martha L. Mooney, MD, FACP

8:30 AM (320) **Microbial Biofilm Formation and Migration on Ventricular Assist Device Drivelines: Implications for Infection**; Y. Qu¹, D. C. McGiffin², C. E. Kure³, B. Ozcelik³, H. Thissen³, J. F. Fraser⁴, A. Y. Peleg¹. ¹Dept of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia, ²Cardiothoracic Surgery, The Alfred Hospital, Prahran, Australia, ³CSIRO Manufacturing, CSIRO, Clayton, Australia, ⁴Critical Care Research Group & Adult Intensive Care Service, The Prince Charles Hospital, Brisbane, Australia


9:00 AM (322) **Bloodstream Infections in Left Ventricular Assist Device Recipients Awaiting Transplantation**; A. Kyvernitakis¹, O. Pappas², D. Farmakiotis³, E. T. Horn⁴, R. L. Benza⁵, S. H. Bailey⁶, R. Agarwal⁷. ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA, ³Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, ⁴Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

9:15 AM (323) **Telemonitoring of Driveline Exit Site for Early Detection of Relevant Driveline Infections**; N. Reiss¹, S. Jansen², N. Luneburg², C. Feldmann³, R. Wendl³, J. Schmitto³, R. Neubert². ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²Target Holding, Groningen, Netherlands, ³Hannover Medical School, Hannover, Germany

9:30 AM (324) **Antimicrobial Prophylaxis for Left Ventricular Assist Device Implantation: Comparing Infection Rates with Single or Multiple Drug Regimens**; S. A. Schubert¹, L. T. Yarboro¹, J. S. Green², R. J. Cogswell³, J. L. Kennedy⁴. ¹Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, ²Infectious Disease and International Medicine, University of Minnesota, Minneapolis, MN, ³Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, ⁴Cardiovascular Medicine, University of Virginia, Charlottesville, VA

9:45 AM (325) **Hepatitis C Virus Antibody Formation After LVAD Implantation**; D. B. Sims¹, S. Rangasamy¹, S. Murthy¹, S. Forest², S. Vukelic¹, O. Saeed¹, J. Shin¹, S. Patel¹, D. Goldstein², U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center, Bronx, NY, ²Cardiac Surgery, Montefiore Medical Center, Bronx, NY
8:30 AM - 10:00 AM
ORAL SESSION 31: Spotlight on a Heart Transplant Donor

Location: Uranie/Calliope
Target Audience: HTX

Chairs: Marian Urban, MD, and David C McGiffin, MB, BS, FRACS

8:30 AM (326) Prevalence, Characteristics and Prognostic Impact of Wall Motion Abnormalities in Brain-dead Cardiac Donors With Transient Left Ventricular Systolic Dysfunction (LVSD); S. Madan1, S. R. Patel1, O. Saeed1, O. Buhari2, W. Jakobeff3, S. Murthy1, J. Shin1, D. J. Goldstein3, D. B. Sims1, U. P. Jorde1. 1Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY


9:00 AM (328) Forgotten Women: Use of Female Donors and Survival Outcomes; D. A. Baran1, H. Copeland2, J. Copeland3, C. Gidea4, M. Camacho5. 1Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, 2University of Mississippi Medical Center, Jackson, MS, 3University of Arizona, Tucson, AZ, 4Newark Beth Israel Medical Center, Newarl, NJ, 5Newark Beth Israel Medical Center, Newark, NJ

9:15 AM (329) Interaction Between Ischemic Interval and Donor Age on Adult Heart Transplant Outcomes in the Modern Era; M. M. John1, T. P. Martens1, N. W. Hasaniya1, B. Jabo2, A. J. Razzouk1, L. L. Bailey1, D. G. Rabkin1. 1Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA, 2Research Consulting Group, School of Public Health, Loma Linda University Medical Center, Loma Linda, CA

9:30 AM (330) Regional Variation and Outcomes of Thoracic Organ Transplantation from Drug Overdose; X. Zhou1, C. D. Fraser1, A. Suarez-Pierre1, C. Lui1, A. Kilic1, C. M. Sciortino2, R. S. Higgins1, K. J. Zehr1. 1Johns Hopkins Hospital, Baltimore, MD, 2University of Pittsburgh Medical Center, Pittsburgh, PA

9:45 AM (331) Implications of the Refusal of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation; M. S. Mulvihill1, M. A. Bishawi1, M. L. Cox1, A. A. Osho2, C. B. Patel3, M. G. Hartwig1, C. A. Milano1, J. N. Schroder1. 1Dept of Surgery, Duke University, Durham, NC, 2Dept of Surgery, Massachusetts General Hospital, Boston, MA, 3Dept of Medicine, Duke University, Durham, NC
8:30 AM - 10:00 AM
ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas: The Best of the Best

Location: Hermes
Target Audience: ALL

Chairs: Joshua Mooney, MD, and Agnieszka Ciarka

8:30 AM (332) Case of Combined Heart-Kidney Transplant from Hepatitis C (+) Donor to a HCV (-) Recipient; N. Wettersten, H. Tran, V. Pretorius, S. Aslam, E. Adler. University of California, San Diego, La Jolla, CA

8:35 AM Expert Discussant (Heart Failure/Transplantation)
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

8:40 AM Discussion

8:45 AM (333) Post Transplant Lymphoproliferative Disease in Two Recipients From a Single Donor, Donor Derived Disease?; O. Shtraichman, A. Umterman, D. Rosengarten, D. Shitenberg, Y. Shostak, M. R. Kramer. Pulmonary Institute, Rabin Medical Center Belinson Campus, Petach Tikva, Israel

8:50 AM Expert Discussant (Lung Failure/Transplantation)
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

8:55 AM Discussion

9:00 AM (334) Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension; V. N. Selby¹, N. K. Tarango², M. Janmohamed³, N. H. Kim⁴, T. De Marco⁴. ¹Cardiology, University of California, San Francisco, San Francisco, CA, ²Nursing, UCSF, San Francisco, CA, ³Pulmonary and Critical Care Medicine, UCSD, La Jolla, CA

9:05 AM Expert Discussant (Pulmonary Hypertension)
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

9:10 AM Discussion

9:15 AM (335) Third Party HLA Antibody as a Surrogate Marker for Treatment of Non-HLA AMR; T. K. Roberts¹, J. Sparks². ¹Dept of Pathology, University of Louisville, Louisville, KY, ²Dept of Pediatrics, Cardiology, University of Louisville, Louisville, KY

9:20 AM Expert Discussant (Pediatrics)
Lori J. West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

9:25 AM Discussion

9:30 AM (336) An Under-Recognized Cause of Malnutrition After Lung Transplant; M. Howsare¹, D. R. Nunley¹, V. Van Berkel², A. Ramirez¹. ¹Pulmonary, Critical Care, and Sleep Medicine, University of Louisville, Louisville, KY, ²Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

9:35 AM Expert Discussant (Infectious Diseases)
Erika D. Lease, MD, University of Washington, Seattle, WA, USA

9:40 AM Discussion

9:45 AM (337) Pseudoconstriction Secondary to Epicardial Pacing Following HeartWare Left Ventricular Assist Device (HVAD) Implant; A. L. French, R. Kociol. Advanced Heart Failure and Transplant Cardiology, Beth Israel Deaconess Medical Center, Boston, MA

9:50 AM Expert Discussant (Mechanical Circulatory Support)
Jan D. Schmitto, MD, PhD, Hannover Medical School, Hannover, Germany

9:55 AM Discussion
8:30 AM - 10:00 AM
SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself?

Location: Mediterranee 6
Target Audience: PEDS, EEP, HF/HTX, LF/LTX, MCS, NHSAH, PHARM

Chairs: Susan W. Denfield, MD, and Stuart Sweet, MD

Session Summary: Re-transplantation remains a clinical challenge in children and young adults. The demographics of primary transplantation have changed affecting retransplantation. Current outcomes of retransplantation, as well as the timing of retransplant work up, indications, contraindications and comorbidities affecting heart or lung retransplant will be reviewed as well as support strategies while listed for retransplant. The ethics of retransplantation will be discussed. A panel discussion with all speakers will conclude this session.

8:30 AM Thoracic Retransplantation - Population at Risk and Outcomes
Zdenka Reinhardt, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

8:45 AM When Should the Cardiac Transplant Patient Be Considered for Retransplant?
Elfriede Pahl, MD, Lurie Children's Hospital, Chicago, IL, USA

9:00 AM Trials and Tribulations of Supporting the Cardiac Transplant Patient to Retransplant
Jennifer Conway, MD, Alberta Health Services, Edmonton, AB, Canada

9:15 AM When Should the Lung Transplant Patient Be Considered for Retransplant?
Ernestina Melicoff-Portillo, MD, Texas Children's Hospital, Houston, TX, USA

9:30 AM Should Anyone Be Considered for Retransplantation – Ethical Issues
Beth Kaufman, MD, Stanford University, Stanford, CA, USA

9:45 AM Panel Discussion
10:30 AM - 12:30 PM
PLENARY 2: Plenary Session: Moving Cardiothoracic Transplantation Forward

**Location:** Apollon

**Target Audience:** ALL

**Chairs:** Lori J West, MD, DPhil, and Allan R Glanville, MBBS, MD, FRACP

10:30 AM **New Technologies to Advance Future Transplant Patient Care**
Stefan Schneeberger, MD, Innsbruck Medical University, Innsbruck, Austria

10:50 AM (340) **Right Ventricular Remodeling in Chronic Thrombo-Embolic Pulmonary Hypertension**; S. Guimaron¹, J. Guihaire¹, M. Amsalle¹, J. Athur-Ataam¹, A. Amato-Gauberville², M. Isorni³, L. Mabille³, A. Potier⁴, S. Arthur-Ataam¹, P. Dorfmüller¹, L. Lamrani¹, P. Deleuze⁵, S. Musso⁵, E. Fadel⁶, O. Mercier⁶. ¹Research and Innovation Unit Research Lab, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ²Dept of Radiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ³Dept of Nuclear Medicine and Radiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁴Dept of Cardiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁵Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁶Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France

11:05 AM (338) **Reimbursement**
William Auger, MD, University of California San Diego Medical Center, La Jolla, CA, USA

11:10 AM **Transplant Registries to Improve Results: ItRelates to Research, Regulation, Reporting and Reimbursement**
David Reich, MD, FACS, Drexel University College of Medicine, Philadelphia, PA, USA

11:30 AM (339) **Outcome and Primary Endpoint Results From a Prospective Multi-center Study of Myocardial Recovery Using LVADs: Remission from Stage D Heart Failure (RESTAGE-HF)**; E. J. Birks¹, S. G. Drakos², B. D. Lowes³, S. R. Patel⁴, C. Selzman⁵, M. S. Slaughter⁶, P. Alturi⁷, D. Goldstein⁸, J. Um⁹, C. Cunningham¹⁰, K. B. Margulies¹¹, J. Stehlik², R. Starling¹², D. Farrar¹³, E. Rame¹¹. ¹Dept of Cardiovascular Medicine, Univ of Louisville, Louisville, KY, ²Dept of Cardiovascular Medicine, Univ of Utah, Salt Lake City, UT, ³Dept of Cardiovascular Medicine, Univ of Nebraska, Omaha, NE, ⁴Dept of Cardiovascular Medicine, Montefiore Medical Center, New York, NY, ⁵Dept of Cardiothoracic Surgery, Univ of Utah, Salt Lake City, UT, ⁶Dept of Cardiovascular Surgery, Univ of Louisville, Louisville, KY, ⁷Dept of Cardiovascular Surgery, Univ of Pennsylvania, Philadelphia, PA, ⁸Dept of Cardiovascular Surgery, Montefiore, New York, NY, ⁹Dept of Cardiovascular Surgery, Univ of Nebraska, Omaha, NE, ¹⁰Clinical Trials Unit, Univ of Louisville, Louisville, KY, ¹¹Dept of Cardiovascular Medicine, Univ of Pennsylvania, Philadelphia, PA, ¹²Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ¹³Medical Affairs, Abbott, Pleasanton, CA

11:45 AM (339) **Interactive Discussant for Presentation 338**
Guy A MacGowan, MD, FACC, FRCPI, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:50 AM (340) **Tissue-Engineered Matrix to Generate Organs**
Simon P Hoerstrup, MD, PhD, IREMC, University of Zurich, Zurich, Switzerland

12:10 PM (340) **Transplanting Thoracic Organs from Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients**; A. E. Woolley¹, S. K. Singh², H. R. Mallidi³, M. M. Givertz⁴, H. J. Goldberg⁵, M. R. Mehra⁴, L. L. Coakley⁴, A. E. Kusztos¹, K. Chen⁷, J. Fanikos⁸, D. Harrington⁷, P. C. Camp⁵, L. R. Baden¹. ¹Infectious Diseases, Brigham and Women's Hospital, Boston, MA, ²Cardiac and Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, ³Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Cardiology, Brigham and Women's Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Pharmacy, Brigham and Women's Hospital, Boston, MA, ⁷Dana Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, MA, ⁸Thoracic Surgery, Brigham and Women's Hospital, Boston, MA

12:25 PM (340) **Interactive Discussant for Presentation 340**
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS

Location: Apollon
Target Audience: MCS, HF/HTX, NHSAH, PEDS, PHARM
Chairs: Jaime A Hernandez Montfort, MD MPH, and Stephan Schueler, MD, PhD, FRCS

Session Summary: Despite recent advances in the treatment of end-stage heart failure, cardiogenic shock remains a challenging condition. Short-term mcs is increasingly being used as a bridge to decision making in patients with refractory cardiogenic shock. The aim of this symposium is to review the clinical data on cardiogenic shock and the outcome. The use of mcs with particular emphasis on ECMO will be discussed. Patient selection, timing of device implantation, bridging to decision making under short-term mcs will be evaluated.

2:00 PM Do We Need a New Classification for Cardiogenic Shock?
J. Eduardo Rame, MD, Penn Heart and Vascular Center, Philadelphia, PA, USA

2:15 PM Q&A

2:20 PM Counterpulsation Response in Low-Output Heart Failure: Secondary Shock Prevention?
Jerry D Estep, MD, The Methodist Hospital, Houston, TX, USA

2:35 PM Q&A

2:40 PM Door to...Recovery! Contemporary Treatment of Acute Myocardial Infarction Maximizing Potential for Myocardial Recovery
Navin K Kapur, MD, Tufts Medical Center, Boston, MA, USA

2:55 PM Q&A

3:00 PM Decision-Making in Complex Cardiogenic Shock: The Surgeon’s View
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

3:15 PM Q&A

3:20 PM Veno-Arterial ECMO: Indications and Surveillance
Shelley A. Hall, MD, Baylor University Medical Center, Dallas, TX, USA

3:35 PM Q&A

3:40 PM Weaning from ECMO
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

3:55 PM Q&A
SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure

**Location:** Athena

**Target Audience:** LF/LTX, BSTR, ID, NHSAH, PEDS, PHARM

**Chairs:** Keith M Wille, MD, MSPH, and Michael Durheim, MD

**Session Summary:** With the introduction of new medications for lung failure, concerns have surfaced about their preoperative safety and some programs restrict their use in candidates. This creates clinical quandaries revolving around assessing risk of disease progression vs. preoperative risks of using such medications. Debate also exists whether to continue to use some of these medications after the transplant. We will discuss some of the more common and controversial examples.

**2:00 PM** *Use of Anticoagulation or Anti-Platelet Therapy While Waiting: Can It Be Done Safely?*
Matthew G Hartwig, MD, Duke University Medical Center, Durham, NC, USA

**2:15 PM** Q&A

**2:20 PM** *Is it Safe to Use mTOR Inhibition (Sirolimus or Everolimus) While Awaiting Lung Transplantation in Lymphangioleiomyomatosis (LAM)?*
Daniel F Dilling, MD, Loyola University Medical Center, Chicago, IL, USA

**2:35 PM** Q&A

**2:40 PM** *Planning for the Far Side: Antimicrobial Agents in Patients on the Wait List for Lung Transplantation*
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

**2:55 PM** Q&A

**3:00 PM** *Are the Novel Antifibrotic Medications Safe for Use in Candidates for Lung Transplantation?*
Hilary J Goldberg, MD, Brigham & Women's Hospital, Boston, MA, USA

**3:15 PM** Q&A

**3:20 PM** *Lumacaftor/Ivacaftor Use Before and After Transplant in Cystic Fibrosis: Is It Indicated?*
Adam B Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

**3:35 PM** Q&A

**3:40 PM** *Analgesia and Neuropharmacology: What is Acceptable in Lung Transplant Candidates*
Linda Stuckey Fitzgerald, PharmD, BCPS, University of Michigan Hospital, Ann Arbor, MI, USA

**3:55 PM** Q&A
2:00 PM - 4:00 PM
SYMPOSIUM 27: DCD Lungs- Expanding Utilization

Location: Mediterrane ABC
Target Audience: LF/LTX, NHSAH

Chairs: Aleem Siddique, MBBS, and John Dark, MB, FRCS

Session Summary: Ample data has accrued on the outcomes with DCD lungs demonstrating equivalence with DBD donors. Yet DCD lung utilization remains low outside of well-established centers. This session will attempt to breakdown some of the barriers to broader utilization and describe strategies that have proven to be successful while highlighting lessons that we can all learn from. A panel discussion with all speakers will conclude this session.

2:00 PM Establishing a DCD Program
Dirk E Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

2:20 PM Uncontrolled DCD: Can We Use It for Lung Transplant and How?
Thomas M. Egan, MD, MSC, UNC School of Medicine, Chapel Hill, NC, USA

2:40 PM Which Potential DCD Donor Will Progress to Donation? Measures to Predict and Optimize Resources
Peter M Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia

3:00 PM DEBATE (Pro): We Need EVLP to Use Lungs from DCD
Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

3:15 PM DEBATE (Con): We Need EVLP to Use Lungs from DCD
Kumud K Dhital, MD, PhD, St. Vincent's Hospital, Sydney, Australia

3:30 PM Debate Rebuttal (Pro)
Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

3:35 PM Debate Rebuttal (Con)
Kumud K Dhital, MD, PhD, St. Vincent's Hospital, Sydney, Australia

3:40 PM Panel Discussion
2:00 PM - 4:00 PM
SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant

Location: Clio/Thalie/Erato
Target Audience: HF/HTX, MCS, PHARM, PH

Chairs: Marta Farrero Torres, MD, PhD, and Michael Pham, MD

Session Summary: This session will focus on four important aspects of peri-operative care: pre-op optimization, post-transplant haemodynamics, post-transplant rhythm disturbances and early graft dysfunction. Each topic will start with case presentation with several open-ended questions that will lead to a lecture. A panel discussion with all speakers will conclude this session.

2:00 PM CASE PRESENTATION: Patient with Co-Morbidities on LVAD Awaiting Heart Transplantation: What Should We Be Doing?
Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA

2:05 PM Preparing for Heart Transplantation: Are You Ready to Rumble?
Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

2:25 PM CASE PRESENTATION: A Patient Immediately Post Heart Transplant in ICU with PH, Vasoplegia, and Renal Failure on Multiple Vasoactive Agents: Now What?
Munir S Janmohamed, MD, UCSF Medical Center, San Francisco, CA, USA

2:30 PM Managing the Immediate Post-Transplant Patient: It’s All About the Volume, It’s All About the Pressure
Jason N Katz, MD, MHS, University of North Carolina, Chapel Hill, NC, USA

2:50 PM CASE PRESENTATION: A Thin Patient on LVAD as Bridge to Transplantation Early Post-Transplant with Bradycardia, Intermittent Atrial Fibrillation and Prolonged ITU Stay
Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

2:55 PM And the Beat Goes On: Managing the Immediate Post-Transplant Patient: Rhythm, Pulse, Fuel and Movement!
David A. Hormuth, MD, Indiana University Health Physicians, Indianapolis, IN, USA

3:15 PM CASE PRESENTATION: A Patient in ICU with Primary Graft Dysfunction on ECMO and CRRT: God Help Us!
Mitchell Psotka, MD PhD, UCSF Medical Center, San Francisco, CA, USA

3:20 PM The Heart is Not Working… Don’t Panic
Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

3:40 PM Panel Discussion
2:00 PM - 4:00 PM  
**SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT**

**Location:** Uranie/Calliope  
**Target Audience:** PH, BSTR, HF/HTX, NHSAH, PATH, PEDS, PHARM  
**Chairs:** Irene Lang, MD, and Stephan Rosenkranz, MD

**Session Summary:** This session, supported by a collaborative effort with the European Society of Cardiology (ESC), will discuss and debate the latest advances in PH due to left heart diseases, the leading cause of PH, after the World Symposium on PH held in Nice (Feb 25th to March 1st 2018). A panel discussion with all speakers will conclude this session.

2:00 PM **From Nice 2013 to Nice 2018: Same Venue but Some Changes**  
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

2:15 PM **The PH-HFpEF Phenome: Redefining the Disease**  
Sanjiv J. Shah, MD, Northwestern University, Chicago, IL, USA

2:30 PM **The Failing Right Heart in Left Heart Diseases: Any Different from What We See in PAH?**  
Stephan Rosenkranz, MD, University Heart Center, Cologne, Germany

2:45 PM **Provocative Testing in the Cath Lab to Unmask Pulmonary Hypertension Due to Left Heart Disease**  
Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada

3:00 PM **DEBATE (Pro): PH Due to LHD Should Not Be Treated with Vasodilators**  
Nazzareno Galiè, MD, Prof., Bologna University Hospital, Bologna, Italy

3:15 PM **DEBATE (Con): PH Due to LHD Should Not Be Treated with Vasodilators**  
Mardi Gomberg-Maitland, MD, Inova Fairfax, Falls Church, VA, USA

3:30 PM **Debate Rebuttal (Pro)**  
Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy

3:35 PM **Debate Rebuttal (Con)**  
Mardi Gomberg-Maitland, MD, Inova Fairfax, Falls Church, VA, USA

3:40 PM **Panel Discussion**
2:00 PM - 4:00 PM
SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads

Location: Hermes
Target Audience: ID, EEP, HF/HTX, LF/LTX, NHSAH, PEDS, PHARM

Chairs: Clarisse Machado, MD, and Michael G Ison, MD MS

Session Summary: This symposium draws experts from ISHLT and the international Transplant Infectious Diseases (TID) section of The Transplantation Society (TTS) to create a joint symposium which addresses important and timely topics in Infectious Diseases.

2:00 PM What's All the Fuss? Emerging Arboviral Infections
Clarisse Machado, MD, University of São Paulo, São Paolo, Brazil

2:15 PM Q&A

2:20 PM Cryptococcus: A Perennial Problem
John W Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

2:35 PM Q&A

2:40 PM The Latest and Greatest in the Prevention and Management of CMV
Camille Kotton, MD, Massachusetts General Hospital, Boston, MA, USA

2:55 PM Q&A

3:00 PM Time to Man the Global Barricades: Multi-Drug Resistant Organisms on the March
Stephanie Pouch, MD, Emory University, Atlanta, GA, USA

3:15 PM Q&A

3:20 PM To Screen or Not to Screen: That is the Question! Global Donor Screening Issues
Ban Hock Tan, MD, Singapore General Hospital, Singapore, Malaysia

3:35 PM Q&A

3:40 PM Parasitic Cases: Hot Bugs in a Warming World
Joanna M Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

3:55 PM Q&A
2:00 PM - 4:00 PM
SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction

Location: Mediterraneo 6
Target Audience: PEDS, HF/HTX, MCS

Chairs: Estela Azeka, MD, and Holger W. Buchholz, MD

Session Summary: The goal of this session is to gain a better understanding of the evaluation and treatment of the failing heart in the intensive care unit setting. This will include discussions on evaluation and treatment of acute heart failure in both cardiomyopathy and congenital heart disease, care of patients on mechanical circulatory support while awaiting heart transplant and care in the ICU after transplantation.

2:00 PM Short-Term Mechanical Support for Children: A Bridge Across Troubled Waters
Katsuhide Maeda, MD, Stanford University, Stanford, CA, USA

2:15 PM Q&A

2:20 PM Pushing the Limits of Organ Acceptance: Take It or Leave It
Farhan Zafar, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

2:35 PM Q&A

2:40 PM Anesthesia and ICU Considerations in the First 24 Hours: Best Day of My Life
Martin Schweiger, MD, PhD, Children's Hospital Zurich, Zurich, Switzerland

2:55 PM Q&A

3:00 PM Non-Cardiac Organ Dysfunction After Heart Transplant in Children and Adults with Congenital Heart Disease: Don't You Forget About Me
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

3:15 PM Q&A

3:20 PM Proceed with Caution After Positive Crossmatch: Breaking In a Brand New Broken Heart
Steven A. Webber, MBChB, Monroe Carrell Jr. Children's Hospital, Nashville, TN, USA

3:35 PM Q&A

3:40 PM It Just Needs a Little Time: Graft Failure After Heart Transplant
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

3:55 PM Q&A
4:30 PM - 6:00 PM
ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS

Location: Apollon
Target Audience: MCS, HF, NHSAH, PHARM

Chairs: Shashank S Desai, MD, and Douglas A. Horstmanshof, MD

4:30 PM (341) Continuous-flow LVAD Therapy: A ‘Forme-fruste’ of Diastolic Heart Failure; P. Jain¹, K. Muthiah¹, A. Jabbour¹, E. Kotlyar¹, A. Keogh¹, D. Robson¹, P. Jansz², S. Nanayakkara², J. Mariani², P. Macdonald¹, C. Hayward¹, D. Kaye². ¹Heart failure and transplant unit, St Vincent’s Hospital, Sydney, Australia, ²Heart failure-transplant unit, The Alfred Hospital, Melbourne, Australia

4:45 PM (342) LVAD Pump Speed Increase is Associated with Improvement of Cardiac Output, O2 Kinetic and O2 Muscle Extraction; S. Paolillo¹, C. Vignati², A. Apostolo², N. Bonini², F. M. Righini², G. Gerosa³, T. Bottio⁴, V. Tarzia⁴, J. Beiko⁴, P. Agostoni². ¹IRCCS SDN, Napoli, Italy, ²Centro Cardiologico Monzino, IRCCS, Milan, Italy, ³Cardiac Surgery Unit, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁴Cardiac Surgery Unit, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

5:00 PM (343) Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated With a Continuous Flow Left Ventricular Assist Device: A Multicentre Study; K. K. Mirza¹, M. H. Jung¹, K. Cuomo², S. Russell³, F. Gustafsson¹. ¹Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark, ²Johns Hopkins Hospital, Baltimore, MD, ³Dept of Medicine, Duke University School of Medicine, Durham, NC

5:15 PM (344) Development of Exercise Capacity in LVAD Patients During Inpatient Cardiac Rehabilitation Depending on Exercise Tolerance at the Time of Admission; N. Reiss¹, S. Mommertz¹, S. Schulte-Eistrup², J. Sindermann³, T. Schmidt¹. ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²Dept of Cardiac Surgery, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ³Cardiac Rehabilitation, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany

5:30 PM (345) Right Atrial and Ventricular Ejection Fractions at Rest Measured by Cardiac CT Predict Right Heart Function During Exercise But Do Not Determine Exercise Capacity in LVAD Recipients; K. K. Mirza, M. H. Jung, P. E. Sigvardsen, K. K. Mirza, K. Rossing, F. Gustafsson. Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark

5:45 PM (346) Ventricular Fibrosis and Other Factors Influencing Exercise Tolerance in LVAD Patients; M. Racherla¹, J. Heath¹, E. Sorensen¹, H. Voorhees¹, L. Dees¹, E. Feller¹, D. Kaczorowski¹, Z. Kon¹, S. Russell², V. Ton¹. ¹University of Maryland School of Medicine, Baltimore, MD, ²Duke University School of Medicine, Durham, NC
4:30 PM - 6:00 PM
ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure

Location: Athena
Target Audience: MCS

Chairs: Ahmet Kilic, MD, and Evgenij V Potapov, MD, PhD

4:30 PM (347) Evaluation of HeartWare HVAD Appearance on Serial Chest Radiographs: Pump Position and Migration Influence Adverse Outcomes; C. M. Pietras¹, S. Maltais², V. Tchantchaleishvili³, S. Podd³, S. M. Dunlay², R. C. Daly², F. D. Pagani⁴, J. M. Stulak². ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ³Division of Cardiovascular Surgery, Thomas Jefferson University, Philadelphia, PA, ⁴Division of Cardiovascular Surgery, University of Michigan, Ann Arbor, MI

4:45 PM (348) Worldwide Experience of Adult Patients with Small Body Size Supported by a Continuous-Flow Left Ventricular Assist Device - An IMACS Analysis; S. Lee¹, R. Xie², K. Lemstrom³, M. G. Dickinson¹, T. Boeve¹, M. Leacche¹, J. Cowger⁴, T. de By⁵, J. K. Kirklin². ¹Spectrum Health, Grand Rapids, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Henry Ford Hospital, Detroit, MI, ⁵EUROMACS, EACTS House, Windsor, United Kingdom

5:00 PM (349) HVAD Thrombosis - Searching for the Source; F. Kaufmann, C. Hörmandinger, E. Potapov, T. Krabatsch, V. Falk. German Heart Center Berlin, Berlin, Germany

5:15 PM (350) A Single Center Experience: Four Cases of Late Twisting of Outflow Grafts in HeartMate 3; M. Mueller, J. Mulzer, C. Hoermandinger, F. Kaufmann, S. Dreysse, V. Falk, E. Potapov. Surgery, DHZB, Berlin, Germany

5:30 PM (351) Alternative Outflow Graft Placement During Thoracotomy Implant of the HVAD System for the Treatment of Advanced Heart Failure; D. Zimpfer¹, J. D. Schmitto², V. Horvathi³, S. Klotz³, U. Kervan⁵, M. Pac⁵, J. C. Roussel⁶. ¹Medical University Vienna, Vienna, Austria, ²Hannover Medical School, Hannover, Germany, ³Center of Cardiovascular and Transplant Surgery, Prague, Czech Republic, ⁴University Hospital Luebeck, Luebeck, Germany, ⁵Turkiye Yuksek Ihtisas Education & Research Hospital, Ankara, Turkey, ⁶University of Nantes, Nantes, France

5:45 PM (352) Evidence for Subclinical, Progressive Outflow Graft Stenosis in Patients With Heartware HVAD; P. Jain, D. Robson, P. Jansz, C. Hayward. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia
4:30 PM - 6:00 PM
ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP

Location: Mediterrane ABC
Target Audience: LTX

Chairs: Marcelo Cypel, MD, and Goran Dellgren, MD, PhD

4:30 PM (353) Results of the OCS Lung EXPAND International Trial Using Portable Normothermic OCS Lung Perfusion System (OCS) to Recruit and Evaluate Extended Criteria Donor (ECD) Lungs: G. Loor1, G. Warnecke2, M. Villavicencio3, M. Smith4, J. Kukreja5, A. Ardehali6, M. Hartwig7, M. Daneshmand8, M. Hertz9, A. Haverich10, J. Madsen11, D. Van Raemdonck12. 1Surgery, University of Minnesota, Minneapolis, MN, 2Hannover Medical School, Hannover, Germany, 3Massachusetts General Hospital, Boston, MA, 4St. Joseph’s Medical Center, Phoenix, AZ, 5University of California San Francisco Medical Center (UCSF), San Francisco, CA, 6UCLA Medical Center, Los Angeles, CA, 7Duke University Medical Center, Durham, NC, 8University of Minnesota, Minneapolis, MN, 9Leuven University Hospital, Leuven, Belgium

4:45 PM (354) Negative Impact of Ischemia on Short and Long Term Outcomes in Standard Criteria Double Lung Transplants Prospective Evidence from the OCS Lung INSPIRE International Trial Results: G. Warnecke1, D. Van Raemdonck2, J. Kukreja3, M. Smith4, G. Loor5, F. Rea6, G. Massard7, F. De Robertis8, J. Nagendran9, J. Moradiellos10, K. Dhital11, C. Nosalla12, C. Bermudez13, S. Tsui14, J. Madsen15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, I. Tudorache1, B. Wiegmann1, M. Schiavon2, F. Calabrese3, N. Santelmo4, A. Olland1, P. Falcoz5, A. Varela6, M. Hertz7, A. Simon8, H. Resichenspurner18, A. Haverich1, A. Ardehali20. 1Hannover Medical School, Hannover, Germany, 2Leuven University Hospital, Leuven, Belgium, 3University of California San Francisco Medical Center (UCSF), San Francisco, CA, 4St. Joseph’s Medical Center, Phoenix, AZ, 5University of Minnesota Medical Center, Minneapolis, MN, 6University of Padua Hospital, Padua, Italy, 7University Hospital of Strasbourg, Strasbourg, France, 8Harefield Hospital, London, United Kingdom, 9University of Alberta Medical Center, Edmonton, AB, Canada, 10University Puerta de Hierro Hospital, Madrid, Spain, 11St. Vincent’s Hospital, Sydney, Australia, 12German Heart Institute, Berlin, Germany, 13University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 14Papworth Hospital, Cambridge, United Kingdom, 15Massachusetts General Hospital, Boston, MA, 16Indiana University Health Methodist Hospital, Indianapolis, IN, 17Cleveland Clinic Foundation, Cleveland, OH, 18Hamburg University Hospital, Hamburg, Germany, 19University Hospitals of Marseille, Marseille, France, 20UCLA Medical Center, Los Angeles, CA

5:00 PM (355) Ex-Vivo Lung Perfusion in Donation After Circulatory Death Lung Transplantation Increases Donor Utilization: Analysis of the NOVEL Extension Trial: B. A. Whitson1, B. Shukrallah1, M. S. Mulligan2, J. D'Cunha3, M. Daneshmand4, T. Wozniak5, Z. Kon6, T. Machuca7, M. Jessen8, P. Sanchez9, E. Cantu9. 1Dept of Surgery, Wexner Med Ctr, Columbus, OH, 2University of Washington, Seattle, WA, 3University of Pittsburgh, Pittsburgh, PA, 4Duke, Raleigh, NC, 5Indiana University, Indianapolis, IN, 6University of Maryland, Baltimore, MD, 7University of Florida, Gainesville, FL, 8University of Texas Southwestern, Dallas, TX, 9University of Pennsylvania, Philadelphia, PA

5:15 PM (356) A Novel Parameter of Lung Evaluation Utilizing PaO2/FiO2 Difference at the Different FiO2 in Ex Vivo Lung Perfusion: H. Niikawa1, T. Okamoto1, K. S. Ayyat1, Y. Itoda2, J. Hata2, K. R. McCurry1. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 2General Anesthesiology, Cleveland Clinic, Cleveland, OH


4:30 PM - 6:00 PM
ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies

**Location:** Clio/Thalie/Erato

**Target Audience:** HTX, BSTR, EEP, HF, NHSAH, PATH

**Chairs:** Fabio M Turazza, MD, and Kiran Khush, MD, MAS


1Cedars-Sinai Heart Institute, Los Angeles, CA, 2Cardiology, Mount Sinai Health System, New York, NY, 3Stanford University, Stanford, CA, 4University of Pittsburgh, Pittsburgh, PA, 5CareDx, Brisbane, CA

(360) **WITHDRAWN**


1Medicine, Stanford University, Palo Alto, CA, 2HLA laboratory and Dept of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada, 3Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada, 4Medicine, Division of Cardiology, Universidade Federal do Rio Grande do Sul, Porto Allegre, Brazil, 5Biostatistics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 6Biostatistics and Epidemiology, McMaster University, Hamilton, ON, Canada, 7Medicine, Division of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

5:00 PM (361) **The Evolving (In)significance of Panel Reactive Antibody on Cardiac Transplantation Outcomes in the Modern Era;** J. J. Chung, A. Thomasson, C. W. Chen, C. Pietras, A. C. Gaffey, J. Han, M. A. Acker, E. Y. Birati, P. Atluri.

1Surgery, University of Pennsylvania, Philadelphia, PA, 2Penn Transplant Institute, University of Pennsylvania, Philadelphia, PA, 3Medicine, University of Pennsylvania, Philadelphia, PA


1Dept of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, 3Dept of Surgery, Mayo Clinic, Rochester, MN, 4Dept of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 5Dept of Cardiovascular Disease; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN


1Cardiology, Emory Univ Sch of Med, Atlanta, GA, 2George Washington University School of Medicine, Washington D.C., DC, 3Cardiothoracic Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 4Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA, 5Inova Heart and Vascular Institute, Falls Church, VA


1Cedars-Sinai Heart Institute, Los Angeles, CA
4:30 PM - 6:00 PM
ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension

Location: Uranie/Calliope
Target Audience: PH, HF, MCS, PHARM

Chairs: Marc A. Simon, MD, and Dana McGlothlin, MD

4:30 PM (365) Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function; R. L. Benza1, P. A. Corris2, J. R. Klinger3, D. Langleben4, R. Naeije5, G. Simonneau6, C. Vizza7, H. Wirtz8, M. Patarroyo-Aponte9, M. Chang10, P. Colorado11, C. Meier10, D. Busse12, M. M. Hoeper13, 1Allegheny Gen Hosp, Pittsburgh, PA, 2Institute of Cellular Medicine, Newcastle University, Newcastle, UK, 3Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 4Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada, 5Dept of Cardiology, Erasme University Hospital, Brussels, Belgium, 6Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France, 7Dept of Cardiovascular and Respiratory Sciences, Sapienza University of Rome, Rome, Italy, 8Dept of Respiratory Medicine, University of Leipzig, Leipzig, Germany, 9Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 10Global Medical Affairs, Bayer AG, Berlin, Germany, 11Global Clinical Development, Bayer AG, Barcelona, Spain, 12Chrestos Concept GmbH & Co. KG, Essen, Germany, 13Clinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany

4:45 PM (366) Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial Hypertension; M. E. Corkish1, L. T. Devine2, M. M. Clarke1, B. P. Murray1, I. B. Hollis1, L. J. Rose-Jones1, 1University of North Carolina Medical Center, Chapel Hill, NC, 2Massachusetts General Hospital, Boston, MA

5:00 PM (367) OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs); A. Ravichandran1, R. Channick2, K. M. Chin3, N. H. Kim4, M. Brand5, M. Selej6, V. V. V. Mclaughlin7, 1St. Vincent Heart Center, Indianapolis, IN, 2Massachusetts General Hospital, Boston, MA, 3UT Southwestern Medical Center, Dallas, TX, 4University of California San Diego, La Jolla, CA, 5Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 6Actelion Pharmaceuticals US, Inc, South San Francisco, CA, 7University of Michigan, Ann Arbor, MI

5:15 PM (368) Characteristics of Patients With CTD-associated PAH Treated With Selexipag in the Real-world Setting: Interim Data From the SPHERE Registry; K. B. Highland8, H. W. Farber9, N. H. Kim3, K. M. Chin4, A. R. Hemnes9, M. M. Chakinala9, C. Zhao7, M. Keating4, B. Hartline4, V. Mclaughlin7, 1Cleveland Clinic, Cleveland, OH, 2Boston University School of Medicine, Boston, MA, 3University of California San Diego Medical Center, San Diego, CA, 4University of Texas, Southwestern Medical Center, Dallas, TX, 5Vanderbilt University Medical Center, Nashville, TN, 6Washington University School of Medicine, St. Louis, MO, 7Actelion Pharmaceuticals US, Inc., South San Francisco, CA, 8University of Michigan Medical Center, Ann Harbor, MI

5:30 PM (369) Intravenous Treprostinil Delivered by Implantable Pump for the Treatment of Pulmonary Arterial Hypertension - Report of First 11 Cases; D. Rosengarten1, B. D. Fox2, R. G. Balmor1, A. Balenky1, N. Natif2, A. Unterman1, A. Avriel3, Y. Adir4, M. J. Segel5, M. R. Kramer6, 1Rabin medical center, Petach tikva, Israel, 2Assaf Harofeh, Rishon-Le-Zion, Israel, 3Soroka medical center, Beer sheva, Israel, 4Carmel medical center, Haifa, Israel, 5Sheba medical center, Ramat gan, Israel

5:45 PM (370) LVAD Does Not Improve Outcomes in Patients with Pulmonary Hypertension after Heart Transplantation; C. R. Brown1, F. N. Khurshan1, Z. Chen1, P. Zamani2, J. A. Mazurek2, F. H. McCarthy1, M. A. Acker1, N. D. Desai1, J. Rame2, 1Division of Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, 2Cardiovascular Division, University of Pennsylvania, Philadelphia, PA
4:30 PM - 6:00 PM
ORAL SESSION 38: Hot Topics in Infectious Diseases

Location: Hermes
Target Audience: ID, HTX, LTX, MCS

Chairs: Cameron R Wolfe, MBBS MPH, and Orla Morrissey, MD

4:30 PM (371) Mortality Outcomes Related to Multi-drug Resistant Organisms in Cystic Fibrosis Lung Transplant Recipients: An International Society of Heart and Lung Transplantation (ISHLT) Registry Study; C. Lay, N. Law, A. M. Holm, B. Bend, S. Aslam, University of California, San Diego, San Diego, CA, 2Oslo University Hospital, Oslo, Norway, 3University Hospital Zurich, Zurich, Switzerland

4:45 PM (372) A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients; J. Gottlieb, F. Torres, T. Haddad, G. Dhillon, D. F. Dilling, C. Knoop, R. Rampolla, V. Ahya, R. Kessler, D. P. Mason, M. Budev, C. Neurohr, A. R. Glanville, R. Jordan, D. Porter, M. T. McKeveitt, P. German, Y. Guo, J. W. Chien, T. R. Watkins, Hannover Medical School, Hannover, Germany, 2University of Texas Southwestern Medical Center, Dallas, TX, 3Tampa General Hospital, Tampa, FL, 4Stanford University Medical Center, Stanford, CA, 5Loyola University Chicago, Maywood, IL, 6Erasmus University Hospital, Brussels, Belgium, 7Ochsner Clinic Foundation, New Orleans, LA, 8St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 9Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 10University of Strasbourg, Strasbourg, France, 11 Baylor University Medical Center, Dallas, TX, 12Cleveland Clinic Foundation, Cleveland, OH, 13University of Munich, Munich, Germany, 14St. Vincent’s Hospital, Darlinghurst, Australia, 15Gilead Sciences Inc., Foster City, CA, 16University of Colorado at Denver Health Sciences Center, Aurora, CO


5:45 PM (376) Defining Severe Antibody Deficiency in Heart and Lung Transplantation; J. Carbone, I. Sousa, J. Cifrian, M. Gomez-Sanchez, R. Laporta, M. Crespo-Leiro, C. Bravo, L. Almenar, A. Sole, G. Rabago, J. Segovia, A. de Pablos, J. Lopez, S. Mirabet, J. Navarro, E. Sarmiento, 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Pneumology, Hospital Marques de Valdecilla, Santander, Spain, 4Cardiology, Hospital Universitario Doce de Octubre, Madrid, Spain, 5Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 6Cardiology, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, 7Pneumology, Hospital Valle de Hebron, Barcelona, Spain, 8Cardiology, Hospital Universitario La Fe, Valencia, Spain, 9Pneumology, Hospital Universitario La Fe, Valencia, Spain, 10Heart Surgery, Clínica Universitaria de Navarra, Navarra, Spain, 11Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 12Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, 13Cardiology, Hospital Clínico Universitario, Valladolid, Spain, 14Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
4:30 PM - 6:00 PM
ORAL SESSION 39: All Is Not Lost: Improving Outcomes in Children with a Failing Heart

Location: Mediterranee 6
Target Audience: PEDS, HF, HTX, MCS, NHSAH

Chairs: Adam Putschoegl, DO, and Estela Azeka, MD

4:30 PM (377) Survival and Outcome in Pediatric Myocarditis - 3 Year Data from the German Multi-center Prospective Myocarditis Registry: “MYKKE”
S. Schubert1, B. Opgen-Rhein2, M. Böhne3, A. Weigelt4, R. Wagner5, G. Müller6, A. Rentzsch7, A. Racolta8, K. Papakostas9, G. Wiegand10, B. Ruf11, T. Hannes12, K. Reineker13, D. Kiski14, M. Khalili15, M. Steinmetz16, G. Fischer17, T. Pickardt18, K. Klingel19, D. Messroghli20, F. Degener1. 1Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Klinik für Pädiatrie mit Schwerpunkt Kardiologie, Charité Univ Berlin, Berlin, Germany, 3Pediatric Cardiology, Med Hochschule Hannover, Hannover, Germany, 4Pediatric Cardiology, Univ Erlangen, Erlangen, Germany, 5Pediatric Cardiology, Herzzentrum Frankfurt, Frankfurt, Germany, 6Pediatric Cardiology, Univ Herzzentrum Hamburg, Hamburg, Germany, 7Pediatric Cardiology, Univ des Saarlandes, Homburg, Germany, 8Pediatric Cardiology, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, 9Pediatric Cardiology, Klinikum Links der Weser, Bremen, Germany, 10Pediatric Cardiology, Univ Tübingen, Tübingen, Germany, 11Pediatric Cardiology, Deutsches Herzzentrum München, München, Germany, 12Pediatric Cardiology, Uniklinik Köln, Köln, Germany, 13Pediatric Cardiology, Univ-Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany, 14Pediatric Cardiology, Univ Münster, Münster, Germany, 15Pediatric Cardiology, Univ Gießen, Gießen, Germany, 16Pediatric Cardiology, Univ Göttingen, Göttingen, Germany, 17Pediatric Cardiology, Univ Schleswig-Holstein, Kiel, Germany, 18Kompetenzzentrum Angborne Herzfehler, Berlin, Germany, 19Dept for Pathology, Univ Tübingen, Tübingen, Germany, 20Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

4:45 PM (378) Acute Decompensated Heart Failure in the Pediatric Population: A Report from the Pediatric Cardiac Critical Care Consortium (PC4)
J. J. Lasa1, M. Gaies2, J. Rossano3, L. Retzloff4, W. Zhang2, M. Banerjee4, J. Elhoff5, A. Lorts5, K. Schumacher6, R. Butts6, A. Cabrera7, J. Alten8, J. Price9. 1Critical Care Medicine and Cardiology, Texas Children's Hospital, Houston, TX, 2Cardiology, C.S. Mott Children's Hospital, Univ of Michigan, Ann Arbor, MI, 3Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 4Institute for Healthcare Policy and Innovation, Univ of Michigan, Ann Arbor, MI, 5Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, 6Cardiology, Children's Health, UT Southwestern, Dallas, TX, 7Cardiology, Texas Children's Hosp, Houston, TX, 8Critical Care Medicine, Univ of Alabama-Birmingham, Birmingham, AL

5:00 PM (379) The First Analysis of the International Pediatric Heart Failure Registry (iPHFR) - Heart Failure Hospitalizations
A. I. Dipchand1, W. Zuckerman2, S. Auerbach3, J. Conway4, W. Cherikh5, D. Peng6, A. Barnes7, B. Kaufman8, P. Thrush9, A. Sadavarte10, C. Almond11, E. Pahl12, E. Azeka13, R. Gajarski14, Y. Law15, A. Lorts16, C. VanderPluym17, R. Kirk18. 1Hosp for Sick Children, Toronto, ON, Canada, 2Morgan Stanley Children's Hospital of New York, Columbia Univ Medical Center, New York, NY, 3Children's Hospital Colorado Heart Institute, Denver, CO, 4Stollery Children's Hospital, Edmonton, AB, Canada, 5United Network for Organ Sharing, Richmond, VA, 6Congenital Heart Center at Mott Children's Hospital, Ann Arbor, MI, 7Children's Mercy Hospital and Clinics, Kansas City, MO, 8Lucile Packard Children's Hospital at Stanford, Stanford, CA, 9Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 10Heart Institute (InCor) Univ of São Paulo Medical School, Sao Paulo, Brazil, 11Nationwide Children's Hospital, Columbus, OH, 12Seattle Children's Hospital, Seattle, WA, 13Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14Boston Children's Hospital, Boston, MA, 15Children's Medical Center, Dallas, TX

5:15 PM (380) Trends in Pediatric Mechanical Circulatory Support: Are Patients, Devices, and Outcomes Changing?
R. S. Cantor1, D. C. Nattel1, D. N. Rosenthal2, E. D. Blume3, J. K. Kirklin4. 1Kirklin Institute for Research in Surgical Outcomes (KIRSO), Univ of Alabama at Birmingham, Birmingham, AL, 2Stanford Univ, Palo Alto, CA, 3Boston Children's Hosp, Boston, MA

5:30 PM (381) Impact of Pre-implant Illness Severity on Outcomes of Pediatric VAD Patients
A. Butto1, S. A. Teele1, L. A. Sleeper1, P. T. Thrush2, J. Philip3, M. Lu4, R. S. Cantor4, J. W. Rossano5. 1Dept of Cardiology, Boston Children's Hospital, Boston, MA, 2Division of Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 3Congenital Heart Center, Univ of Florida, Gainesville, FL, 4Kirklin Institute for Research in Surgical Outcomes, Univ of Alabama at Birmingham, Birmingham, AL, 5The Cardiac Center, Div of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA
5:45 PM (382) Outcomes of Children With Congenital Heart Disease Implanted With Ventricular Assist Devices: Analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs): D. M. Peng¹, D. A. Koehl², R. S. Cantor², K. N. McMillan³, A. P. Barnes⁴, P. I. McConnell⁵, J. Jordan¹, N. D. Andersen⁶, J. D. St. Louis⁴, K. Maeda⁷, J. K. Kirkin³, S. J. Kindel⁸. ¹Pediatrics (Cardiology), Univ of Michigan, Ann Arbor, MI, ²Univ of Alabama at Birmingham, Birmingham, AL, ³Johns Hopkins Univ, Baltimore, MD, ⁴Univ of Missouri-Kansas City, Kansas City, MO, ⁵Ohio State Univ, Columbus, OH, ⁶Harvard Univ, Boston, MA, ⁷Stanford Univ, Palo Alto, CA, ⁸Medical College of Wisconsin, Milwaukee, WI
6:15 PM - 7:15 PM
MINI ORAL 13: Mechanical Circulatory Support: Bleeding

Location: Athena
Target Audience: MCS, PHARM

Chairs: Dipanjan Banerjee, MD, and Claudius Mahr, DO

6:15 PM (383) **Higher Soluble Thrombomodulin and Angiogenic Markers in LVAD Supported Patients Associate with Arteriovenous Malformation and Non-Surgical Bleeding:** K. Muthiah1, L. L. Dunn2, D. Connor3, J. Joseph4, D. Robson1, P. Macdonald1, R. Stocker2, C. S. Hayward1. 1Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia, 2Victor Chang Cardiac Research Institute, Sydney, Australia, 3St. Vincent's Center For Applied Medical Research, Sydney, Australia, 4Dept of Haematology, St. Vincent's Hospital, Sydney, Australia

6:20 PM (384) **Enhanced Thrombin Formation in Patients with Implanted LVADs Experiencing GI and Other Bleeding: Insights from the Multi-center PREVENT Study:** W. P. Jeske1, P. Maia1, J. Ransom2, M. Keebler3, J. Katz4, A. Kilic5, J. Lindenfeld5, G. Egnaczyk6, P. Shah7, A. Brieke8, N. Uriel9, S. Maltais10, D. Crandall11, K. Sundareswaran11, D. Farrar11, J. Walenga1. 1Loyola Univ Medical Center. Maywood, IL, 2Baptist Health Heart and Transplant Institute, Little Rock, AR, 3Vanderbilt Univ, Nashville, TN, 4Univ of North Carolina, Chapel Hill, NC, 5Ohio State Univ, Columbus, OH, 6Christ Hospital, Cincinnati, OH, 7Inova Heart and Vascular Institute, Falls Church, VA, 8Univ of Colorado, Aurora, CO, 9Univ of Chicago, Chicago, IL, 10Mayo Clinic, Rochester, MN, 11Abbott, Chicago, IL

6:25 PM (385) **SSRI/SNRI Therapy is Associated with a Higher Risk of GI Bleed in LVAD Patients:** G. Mawardi1, T. Markman2, R. Muslem3, M. Sobhanian4, M. Converse5, H. Meadows6, W. E. Uber4, D. P. Judge4, R. J. Tedford7, B. A. Houston4. 1Internal Medicine, Medical University of South Carolina, Charleston, SC, 2Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA, 3Cardiology, The Johns Hopkins School of Medicine, Baltimore, MD, 4Cardiology, Medical University of South Carolina, Charleston, SC

6:30 PM (386) **Impact of Anemia on Survival Among Patients with Durable Ventricular Assist Device: An Analysis of the Prevent Study:** S. Zalawadiya1, A. Shah1, M. Keebler1, R. John2, I. Gregoric3, A. Kilic4, R. Adamson5, P. Shah6, R. Agarwal7, S. Maltais8, D. Crandall8, K. Sundareswaran9, D. Farrar8, J. Lindenfeld1. 1Vanderbilt, Nashville, TN, 2University of Minnesota, Minneapolis, MN, 3Memorial Hermann, Houston, TX, 4Ohio State University, Columbus, OH, 5Sharp Memorial, San Diego, CA, 6Inova Heart and Vascular Institute, Fall Church, VA, 7Allegheny General Hospital, Pittsburgh, PA, 8Mayo Clinic, Rochester, MN, 9Abbott (formerly St Jude Medical), Chicago, IL

6:35 PM (387) **Ticagrelor but not Aspirin Limits Shear-Mediated Platelet Activation:** J. Sheriff1, P. L. Tran2, L. Valerio3, M. Hutchinson4, D. Bluestein5, M. J. Slepian4. 1Biomedical Engineering, Stony Brook University, Stony Brook, NY, 2Biomedical Engineering, University of Arizona, Tucson, AZ, 3Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy, 4Biomedical Engineering and Sarver Heart Center, University of Arizona, Tucson, AZ

6:40 PM (388) **A Prospective Validation of the First Endoscopic Management Algorithm for Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices:** J. E. Axelrad1, A. Pinsino2, A. Thanataweerat3, B. Cagliostro3, M. A. Flannery2, K. Ross2, R. T. Te-Frey2, L. Effner2, A. R. Garan2, V. K. Topkara2, H. Takayama4, K. Takeda4, Y. Nakao4, P. Colombo5, T. Gonda1, M. Yuazepolskaya2. 1Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, 2Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, 3Epidemiology, Mailman School of Public Health, New York, NY, 4Surgery, Columbia University Medical Center, New York, NY

6:45 PM (389) **MCS Shear-Medicated Platelet Activation Does not Cause Integrin GPIIbIIIa Activation, Rather Shedding and Microparticle Generation:** Y. Roka-Moia1, D. E. Palomares1, J. Sheriff1, D. Bluestein2, M. J. Slepian1. 1Dept of Medicine and Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, 2Dept of Biomedical Engineering, Stony Brook University, Stony Brook, NY

6:50 PM (390) **Reduced Rate of Gastrointestinal Bleeding in Recipients of the HeartMate3 Compared to HeartMate II Ventricular Assist Devices:** G. Faerber, H. Kirov, T. Sandhaus, S. Tkebuchava, T. Boeve, M. Leacche, S. Jovinge, S. Lee. Spectrum Health, Grand Rapids, MI

7:00 PM (392) Association Between Angiotensin II Receptor Blockade and Recurrent Gastrointestinal Bleeding on Left Ventricular Assist Device Support; J. N. Schultz¹, K. Goodwin², R. John³, T. Alexy⁴, F. Kamdar⁴, C. Martin⁴, R. Cogswell⁴. ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ⁴Dept of Cardiology, University of Minnesota, Minneapolis, MN

7:05 PM (393) A Multidisciplinary Continuous Support Heart Team Approach Improves Hemocompatibility Related Outcomes in Continuous Flow LVAD Recipients; A. M. Shah¹, E. Ong¹, D. Sims¹, N. Siddiqi¹, A. Luke¹, O. Saeed¹, S. Patel¹, S. Murthy¹, J. Shin¹, S. Watts¹, W. Jakobleff², S. Forest², S. Vukelic¹, D. Belov¹, Y. Puius³, G. Minamoto³, V. Muggia³, A. Carlese⁴, S. Leung⁴, M. Rahmanian⁴, J. Leff⁵, D. Goldstein², U. Jorde¹. ¹Division of Cardiology, Montefiore Medical Center, Bronx, NY, ²Division of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, ³Division of Infectious Disease, Montefiore Medical Center, Bronx, NY, ⁴Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, ⁵Division of Cardiothoracic Anesthesia, Montefiore Medical Center, Bronx, NY

7:10 PM (394) Omega-3 Reduces Gastrointestinal Bleeding in Patients With Continuous-flow Left Ventricular Assist Device; T. Imamura¹, D. Rodgers¹, G. Kim¹, J. Raikhelkar¹, N. Sarswat¹, S. Kalantari¹, A. Nguyen¹, B. Chung¹, C. Juricek¹, D. Burkhoff², T. Song¹, T. Ota¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY
6:15 PM - 7:15 PM
MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection

Location: Clio/Thalie/Erato
Target Audience: LTX

Chairs: Olivier Brugièreme, and Kevin M Chan, MD


6:20 PM (396) Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis; P. Pradère, I. Tudorache, J. Magnusson, L. Savale, O. Brugièreme, B. Douvry, M. Reynaud-Gaubert, J. Claustre, A. Le Borgne, A. M. Holm, H. H. Schulz, C. Knoop, L. Godinas, A. Fisher, S. Hirschi, J. Gottlieb, J. Le Page. 1Service de chirurgie thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France; 2Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hanover, Germany; 3Dept of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, University of Gothenburg, Sweden; 4Service de pneumologie, Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; 5Service de pneumologie, Hôpital Bichat, Paris, France; 6Service de pneumologie, Hôpital Foch, Suresnes, France; 7Service de pneumologie, Marseille North University Hospital, Marseille, France; 8Service de pneumologie, Centre Hopitalo-Universitaire, Grenoble, France; 9Pôles des voies respiratoires, Hôpital Larrey, Toulouse, France; 10Dept of Respiratory Medicine, Oslo University Hospital and Institute for Clinical Medicine University of Oslo, Oslo, Norway; 11Dept of Cardiology, Section for lung transplantation, Copenhagen University Hospital, Copenhagen, Denmark; 12Brussels Lung Transplant Program, Dept of Chest Medicine, Erasme University, Brussels, Belgium; 13Service de pneumologie, Centre Hopitalo-Universitaire UCL, Namur, Belgium; 14Institute of Transplantation, Newcastle Upon Tyne Hospitals, Newcastle, United Kingdom; 15Dept of Respiratory Diseases and Lung Transplantation Group, Strasbourg University Hospital, Strasbourg, France; 16Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany

6:25 PM (397) Outcomes of Lung Transplantation for Patients Undergoing Previous or Simultaneous Cardiac Surgery; H. Niikawa, T. Okamoto, L. Thuita, K. S. Ayat, Y. Itoda, S. Unai, D. Johnston, U. Ahmad, A. Zeeshan, E. H. Blackstone, K. R. McCurry. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; 2Transplant Center, Cleveland Clinic, Cleveland, OH; 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; 4Cardiothoracic Surgery, Zagazig University, Zagazig, Egypt

6:30 PM (398) Lower Six Minute Walk distance or FEV1 Predict a Survival Benefit of Lung Transplantation compared to Medical Management for End Stage COPD; I. Timofte, M. Wjesinha, R. Vesselinov, J. Kim, Z. Kon, R. Reed, K. Rajagopala, S. Scharf, R. Wise, A. Sternberg, D. Kaczorowski, B. Griffith, M. Terrin, A. Iacono. 1Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore, MD; 2Epidemiology & Public Health, UMMC, Baltimore, MD; 3UMMC, Baltimore, MD; 4Pulmonary and Critical Care, UMMC, Baltimore, MD; 5University of Texas, Huston, TX; 6Pulmonary and Critical Care, JHU, Baltimore, MD; 7JHU, Baltimore, MD; 8Epidemiology and Public Health, UMMC, Baltimore, MD; 9University of Maryland School of Medicine, Baltimore, MD

6:35 PM (399) Frailty as a Predictor of Prognostic Outcomes in Patients with Interstitial Lung Disease Referred for Lung Transplantation; E. Montgomery, P. Macdonald, P. Newton, S. Jha, M. Hannu, C. Thomson, A. Glavine, A. Havryk, M. Pilt, R. Pearson, M. Benzimra, M. Harkess, M. Malouf. 1Heart & Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia; 2University of Western Sydney, Sydney, Australia

6:40 PM (400) A Nordic Multicenter Study on Size Mismatch in Bilateral Lung Transplantation; H. Auråen, A. E. Fiane, O. Geiran, P. Håmmäinen, M. Perch, H. Larsson, G. Dellgren, M. Durheim, A. M. Holm. 1Dept. of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Dept. of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway; 3Dept. of Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland; 4Division of Lung Transplantation, Dept. of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 5Division of Respiratory Medicine and Allergology, Dept. of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden; 6Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

6:50 PM (402) **Blood Group O is Associated with Decreased Rates of Transplantation and Increased Waitlist Mortality in Lung Transplantation: A Propensity-Matched Registry Analysis**; Y. Barac, M. Mulvihill, M. Cox, M. Bishawi, J. Klapper, J. Haney, M. Daneshmand, M. Hartwig. Duke University Medical Center, Durham, NC

6:55 PM (403) **Geographic Disparities in Donor Lung Availability Impact Waitlist Outcomes in Lung Transplant Candidates: A Retrospective Cohort Study**; L. J. Benvenuto1, D. R. Anderson2, H. P. Kim3, J. L. Hook1, L. Shah1, H. Robbins1, F. D'Ovidio4, M. Bacchetta4, J. R. Sonett4, S. M. Arcasoy1. 1Medicine, Columbia University Medical Center, New York, NY, 2Dept of Management, Baruch College, New York, NY, 3Medicine, New York Presbyterian, New York, NY, 4Surgery, Columbia University Medical Center, New York, NY

7:00 PM (404) **BLTX on Intraoperative ECMO Sets the New Benchmark for Postoperative Graft Function: Results of a Prospective Trial**; K. Hoetzenecker, A. Benazzo, T. Stork, K. Sinn, S. Schwarz, D. Baron, H. Hager, P. Faybik, A. Bacher, C. Krenn, H. Prosch, W. Klepetko. Medical University of Vienna, Vienna, Austria

7:05 PM (405) **Outcomes of ECMO Bridge to Lung Transplantation are Dependent on Age**; M. Caceres Polo1, A. Iyengar2, O. Kwon1, J. Schaenman1, R. Biniwale1, D. Ross1, E. DePasquale1, A. Ardehali1. 1University of California - Los Angeles, Los Angeles, CA, 2David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA

7:10 PM (406) **Pre-Transplant Opioid Use is Associated with Increased Early Mortality and Readmission after Lung Transplantation**; H. Heiney1, C. J. Iasella1, C. A. Moore1, R. Venkataramanan1, M. R. Morrell1, J. Hayanga2, N. Shigemura3, A. Zeevi1, J. F. McDyer1, C. R. Ensor1. 1University of Pittsburgh, Pittsburgh, PA, 2West Virginia University, Morgantown, WV, 3Temple University, Philadelphia, PA
6:15 PM - 7:15 PM
MINI ORAL 15: Heart Transplantation: Donor Issues

Location: Uranie/Calliope
Target Audience: HTX, BSTR, EEP, NHSAH, PATH

Chairs: Lars H Lund, MD, PhD, and Alejandro M Bertolotti, MD

1Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Surgery, Massachusetts General Hospital, Boston, MA, 3Division of Transplant Surgery, Massachusetts General Hospital, Boston, MA, 4Dept of Cardiology, Massachusetts General Hospital, Boston, MA

6:20 PM (408) Left Ventricular Dysfunction in Potential Heart Donors and Its Impact on Recipient Outcomes; J. Oras1, L. Johansson1, B. Redfors2, E. Omerovic2, G. Dellgren3, 1Dept of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, Göteborg, Sweden, 2Dept of Cardiology, Institute of Medicine, Sahlgrenska Academy, Göteborg, Sweden, 3Dept of Cardiothoracic Surgery, Institute of Medicine, Sahlgrenska Academy, Göteborg, Sweden

6:25 PM (409) Donor Simvastatin Treatment Alters Protein Expression in the Recipient after Heart Transplantation; J. Lukac1, E. Holmström1, S. Joenvääraa1, M. Saraswat1, R. Krebs1, T. Tohmola1, A. Nykänen2, R. Renkonen1, K. Lemström2. 1Cardiopulmonary Research Group, Transplantation Laboratory Univ of Helsinki, Helsinki, Finland, 2Cardiopulmonary Research Group, Transplantation Laboratory Cardiothoracic Surgery, Helsinki Univ Hospital, Helsinki, Finland

6:30 PM (410) Donor Age and Ischemic Time - Implications for Efficacy of Ex-Vivo Organ Perfusion; V. Jemryd1, J. Stehlik2, G. J. Smith3, L. H. Lund4, B. Andersson3, H. Bergenfeldt4, J. Nilsson1. 1Clinical Sciences Lund, Cardiovascular Surgery, Lund University, Skane Univ Hospital, Lund, Sweden, 2Cardiovascular Medicine, Univ of Utah School of Medicine, Salt Lake City, UT, 3Clinical Sciences Lund, Cardiology, Lund University, Skane Univ Hospital, Lund, Sweden, 4Medicine and Heart and Vascular Theme, Karolinska Institutet, Karolinska Univ Hospital, Stockholm, Sweden, 5Clinical Sciences Lund, Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden

6:35 PM (411) Optimal Characteristics of Donor Hearts With Diminished Left Ventricular Function; A. B. Davila1, D. Estevez2, L. L. Bailey1, A. J. Razzouk1, D. G. Rabkin1. 1Cardiovascular and Thoracic Surgery, Loma Linda Univ Medical Center, Loma Linda, CA, 2Research Consulting Group, Loma Linda Univ School of Public Health, Loma Linda, CA

6:40 PM (412) Survival and Graft Function in Heart Transplant Patients Receiving Adverse Risk Profile Donor Hearts; K. Berg, Health, AU, Aarhus University, Århus, Denmark

6:45 PM (413) Coronary Angiography of Potential Cardiac Donors Increases Cardiac Transplantation Rates; A. Zuckermann1, K. Auersperg2, A. Kaider3, M. De Pauw4, Z. Sutlic5, J. Gummet6, M. Berchtold-Herz7, C. Schulze8, I. hartynszky9, K. Caliskan10, I. Knezevic11, J. Smits12, A. Strēlniece13, G. Laufer14. 1Medical Univ of Vienna, Vienna, Austria, 2Dept of Cardiovascular Surgery, Medical Univ of Vienna, Vienna, Austria, 3Institute of Clinical Biometrics, Medical Univ of Vienna, Austria, 4Dept of Cardiology, Ghent Univ, Vienna, Belgium, 5Dept of Cardiac Surgery, Clinical Hospital Dubrava, Zagreb, Croatia, 6Klinik für Thorax- und Kardiovaskulärchirurgie, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany, 7Klinik für Herz-, und Gefäßchirurgie, Herzzentrum Freiburg-Bad Krozingen, Freiburg, Germany, 8Klinik für Kardiologie, Univ Jena, Jena, Germany, 9Dept of Cardiac Surgery, Semmelweis Medical Univ, Budapest, Hungary, 10Afdeling Cardiologie, Erasmus MC, Rotterdam, Netherlands, 11Dept of Cardiovascular Surgery, Univ Medical Center Ljubljana, Ljubljana, Slovenia, 12Eurotransplant Foundation, Leiden, Netherlands, 13Eurotransplant Foundation, Leiden, Netherlands, 14Dept of Cardiac Surgery, Medical Univ of Vienna, Vienna, Austria

6:50 PM (414) Using Deep Neural Networks to Simulate Heart Allocation Policies; D. Medved1, P. Nugets1, M. Ohslo2, P. Högglund3, B. Andersson4, J. Nilsson5. 1Computer Science, Lund Univ, Lund, Sweden, 2Astronomy and Theoretical Physics, Computational Biology and Biological Physics, Lund Univ, Lund, Sweden, 3Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund Univ, Skane Univ Hospital, Lund, Sweden, 4Clinical Sciences Lund, Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden, 5Clinical Sciences Lund, Cardiothoracic Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden

Scientific Program
6:55 PM (415) **Do High Risk Patients Really Achieve a Survival Benefit from Heart Transplantation? A Step Towards a Cardiac Allocation Score:** M. Masetti\(^1\), M. Bellettini\(^1\), A. Centritto\(^1\), M. Sabatino\(^1\), A. Russo\(^1\), S. Martin Suarez\(^2\), A. Loforte\(^2\), G. Marinelli\(^2\), F. Grigioni\(^1\), L. Potena\(^1\). \(^1\)Cardiology, Univ of Bologna, Bologna, Italy, \(^2\)Cardiac Surgery, Univ of Bologna, Bologna, Italy

7:00 PM (416) **National Trends in Heart Donor Utilization Rates: What is in the Numbers?**; H. Jaeger\(^1\), T. Hess\(^1\), J. Hermsen\(^2\), L. Lozonschi\(^2\), D. Murray\(^1\), T. Kohmoto\(^2\), R. Dhingra\(^1\). \(^1\)Cardiovascular Medicine, Univ of Wisconsin-Madison, Madison, WI, \(^2\)Cardiothoracic Surgery, Univ of Wisconsin-Madison, Madison, WI

7:05 PM (417) **The Introduction of a Super-Urgent Heart Allocation Scheme in the United Kingdom:** S. Rushton\(^1\), N. Al-Attar\(^2\), N. Banner\(^3\), C. Lewis\(^4\), S. Schueler\(^5\), J. Townend\(^6\), R. Venkateswaran\(^7\), S. Tsui\(^4\). \(^1\)NHS Blood and Transplant, Bristol, United Kingdom, \(^2\)Golden Jubilee National Hospital, Glasgow, United Kingdom, \(^3\)Harefield Hospital, London, United Kingdom, \(^4\)Papworth Hospital, Cambridge, United Kingdom, \(^5\)Freeman Hospital, Newcastle, United Kingdom, \(^6\)Queen Elizabeth Hospital, Birmingham, United Kingdom, \(^7\)Wythenshawe Hospital, Manchester, United Kingdom

7:10 PM (418) **Impact of Donor Smoking History on Graft Survival Following Cardiac Transplantation:** H. K. Lamba, D. Yoeli, F. H. Cheema, R. Delgado, L. Simpson, A. Nair, A. B. Civitello, T. Rosengart, O. Frazier, O. Frazier. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor CoM, Houston, TX
6:15 PM - 7:15 PM
MINI ORAL 16: Basic Science and Infectious Disease Issues

Location: Hermes
Target Audience: ID, BSTR, HTX, LTX, MCS

Chairs: Stephen C Juvet, MD, PhD, FRCPC, and Joanna M Schenman, MD, PhD

6:15 PM (419) Inflammation and Lymphoid Neogenesis Induced by Deletion of Lymphatics in Healed Lung Isografts Show the Importance of Lymphatics in Lung Homeostasis and Function; L. Wang1, H. Reed2, R. Han1, M. Kahn2, W. W. Hancock1. 1Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA

6:20 PM (420) Circulating Monocyte Subtypes Correlate with Cardiac Allograft Vasculopathy and Differ from Atherosclerotic Disease: A Tool for Monitoring?; L. Holzhauser1, K. A. Arnold1, A. Schroeder1, T. Imamura1, A. Nguyen1, B. Chung1, N. Narang1, M. Costanzo2, V. Jeevanandam1, C. Murks1, T. Riley1, J. Powers1, N. Sarswat1, S. Kalantari1, J. Raikhelkar1, G. Sayer1, G. Kim1, N. Uriel1, F. J. Alenghat1. 1University of Chicago, Chicago, IL, 2Advocate Health Care, Chicago, IL

6:25 PM (421) Kidney Allografts Confer Tolerance Upon Co-Transplanted Heart Allografts by Promoting Tregs; C. Yang1, T. M. Ashry1, L. Rosales2, J. Ge3, T. F. O'shea2, R. White2, P. S. Russell1, J. C. Madsen1, R. B. Colvin2, A. Alessandrini1. 1Center for Transplantation Sciences, Dept of Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Pathology, Massachusetts General Hospital, Boston, MA

6:30 PM (422) Lung Microbiome and Metabolome Differentiates Allograft from Native Lung in Single Lung Transplant Recipients; N. S. Sharma1, K. M. Wille2, K. K. Patel1, M. Pachinbuvaran1, D. Weill3, J. Deshane4. 1Center for Advanced Lung Diseases, University of South Florida, Tampa, FL, 2Center for Advanced Lung Diseases, UAB, Birmingham, AL, 3Institute for Advanced Organ Disease and Transplantation, University of South Florida, Tampa, FL, 4Pulmonary and critical care, UAB, Birmingham, AL

6:35 PM (423) Superior Isolation of Non-tuberculous Mycobacteria, Including Mycobacterium abscessus Complex, From Lung Transplant Patients Using RGM Medium Compared With Traditional AFB Culture; A. Perry, D. Stephenson, J. D. Perry, M. Appleby, J. Samuel, F. K. Gould. Microbiology Dept, Freeman Hospital, Newcastle upon Tyne, United Kingdom

6:40 PM (424) Simkania negevensis and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients; C. Aguilar1, Y. Li2, T. Martinu3, J. Tikkkanen3, W. Kent3, S. Juvet3, A. Humar1, D. Kumar4, J. K. Kolls4, S. Keshavjee3, L. G. Singer3, S. Husain1. 1Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Kidney Transplant Program, University Health Network, Toronto, ON, Canada, 3Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 4Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada, 5Center for Translational Research in Infection and Inflammation, Tulane School of Medicine, New Orleans, LA

6:45 PM (425) CMV-specific T-cell Response After Lung Transplantation; V. Rossetti1, L. Morlacchi1, G. Lunghi2, D. Briganti1, S. Uceda Renteria2, P. Tarsia1, F. Damaco1, P. Mendogni1, A. Palleschi3. 1Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 2Virology Unit, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 3Thoracic and Lung Transplantation Surgery, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

6:50 PM (426) Cytomegalovirus Donor Seropositivity Negatively Affects Mid- and Long-term Survival After Heart Transplantation; C. Heim1, P. Müller2, R. Tandler2, W. Cherikh3, A. Toll3, A. Kucheryavaya3, K. Kush4, M. Weyand2, S. M. Ensinger2. 1University of Erlangen Dept of Cardiac Surgery, Erlangen, Germany, 2Dept of Cardiac Surgery, University of Erlangen, Erlangen, Germany, 3UNOS, Richmond, VA, 4Stanford University, Palo Alto, CA, 5Dept of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany

7:00 PM (428) Infections and Subsequent Events in the ENDURANCE and ENDURANCE Supplemental Trials; R. L. Kormos¹, J. A. Cowger², K. D. Aaronson³, E. J. Birks⁴, C. H. Selzman⁵, N. A. Mokadam⁶, N. Uriel⁷, F. D. Pagani³, T. A. Vassiliades⁸, J. G. Rogers⁹. ¹University of Pittsburgh, Pittsburgh, PA, ²St. Vincent Heart Center, Indianapolis, IN, ³University of Michigan, Ann Arbor, MI, ⁴University of Louisville, Louisville, KY, ⁵University of Utah, Salt Lake City, UT, ⁶University of Washington, Seattle, WA, ⁷University of Chicago, Chicago, IL, ⁸Medtronic, Framingham, MA, ⁹Duke University, Durham, NC

7:05 PM (429) Preemptive vs. Upfront CMV Prophylaxis Strategies and Risk of Non-CMV Herpesvirus Infections in Intermediate Risk Heart Transplant Recipients; N. Eng¹, C. Chen², M. Aldridge³, A. Osborne⁴, J. Vega⁵, H. Mitchell⁶, A. Smith⁴, M. Hurtik⁴, A. Morris⁶, D. Gupta⁴, K. Bhatt⁷, S. Laskar⁴, R. T. Cole⁴. ¹Emory Univ Sch of Med, Atlanta, GA, ²Internal Medicine, Emory Univ Sch of Med, Atlanta, GA, ³Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁴Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁵Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA, ⁶Cardiology, Emory Univ School of Medicine, Atlanta, GA, ⁷Cardiology, Emory Univ Sch of Med, Atlanta, GA

7:10 PM (430) Preemptive Tuberculosis Prophylaxis vs. Watchful Waiting After Heart Transplantation; G. Poglajen, A. Cesar, S. Frljak, G. Zemljič, V. Andročec, R. Okrajšek, M. Šebeštjen, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia
SATURDAY, APRIL 14, 2018

8:15 AM - 9:45 AM
ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS

Location: Athena
Target Audience: MCS, HTX

Chairs: Nicolaas De Jonge, MD, and Nahush A. Mokadam, MD

8:15 AM (431) **Right Atrial Pressure is the Best Hemodynamic Predictor of Mortality Among LVAD Recipients: Analysis of the INTERMACS Database**; M. Guglin, H. Omar. University of Kentucky, Lexington, KY

8:30 AM (432) **Hemodynamic Response to Continuous-flow Left Ventricular Assist Device Ramp Test and Volume Loading Predicts Successful Weaning from the Device Support**; S. Saito, K. Toda, S. Miyagawa, Y. Yoshikawa, H. Hata, K. Domae, R. Matsuura, Y. Sakata, Y. Sawa. 1Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, 2Cardiovascular Medicine, Osaka Univ Graduate School of Medicine, Suita, Osaka, Japan

8:45 AM (433) **Cardiac Power for Prediction of Outcomes in Patients with LVADs**; M. Guglin, H. Omar. 1University of Kentucky, Lexington, KY, 2Mercy Medical Center, Clinton, IA

9:00 AM (434) **Predictors of Hemodynamic Success in Advanced CHF Patients Supported by Ambulatory Counterpulsation**; V. Jeevanandam, T. Song, D. Onsager, T. Ota, C. Juricek LaBuhn, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, S. Kalantari, N. Uriel. 1University of Chicago Medicine, Chicago, IL, 2NuPulseCV, Raleigh, NC


9:30 AM (436) **Neurohormonal Blockade Reduces Adverse Events During LVAD Support**; P. Mehta, T. Imamura, M. N. Belkin, D. Rodgers, N. Sarwat, G. Kim, J. Raikhelkar, S. Kalantari, C. Murks, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. 1Internal Medicine, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL, 3Cardiac Surgery, University of Chicago, Chicago, IL
8:15 AM - 9:45 AM
ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation

Location: Mediterranee ABC
Target Audience: HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM
Chairs: Alexander M Bernhardt, MD, and Sean P Pinney, MD

8:15 AM (437) Cardiac Allocation Score: A Survival-Benefit Model for Heart Transplantation; E. Z. Xing1, S. G. Margelis1, P. L. Karas1, S. Emmanuel2, Y. S. Kim1, P. Macdonald2, K. Dhital2. 1The University of New South Wales, Sydney, Australia, 2Heart & Lung Transplant Unit, St Vincent's Hospital Sydney, Sydney, Australia

8:30 AM (438) Geographic Variation in the Treatment of US Heart Transplant Candidates; W. Parker1, M. M. Churpek1, D. Hedeker2, E. S. Huang1, E. R. Garrity Jr1, M. Siegler1, A. S. Anderson3. 1Univ of Chicago Medicine, Chicago, IL, 2Public Health Sciences, Univ of Chicago Medicine, Chicago, IL, 3Medicine, Northwestern Univ, Chicago, IL

8:45 AM (439) Longer Donor Management Time by Organ Procurement Organizations Improves Survival in Heart Transplant Recipients; Y. Xia1, S. Forest1, O. Saeed2, S. Patel2, D. Sims2, U. Jorde2, D. Goldstein1. 1Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

9:00 AM (440) A Novel Transplant RiskScore (TRS) Incorporating Recipient and Donor Variables and Center Effect; C. Jasseron1, C. Legeai1, C. Jacquelinet1, K. Nubret-Le Coniat2, E. Flecher3, C. Cantrelle1, B. Audry1, O. Bastien1, R. Dorent1. 1Agence de la biomedecine, Saint-Denis la plaine, France, 2CHU Bordeaux, Bordeaux, France, 3CHU Rennes, Rennes, France

9:15 AM (441) Changing Trends in Acceptance Criteria for Cardiac Donors: 15 Year UK Experience; A. Page1, E. Wong2, S. Rushton2, J. Mehew2, M. Berman1, S. Tsui1. 1Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, 2NHS Blood and Transplant, Bristol, United Kingdom

9:30 AM (442) Human Leukocyte Compatibility and Heart Transplant Survival Using a Validated Matching Algorithm; A. Rivard1, N. Koizumi2. 1Dept of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates, 2George Mason University, Arlington, VA
8:15 AM - 9:45 AM
ORAL SESSION 42: Lung Allocation: New Rules and Old Age

Location: Clio/Thalie/Erato
Target Audience: LTX, EEP

Chairs: Antoine Roux, MD, PhD, and Paul A. Corris, MB FRCP

8:15 AM (443) Lung Transplant Wait list Outcomes After Implementation of the Revised Lung Allocation Score; S. Pasupneti, G. Dhillon, J. Mooney. Dept of Medicine, Division of Pulmonary and Critical Care, Stanford University School of Medicine, Stanford, CA

8:30 AM (444) Extremes of Age Decrease Survival After Lung Transplant; C. J. Lehr¹, E. H. Blackstone², K. R. McCurry², L. Thuita², W. M. Tsuang¹, M. Valapour¹. ¹Respiratory Institute, Cleveland Clinic, Cleveland, OH, ²Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH


9:00 AM (446) Sarcopenia of the Psoas Muscles Predicts Survival Following Lung Transplantation; J. Hsu¹, A. Krishnan¹, C. T. Lin², P. D. Shah³, S. R. Broderick¹, R. S. Higgins¹, C. A. Merlo³, E. L. Bush¹. ¹Surgery-Thoracic Surgery, Johns Hopkins Univ School of Medicine, Baltimore, MD, ²Radiology, Johns Hopkins Univ School of Medicine, Baltimore, MD, ³Medicine-Pulmonary and Critical Care Medicine, Johns Hopkins Univ School of Medicine, Baltimore, MD

9:15 AM (447) Factors Influencing Outcomes from Listing for Lung Transplantation in the UK; A. Kourliouros¹, R. Hogg², J. Meheu², M. Al-Aloul³, M. Carby², J. Lordan², R. Thompson², S. Tsui², J. Parmar¹. ¹Cardiothoracic Transplantation, Papworth Hospital, Cambridge, United Kingdom, ²Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, ³Cardiothoracic Transplantation, Wythenshawe Hospital, Manchester, United Kingdom, ⁴Cardiothoracic Transplantation, Harefield Hospital, Harefield, United Kingdom, ⁵Cardiothoracic Transplantation, Freeman Hospital, Newcastle, United Kingdom, ⁶Cardiothoracic Transplantation, Queen Elizabeth Hospital, Birmingham, United Kingdom

9:30 AM (448) The Introduction of Urgent and Super-Urgent Lung Allocation Schemes in the United Kingdom; S. Rushton¹, M. Al-Aloul², M. Carby³, S. Clark³, R. Thompson³, J. Parmar³, S. Tsui³. ¹NHS Blood and Transplant, Bristol, United Kingdom, ²Wythenshawe Hospital, Manchester, United Kingdom, ³Harefield Hospital, London, United Kingdom, ⁴Freeman Hospital, Newcastle, United Kingdom, ⁵Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁶Papworth Hospital, Cambridge, United Kingdom
8:15 AM - 9:45 AM
ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure

**Location:** Uranie/Calliope

**Target Audience:** HF, BSTR, HTX, MCS, PHARM

**Chairs:** Ivan Knezevic, MD, and Eileen M Hsich, MD

---

8:15 AM (449) *Transendocardial Injection of CD34+ Cells Targeting Interventricular Septum Improves Right Ventricular Function in Non-ischemic Dilated Cardiomyopathy;* S. Frljak, M. Jaklic, A. Cerar, G. Zemljic, G. Poglajen, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia

8:30 AM (450) *Immunologic Characterization and Clinical Implication of CD4+CD57+ T Cells in Patients with Acute Heart Failure;* J. Youn1, I. Kim2, M. Jung3, S. Kang4, E. Shin3. 1Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggido, Korea, Republic of, 2Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, 3Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea, Republic of, 4Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

8:45 AM (451) *Ischemic Heart Failure Induces Simultaneous Downregulation of Myocardial E3 Ligases;* K. Klaeske1, V. Adams2, M. Dix1, S. Bowen2, S. Werner2, J. Garbade1, F. Emrich1, S. Lehmann1, K. Jawad1, M. Borger1, M. Dieterlen1. 1Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, 2Clinic for Cardiology, Heart Center Leipzig, Leipzig, Germany

9:00 AM (452) *Hemodynamic Markers of Predominant Right Ventricular Dysfunction are Associated with Paradoxical Decreased Cell-Mediated Immunity in Patients with Advanced Heart Failure;* P. Alvarez1, T. Kitai2, A. Perez2, B. Sperry4, W. Tang3. 1Medicine, University of Iowa, Iowa City, IA, 2Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, 3Medicine, Cleveland Clinic, Cleveland, OH, 4Cleveland Clinic, Cleveland, OH

9:15 AM (453) *Leptin Modifies the Impact of BMI on Heart Failure Progression: The Obesity Paradox Unraveling;* J. E. Rame1, J. M. Ortega-Legaspi1, A. Cappola2, K. R. Dumon3, T. P. Cappola1. 1Cardiovascular Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3Division of Bariatric Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

9:30 AM (454) *NT-proBNP Levels Are Reduced Following Treatment With Growth Hormone in Chronic Heart Failure Due to Ischemic Heart Disease. A Randomized Double Blind Placebo Controlled Trial;* E. Bobbio1, J. Isgaard2, K. Swedberg3, Å. Hjalmarson3, K. Caidahl4, K. Karason1. 1Dept of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 4Dept of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden
8:15 AM - 9:45 AM
ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money

Location: Hermes
Target Audience: EEP, HF, HTX, LTX, MCS, NHSAH

Chairs: Stephen C Clark, MD, and Keki Balsara, MD

8:15 AM (455) The Opioid Use Crisis and Organ Transplantation: A Comparison of the United States and Europe; J. Stehlik1, J. Smit2, J. A. Jarch3, R. Lehman4, W. Cherikh5, M. R. Mehra6. 1University of Utah School of Medicine, Salt Lake City, UT, 2Eurotransplant, Leiden, Netherlands, 3Brigham Health Heart and Vascular Center and Harvard Medical School, Boston, MA, 4United Network for Organ Sharing, Richmond, VA

8:30 AM (456) Good or Bad: CMS Flagging is Associated with Fewer Transplants Performed by Repeat Offenders; J. P. Beller1, R. B. Hawkins1, J. H. Mehaffey1, W. Z. Chancellor1, R. Teaster1, D. M. Walters1, A. S. Krupnick1, R. D. Davis2, C. L. Lau1. 1University of Virginia, Charlottesville, VA, 2Florida Hospital, Orlando, FL

8:45 AM (457) Financial Impact of One Year of Advanced Heart Failure Therapies to a Hospital System; A. S. Vohra1, B. Chung2, T. Ota3, G. Sayer4, V. Jeevanandam5, N. Uriel6. 1Medicine, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL, 3Cardiac Surgery, University of Chicago, Chicago, IL

9:00 AM (458) Family Participation in Daily ECMO Rounds; M. Stahovich1, S. Lerum2, R. Price2, S. Chillcott2, R. Adamson2, W. Dembisky2. 1Sharp Memorial Hospital, San Diego, CA, 2Mechanical Circulatory Support, Sharp Memorial Hospital, San Diego, CA

9:15 AM (459) Race and Baseline Severity of Heart Failure in the Registry Evaluation for Vital Information on VADs in Ambulatory Life (REVIVAL); D. E. Lanfear1, R. Forde-McLean2, D. Haas3, S. Robinson4, J. Thibodeau5, J. Teuteberg6, U. Jorde7, S. Khalatbari8, C. Spino8, N. Jeffries9, L. Stevenson10, D. Mann11, G. Stewart12, K. Aaronson6. 1Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, 2Univ of Pennsylvania, Philadelphia, PA, 3Abington Hospital, Abington, PA, 4Univ of Maryland, Baltimore, MD, 5Univ of Texas Southwestern, Dallas, TX, 6Stanford, Palo Alto, CA, 7Montefiore, New York, NY, 8Univ of Michigan, Ann Arbor, MI, 9NHLBI, Bethesda, MD, 10Vanderbilt Univ, Nashville, MI, 11Washington Univ in St.Louis, St. Louis, MO, 12Brigham and Women's Hospital, Boston, MA

9:30 AM (460) Impact of Socioeconomic Factors on Patient Desire for LVAD Therapy; I. Tchoukina1, K. B. Shah1, J. Thibodeau2, J. D. Estep3, A. Lala4, D. Lanfear5, N. Gilotra6, S. Pamboukian7, D. A. Horstmanshof8, D. McNamara9, D. C. Haas10, U. Jorde11, R. Forde-McLean12, S. Khalatbari13, C. A. Spino13, J. Baldwin14, D. L. Mann15, K. D. Aaronson13, G. C. Stewart16. 1Virginia Commonwealth Univ, Richmond, VA, 2Univ of Texas Southwestern Medical Center, Dallas, TX, 3Houston Methodist Research Institute, Houston, TX, 4Mount Sinai Hospital, New York, NY, 5Henry Ford Hospital, Detroit, MI, 6Johns Hopkins Hospital, Baltimore, MD, 7Univ of Alabama, Birmingham, AL, 8INTEGRIS, Oklahoma City, OK, 9Univ of Pittsburgh, Pittsburgh, PA, 10Abington Hospital - Jefferson Health, Abington, PA, 11Montefiore Medical Center, Bronx, NY, 12Univ of Pennsylvania, Philadelphia, PA, 13Univ of Michigan, Ann Arbor, MI, 14National Heart, Lung, and Blood Institute, Bethesda, MD, 15Washington Univ, St. Louis, MO, 16Brigham and Women's Hospital, Boston, MA
8:15 AM - 9:45 AM
ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant

Location: Mediterranee 6
Target Audience: Peds, HTX, NSHAH, PHARM

Chairs: Robert G. Weintraub, FRACP, FACC, and Ryan Butts, MD

8:15 AM (466) The Reality of Limping to Heart Transplant: K. W. Riggs1, F. Zafar1, A. Lorts2, C. Chin2, R. Bryant III1, J. S. Tweddell1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH

8:30 AM (462) Practice Variation in the Diagnosis of Acute Rejection Among Pediatric Heart Transplant Centers: An Analysis of the Pediatric Heart Transplant Study (PHTS) Database: J. Godown1, E. Pruitt2, J. Vo3, D. A. Dodd4, I. Lytri5, G. J. Boyle6, D. Sutcliffe6, J. A. Kleinmahon7, R. Shih8, S. Urcel6, B. Das6, W. F. Carlo10, W. A. Zuckerman11, S. West12, M. A. McCulloch13, M. D. Zinn15, K. Simpson14, S. J. Kindel15, J. R. Szmuszkovicz16, M. Chrisant17, S. R. Auerbach7, M. P. Carboni18, D. T. Hsu19. 1Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2The Pediatric Heart Transplant Study Group, The University of Alabama at Birmingham, Birmingham, AL, 3Pediatric Heart Transplant Study Group, Birmingham, AL, 4Pediatric Cardiology, Mount Sinai Medical Center, New York, NY, 5Pediatric Cardiology, Cleveland Clinic, Cleveland, OH, 6Pediatric Cardiology, UT Southwestern Medical Center, Dallas, TX, 7Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO, 8Pediatric Cardiology, University of Florida, Gainesville, FL, 9Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada, 10Pediatric Cardiology, University of Alabama at Birmingham, Birmingham, AL, 11Pediatric Cardiology, Columbia University Medical Center, New York, NY, 12Pediatric Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 13University of Virginia Children's Heart Center, Charlottesville, VA, 14Pediatric Cardiology, Washington University School of Medicine, St. Louis, MO, 15Pediatric Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI, 16Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA, 17Pediatric Cardiology, Joe DiMaggio Children's Hospital, Hollywood, FL, 18Pediatric Cardiology, Duke Children's Hospital, Durham, NC, 19Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, NY

8:45 AM (463) Intravascular Ultrasound in the Diagnosis of Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: A 20 Year Single Center Review: M. A. Kuhn1, B. M. Gordon1, A. J. Razzouk2, M. J. Bock1, R. E. Chinnock1, L. L. Bailey2. 1Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, 2Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA

9:00 AM (464) Earlier Cardiac Allograft Vasculopathy and Graft Failure in Pediatric Heart Transplant Recipients After Rejection with Severe Hemodynamic Compromise: J. A. Kleinmahon1, J. Gralla2, S. R. Auerbach1, G. A. Wallis3, K. Ramakrishnan4, R. Singh5, R. L. Caldwell6, R. Kirk7, A. J. Savage8, H. T. Henderson9, M. D. Everitt1. 1Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO, 2Pediatrics, University of Colorado, Denver, Denver, CO, 3Pediatric Cardiology, Levine Children's Hospital, Charlotte, NC, 4Cardiac Surgery, Children's National Health System, Washington, DC, 5Pediatric Cardiology, Rady Children's Hospital, San Diego, CA, 6Pediatric Cardiology, Riley Hospital for Children, Indianapolis, IN, 7Pediatric Cardiology, UT Southwestern, Children's Medical Center, Dallas, TX, 8Pediatric Cardiology, Medical University of South Carolina, Charleston, SC


9:30 AM (466) The Reality of Limping to Heart Transplant: K. W. Riggs1, F. Zafar1, A. Lorts2, C. Chin2, R. Bryant III1, J. S. Tweddell1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH
10:00 AM - 12:00 PM
PLENARY 3: Plenary Session

Location: Athena
Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Lara Danziger-Isakov, MD, MPH

10:00 AM Awards Presentations
Stephan Ensminger, MD, DPhil, Daniel Kreisel, MD, PhD, and Kathleen Grady, PhD, APN, FAAN
Grants & Awards Committee Co-Chairs

10:30 AM What's Hot, What's New? - Basic Science
Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

10:55 AM What's Hot, What's New? - Clinical Science
Laurie D Snyder, MD, Duke University Medical Center, Durham, NC, USA

11:20 AM PRESIDENT'S DEBATE: Dead in Melbourne, Alive in Philadelphia: DCDo's and DCDon'ts - We DCDo
Gregory I Snell, FRACP, MBBS, Alfred Hospital, Melbourne, Australia

11:35 AM PRESIDENT'S DEBATE: Dead in Melbourne, Alive in Philadelphia: DCDo's and DCDon'ts - We DCDon't
Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

11:50 AM Debate Rebuttal: We DCDo
Gregory I Snell, FRACP, MBBS, Alfred Hospital, Melbourne, Australia

11:55 AM Debate Rebuttal: We DCDon't
Howard Eisen, MD, Drexel University, Philadelphia, PA, USA
12:15 PM - 1:45 PM
ORAL SESSION 46: Flight Plan: Planning the LVAD Implant

Location: Athena
Target Audience: MCS, NHSAH, PHARM, PH

Chairs: Markus J Wilhelm, MD, and Daniel J Goldstein, MD

12:15 PM (467) Bayesian Model for Predicting 90 Day Event Free Survival in LVAD Patients; M. Kanwar1, L. Lohmueller2, R. Kormos3, C. McIvinnan4, S. Bailey1, S. Murali1, J. Antaki2. 1Allegheny General Hospital, Pittsburgh, PA, 2Carnegie Mellon University, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA, 4University of Colorado, Denver, CO

12:30 PM (468) Impact of Pre-Procedural Planning with 3D Printed Models on Patient Outcomes for Ventricular Assist Device Placement in Adults with Congenital Heart Disease: Rationale and Design of a Multicenter Prospective Registry; K. M. Farooqi1, A. Chelliah1, P. J. Chi2, E. A. Bacha2, O. Saeed3, U. P. Jorde3, A. J. Einstein4. 1Pediatrics, Columbia Univ Medical Center, New York, NY, 2Surgery, Columbia Univ Medical Center, New York, NY, 3MedStar Health, Washington, DC, 4Univ of Louisville, Louisville, KY, 5Univ of Utah, Salt Lake City, UT, 6Northwestern, Chicago, IL, 7Medtronic, Framingham, MA, 8Duke Univ, Durham, NC

12:45 PM (469) The Effects of Concomitant Procedures at the Time of LVAD Implant for Patients in the ENDURANCE and ENDURANCE Supplemental Trials; N. A. Mokadam1, F. D. Pagani2, S. W. Boyce3, M. S. Slaughter4, C. H. Selzman5, D. T. Pham6, K. D. Aaronson7, T. A. Vassiliades7, C. A. Milano7, 1Univ of Washington, Seattle, WA, 2Univ of Michigan, Ann Arbor, MI, 3Univ of Pennsylvania, Philadelphia, PA, 4Univ of Michigan School of Medicine, Ann Arbor, MI, 5MedStar Health, Washington, DC, 6Univ of Louisville, Louisville, KY, 7Univ of Utah, Salt Lake City, UT, 8Northwestern, Chicago, IL, 9Medtronic, Framingham, MA, 10Duke Univ, Durham, NC

1:00 PM (470) Outcomes of Durable Mechanical Circulatory Support in Myocarditis: Analysis of the IMACS Registry; S. G. Al-Kindi1, R. Xie2, J. K. Kirklin3, G. H. Oliveira1, T. Krabatsch4, T. Nakatani5, S. Schueler6, A. Leet1, C. Elam7. 1University Hospitals Cleveland Medical Center, Cleveland, OH, 2The University of Alabama at Birmingham, Birmingham, AL, 3Dept of Surgery, The University of Alabama at Birmingham, Birmingham, AL, 4Deutsches Herzzentrum Berlin, Berlin, Germany, 5Dept of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 6Dept of Cardiothoracic Vascular Surgery, Newcastle/Freeman Hospital, UK, 7Newcastle, United Kingdom

1:15 PM (471) Pre-implant Phosphodiesterase-5 Inhibitor Use is Associated With Higher Rates of Severe Early Right Heart Failure After LVAD Implantation: An INTERMACS Analysis; G. Gulati1, E. W. Grandin2, K. F. Kennedy3, F. Cabezas4, D. DeNofrio5, R. Kociol6, J. E. Rame7, F. D. Pagani8, J. K. Kirklin9, R. L. Kormos10, J. Teuteberg11, M. S. Kiernan12. 1Cardiovascular Center, Tufts Medical Center, Cambridge, MA, 2Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, 3Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, 4Heart and Vascular Institute, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Division of Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor, MI, 6Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, 7Univ of Michigan School of Medicine, Ann Arbor, MI, 8Univ of Pittsburgh, Pittsburgh, PA, 9Univ of Michigan, Ann Arbor, MI, 10National Heart Lung and Blood Institute, NIH, Bethesda, MD, 11Univ of Colorado, Aurora, CO, 12Inova Heart and Vascular Institute, Falls Church, VA, 13Henry Ford Hospital, Detroit, MI, 14Washington University in St. Louis, St. Louis, MO, 15Division of Cardiology, Univ of Utah, Salt Lake City, UT, 16Mount Sinai School of Medicine, New York, NY, 17Division of Cardiology, Brigham and Women's Hospital, Boston, MA, 18Division of Cardiology, Washington University in St. Louis, St. Louis, MO
12:15 PM - 1:45 PM
ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation

Location: Mediterranee ABC
Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAH, PATH
Chairs: Marco Masetti, MD, and Eugene C DePasquale, MD

12:15 PM (473) Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients - 1 Year Follow Up (The HITT Study); K. Nytrøen¹, K. Rolid², A. K. Andreassen¹, M. Yardley¹, E. Bjørkelund¹, A. R. Authen¹, I. Grov¹, E. Gude¹, J. P. Wigh², C. H. Dall³, F. Gustafsson⁴, K. Karason², L. Gullestad¹. ¹Dept of Cardiology, Oslo University Hospital, Oslo, Norway, ²Sahlgrenska University Hospital, Gothenburg, Sweden, ³Dept of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, ⁴Rigshospitalet University Hospital, Copenhagen, Denmark

12:30 PM (474) Trends in Renal Function Among Heart Transplant Recipients of Donors With Hepatitis C; S. Zalawadiya¹, J. Lindenfeld¹, A. Shah², M. Wigger¹, M. Keebler¹, M. Danter², M. Brinkley¹, J. Menachem¹, S. B. Sacks¹, H. Ooi¹, C. Chung³, R. Perri³, J. Awad³, S. Smith¹, R. Hayes¹, C. Rueda Rios¹, H. O'Dell⁴, C. Darragh⁵, S. Ruzevich-Scholl⁶, K. Schlendorf¹. ¹Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Cardiothoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, ³Gastroenterology and hepatology, Vanderbilt University Medical Center, Nashville, TN, ⁴Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN, ⁵Vanderbilt University Medical Center, Nashville, TN

12:45 PM (475) CT Coronary Angiography Predicts Cardiovascular Outcomes after Heart Transplantation; E. Zambon, G. Karagiannis, P. Kourkoveli, N. Salterain Gonzalez, A. R. Simon, N. R. Banner, T. Mittal. Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

1:00 PM (476) Transplant Outcomes of Adult Donor Hearts with Prior Quality-based Offer Refusals; N. Koizumi¹, A. Rivard². ¹George Mason University, Arlington, VA, ²Cleveland Clinic, Abu Dhabi, United Arab Emirates

1:15 PM (477) One-Year Outcomes Following Heart Transplantation from Donation After Circulatory Determined Death (DCD) Donors; V. Hudson¹, S. Messer¹, A. Page¹, M. Berman¹, J. Dunning¹, E. Pavlushkov¹, K. Tweed², J. Parameshwar¹, Y. Abu Omar¹, M. Goddard¹, S. Pettit¹, C. Lewis¹, A. Kydd¹, D. Jenkins¹, C. Sudarshan¹, P. Catarino¹, A. Ali¹, S. Tsui¹, S. R. Large¹, S. Bhagra¹. ¹Dept of Transplantation, Papworth Hospital, Papworth Everard, United Kingdom, ²Dept of Radiology, Papworth Hospital, Papworth Everard, United Kingdom

1:30 PM (478) Donor-derived Cell Free DNA Correlates More Closely With Intragraft mRNA Transcripts Rather Than Pathology Read Biopsies; J. A. Kobashigawa¹, J. Patel¹, M. Kittleson¹, L. Czer¹, D. H. Chang¹, E. Kransdorf¹, S. Sana¹, R. Levine¹, S. Dimbil², D. Luthringer¹, J. Yee², R. Woodward², P. Halloran³. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²CareDx, Inc, Brisbane, CA, ³University of Alberta, Edmonton, AB, Canada
12:15 PM - 1:45 PM
ORAL SESSION 48: Procedures and Standards in Lung Transplantation

Location: Clio/Thalie/Erato
Target Audience: LTX, BSTR, PATH

Chairs: Mark Benzimra, MD, MRCP, and Alice L Gray, MD

12:15 PM (479) Bronchoalveolar Lavage Practices in Lung Transplantation: Results of a Large-scale International Survey
- Of a High
- 1:30 PM (484) G. Hartwig

1:00 PM (482) Is the Current PGD Grading Still Valid in Modern Lung Transplantation? - A Retrospective Analysis of a High-Volume Center
- S. Schwarz, M. Muckenhuber, A. Benazzo, L. Beer, F. Gittler, O. Bata, H. Prosch, J. R. Matilla, B. Moser, G. Lang, S. Taghavi, W. Klepetko, K. Hoetzenecker
- Thoracic surgery, Medical University of Vienna, Vienna, Austria
- Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
- Radiology, National Institute of Oncology, Budapest, Hungary

1:15 PM (483) Implications of the Refusal of Increased Risk Donor Offers on Waitlist Survival in Lung Transplantation
- Dept of Surgery, Duke University, Durham, NC
- Dept of Surgery, Massachusetts General Hosp, Boston, MA

1:30 PM (484) Consequences of Delayed Chest Closure During Lung Transplantation
- Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
- Cleveland Clinic, Cleveland, OH
- Cleveland Clinic, Cleveland, OH

Scientific Program Saturday, April 14
12:15 PM - 1:45 PM
ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation

**Location:** Uranie/Calliope

**Target Audience:** HF, HTX, PHARM

**Chairs:** Gabriela C Lima, and Chetan B Patel, MD

**12:15 PM (485) Outcomes Following Mitraclip in Advanced Heart Failure Patients: A Meta-Analysis**; M. N. Belkin¹, J. Nnanabu¹, P. P. Mehta¹, T. Feldman², M. Penicka³, C. Giannini⁴, F. Fiorelli⁴, D. Braun⁵, M. Swaans⁶, J. v. Heyden⁶, M. Claeyss⁷, M. Orban⁸, S. Kalantari⁹, J. Raikhelkar⁹, N. Sarswat⁹, G. Kim⁹, G. Sayer⁹, N. Uriel⁹. ¹Internal Medicine Residency Program, Dept of Medicine, University of Chicago, Chicago, IL, ²Cardiology, NorthShore University Health System, Evanston, IL, ³Cardiology, OLV Clinic, Aalst, Belgium, ⁴Cardiology, Azienza Ospedaliero Universitaria Pisana, Pisa, Italy, ⁵Cardiology, Klinikum der Universität München, Munich, Germany, ⁶Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands, ⁷Cardiology, University Hospital Antwerp, Edegem, Belgium, ⁸Cardiology, Ludwig-Maximilians-Universität München, Munich, Germany, ⁹Cardiology, University of Chicago, Chicago, IL


**12:45 PM (487) Repeated, Planned Levosimendan Infusions in Patients With Advanced Heart Failure Eligible for Heart Transplantation**; L. F. Bertoldi, E. Perna, A. Garascia, M. G. Cipriani, G. Masciocco, G. Foti, F. Macera, F. M. Turazza, E. Ammirati, P. Campadello, M. Frigerio. DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy

**1:00 PM (488) Intravenous Inotropes, Beta Blockers and Survival in Ambulatory Heart Failure Patients - A Contemporary Analysis of 3,313 Patients**; O. Havakuk¹, J. Tran², T. Artig-Brown³, A. Yoon⁴, M. W. Fong⁴, N. Meaux⁵, L. Grazette⁴. ¹Cardiovascular Medicine, Sackler School of Medicine, Tel Aviv Univ, Tel Aviv, Israel, ²Internal Medicine, Keck Medical School of USC, Los Angeles, CA, ³Cardiovascular Medicine, Option Care, Buffalo Grove Illinois, IL, ⁴Cardiovascular Medicine, Keck Medical School of USC, Los Angeles, CA, ⁵Heart Failure, Option Care, Buffalo Grove, IL

**1:15 PM (489) Differential Effects of Levosimendan and Dobutamine on GFR in Patients With Heart Failure and Renal Impairment. A Randomized Double-blind Controlled Trial**; K. Karason¹, L. Lannemyr², B. Rundqvist³, B. Andersson³, S. Bartfay³, C. Ljungman³, P. Dahlberg³, N. Bergh³, C. Hjalmarsson³, T. Gilljam³, E. Bollano³, S. Ricksten³. ¹Dept of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Dept of Anesthesiology and Intensive Card Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Dept of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

**1:30 PM (490) Relevant-HF REPetitive LEVosimendan in AdvaNced refracTory Heart Failure: A Multicenter Collaborative Experience**; F. Oliva¹, E. Perna², M. Marini³, D. Nassiacos⁴, G. Malfatto⁵, F. Morandi⁶, A. Ciro⁷, I. Caiço⁸, R. De Maria⁹. ¹ASST Niguarda, Milan, Italy, ²Cardiovascular, ASST Niguarda, Milan, Italy, ³University Hospital of Ancona, Ancona, Italy, ⁴Saronno General Hospital, Saronno, Italy, ⁵Istituto Auxologico, Milan, Italy, ⁶Circolo Hospital Varese, Varese, Italy, ⁷San Gerardo Hospital, Monza, Italy, ⁸S. Antonio Abate Hospital, Gallarate, Italy, ⁹CNR Clinical Physiology Institute, Milan, Italy
12:15 PM - 1:45 PM
ORAL SESSION 50: What is Really Going On in The Lung Transplant

Location: Hermes
Target Audience: BSTR, LTX, PATH

Chairs: Christine Falk, MD, and Ciara M Shaver, MD, PhD


12:30 PM (492) Donor Lung Specific Exosome Profiles for Noninvasive Monitoring of Acute Rejection in a Rat Orthotopic Left Lung Transplant Model; A. Habertheuer1, L. Korutla1, S. Rostami1, S. Siddiqui2, Y. Xin2, R. Rizi2, A. Naji3, P. Zielinski1, R. Hu1, T. Ochiya4, P. Vallabhajosyula1. 1Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

12:45 PM (493) Bronchoalveolar Lavage Fluid Proteome in Chronic Lung Allograft Dysfunction; J. L. Todd1, V. Venkat1, R. Henao1, C. Brinkley1, F. L. Kelly1, C. W. Frankel1, A. Frear1, M. A. Moseley1, J. W. Thompson1, J. A. Belperio2, M. Budev3, P. D. Shah4, L. G. Singer5, J. M. Reynolds1, M. W. Foster1, S. M. Palmer1. 1Duke Univ Med Ctr, Durham, NC, 2University of California Los Angeles, Los Angeles, CA, 3Cleveland Clinic, Cleveland, OH, 4Johns Hopkins University, Baltimore, MD, 5University of Toronto, Toronto, ON, Canada

1:00 PM (494) Differential Gene Expression Profiling of Reperfusion During Ex Vivo Lung Perfusion and Lung Transplantation in Humans; A. K. Wong1, R. Zamel2, C. Dos Santos3, G. Bader4, S. Keshavjee2, M. Liu2. 1Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 2Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, Toronto, ON, Canada, 3Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada, 4Molecular Genetics, University of Toronto, Toronto, ON, Canada

1:15 PM (495) Ex vivo Lung Perfusion Using the Portable OCS Maintains Endothelial Integrity in the Context of Reduced Severe PGD Rates; B. Wiegmann1, R. BellmasSanz2, A. Hitz2, I. Tudorache1, C. Kühn1, M. Avsar1, A. Haverich1, G. Warnecke1, C. S. Falk2. 1Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany

1:30 PM (496) Distinct Phenotypic, Molecular and Immune Characteristics of Circulating Exosomes From Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome versus Stable Patients; M. Gunasekaran, M. Sharma, F. Rodriguez, S. Elnahas, R. Hachem, R. Walia, M. Smith, R. Bremner, T. Mohanakumar. Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ
ORAL SESSION 51: I'm at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension

Location: Mediterranea 6
Target Audience: PH, HF

Chairs: Goran Radegran, MD, and Jose M Cifrian, MD

12:15 PM (497) The United States Pulmonary Hypertension Scientific Registry (USPHSR): Objectives and Preliminary Data; H. Farber1, J. Badlam2, A. Frost3, R. Benza4, E. Austin5, D. Badesch6, W. Chung6, A. Poms7, K. Feldkircher8, C. Yu8, M. Pauciulo8, W. Nichols10, C. Elliott11. 1Medicine, Boston University School of Medicine, Boston, MA, 2Medicine, University of Colorado, Aurora, CO, 3Medicine, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, 4Medicine, Allegheny General Hospital, Pittsburgh, PA, 5Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 6Clinical Genetics and Genomics, New York Presbyterian, Columbia University, New York, NY, 7E Squared Trials and Registries, Inc, Half Moon Bay, CA, 8Biostatistics, Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, 9Cincinnati Children's Hospital Biobank, Cincinnati, OH, 10Pediatrics, National Biological Sample and Data Repository for PAH, University of Cincinnati, Cincinnati, OH, 11Medicine, Intermountain Medical Center, University of Utah School of Medicine, Murray, UT

12:30 PM (498) Non-invasive Right Ventricle-pulmonary Artery Coupling Predicts Events in Pulmonary Arterial Hypertension and in Left Heart Disease; M. Vicenzi1, R. Casella2, G. Deboeck3, R. Naeije4, J. Vachiery4. 1Cardiovascular Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2Cardiovascular Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 3Faculté des Sciences de la Motricité, Dept of Physiology, Université Libre de Bruxelles, Bruxelles, Belgium, 4Dept of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Bruxelles, Belgium

12:45 PM (499) Echocardiography Predicts the Outcome in Pulmonary Arterial Hypertension Patients Treated With Parenteral Prostanoids; R. Badagliacca, R. Poscia, B. Pezzuto, G. Manzi, S. Papa, M. Minnucci, R. Torre, S. Sciomer, F. Fedele, C. Vizza. Cardiovascular and Respiratory Sciences, Sapienza University of Rome, Rome, Italy

1:00 PM (500) Stroke Volume Response to Exercise is Dependent on Disease Severity in Pulmonary Arterial Hypertension; C. Göransson, N. Vejlstrup, J. Carlsen. Dept of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

1:15 PM (501) Application of Bayesian Model to Predict Outcomes in Pulmonary Arterial Hypertension; M. Kanwar1, L. Lohmueller2, P. Correa1, J. Kraisangka2, M. Druzdzel3, J. Antaki2, R. Benza1. 1Allegheny General Hospital, Pittsburgh, PA, 2Carnegie Mellon University, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

1:30 PM (502) Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis; R. L. Benza1, J. Zhang2, E. Parsley2, P. Klassen2, F. Torres3, M. Gomberg-Maitland4, O. Sitbon5, H. A. Ghofrani6. 1Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 2Arena Pharmaceuticals, San Diego, CA, 3UT Southwestern Medical Center, Dallas, TX, 4Dept of Medicine, Section of Cardiology, University of Chicago Medical Center, Chicago, IL, 5Centre de Référence de l'Hypertension Pulmonaire Sèvère, Service de Pneumologie et Soins Intensifs Hôpital Universitaire de Bicêtre (AP-HP), Le Kremlin-Bicêtre, France, 6University of Giessen and Marburg Lung Center, Giessen, Germany
BASIC SCIENCE AND TRANSLATIONAL RESEARCH
(AGORA 2)

Poster Discussants: Edward Cantu (USA), Mario Deng (USA), Christine Falk (Germany), Christian Heim (Germany), Eileen Hsich (USA), Howard Huang (USA), Stephen Juvet (Canada), Tomoko Kato (Japan), Pradeep Mammen (USA), Simon Pecha (Germany), Lynn Punnoose (USA), Sonja Schrepfer (USA), Ciara Shaver (USA), Bart M Vanaudenaerde (Belgium), Yoshito Yamada (Switzerland)

(503) Inflammatory Cytokine Profiles in 24-Hour Brain Stem Death Model; A. C. Boon1, L. E. See Hoe1, S. E. Pederson1, N. G. Obonyo1, M. A. Wells2, N. J. Bartnikowski1, M. R. Passmore1, L. Marshall3, L. James4, J. Tung1, J. Y. Suen1, P. S. MacDonald5, D. C. McGiffin5, J. F. Fraser5, 1Critical Care Research Group, The University of Queensland, 2School of Medical Science, Griffith University, Gold Coast, Australia, 3Dept of Cardiothoracic Surgery, The University of Queensland, Chermside, Brisbane, Australia, 4Dept of Surgery, The Princess Alexandra Hospital, Brisbane, Australia, 5Victor Chang Cardiac Research Institute, Sydney, Australia, 6Dept of Cardiothoracic Surgery, The Alfred Hospital, Melbourne, Australia

(504) Extracorporeal Photophoresis Promotes Alveolar Macrophage Production of Anti-fibrogenic Mediators and Prevents Airway Obliteration in a Mouse Lung Allograft Model; Z. Liu1, Y. Furuya2, M. Ibrahim1, D. Kreisel1, H. J. Huang3, R. Hachem2, A. E. Gelman1, 1Dept of Surgery, Washington Univ in St. Louis, St Louis, MO, 2Dept of Medicine, Washington Univ in St. Louis, St. Louis, MO, 3Dept of Pulmonary Medicine, Baylor Univ Med Ctr, Dallas, TX

(505) Toll-like Receptor 4 Signaling Affects Myofibroblasts Expression in Mice Tracheal Allograft; M. Kawashima1, M. Sato1, T. Murakawa2, M. Anraku1, C. Konoeda1, A. Hosoji, K. Kakimi1, J. Nakajima1, 1Dept of Thoracic Surgery, The University of Tokyo, Tokyo, Japan, 2Dept of Thoracic Surgery, Kansai Medical University, Osaka, Japan, 3Dept of Immunotherapeutics, The University of Tokyo, Tokyo, Japan

(506) Overexpression of SOCS3 Attenuates Tracheal Allograft Rejection in the Early Phase After Murine Heterotopic Tracheal Transplantation by the Inhibition of Th1 Response; K. Mesaki1, S. Sugimoto1, H. Watanabe2, M. Fujisawa2, T. Yoshimura1, T. Kurosaki1, S. Otani2, M. Yamane1, S. Toyooka1, A. Matsukawa2, T. Oto3, 1Dept of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2Dept of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Organ Transplant Center, Okayama University Hospital, Okayama, Japan


(509) Recipient Emphysema Differentially Affects Immunologic Responses During Acute Lung Allograft Rejection in a Pre-Clinical Model; K. J. Patel1, Q. Cheng1, D. P. Allen1, A. Aliweah2, H. Knochelmann2, C. Paulos2, M. Goddard3, S. N. Nadig1, C. Atkinson2, 1Surgery, Medical University of South Carolina, Charleston, SC, 2Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 3Transplantation, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

(510) After Clinical Lung Transplantation, NK Cells with a Lung-Resident Phenotype Represent the Most Prominent Donor Passenger Leukocyte Subset; R. BellmasSanz1, B. Wiegmann2, K. Bläsing1, A. Hitz1, C. Neudörfl1, I. Tudorache2, C. Kühn2, M. Avsar2, A. Haverich2, G. Warnecke2, C. Falk1, 1Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany, 2Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
(511) Suppression of Recall Alloantibodies by Combined Therapies With Multi Target Approach; G. D. Wu, I. Kim, N. Chai, S. Jordon, A. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA


(513) Evidence of Maturation Stoppage of Peripheral B-cells Induced by Immunosuppression of Recall Alloantibody Responses; G. D. Wu, I. Kim, N. Chai, S. Jordon, A. S. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(514) Increased Phosphorylation of p70S6 Kinase is Associated With CMV Reactivation in Lung Transplant Patients; V. Besa1, M. Chernéha2, G. Weinreich1, A. Slama3, U. Sommerwerck4, C. Taube1, C. Aigner3, M. Kamler5, B. Wilde2, O. Witzke2. 1Pulmonology, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany, 2Infectiology, University Hospital Essen, Essen, Germany, 3Thorax Surgery, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany, 4Pulmonology, Helios University Hospital Wuppertal, Wuppertal, Germany, 5Thoracic Transplantation, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany, 6Nephrology, University Hospital Essen, Essen, Germany

(515) Identification of Leukocyte Subpopulations as Potential Biomarkers of Long-term Survival With Normal Allograft Function After Lung Transplantation: A. Mendoza-Valderrey1, B. Sáez1, M. P. Hernández-Fuentes2, T. Pereira-Veiga1, R. Escobar1, C. Berastegui1, I. Rebollo-Mesa2, A. Solé3, F. Zurbano3, M. de la Torre3, R. Laporta3, J. Redel3, S. Gomez-Olles4, A. Roman4. 1Lung Transplant Unit, Hospital Universitario Vall d’Hebrón, Barcelona, Spain, 2Experimental Immunobiology, Div of Transplantation Immunology & Mucosal Biology, Medical Research Council Centre for Transplantation, King’s College London, London, United Kingdom, 3Cystic Fibrosis and Lung Transplant Unit, Hospital Universitario La Fe, Valencia, Spain, 4Pulmonology Unit, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Thoracic Surgery Unit, Hospital Universitario A Coruña, A Coruña, Spain, 6Pulmonology Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain, 7Lung Transplant Unit, Hospital Universitario Reina Sofia, Córdoba, Spain, 8Lung Transplant Unit, Hospital Universitario Vall d’Hebrón. Ciber Enfermedades Respiratorias (Ciberes), Barcelona, Spain

(516) Macrophages Represent the Major Pool of Interleukin-7 Receptor-α Expressing Immune Cells in Patients with Myocarditis: N. Kubin1, A. Cetinkaya2, K. Wörner3, P. Löw2, M. Schönburg2, T. Ziegelhöffer2, S. Kostin2, M. H. Richter2. 1Heart and Lung Research, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 2Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany

(517) Spred-2 is Necessary to Protect Against Lung Graft Injury After Mouse Lung Transplantation; K. Hashimoto1, S. Sugimoto1, T. Kurosaki2, S. Otani2, M. Yamane1, S. Toyooka1, T. Oto1. 1Dept of Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(518) Natural Polyreactive Antibodies and Inflammatory Markers Following Left Ventricular Assist Device Implantation; S. B. See1, A. Pinsino2, N. Kunifume3, D. Onat4, M. Nasirahmadabadi5, M. Yuzefpolskaya6, A. R. Garan2, V. K. Topkara2, Y. Naka4, H. Takayama4, K. Takeda4, P. C. Colombo2, E. Zorn1. 1Columbia Center for Translational Immunology, Dept of Medicine, Columbia University, New York, NY, 2Division of Cardiology, Dept of Medicine, Columbia University, New York, NY, 3Columbia Center for Translational Immunology, Columbia University, New York, NY, 4Division of Cardiothoracic Surgery, Dept of Surgery, Columbia University, New York, NY

(519) Frequency of Monocyte Subtypes and TLR4 Expression Correlate with Clinical Outcomes After Mechanical Circulatory Device Implantation; J. M. Schaeenman, M. Rossetti, T. Sidwell, V. Groyssberg, G. Sunga, E. Liang, S. Vangala, E. Chang, M. Bakir, G. Bondar, M. Cadeiras, M. Kwon, E. F. Reed, M. Deng. UCLA School of Medicine, Los Angeles, CA

(520) Immunologic Impacts of Natural Killer Cell-Related Innate Immune Rejection Mediated by CD226 and NKG2D on the Engraftment of Syngeneic Cardiomyocyte Derived from Induced Pluripotent Stem Cell; Y. Nakamura1, S. Miyagawa1, S. Yoshida1, T. Toyofuku2, Y. Sawa1. 1Cardiovascular Surgery, Osaka University, Suita, Japan, 2Immunology and Regenerative Medicine, Osaka University, Suita, Japan

(521) Recipient Bone Marrow-derived Cells Are Important Targets of IL-17 in Development of Allograft Fibrosis in the Mouse Intrapulmonary Tracheal Transplantation Model; T. Watanabe1, K. Boonstra1, Z. Guan1, B. Joe1, M. Maxim1, J. K. Kolls2, S. Kashavjee1, S. Juvet1, T. Martinu1. 1Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada, 2Medicine and Pediatrics, Tulane School of Medicine, New Orleans, LA
(522) Alloimmunity Contributes to and is Enhanced by Acute Lung Injury Following Prolonged Ischemia in Mouse Orthotopic Lung Transplantation: T. Watanabe1, T. Martinu1, K. Boonstra1, M. Horie2, Z. Guan1, D. Hwang3, S. Keshavjee1, S. Juvet1. 1Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada, 2Joint Dept of Medical Imaging, University Health Network, Toronto, ON, Canada, 3Dept of Pathology, University Health Network, Toronto, ON, Canada

(523) WITHDRAWN


(525) Intracellular C3 Protects Human Airway Epithelial Cells from Oxidant-Stress Induced Apoptosis: Implications for Lung Allograft Injury: H. S. Kulkarni1, C. Frakouh2, D. E. Byers1, S. L. Brody1, A. E. Gelman3, J. P. Atkinson2. 1Medicine, Division of Pulmonary and Critical Care, Washington University in St Louis, Saint Louis, MO, 2Medicine, Division of Rheumatology, Washington University in St Louis, Saint Louis, MO, 3Surgery; Pathology and Immunology, Washington University in St Louis, Saint Louis, MO

(526) Epithelial Cell Death Markers in Bronchoalveolar Lavage Correlate with Chronic Lung Allograft Dysfunction Phenotypes: L. Levy1, A. Tigert1, S. Moshkelgosh1, B. Joe1, K. Boonstra1, T. Saito2, J. Tikkonen1, S. Keshavjee1, S. Juvet1, T. Martinu1. 1Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada, 2Dept of Thoracic Surgery, Kansai Medical University, Hirakata, Japan

(527) Predictive Cytokine Profile for Invasive Aspergillosis in Lung Transplant Recipients in the Setting of Preemptive Prophylaxis: S. Herrera1, W. Goh1, C. Aguilar1, S. Juvet2, T. Martinu2, L. Singer2, S. Keshavjee2, C. Rotstein1, D. Kumar1, A. Humar1, S. Husain1. 1Infectious diseases, University Health Network, Toronto, ON, Canada, 2Lung Transplant, University Health Network, Toronto, ON, Canada

(528) Longitudinal Mass Cytometric Profiling of BAL Cells in Lung Transplant Recipients: S. Moshkelgosh1, L. Levy1, T. Martinu1, B. Joe1, C. Guidos2, S. Keshavjee1, S. C. Juvet1. 1Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 2Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada


(530) Using a Non-supervised Network Analysis to Contextualize a 28 Predictive Gene Classifier Accessing Functional Recovery Potential of Patients Undergoing Mechanical Support: R. Togashi1, L. Masukawa1, T. Bao1, M. Cadeiras1, J. Schaeman1, J. Hai1, D. Chu1, E. Chang1, A. Esmailii2, S. Kupiec-Weglinski2, V. Grovers1, A. Le1, R. Dod1, C. Kahn1, E. Oh1, J. Do1, C. Lumintang1, T. Grogan1, J. Meltzer1, M. Kwon1, M. Rossetti1, D. Elashoff1, E. Reed1, P. Ping1, G. Bondar1, M. Deng1. 1University of California, Los Angeles, Los Angeles, CA, 2University of Oklahoma, Oklahoma City, OK, 3Cornell University, Ithaca, NY

(531) Effect of Erthropoietin on Cardiac Allograft Survival in Non-Human Primates: J. O1, K. A. Robinson1, W. Sommer1, K. Pruner1, J. Paster1, I. M. Hanekamp1, A. Dehnadi1, I. Rosales1, R. N. Smith1, P. Cravedi2, P. S. Heeger2, G. Benichou1, J. C. Madsen1. 1Center for Transplantation Sciences, MGH, Boston, MA, 2Center for Transplant Research, Icahn School of Medicine at Mount Sinai, New York, NY

(532) A Non-cuff Surgical Technique and Potent Peri-Transplant Immunomodulation Together Promote Long-term Survival of Murine Orthotopic Lung Allografts: L. Wang1, R. Han1, L. Kobzik2, W. W. Hancock1. 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Harvard School of Public Health & Brigham and Women's Hospital, Boston, MA

(533) Antibodies to Lung Self-antigens in Lung Transplant Recipients and Implications for Outcomes: V. Kaza1, U. Rao2, M. Sharma3, M. Mohanka1, A. Banga1, S. Bollineni1, J. Mullins1, F. Torres1, T. Mohanakumar3. 1UT SW Med Ctr, Coppell, TX, 2Kaiser Permanente San Jose Med Ctr, San Jose, CA, 3St. Joseph’s Hospital & Med Ctr, Phoenix, AZ

(535) Comparison of IgG SAB and C1q Assay: A Matter of Complement Fixing or Sensitivity; C. Murphy1, J. Rek2, M. Kwan3, C. Kunavarapu3. 1Southwest Immunodiagnostics, San Antonio, TX, 2Advanced Heart Failure and Transplant Program, Methodist Hospital, San Antonio, TX

(536) Elamipretide Normalizes Protein and mRNA Expression Levels of Mitofilin in Left Ventricular Myocardium of Dogs with Advanced Heart Failure; H. N. Sabbah, R. C. Gupta. Henry Ford Health System, Detroit, MI


(538) Ischemia Reperfusion Injury Significantly Differences Between Lung vs. Heart Transplantation with Respect to Lead Cytokines and Correlation to Clinical Outcome; B. Wiegmann1, N. Ledwoch2, J. Iske2, R. BellmasSan2, C. Neudörfl2, I. Tudorache1, C. Kühn1, T. Kaufeld1, F. Ius1, S. RojasHernandez1, M. Avsar1, A. Haverich1, C. Falk2, G. Warnecke1, G. Warnecke1, 1Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany

(539) Cytokine Dynamics Insights into Improved Lung Preservation Using the Organ Care System in a Porcine Transplantation Model in Comparison to the INSPIRE Trial; T. Siemeni1, R. Sanz2, J. Salman1, K. Janssens1, A. Knöfel1, F. Ius1, W. Sommer1, K. Höfler1, A. Haverich1, I. Tudorache1, C. Falk2, G. Warnecke1, 1Hannover HTTG, Hannover, Germany, 2Institute of Transplant Immunology, Hannover, Germany

(540) Inflammation and Innate Immune Activation During Ex Vivo Heart Perfusion; X. Qi1, S. Hatami1, C. W. White1, S. Himmat1, N. Abeolazer1, M. Ondrus1, Y. Wu2, A. Kinnear1, J. Nagendran1, D. Freed1, 1Surgery, University of Alberta, Edmonton, AB, Canada, 2Physiology, University of Alberta, Edmonton, AB, Canada

(541) S-Nitroso-Human-Serum-Albumin Administration to Donor Prior to Organ Procurement Attenuates Cardiac Isograft Fibrosis and Alters Myocardial Micro-RNA-126-3p Expression in a Murine Heterotopic Heart Transplant Model; A. Schaefer1, A. Kiss1, A. Oszwald2, R. Kain2, B. K. Podesser1, 1Ludwig Boltzmann Cluster for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Vienna, Austria, 2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, 3TAmiRNA, Vienna, Austria

(542) Double-Negative αβ T cells: A Novel Player in Lung Ischemic-Reperfusion Injury; J. Hsu1, A. Krishnan1, S. Lee2, J. M. Dodd-o3, B. Kim4, A. R. Hamad5, H. Rabb2, E. L. Bush1, 1Surgery-Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine-Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 4Medicine-Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 5Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

(543) CXCR4 Inhibition Improves Donor Leukocyte Depletion During Ex Vivo Lung Perfusion; R. Davis, Q. Gao, J. Yerxa, M. Daneshmand, J. Haney, J. Klapper, M. Hartwig, A. Barbas. Dept of Surgery, Duke University, Durham, NC

(544) Dual Ex-vivo Lung Perfusion Using Human Lungs; K. Noda1, S. Tane1, J. Sembrat2,3, M. Rojas2,3, J. D'Cunha1, J. D. Luketic1, N. Shigemura4, 1Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 3The Dorothy P. and Richard P. Simmons Center For Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, PA, 4Cardiovascular Surgery, Temple University, Philadelphia, PA

(545) Cyclosporine Preconditioning During Ex Vivo Lung Perfusion Improves the Quality of Post Transplant Lung Grafts; K. Noda1, S. Haam1, S. Tane1, J. D'Cunha1, J. D. Luketic1, N. Shigemura2, 1Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Cardiovascular Surgery, Temple University, Philadelphia, PA

(546) GALA-based SOM (Somah) Protects Coronary Endothelial and Vasomotor Function Following Ex Vivo Heart Perfusion; R. V. Ribeiro, F. Yu, A. Ghashghai, L. Xin, B. Gellner, G. Ruggeri, J. Alvarez, D. Banner, M. Meineri, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada
(547) Mitochondrial Integrity at Early Reperfusion Predicts Post-Ischemic Cardiac Graft Recovery; R. K. Wyss, N. Méndez Carmona, M. N. Sanz, M. Arnold, T. P. Carrel, S. Djafarzadeh, H. T. Tevaearai, S. L. Longnus. 1Dept of Cardiovascular Surgery, University Hospital of Bern, Bern, Switzerland, 2Dept of Intensive Care Medicine, University Hospital of Bern, Bern, Switzerland

(548) Conservation of Hearts from Brain Dead Donors with a Preservation Solution Supplemented by a Conditioned Medium from Mesenchymal Stem Cells, Improves Graft Contractility After Heart Transplantation in Rats; S. Korkmaz-Icöz, K. Li, M. Ruppert, S. Loganathan, T. Radovits, P. Briecic, M. Karck, G. Szabó. 1Cardiac Surgery, Univ of Heidelberg, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis Univ, Budapest, Hungary


(550) Nitrite Attenuates Ischemia/Reperfusion (I/R) Injury of Lung by Regulating Endothelial Barrier Function; A. Kumar, K. Noda, B. Philips, M. T. Gladwin, J. D'Cunha. University of Pittsburgh Medical Center, Pittsburgh, PA

(551) Effects of Short and Long Term Cold Static Preservation Followed by Normothermic Ex Vivo Lung Perfusion in a Porcine Model; C. Olbertz, N. Pizanis, H. Bämker, U. Rauen, I. Nolte, M. Kamler, A. Koch. 1Dept of Thoracic- and cardiovascular surgery, Division of Thoracic Transplantation, University of Essen-Duisburg, Essen, Germany, 2Institute of Physiological Chemistry, University of Essen-Duisburg, Essen, Germany, 3Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany

(552) Cold and Warm Ischemia Result in Different Histological Characteristics of Reperfusion Injury After Lung Transplantation in Mice; X. Wang. Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

(553) Facilitating Donation After Circulatory Death in Heart Transplantation: Effects of Cardioprotective Reperfusion Strategies on Mitochondria; M. N. Sanz, E. Farine, P. Niederberger, N. Méndez-Carmona, R. K. Wyss, M. Arnold, P. Gulak, T. P. Carrel, H. T. Tevaearai Stahel, S. L. Longnus. Dept of Cardiovascular Surgery, Inselspital, Bern University Hospital, Dept for BioMedical Research, University of Bern, Bern, Switzerland

(554) Characterization of Endothelial Function Following Various Ischemic Durations in an Isolated Rat Heart Model of Donation After Circulatory Death; N. Mendez Carmona, R. K. Wyss, M. Arnold, T. P. Carrel, H. T. Tevaearai Stahel, S. L. Longnus. Dept of Cardiovascular Surgery, Bern University Hospital, Bern, Switzerland

(555) Bronchial-arterial-circulation-sparing (BACS) Lung Preservation: A Novel Strategy in Lung Transplantation; S. Tane, K. Noda, J. D'Cunha, J. D. Luketich, N. Shigemura. 1Dept of Cardiothoracic Surgery, University of Pittsburgh Med Ctr, Pittsburgh, PA, 2Division of Cardiovascular Surgery, Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA


(557) Functional Decline of the Ex Vivo PerfusedHeart is Not Due to Cell Death; S. Hatami, X. Qi, A. Haromy, N. Aboelnazar, S. Himmat, C. W. White, M. Ondrus, A. Kinnear, A. Wu, M. Buchko, J. Nagendran, D. H. Freed. 1Dept of Surgery, University of Alberta, Edmonton, AB, Canada, 2Dept of Medicine, University of Alberta, Edmonton, AB, Canada, 3Dept of Medicine, University of Calgary, Edmonton, AB, Canada, 4Dept of physiology, University of Alberta, Edmonton, AB, Canada

(558) A New Ex-Vivo Working Heart Model without Ischemia-Reperfusion Damage to Analyze Electrophysiological Properties of a Denervated Heart; A. M. Bernhardt, N. Klatt, C. Junger, K. Scherschel, S. Willems, H. Reichenspurner, C. Meyer. 1Dept of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Dept of Electrophysiology, Univ Heart Ctr Hamburg, Hamburg, Germany

(559) Cell Recovery and Regeneration in Severely Damaged Lungs on Cross-Circulation; B. A. Guenthart, J. O'Neill, A. Hozain, Y. Tipograf, G. Vunjak-Novakovic, M. Bacchetta. 1Surgery and Biomedical Engineering, Columbia Univ Hospital, New York, NY, 2Biomedical Engineering, Columbia Univ Hospital, New York, NY, 3Surgery, Columbia Univ Hospital, New York, NY, 4Biomedical Engineering and Medicine, Columbia Univ Hospital, New York, NY
(560) Novel Rat Lung Transplant Model of Primary Graft Dysfunction by Histone Administration; K. Nakao¹, M. Anraku¹, T. Murayama¹, M. Kawashima¹, A. Hosoi², J. Nakajima¹. ¹Dept of Thoracic Surgery, Graduate School of Medicine, Univ of Tokyo, Tokyo, Japan, ²Dept of Immunotherapeutics, Univ of Tokyo Hospital, Tokyo, Japan

(561) Creatine Supplementation Attenuates Apoptosis and Proliferation of Inflammatory Cells in a Lung Transplantation Model; F. M. Almeida¹, A. S. Battochio¹, J. P. Napoli², K. A. Alves², G. S. Balbin², M. Oliveira-Junior³, H. T. Moriya¹, P. Pego-Fernandes¹, R. P. Vieira¹, R. Pazetti¹. ¹Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ³Univerteidade Nove de Julio – UNINOVE, Sao Paulo, Brazil, 4Laboratorio de Engenharia Biomedica (LEB), Universidade de Sao Paulo, Sao Paulo, Brazil, 5IBEPIPE, School of Medical Sciences of Sao Jose dos Campos Humanitas and Universidade Brazil, Sao Jose dos Campos, Brazil

(562) Optimizing Perfusion of Human DCD Hearts in an Ex-Vivo System, and Histologic Assessment; N. Roy¹, W. Sommer², S. E. Kilmarx², U. J. Dudgeon², M. N. Jodhan², J. M. Camuso², M. A. Villavicencio², J. C. Madsen², S. R. James³, D. A. D’Alessandro². ¹Cardiac Surgery, Boston Children’s Hospital, Boston, MA, ²Surgery, Massachusetts General Hospital, Boston, MA, ³Pathology, Massachusetts General Hospital, Boston, MA

(563) 2D Speckle Tracking to Assess Left Ventricular Function in a Model of Ex Vivo Heart Perfusion; G. Ruggeri¹, R. Vanin Pinto Ribeiro², B. Gellner³, L. Xin³, J. Qua Hiansen³, M. Badiwala³, M. Meineri¹. ¹Dept of Anesthesia, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ²Dept of Cardiovascular Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ³Dept of Mechanical & Industrial Engineering, University of Toronto, Toronto, ON, Canada

(564) Porcine Model of Sepsis-Induced Systemic Inflammation and Acute Lung Injury: Can Injured Lungs be Recovered with EVLP alone?: A. Menouar¹, C. Landry¹, J. F. Germain¹, J. F. Cailhier², N. Noiseux², P. Laplante², S. Der Sarkissian¹, M. Liberman¹, Y. Berthiaume¹, P. Ferraro¹. ¹Dépt. Chirurgie, CHUM Université de Montréal, Montréal, QC, Canada, ²Dépt. Médecine, CHUM Université de Montréal, Montréal, QC, Canada, ³Dépt. Médecine, IRCM Université de Montréal, Montréal, QC, Canada


(566) Computed Tomography for Rejection Monitoring in a Murine Orthotopic Lung Transplantation Model; T. Nakagiri¹, L. Ahrens¹, S. Lienenklaus², A. Knöffel¹, D. Jonigk³, N. Madrahimov¹, K. Jansson¹, A. Haverich¹, G. Warnecke¹. ¹Dept of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany, ³Institute of Pathology, Hannover Medical School, Hannover, Germany

(567) Increased Plasma Levels of Donor-derived Cell-free DNA Correlate With Acute Rejection in the Recipients of Living Donor-lobar Lung Transplantation; S. Tanaka, S. Sugimoto, T. Kurosaki, S. Otani, M. Yamane, S. Toyooka, T. Oto. General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(568) Intracellular Remodeling in a Rodent Model of Cardiac Mechanical Unloading - Influence of Phospholamban on Expression of Cardiac Ion Currents; S. Westhofen¹, L. Dreher², H. Vitzthum², H. Reichenspurner¹, H. Ehmke², A. P. Schwoerer². ¹Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Institute for Cellular and Integrative Physiology, UKE, Hamburg, Germany

(569) Mitral Valve 3D Computational Modeling and Simulation Characterized by Left Ventricular Shape Dynamics in Dilated Cardiomyopathy; J. Park¹, P. Bonde². ¹Yale School of Medicine, New Haven, CT, ²Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT

(570) Relationship Between Oral Microbiota, Inflammation and Congestion Among Advanced Heart Failure Patients; R. T. Demmer¹, M. Nasiri², D. Onat², P. Trinh², N. Akter², J. Nwokocha², E. A. Royzman², A. Clemons², A. Pinsino², D. L. Brunjes², A. M. Zuver², A. R. Garan², V. K. Topkara², K. Takeda², H. Takayama², Y. Naka², M. A. Farr², A. Uhlmann², P. C. Colombo², M. Yuzefpolskaya². ¹University of Minnesota, Columbia University, New York, NY, ²Columbia University, New York, NY

(572) A Mouse Model of Recovery from Non-Ischemic Heart Failure: A. S. Cruz-Solbes, K. A. Youker, J. P. Cooke, G. Torre-Amione, B. Trachtenberg, A. Guha, M. H. Park, J. Estep, I. Hussain, A. Bhimaraj. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(573) Impaired Mitochondrial Quality Control in African Americans With Chronic Heart Failure: S. Marek-Iannucci, D. Taylor, A. Thomas, B. Coleman, K. Tucker, A. Andres, L. S. Czer, R. A. Gottlieb. Heart Institute, Cedars Sinai, Los Angeles, CA

(574) Hyperlipidemia Impairs Autophagy in Chronic Heart Failure: S. Marek-Iannucci, D. Taylor, A. Thomas, K. Tucker, A. Andres, L. S. Czer, R. A. Gottlieb. Heart Institute, Cedars Sinai, Los Angeles, CA

(575) Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis: T. Ko1, K. Fujita1, S. Nomura1, M. Tsuji1, D. Nitta1, H. Maki1, Y. Hosoya1, E. Amiya1, M. Hatano1, M. Ono2, I. Komuro1. 1Dept of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan, 2Dept of Cardiac & Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan

(576) sCD146 - a Novel Marker of Systemic Venous Congestion - Positively Correlates With Plasma Endothelin-1 - Marker of Vasconstriction and Inflammation - in Heart Failure: P. C. Colombo1, M. Yuzefpolskaya1, M. Nasiri1, A. Pinsino1, D. Onat1, J. Nwokocha1, A. M. Clemons1, F. Castagna2, A. Klee1, K. Axsom1, E. Lin1, J. Haythe1, E. Gayat3, A. Mabaaza3, R. T. Demmer4. 1Columbia University, New York, NY, 2Columbia University/Yale New Haven Bridgeport, New York, NY, 3Paris Diderot University, Paris, France, 4University of Minnesota/Columbia University, New York, NY

(577) Establishing Chronic Stable Heart Failure in Ovine Model: is It Feasible?: C. Torregroza1, N. Sadat1, J. von der Beek2, D. Scheiber2, I. J. Knorr2, M. Sager2, P. Akhyari1, A. Lichtenberg1, D. Saeed1. 1Cardiovascular Surgery, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 2Dept of Animal Research and Animal Protection Task, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 3Cardiology, Angiology and Pulmology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

(578) Warfarin Genotype Polymorphisms in Kazakhstani Patients with Mechanical Circulatory Support - Left Ventricular Assist Devices: A. R. Akilzhanova1, S. E. Rakhimova1, S. A. Andosova2, Z. S. Zhumadilov2, M. S. Bekbossynova4. 1Laboratory of Genomic and Personalised Medicine, National Laboratory Astana, Center for life sciences, Nazarbayev University, Astana, Kazakhstan, 2Chronic Heart Failure Dept, National Scientific Cardiac Surgery Center, Astana, Kazakhstan, 3National Laboratory of Cardiac Research, Center for life sciences, Nazarbayev University, Astana, Kazakhstan, 4National Scientific Cardiac Surgery Center, Astana, Kazakhstan


(580) Club Cell Secretory Protein Replacement Therapy in a Murine Lung Transplant Model of Obliterative Bronchiolitis: C. Konoeda1, Z. Guan1, T. Watanabe1, M. Horig2, A. Pilon2, M. Liu1, T. K. Waddell1, S. C. Juvelti1, S. Keshayee1, T. Martinu1. 1Toronto General Hospital, Toronto, ON, Canada, 2Joint Dept of Medical Imaging, Toronto General Hospital, Toronto, ON, Canada, 3Therabon Therapeutics, Inc., Rockville, MD

(581) Model of Pediatric Pulmonary Hypertension and Right Heart Failure by Chronic Pulmonary Artery Ligation With Invasive Echocardiographic Evaluation: P. Hala1, B. Carr2, C. Poling3, M. Caceres-Quinones2, T. Johnson2, M. Langley2, O. Behbahi-Nejad2, P. Yarramilli2, A. Prater2, R. H. Bartlett3, W. R. Lynch3, A. Rojas-Pena2, R. B. Hirsch2. 1University of Michigan, ECLS laboratory, Charles University, Homolka Hospital, Ann Arbor, MI, 2ECLS laboratory, University of Michigan, Ann Arbor, MI
ECONOMICS, ETHICS, PUBLIC POLICY
(Muses)

Poster Discussants: John Aubert (Switzerland), Jacob Lavee (Israel)

(582) Acceptable Peri-Operative Risk for Cardiac Transplant: Physician and Patient Perspectives; A. Savtchenko¹, J. Milligan¹, C. Alba², J. Kobulnik³. ¹Core Internal Medicine, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital: University Health Network, Toronto, ON, Canada, ³Cardiology, Sinai Health System, Toronto, ON, Canada

(583) Elective and Emergency Heart Transplantation: Costs Comparison in a Single Center; M. Farrero Torres, J. L. Pomar, J. Sagarra, E. Santiago, A. Castel, A. Garcia, F. Perez-Villa. Hospital Clinic, Barcelona, Spain

(584) Discrepancies between Costs and Reimbursement Values May Be Associated with Low Heart Transplants Numbers in Brazil; L. Goldraich¹, J. Neyeloff¹, L. M. Zeilmann¹, V. M. Oliveira¹, E. C. Ghisleni², L. C. Hastenteufel², N. Clausell³. ¹Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

(585) Impact of the Affordable Care Act on Patients Listed for Cardiac Transplant; M. S. Ising¹, J. R. Trivedi¹, E. J. Birks², R. Vijayakrishnan², B. Alkhalli³, M. S. Slaughter³. ¹Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, ²Dept of Medicine, Division of Cardiology, University of Louisville, Louisville, KY, ³Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(586) The Impact of the Affordable Care Act on Patients Listed for Lung Transplantation; M. S. Ising, J. R. Trivedi, K. Marino, F. P. Matthew, V. van Berkel. Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(587) Evaluation of the Urgency Based Lung Allocation System in Korea Using the Lung Allocation Score (LAS) System; W. Yu¹, J. Lee², J. Suh², S. Kim³, M. Park³, H. Paik³. ¹Dept of Medicine, The Graduate School of Yonsei University, Seoul, Korea, Republic of, ²Dept of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Division of Pulmonology, Dept of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

(588) Can Prolonged Become Too Long? Medical Futility and Duration of Hospitalization Following Lung Transplantation; A. Courtwright¹, E. Rubin², E. Robinson³, A. Thomasson⁴, S. El-Chemaly⁵, J. Diamond⁶, H. Goldberg⁵. ¹Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ²Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, ³Cardiology, University of Chicago, Chicago, IL, ⁴Cardiac Surgery, University of Chicago, Chicago, IL

JUNIOR FACULTY CLINICAL CASE REPORTS
(Agora 3)

Poster Discussants: Karen Booth (United Kingdom), Laveena Chhatwani (USA), Hannah Copeland (USA), Jens Gottlieb (Germany), Chi-Hsin Hsu (Taiwan), Manreet Kanwar (USA), Shalika Katugaha, (USA), Sofia Masri (USA), Omar Mohamedaly, (USA), Martha Mooney, (USA), Johan Nilsson (Sweden), Isabelle Opitz (Switzerland), Caroline Patterson (United Kingdom), Stephanie Pouch (USA)

(1288) First in the World Heart Kidney Transplant in HIV Positive Patient; B. Chung¹, J. Powers¹, A. Nguyen¹, N. Narang¹, T. Riley¹, C. Murks¹, M. Reilly¹, V. Jeevanandam², T. Song², T. Ota², S. Kalantari¹, J. Raikhelkar¹, G. Kim¹, N. Sarswat¹, G. Sayer¹, N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiac Surgery, University of Chicago, Chicago, IL

(1289) Isolated IgG4-RD Myocarditis Treated With Heart Transplantation; F. F. Lin, J. R. Cook, J. E. Diamond, N. O. Palmeri. Medicine, Division of Cardiology, Columbia University, New York, NY

(1290) Putting Out the Fire: Stabilization of Aggressive Cardiac Allograft Vasculopathy; K. J. Clerkin, M. V. Habal, S. W. Restaino, E. Zorn, M. A. Farr, S. Bokhari. Cardiology, Columbia University Medical Center, New York, NY

(1291) Old Before His Time - A Case of Neonatal Myocardial Infarction; A. Pisesky, A. Dipchand, E. Hickey, E. Jean-St-Michel, A. Jeewa. Paediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

(1293) Acute Necrotizing Eosinophilic Myocarditis Treated With Anti-IL-5 Inhibitor and Mechanical Support; E. Seif, I. Gosev, H. Vidula. 1Cardiology, University of Rochester Medical Center, Rochester, NY, 2Cardiothoracic Surgery, University of Rochester Medical Center, Rochester, NY

(1294) Autoantibodies Before and After Heart Transplantation. Can They Predict Immunologic Risk?; N. Aleksova, M. Lamacie, A. Chruscinski, A. Luk, M. Epstein, M. McDonald, H. J. Ross. 1Cardiology, University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada


(1296) Extracorporeal Photopheresis (ECP) and Calcineurin Inhibitor (CNI) Delay After Heart Transplantation; J. Goekler, A. Zuckermann, J. Riebandt, U. Just, N. Worel, R. Knobler, E. Osorio, R. Moayedifar, G. Laufer, A. Aliabadi-Zuckermann. Medical University Vienna, Vienna, Austria

(1297) Rosai-Dorfman Disease Causing Heart Failure: A Case Report and Review of Literature; M. P. Laubham, A. Dark. 1Internal Medicine-Pediatrics, Loyola University Medical Center, Chicago, IL, 2Internal Medicine, Loyola University Medical Center, Chicago, IL

(1298) Cardiac Cells with Hoarding Behavior: An Interesting Case of Heart Failure; D. F. Miranda, K. Mudy, S. M. Mackey-Bojack, S. O. Sanderson, P. Zimbwa. 1Cardiology Dept, Minneapolis Heart Institute, Minneapolis, MN, 2Division of Surgery, Minneapolis Heart Institute, Minneapolis, MN, 3Medical Director, Jesse E. Edwards Registry of Cardiovascular Disease, Minneapolis, MN, 4Pathology Dept, Abbott Northwestern Hospital, Minneapolis, MN

(1299) Bilateral Sympathectomy for Treatment Refractory Ventricular Tachycardia; A. Bindra, A. Afzal, T. Gong, M. Assar, M. D. M. A. Donsky, P. Kale, J. Felius, S. Hall. Baylor University Medical Center, Dallas, TX

(1300) A Successful Case of Heart Transplantation Following Restrictive Cardiomyopathy Due to Systemic Mastocytosis; A. Braga, G. Koukoulis, J. Calquinta, B. Ferreira, C. Alfonso, M. Chorão, R. Gouveia, S. Ramos, M. Rebocho, M. Abecasis, M. Mendes, J. Neves. 1Hospital de Santa Cruz, Lisboa, Portugal, 2Hospital de São Francisco Xavier, Lisboa, Portugal, 3Hospital Egaz Moniz, Lisboa, Portugal

(1301) Persistent Heart Failure Early Post-Transplant Due to Constrictive Pericarditis: Conservative Management and Response; A. Abbas, I. Hussain. 1Houston Methodist, Houston, TX, 2Houston Methodist Hospital, Houston, TX

(1302) Serotonin Syndrome from Methylene Blue Administration for Severe Vasoplegia Immediately Post Heart Transplant; A. Abbas, I. Hussain. Houston Methodist, Houston, TX

(1303) Familial Dilated Cardiomyopathy in a 32-Year-Old Woman Diagnosed with Mucolipidosis III by Whole Exome Sequencing; H. Lee, S. Song, S. Kim, J. Shin, M. Kwak, S. Shin, M. Kim, S. Oh, N. Jeong. 1Dept of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of, 2Dept of Cardiovascular Surgery, Pusan National University Hospital, Busan, Korea, Republic of, 3Dept of Pathology, Pusan National University Hospital, Busan, Korea, Republic of

(1304) Takotsubo Cardiomyopathy in a Young Adult With Transplanted Heart: What Happened to Denervation?; D. De Angelis, M. Chinali, R. Formigari, C. Esposito, A. Franceschini, S. Alfieri, F. Parisi, G. Grutter. Bambino Gesù Children Hospital, Roma, Italy

(1305) Cardiac Transplantation for Ventricular Tachycardia Storm Due to Cardiac Hemangioma; F. Scusse, M. Krishnan, R. M. Kulchetski, S. Mangini, F. G. Marcondes-Braga, M. S. Ávila, L. F. Seguro, S. R. Siqueira, L. L. Trevizan, S. M. Ayub-Ferreira, F. Gaiotto, F. Bacal. 1Heart Transplant, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil, 2Cardiology, Guthrie Robert Packer Hospital, Sayre, PA, 3Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil
(1306) **Tolerability of Sacubitril/Valsartan in Patients with Durable Left Ventricular Assist Devices**; A. Sharma¹, Y. Moayedii, S. Duclos¹, R. Lee¹, M. Wheeler¹, W. Hiesinger¹, J. Teuteberg¹, D. Banerjee¹. ¹Cardiology, Stanford University, Menlo Park, CA; ²Cardiology, University of Toronto, Toronto, ON, Canada

(1307) **HVAD as a Bridge to Heart Transplantation in Danon Disease**; P. Chau¹, B. D. Kaufman², J. Kwok², J. Murray², S. Chen², D. N. Rosenthal², S. A. Hollander². ¹Pediatrics, University of Michigan, Ann Arbor, MI; ²Pediatrics, Stanford University, Palo Alto, CA

(1308) **Progressive Cardiomyopathy Requiring Heart Transplant Following Metal-on-Metal Total Hip Arthroplasty**; S. Murphy, J. O'Neill. Mater Misericordiae University Hospital, Dublin, Ireland

(1309) **Early Antibody Mediated Rejection After Heart Transplantation: Successful Treatment Using IgM-enriched Human Intravenous Immunoglobulin**; C. Buchholz¹, A. Bernhardt¹, H. Grahn², M. Rybczynski², H. Reichenspurner¹, M. J. Barten¹. ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

(1310) **Successful Treatment of Mediastinitis After Left Ventricular Assist Device Implantation Using IgM-enriched Human Intravenous Immunoglobulin**; C. Buchholz¹, A. Bernhardt¹, H. Grahn², M. Rybczynski², H. Reichenspurner¹, M. J. Barten¹. ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

(1311) **Late-Onset Hypertrophic Cardiomyopathy Arising in an Orthotopic Heart Transplant Recipient**; W. A. Parker¹, A. Sinha², H. J. Ramshaw³, E. K. D'Arcy³, P. C. Braidley³, A. Al-Mohammad³. ¹The Heart & Lung Transplant Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; ²The Medical School, University of Sheffield, Sheffield, United Kingdom


(1313) **Use of Extracorporeal Membrane Oxygenation in a AML Patient With Chemotherapy Induced Acute Heart Failure**; M. Anwer¹, G. Burcu², P. Bonde³. ¹Cardiac Surgery, Yale Sch of Med, New Haven, CT; ²Div of Cardiology, Yale Sch of Med, New Haven, CT; ³Section of Cardiac Surgery, Yale Sch of Med, New Haven, CT

(1314) **Successful Heart Transplantation Alone in a Patient With Congenital Heart Disease and Severe Pulmonary Hypertension**; J. N. Menachem¹, E. Y. Birati², P. Zamani², A. L. Fox², M. Tanna², A. T. Owens², P. Atlun³, N. Hornsby², A. Kayser², D. Drajpuch², L. Tobin², Y. Y. Kim², J. Wald², R. Forde-Mclean², J. E. Rame², L. R. Goldberg², C. E. Mascio³, C. A. Bermudez³, M. A. Acker³, J. A. Mazurek³. ¹Cardiovascular Division, Vanderbilt University, Nashville, TN; ²Cardiovascular Division, University of Pennsylvania, Philadelphia, PA; ³Cardiovascular Surgery Division, University of Pennsylvania, Philadelphia, PA

(1315) **An Overlooked Cause of Heart Failure in Patients on Hemodialysis**; H. Keshmiri¹, C. Rajiyaguru², S. Danciu¹, S. Pauwaa³, m. Bazavan¹. ¹Advocate Illinois Masonic Medical Center, Chicago, IL; ²UCSF Fresno, Fresno, CA; ³Advocate Christ Medical Center, Oak Lawn, IL

(1316) **WITHDRAWN**

(1317) **Avoiding Cardiac Transplantation With His Bundle Pacing and LVAD Support: A Severe Form of RV Pacing Induced Cardiomyopathy in a Teenager**; S. Bhattacharyya¹, M. Caccamo², G. Dandamudi¹, I. Wang¹, B. Angela¹. ¹Krannert Institute of Cardiology, Indiana Univ, Indianapolis, IN; ²Cardiology, West Virginia Univ, Morgantown, WV


(1319) **Life Threatening Iron Pill Gastritis in Heart Transplant Recipient**; A. Gampa¹, B. Chung¹, A. Nguyen², G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL; ²Cardiology, University of Chicago, Chicago, IL

(1320) **WITHDRAWN**

Poster Session 1 – Wednesday, April 11  
Junior Faculty Clinical Case Reports
(1321) WITHDRAWN

(1322) **Conduction Dysfunction Then It's Expunction: Giant Cell Myocarditis**; A. Yoruk, C. Gleber, B. I. Goldman, S. J. Cameron, L. Chen. University of Rochester, Rochester, NY

(1323) **A Case Report of Severe Antibody Rejection and the Use of Eculizumab and Mechanical Support**; J. C. Krisl, S. Varnado, A. Bhimaraj, A. Guha, J. Estep. Houston Methodist Hospital, Houston, TX

(1324) WITHDRAWN

(1325) **Mysterious Multi-Organ Failure in Prior Cardiac Transplant Patient**; S. Byun1, J. M. Clark2, R. J. Alvarez2.  
1Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, 2Advanced Heart Failure/Cardiac Transplantation, Temple University Hospital, Philadelphia, PA

(1326) **Methotrexate as a Rescue Therapy for Persistent Cellular Rejection and Donor Specific Antibody Reduction**; S. R. Siqueira, S. Mangini, F. Marcondes-Braga, F. Scussel, M. S. Avila, L. L. Trevizan, L. F. Seguro, T. F. Piccirillo, F. Gaioffe, F. Bacal. Heart Transplant Unit, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil


(1328) **Pure Red Cellaplasia in Heart Transplant Recipients Secondary to Immunosuppressive Agent Reduction**; E. Nachum, Y. Kassif, A. Kogan, D. Freimark, A. Wallner, J. Lavee, Y. Peled. Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel

(1329) **A Rare Case of Large Chylous Pericardial Effusion After Heart Transplantation: Is Pericardiocentesis Indicated?**; E. Nachum, Y. Kassif, A. Kogan, D. Freimark, A. Wallner, J. Lavee, Y. Peled. Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel

(1330) **Unique Complication Following Heart Lung Transplantation**; J. Chen1, K. Rajalingam2, G. Dincheva1, M. Brzezinski3, B. Trinh1, T. Deuse1, G. Wieseltahir1, J. Kukreja1. 1Surgery, Univ of California, San Francisco, CA, 2Undergraduate, Univ of California, Berkeley, CA, 3Anesthesiology, Univ of California, San Francisco, CA

(1331) **Malakoplasia of the Colon: A Rare Complication After Lung Transplantation**; I. Saba, N. A. Brozzi, D. Fertel, A. Ghodsizad, S. Shafazand, M. Loobe. University of Miami, Miami, FL

(1332) **Emergence of Daptomycin Resistant Staphylococcus Epidermidis During Treatment of VAD-Associated Bacteremia**; L. Hollis1, K. Levinson2, M. Jones3, A. Lachiewicz4, J. Katz5, D. van Duin6, L. Bartelt4. 1Pharmacy, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, 2Microbiology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, 3Clinical Microbiology/Immunology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, 4Infectious Diseases, Univ of North Carolina at Chapel Hill, Chapel Hill, NC

(1333) **Successful Treatment of Donor-derived Hepatitis C Infection in a Cardiac Transplant Recipient: An Opportunity to Expand Organ Donation**; K. J. Gaj1, C. K. McIuenann2, M. R. Mehra3, L. R. Baden4, D. S. Page3, E. L. Woodcome3, N. E. Ibrahim1, A. E. Woolley4. 1Division of Advanced Heart Disease and Cardiac Transplantation, Massachusetts General Hospital, Boston, MA, 2Advanced Heart Failure, Mechanical Circulatory Support and Transplantation, Univ of Colorado Denver, Anschutz Med Ctr, Aurora, CO, 3Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, 4Transplant Infectious Disease, Brigham and Woman's Hospital, Boston, MA

(1334) **Treatment of Viral Hepatitis After Lung Transplant**; M. Howsare1, B. Jalil1, D. R. Nunley1, V. Van Berkel2, A. Ramirez1. 1Pulmonary, Critical Care, and Sleep Medicine, University of Louisville, Louisville, KY, 2Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(1335) **Not Your Usual Chagas Rash: Cutaneous Chagas Reactivation as Violaceous Lesions and Reticular Ulcers Post-Heart Transplantation**; M. Krishnan1, C. R. Andrade2, S. Mangini3, F. G. Marcondes-Braga2, M. S. Avila2, L. F. Seguro2, T. M. Strabelli3, F. Baca4. 1Cardiology, Guthrie Robert Packer Hospital, Sayre, PA, 2Heart Transplant, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil, 3Infection Control Unit, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil

(1336) WITHDRAWN
(1337) **Time to Relapse: Infection in Destination LVAD Recipients**; M. K. Kim¹, S. B. Katugaha¹, P. Shah², S. Desai², L. Bogar², R. Singh², A. C. Carter². ¹Dept of Medicine, Inova Fairfax Hospital, Falls Church, VA, ²Inova Fairfax Hospital, Falls Church, VA

(1338) **Successful Treatment of De Novo Airway Stent-Associated Mycobacterium abscessus Infection After Lung Transplantation**; M. G. Patel¹, E. Lushin², D. W. Roe³, C. A. Hage¹. ¹Dept of Pulmonary/Critical Care Medicine, Methodist Hospital, Indiana University Health, Indianapolis, IN, ²Dept of Pharmacy, Methodist Hospital, Indiana University Health, Indianapolis, IN

(1339) **A Wolf in Sheep’s Skin: Invasive Abdominal Wall Fungal Infection After LVAD Implantation**; S. Gohar¹, J. P. Herlity², S. Saatée³, K. Heck⁴, A. Civitello¹, A. Nair¹. ¹Heart Failure/Cardiology, Baylor College of Medicine/Texas Heart institute, Houston, TX, ²Pulm/CC, Baylor College of Medicine, Houston, TX, ³Anesthesia/CC, Baylor College of Medicine/Texas Heart institute, Houston, TX, ⁴Pathology, Baylor College of Medicine/Texas Heart institute, Houston, TX

(1340) **A Case of Persistent Candida Lusitaniae Fungemia in a LVAD Recipient**; K. Kapoor¹, S. Katugaha², D. Nandamu³, P. Shah², L. Cooper², S. Desai², C. May², A. C. Carter², L. G. Edwards², M. Binetti², M. Kim². ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²INOVA Heart and Vascular Institute, Falls Church, VA, ³Virginia Commonwealth University School of Medicine, INOVA Campus, Falls Church, VA

(1341) **BK Virus in Cardiac Transplant Patients**; L. Peters, C. Mclveenan, L. Allen, A. Ambardekar, P. Khazanie. University of Colorado, Aurora, CO

(1342) **Pseudomonas Aeruginosa Endophthalmitis and Meningitis in a Heart Transplant Patient**; K. Dulnuan, N. Rajagopalan. University of Kentucky, Lexington, KY

(1343) **Post Lung Transplant Recurrence of Diffuse Panbronchiolitis; What Should Be Reconsidered? "Peri-Lung Transplant Management" or "Indication for Lung Transplant"?**; R. Waseda, T. Shiraishi, M. Hiratsuka, T. Moroga, S. Miyahara, A. Nagata, A. Iwasaki. Fukuoka University, Fukuoka, Japan


(1345) **Simultaneous Bilateral Lung Transplantation and Pectus Excavatum Correction Using the Nuss Technique with Femoro-Femoral ECMO Support**; D. Valdivia, A. Slama, V. Besa, A. Koch, M. Kamler, C. Taube, C. Aigner. West German Center for Lung Transplantation, Essen, Germany

(1347) **Successful Unilateral Lung Transplantation Using Bilateral Upper-lobe Grafts**; Y. Shikatani. Okayama University Hospital, Okayama, Japan

(1348) **Successful Staged Bilateral Lung Retransplant Followed by Living Related Renal Transplant in a Hemodialysis Patient**; E. A. Lendermon, S. Iturra Urriola, M. Morrell, J. D’Ounha. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA

(1349) **Systemic Capillary Leak Syndrome as a Cause of Recurrent Respiratory Failure in a Lung Transplant Recipient**; B. C. Keller¹, S. Kirkby¹, P. Lee², B. Shukrallah², B. A. Whitson², A. Pope-Harman¹. ¹Internal Medicine, The Ohio State University, Columbus, OH, ²Cardiac Surgery, The Ohio State University, Columbus, OH

(1350) **To Treat or Not to Treat: Incidental Bilateral Pan-Lobar Node Negative Mucinous Adenocarcinoma of the Lung**; H. Aziz¹, K. Walker¹, T. Ellison¹, S. Broderick¹, C. Merlo², P. Shah², L. Silhan², P. Ille³, R. Higgins¹, J. Orens¹, E. L. Bush¹. ¹Cardiothoracic Surgery, Johns Hopkins Hospital, Baltimore, MD, ²Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, ³Pathology-Cytopathology, Johns Hopkins Hospital, Baltimore, MD

(1351) **Metastatic Squamous Cell Carcinoma of the Skin in a Lung Transplant Recipient**; G. A. Fernandez Romero¹, C. A. Nieves Prado², S. Taralí³, S. Kartkl¹. ¹Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA, ²Internal Medicine, Lansdale Hospital, Philadelphia, PA

(1352) **Marginal Donor for a Marginal Patient: Life Over Lobe**; G. N. Mody¹, S. K. Singh², H. R. Mallidi¹. ¹Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA, ²Cardiac Surgery, Brigham and Women’s Hospital, Boston, MA
(1353) **Inhaled Epoprostenol-Mediated Shunt in a Lung Transplant Recipient;** L. Cherrier¹, M. A. Smith², S. Biswas Roy³, A. Omar⁴, S. Tokman⁴. ¹St. Joseph’s Hospital and Medical Center, Phoenix, AZ, ²Lung Transplantation, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ³Internal Medicine, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ⁴Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ

(1354) **Lung Transplantation in a Patient With Burkholderia Ambifaria Infection;** S. Tokman¹, N. Madan², A. Omar¹, J. Huang², R. Walia¹. ¹Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ²Lung Transplantation, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ

(1355) **Extensive Stage Small Cell Lung Cancer Diagnosed on Explant Pathology in a Lung Transplant Recipient;** A. Bery¹, L. Kang², J. P. Gaut³, R. Hachem³, P. Aguilar³. ¹Division of Medical Education, Dept of Medicine, Washington University School of Medicine, St. Louis, MO, ²Dept of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ³Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Washington University School of Medicine, St. Louis, MO

(1356) **Disseminated MAI Infection After Lung Transplant;** A. Bery¹, R. Hachem², P. Aguilar². ¹Division of Medical Education, Dept of Medicine, Washington University School of Medicine, St. Louis, MO, ²Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Washington University School of Medicine, St. Louis, MO

(1357) **Aortic Stenosis and the Sensitized Lung Recipient- What Would You Do?;** A. Siddique¹, M. J. Moulton¹, H. L. Merritt-Genore¹, H. M. Strah². ¹Surgery, University of Nebraska Medical Center, Omaha, NE, ²Medicine, University of Nebraska Medical Center, Omaha, NE

(1358) **Heart-lung Transplantation in an HIV Positive Patient: A Unique Approach to Care;** S. Pasupneti, J. Lee, L. Chhatwani, G. Dhillon. Stanford University Hospitals, Stanford, CA

(1359) **Domino Heart Transplantation: A Feasible Option for a Select Few;** S. Pasupneti, J. Lee, L. Chhatwani. Stanford University Hospitals, Stanford, CA

(1360) **Steeling Home: The Rarest Cause of Pulmonary Hypertension;** Y. Moayed¹, M. M. Aversa², J. G. Duero Posada³, M. Alhussein³, H. J. Ross³, M. Simons⁴, E. M. Horlick⁵, J. Granton⁵, S. Mak⁶. ¹Medicine, Stanford Univ, Palo Alto, CA, ²Medicine, Columbia Univ, NYC, NY, ³Medicine, Univ of Toronto, Toronto, ON, Canada, ⁴Radiology, Univ of Toronto, Toronto, ON, Canada, ⁵Pulmonary Medicine, Univ of Toronto, Toronto, ON, Canada


(1363) **A Hybrid Approach for the Successful Weaning of an EXCOR-LVAD With an Ongoing Intracranial Bleeding;** J. Boehmer¹, B. Soderberg¹, S. Hallhagen². ¹Pediatric Cardiology, The Queen Silvia Children’s Hospital, Gothenburg, Sweden, ²Dept of Pediatric Cardiac Surgery, The Queen Silvia Children’s Hospital, Gothenburg, Sweden

(1364) **Left Ventricular Noncompaction Dilated Cardiomyopathy in Mucopolysaccharidosis VI;** K. A. Balduf¹, H. J. Mroczkowski², J. A. Towbin¹, J. F. Goldberg¹. ¹Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN, ²Pediatric Genetics, University of Tennessee School of Health Sciences, Memphis, TN

(1365) **Recurrent Candidal Esophagitis Associated With Dexamethasone Use in a Cardiac Transplant Patient;** J. A. Lee¹, N. D. Hysmith², J. A. Towbin³, J. F. Goldberg³. ¹Pediatric Gastroenterology, University of Tennessee School of Health Sciences, Memphis, TN, ²Pediatric Infectious Diseases, University of Tennessee School of Health Sciences, Memphis, TN, ³Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN
LUNG TRANSPLANTATION
(Euterpe)

Poster Discussants: Mark Benzimra (Australia), Tobias Deuse (USA), Josh Diamond (USA), Dan Dilling (USA), Alice Gray (USA), Mark Greer (Germany), Matthew Hartwig (USA), Jerome Le Pavec (France), Monique Malouf (Australia)

(589) LUNG TRANSPLANTATION IN JOWAH'S WITNESS PATIENTS- A SINGLE CENTER EXPERIENCE: S. A. Scheinin1, T. Majumdar2, S. M. Forest1, H. Seetharamaju1. 1Ct surgery, Montefiore, Bronx, NY, 2Medicine, Houston Methodist Hospital, Houston, TX

(590) OUTCOMES OF LUNG TRANSPLANTATION IN SEPTUAGENARIAN RECIPIENTS: P. R. Aguilar1, Y. Furuya1, C. A. Witt1, D. E. Byers1, R. Yusen1, V. Pur1, D. Kreisel2, E. P. Trulock1, R. R. Hachem1. 1Medicine-Pulmonary/Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, 2Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(591) EARLY SURVIVAL AFTER LUNG TRANSPLANTATION IS IMPROVING IN PATIENTS OVER AGE 65: A. Iyengar1, M. Caceres Polo2, E. Aguayo1, J. Schauenman2, R. Biniwale2, D. Ross2, E. DePasquale2, A. Ardehali2. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2University of California - Los Angeles, Los Angeles, CA

(592) SUCCESSFUL LUNG TRANSPLANTATION FOR PATIENTS WITH GRAFT VERSUS HOST DISEASE AFTER BONE MARROW TRANSPLANTATION: AN AUSTRALIAN 2 CENTRE CASE SERIES: D. Abelson1, S. Kotecha2, D. Kliman3, M. A. Malouf1, D. Ma3, G. I. Snell2, A. R. Glanville1. 1Lung Transplantation Unit, St Vincent's Hospital, Sydney, Australia, 2Lung Transplantation Service, Alfred Hospital, Melbourne, Australia, 3Dept of Haematology, St Vincent's Hospital, Sydney, Australia

(593) OUTCOMES AFTER LUNG TRANSPLANTATION IN THE ELDERLY: Y. Furuya1, W. Cherikh2, A. Kucheryavaya2, E. P. Trulock1, C. Witt1, D. Byers1, R. Yusen1, P. Aguilar1, H. Kulkarni1, A. Gelman3, D. Kreisel3, R. Hachem1. 1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, 2United Network for Organ Sharing, Richmond, VA, 3Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(594) OUTCOME OF HEART-LUNG OR DOUBLE-LUNG TRANSPLANTATION IN PULMONARY HYPERTENSION SECONDARY TO CONGENITAL HEART DISEASES: S. Hascoet1, M. Pontailler2, O. Mercier1, D. Fabre1, S. Musset2, M. Humbert1, G. Simonneau1, X. Jais3, O. Sitbon3, E. Fadel1. 1Congenital Heart Diseases, Hopital Marie lannelongue, Plessis Robinson, France, 2Thoracic surgery, Hopital Marie lannelongue, Plessis-Robinson, France, 3Pulmonary Hypertension, Hopital Kremlin Bicetre, Kremlin-Bicetre, France

(595) THE USE OF LUNG ALLOCATE SCORE MAY IMPROVE POSTOPERATIVE OUTCOMES IN LUNG TRANSPLANTATION?: I. Bello1, L. Romero1, A. Jauregui1, J. Perez1, V. Montforte2, J. Ochoa1, L. Sanchez1, F. Ascanio1, P. Montoya1, A. Sandiumenge2, J. Sacanel1, P. Bascunana1, A. Roman2, J. Sole1, M. Deu1. 1Thoracic Surgery, Vall d'Hebron University Hospital, Barcelona, Spain, 2Pneumologist, Vall d'Hebron University Hospital, Barcelona, Spain, 3Transplant Coordinator, Vall d'Hebron University Hospital, Barcelona, Spain, 4Intensive Care Unit, Vall d'Hebron University Hospital, Barcelona, Spain

(596) SINGLE CENTER EXPERIENCE OF CONTROLLED DONATION AFTER CIRCULATORY DEATH IN LUNG TRANSPLANTATION AT CLEVELAND CLINIC: T. Okamoto1, H. Niikawa1, C. Tu1, S. Unai1, A. Zeeshan1, U. Ahmad1, M. Tong1, D. Johnston1, M. Budev1, K. R. McCurry1. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 3Pulmonary Medicine, Cleveland Clinic, Cleveland, OH


(598) IMPROVEMENT OF ESOPHAGEAL DYSMOTILITY WITH TRANSELECTRICAL STIMULATION (TES) IN LUNG TRANSPLANT PATIENTS: M. Amaris1, T. Machuca2, M. Pipkin2, S. Nandavaram2, S. Daouk3, S. Chandrashekar3, A. Emtrialjoo3, C. Eagan3, H. Alnaimat3, A. Pelaez3. 1Internal Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL, 2Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, 3Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL

(599) PROLONGED PRESERVATION AND EVALUATION OF HUMAN LUNGS WITH PORTABLE NORMOTHERMIC EVLP: J. R. Spratt1, L. M. Mattison2, N. K. Kerns1, S. J. Huddleston1, L. Meyer1, G. Loor1, P. A. Iaizzo1. 1Dept of Surgery, Univ of Minnesota, Minneapolis, MN, 2Dept of Biomedical Engineering, Univ of Minnesota, Minneapolis, MN, 3LifeSource, Minneapolis, MN
(600) 3-and 5-Year Results of Lung Preservation with the Organ Care System: Insights from a Single-Center Experience; F. Ius1, W. Sommer1, J. Salman1, T. Siemen1, C. Kuehn1, M. Avsar1, D. Bobylev1, D. Boethig1, M. Greer2, J. Gottlieb2, T. Welte2, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Respiratory Medicine, Hannover Medical School, Hannover, Germany

(601) Extended Clinical Normothermic Ex-Vivo Portable Lung Preservation (>8 Hours) is Feasible and Safe; L. J. Ceulemans1, A. Neyrinck2, A. Vos3, A. Stanzi1, M. Boada1, A. Martens2, S. Ordies2, K. Degezelle4, G. Verleden3, D. Van Raemdonck1. 1Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, 2Anaesthesiology, University Hospitals Leuven, Leuven, Belgium, 3Pneumology, University Hospitals Leuven, Leuven, Belgium, 4Perfusion, University Hospitals Leuven, Leuven, Belgium

(602) XPS Jensen Lung as a Low-Cost, High-Fidelity Training Adjunct to Ex-Vivo Lung Perfusion; B. Shukrallah1, C. Eggeman2, D. Mast1, D. Igoe1, J.Ralston1, B. A. Whitson1. 1Dept of Surgery, Wexner Med Ctr, Columbus, OH, 2XVIVO Perfusion, Inc., Englewood, CO

(603) Identifying Potential Predictive Biomarkers of Successful Ex-vivo Lung Perfusion; M. I. Morrison1, J. R. Ferdinand2, A. Chhatwal1, L. A. Bothwick1, W. E. Scott III1, M. Clatworthy2, A. J. Fisher1. 1Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom, 2Molecular Immunity Unit, Dept of Medicine, University of Cambridge, Cambridge, United Kingdom

(604) Impact of Normothermic Ex-vivo-lung Perfusion on Early Post Transplantation Cytomegalovirus Infection; A. Koch1, N. Pizanis1, C. Olbertz1, O. Abou-Issa1, v. besa2, A. Slama3, C. Taube4, C. Aigner5, H. G. Jakob6, M. Kamler7. 1Dept of Thoracic and cardiovascular surgery, Division of Thoracic Transplantation, University of Essen-Duisburg, Essen, Germany, 2Dept of Pulmonology, University of Essen-Duisburg, Essen, Germany, 3Dept of Thoracic surgery and Surgical Endoscopy, University of Essen-Duisburg, Essen, Germany, 4Dept of Pneumonology, University of Essen-Duisburg, Essen, Germany, 5Dept of Thoracic surgery and Surgical Endoscopy, University of Essen-Duisburg, Essen, Germany

(605) Organ Sequence Number (SN) is Not a Proxy for Organ Quality; M. Harhay1, M. J. Crowther2, J. M. Diamond1, T. DiSanto1, S. Rubin1, Z. Penfil1, C. Bermudez1, J. D. Christie1, C. Cantu1. 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Leicester, Leicester, United Kingdom

(606) Size Matters in Single Lung Transplantation for Pulmonary Fibrosis; K. L. Freystaetter1, G. Parry2, G. Meachery2, J. L. Lordan2, A. J. Fisher2, J. Dark1, O. Senbaklavaci1. 1Dept of Cardiothoracic Surgery, Freeman Hosp, Newcastle Upon Tyne, United Kingdom, 2Inst of Transplantation, Freeman Hosp, Newcastle Upon Tyne, United Kingdom

(607) Using a Computerized Virtual Crossmatch Program for Solid Organ Transplant Donor Selection: Evaluation of VxMatch; D. Chen1, C. Brack2, R. Tian1, W. Hanshew1. 1Duke University Health System, Durham, NC, 2HLA Data Systems, Houston, TX

(608) The Impact of Gender-Age-Physiology (GAP) Stage on Time to Lung Transplantation in Intermittent Lung Disease; M. T. Durham1, H. Auråen2, I. Leuckfeld3, H. L. Schultz2, A. M. Holm1. 1Dept of Respiratory Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 2Dept of Cardiothoracic Surgery, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 3Dept of Cardiology, Division of Lung Transplantation, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

(609) Matching Recipient and Donor Risks: Maximizing Benefits from Every Lung Transplant; F. Zafar1, C. Towe2, M. Hossain3, Y. Zhang3, R. Bryant III1, M. Schecter2, D. L. Morales1. 1Cardiothoracic Surgery, Children’s Hospital Med Ctr, Cincinnati, OH, 2Pulmonology, Children’s Hospital Med Ctr, Cincinnati, OH, 3Biostatistics and Epidemiology, Children’s Hospital Med Ctr, Cincinnati, OH

(610) A Donor PO2/FiO2 Less Than 300 Does Not Determine Graft Function or Survival After Lung Transplantation; H. Whitford1, C. E. Kure2, A. Henriksen1, J. Hobson1, G. I. Snell1, B. J. Levvey1, S. F. Marasco2, J. H. Gooi2, A. Zimmert2, J. Negri2, A. Pick2, M. R. Buckland3, T. J. Williams1, G. P. Westall1, M. A. Paraskeva1, C. Martin4, D. C. McGiffin2. 1Lung Transplant Service, The Alfred Hospital, Prahran, Australia, 2Dept of Cardiothoracic Surgery, The Alfred Hospital, Prahran, Australia, 3Dept of Anaesthesia, The Alfred Hospital, Prahran, Australia, 4Dept of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

Poster Session 1 – Wednesday, April 11  Lung Transplantation
(611) Don't Pass the Peanuts: Donor-Derived Nut Allergy in Lung Transplantation; R. Bag1, S. Tlusty2, G. Vece2, K. Lilly3, T. Peterson4, J. Schaenman5, N. Theodoropoulos6, M. Michaels7, C. R. Wolfe8, 1University of Chicago, Chicago, IL, 2United Network for Organ Sharing, Richmond, VA, 3Lifelink of Georgia, Atlanta, GA, 4Baylor University Medical Center, Dallas, TX, 5UCLA, Los Angeles, CA, 6University of Massachusetts, Worcester, MA, 7Children's Hospital of Pittsburgh, UMPC, Pittsburgh, PA, 8Duke University Medical Center, Durham, NC

(612) Impact of Allograft Ischemic Time on Short- and Long-term Survival in Lung Transplantation; M. Fakhr0, H. Ghaidan1, L. Algots0n2, H. Larsson3, S. Lindstedt1, 1Cardiothoracic Surgery, Lund University, Lund, Sweden, 2Thoracic Intensive Care and Anesthesia, Lund University, Lund, Sweden, 3Pulmonary Medicine, Lund University, Lund, Sweden

(613) The Feasibility of Lung Transplantation From Donors Mechanically Ventilated for Prolonged Periods; S. Sugimoto1, M. Yamane1, T. Kurosaki2, S. Otani2, S. Toyooka1, T. Oto2, 1General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(614) Temporal Trends and Regional Variation in Multiple Listing among Lung Transplant Recipients in the United States; S. A. Hirji1, A. Axtell2, A. G. Fiedler2, A. A. Osho2, M. G. Hartwig3, H. Mallidi1, S. Singh1, 1Div of Cardiac Surgery, Dept of Surgery, Brigham and Women's Hospital, Boston, MA, 2Div of Cardiac Surgery, Dept of Surgery, Massachusetts General Hospital, Boston, MA, 3Div of Cardiac Surgery, Dept of Surgery, Duke Univ Medical Center, Durham, NC

(615) Effect of Lung Protective Ventilation on Lung Procurement in a Real-life Setting; c. legeai1, H. Mal2, C. Cantrelle1, L. Durand1, G. Cheisson2, L. Saint Marce1, I. Pipien1, L. Durin1, O. Bastien1, R. Dorent1, 1Agence de la biomédecine, SAINT-DENIS LA PLAIN, France, 2Hôpital Bichat, APHP, Paris, France, 3Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France, 4CH Annecy Gennevill, Annecy, France

(616) Reversibility of Frailty After Lung Transplantation; E. Montgomery1, P. Macdonald1, P. Newton2, S. Jha1, M. Hannu1, C. Thomson1, A. Ganville1, A. Havryk1, M. Pilt1, R. Pearson1, M. Benzimra1, M. Harkess1, R. Fritis-Lamora1, N. De Tullio1, A. Smith1, M. Malouf1, 1Heart & Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, 2University of Western Sydney, Sydney, Australia

(617) Single and Double Redo Lung Transplantation: A Review of UNOS Data; M. A. Kashem1, H. Zhao2, Y. Toyoda3, 1Cardiovascular Surgery, Temple University, Philadelphia, PA, 2Clinical Science, Temple University, Philadelphia, PA, 3Cardiovascular Surgery, Temple University, PHI LA, PA

(618) WITHDRAWN

(619) Donor-recipient Gender-mismatches Correlate With Survival Outcome; J. M. Kwakkel-van Erp1, H. G. Otten2, N. P. van der Kaa11, S. A. Braithwaite4, E. D. Oudijk2, D. A. van Kessel2, J. C. Grutters2, B. Luij1, E. A. van de Graaf1, 1Respiratory Medicine, Univ Med Ctr Utrecht, Utrecht, Netherlands, 2Immunology, Univ Med Ctr Utrecht, Utrecht, Netherlands, 3Cardio-Thoracic Surgery, Univ Med Ctr Utrecht, Utrecht, Netherlands, 4Anesthesiology, Univ Med Ctr Utrecht, Utrecht, Netherlands, 5Respiratory Medicine, St. Antonius Hospital, Nieuwegein, Netherlands

(620) Multiple Listing Does Not Improve Outcomes in Lung Transplantation; D. Joyce1, A. Szabo2, Z. Yin2, G. Haasler3, K. Presberg4, S. Dolan4, L. D. Joyce1, 1Medical College of Wisconsin, Milwaukee, WI, 2Biostatistics, Medical College of Wisconsin, Milwaukee, WI, 3Surgery, Medical College of Wisconsin, Milwaukee, WI, 4Medicine, Medical College of Wisconsin, Milwaukee, WI

(621) The Effect of Pre Transplant Donor Specific HLA Antibodies and Antibodies to Ka1-Tubulin on Survival in Lung Transplant Recipients; L. Walsh1, D. Keegan1, G. Donnelly1, K. Khalib2, P. Riddell3, J. J. Egan3, K. Redmond4, M. Keogan1, 1The National Histocompatibility and Immunogenetics Service for Solid Organ Transplantation, Beaumont Hospital, Dublin, Ireland, 2Dept of Clinical Immunology, Beaumont Hospital, Dublin, Ireland, 3The National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, Ireland, 4Dept of Thoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland

(622) Bronchoscopic Management of Bronchial Anastomotic Defects Using Acellular Cadaveric Dermal Grafts; H. Bedi1, B. D. Shaller1, D. K. Duong1, D. Free1, L. Chhatwani1, J. J. Mooney1, G. Dhillon1, M. J. Simoff2, 1Pulmonary and Critical Care Medicine, Stanford Univ, Stanford, CA, 2Pulmonary and Critical Care Medicine, Henry Ford Hosp, Detroit, MI

(623) Use of Silicon Stents for Stenotic Airway Complications in Lung Transplantation; A. Sundset1, I. Leuckfeld1, R. Gagama1, M. T. Durheim1, A. E. Fiane2, A. M. Holm1, 1Dept of Respiratory Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway, 2Dept of Thoracic Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway
(624) Bronchial Complications in Contemporary Lung Transplantation: A Rare Event in a 5-Year Single Center Study; A. Mariscal1, L. Cañarone1, J. Tikkasen1, W. Klement2, L. Donohoe1, J. Yeung1, K. Yasufuku1, M. de Perrot1, A. Pierre1, M. Binnie1, C. Chow1, C. Chaparro1, L. Singer1, T. Waddell1, S. Juvet1, T. Martinu1, S. Keshavjee1, M. Cypel1. 1Thoracic Surgery, UHN, Toronto Lung Transplant Program, Toronto, ON, Canada, 2Thoracic Surgery, UHN, Toronto, ON, Canada

(625) Posterior Reversible Encephalopathy Syndrome After Lung Transplant: Clinical Characteristics and Outcomes; B. Bottiger1, J. Klapper2, V. Esposito2, N. Hashmi3, M. Berger4, P. Smith5. 1Dept of Surgery, Duke University, Durham, NC, 2Dept of Surgery, Duke University, Durham, NC, 3Dept of Anesthesiology, Duke University, Durham, NC, 4Dept of Psychiatry and Behavioral Sciences, Duke University, Durham, NC

(626) Vocal Cord Paralysis After Lung Transplantation Does Not Influence Early Outcome; B. Seeliger1, N. Drick1, B. A. Bollmann1, M. Avsar2, I. Tudorache3, J. Gottlieb1, M. Greer1. 1Dept. of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 2Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

(627) Ambulatory Status Improves Outcomes in Patients Bridged to Lung Transplantation with ECMO; K. L. Bailey, A. Iyengar, O. Kwon, M. Caceres Polo, C. Eisenring, D. Ross, A. Ardehali. David Geffen SoM at UCLA, Los Angeles, CA

(628) A Study for Bridge to Lung Transplant with Extracorporeal Membrane Oxygenation; T. Yoshizumi, G. Sunagawa, S. Brann, S. Keshavamurthy, V. Dulam, J. Gomez-Abraham, M. Kashem, K. Minakata, N. Shigemura, Y. Toyoda. Cardiovascular Surgery, Temple University Lewis Katz School of Medicine, Philadelphia, PA

(629) Prevalence and Treatment Responsiveness of Lung Transplant Recipients with Post Transplant Lymphoproliferative Disease; O. Berger1, C. J. Isella1, C. A. Moore1, M. R. Morrell1, J. Hayanga2, N. Shigemura3, A. Zeevi1, J. F. McIver1, C. R. Ensr1. 1University of Pittsburgh, Pittsburgh, PA, 2West Virginia University, Morgantown, WV, 3Temple University, Philadelphia, PA

(630) Outcomes After Lung Transplantation for Patients with Occupational Lung Diseases; K. D. Joubert1, C. R. Ensr2, D. C. Strollo3, E. A. Lendermon3, S. A. Yousem4, N. Shigemura5. 1Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Dept of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 3Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Cardiovascular Surgery, Temple University Health System, Philadelphia, PA

(631) The Role of Diaphragm after Lung Transplantation; A. Palleschi1, A. Lo Mauro2, E. Privitera1, M. Vergari2, I. Righi1, M. Sgroia1, D. Tosi1, V. Rossetti4, D. F. Briganti4, A. Aliverti4, C. Colombo2, M. Nosotti1. 1Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, 2Dept of Electronic, Information and Bioengineering, Politecnico, Milan, Italy, 3Clinical Center for Neurostimulation, Neuromodulation, and Movement Disorders, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, 4Pneumology Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, 5Pediatric Cystic Fibrosis Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

(632) Establishing a Lung Transplant Program in a Resource Constrained Setting; V. Rahulan1, A. Jindal1, S. Attawar2, G. Balasubramani3, P. Dutta4. 1Pulmonary, Critical Care & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 2Cardiac Sciences, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 3Cardio-Thoracic Organ Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 4Cardiac Anesthesia, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India

(633) Lung Transplantation in Turkey: One Year Balance Sheet; A. Yeginsu1, A. E. Tasci1, M. Vayvada1, S. Caner2, I. Ozmen3, A. Erkilinc4, E. Gurcu4. 1Thoracic Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey, 2Chest Disease, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey, 3Chest Disease, Sureyyapasa Gogus Hastalıkları EAH Maltepe, Istanbul, Turkey, 4Anesthesia and Reanimation, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey

(634) Intraoperative Assessment of Right Ventricular Strain During Lung Transplant Using Tissue Tracking Technology; A. Berardino1, J. Qua Hiansen2, S. Keshavjee3, M. Meineri4. 1School of Medicine, University of Turin, Torino, Italy, 2Dept of Anaesthesia, Toronto General Hospital, Toronto, ON, Canada, 3Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, 4Dept of Anesthesia and InterDeptal Division of Critical Care, Toronto General Hospital, Toronto, ON, Canada

(636) Unit, Surgeon and Volume: Equal Contributors to Outcome in Lung Transplantation?; V. Rizzo, E. J. Caruana, G. Parry, S. Clark. 1Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2Cardiothoracic Surgery, UK, United Kingdom, 3Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(637) Lobar Lung Transplantation from Brain-dead Donors in Pulmonary Hypertension; H. Etienne, O. Mercier, J. Le Pavec, D. Fabre, S. Mussot, D. Mitilian, E. Fadel. Thoracic Surgery, Marie Lannelongue University Hospital, Le Plessis-Robinson, France

(638) Hemi-Diaphragm Paralysis and Diaphragm Plication After Lung Transplant; I. Diaz-Gutierrez, S. J. Huddleston, K. R. Kane, A. W. Shaffer, M. Soule, S. J. Shumway, M. Hertz, R. F. Kelly. 1Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, 2University of Minnesota, Minneapolis, MN

(639) Factor VIII Does not Contribute to Mortality in Lung Transplant Recipients after Adjustment for Packred Blood Cell Transfusions; S. J. Huddleston, S. Jackson, K. R. Kane, A. W. Shaffer, M. Soule, S. J. Shumway, G. Loo, M. Hertz, R. F. Kelly. 1University of Minnesota, Minneapolis, MN, 2Fairview Health Services, Minneapolis, MN, 3College of Medicine, Houston, TX


(641) Rates of Primary Graft Dysfunction and Overall Survival Are Not Affected by the Laterality of the First Implanted Lung in Bilateral Lung Transplantation; A. L. Axtell, A. G. Fiedler, E. E. Heng, S. Melnitchouk, D. A. D’Alessandro, G. Tolis, T. Astor, Y. Raz, I. P. Neuringer, M. A. Villavicencio. 1Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

(642) Preoperative Epidural Placement Provides Effective Analgesia Without Added Morbidity in Lung Transplantation; E. E. Heng, A. L. Axtell, A. G. Fiedler, S. Melnitchouk, D. A. D’Alessandro, G. Tolis, G. A. Cudemus, T. Astor, M. A. Villavicencio. 1Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, 3Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

(643) Outcomes Among Lung Transplant Recipients with Elevated Left Heart Filling Pressures and Primary Graft Dysfunction; S. Elnahas, R. Panchanathan, M. Olson, P. Kang, V. Patel, A. Hashimi, J. Huang, H. Abdelrazek, M. A. Smith, R. Walia, A. Omar, R. M. Bremer, A. Kalva. 1Norton Thoracic Institute, phoenix, AZ, 2University of Arizona College of Medicine, Phoenix, Phoenix, AZ, 3Grand Canyon University, Phoenix, AZ, 4University of Arizona College of Public Health, Phoenix, AZ, 5Norton Thoracic Institute, Phoenix, AZ


MECHANICAL CIRCULATORY SUPPORT
(Muses)

Poster Discussants: Holger Buchholz (Canada), Sandra Chaparro (USA), Anson Cheung (Canada), Dawn Christensen (USA), Erin Cogliasone (USA), Shashank Desai (USA), Anique Ducharme (Canada), Nicolaas De Jonge (Netherlands), Peter Eckman (USA), Daniel Goldstein (USA), Maria Frigerio/Italy, Ranjit John (USA), Markus Wilhelm (Switzerland)

(645) Flow Performance of the CorWave LVAD Membrane Wave Pump; C. N. Botterbusch, P. Monticone, L. Polverelli. Conwave SA, Clichy-Levallois, France
(646) **Ambulatory Counter Pulsation at Home - A Dream that Became a Reality:** C. LaBuhn1, N. Uriel2, G. Sayer2, T. Song1, D. Onsager1, G. Kim2, T. Lammy1, J. Raikhelkar2, S. Kalantari2, V. Jeevanandam1. 1Cardiac Surgery, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL

(647) **Schematic Evaluation and Conservative Management of the Short-To-Shield Phenomenon Circumventing Pump Exchange:** A. Ali, B. Hannawi, N. Waxali, A. S. Cruz-Solbes, B. Trachtenberg, J. Estep, M. H. Park, I. Hussain, G. Torre-Amione, A. Bhimaraj, A. Guha. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(648) **Augmentation of Right Ventricular Ejection Against Elevated Afterloads Using a Novel Soft Robotic Device:** I. Wamala1, C. J. Payne2, M. Saeed3, D. Bautista-Salinas3, D. Van-Story3, T. Thalhofer4, M. Horvath5, G. Ramirez-Barbieri6, S. J. Staffa6, D. Zurakowski6, S. J. Ghelani7, P. J. del Nido3, C. J. Walsh2, N. V. Vasilyev3. 1Dept of Cardiothoracic and Vascular Surgery, The German Heart Center Berlin, Berlin, Germany, 2Wyss Institute for Biologically Inspired Engineering, Harvard School of Engineering and Applied Sciences, Boston, MA, 3Dept of Cardiac Surgery, Boston Childrens Hospital, Boston, MA, 4Technical University Munich, Munich, Germany, 5Massachusetts Institute of Technology, Boston, MA, 6Dept of Anesthesiology, Perioperative and Pain Medicine Research, Boston Childrens Hospital, Boston, MA, 7Dept of Cardiology, Boston Childrens Hospital, Boston, MA

(649) **Safe Temperature Limits in Wireless Power Transfer for Ventricular Assist Devices:** L. Lucke1, A. Bartnik1, B. Doxtater2, J. Reibson2, W. Weiss2, A. McCabe1. 1Minnetronix, Inc., St. Paul, MN, 2Penn State Hershey Medical Center, Hershey, PA

(650) **Central VA ECMO for Severe Pulmonary Arterial Hypertension: A Novel Cannulation Strategy:** Y. Tipograf1, B. A. Guenthart1, A. Hozaïn2, E. Berman Rosenzweig3, M. Bachetta1. 1Thoracic Surgery, Columbia University Medical Center, New York, NY, 2Biomedical Engineering, Columbia University Medical Center, New York, NY, 3Pediters and Medicine, Columbia University Medical Center, New York, NY

(651) **Development of an Ultra Compact Durable ECMO System and Evaluation in a Chronic Animal Experiment for 4 Weeks:** D. Akiyama, N. Katagiri, K. Iizuka, T. Mizuno, T. Tsukiyama, Y. Takewa, E. Tatsumi. Dept of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan

(652) **A Single Center Experience of the Impella RP in Acute Right Ventricular Failure:** A. Proudfoot1, A. Mulder2, S. Maragiri3, E. Pardington3, E. Osip3, T. Ten Brock3, S. VanOosterhout2, R. Madder2, S. Lee4. 1Perioperative Medicine, St Bartholomew's Hospital, London, United Kingdom, 2Interventional Cardiology, Spectrum Health, Grand Rapids, MI, 3College of Human Medicine, Michigan State University, Grand Rapids, MI, 4Advanced Heart Failure, Spectrum Health, Grand Rapids, MI

(653) **Hemodynamic Effects of an Intra-aortic Micro-axial Flow Pump in a Swine Model of Ischemic Heart Failure:** S. K. Annamalai1, M. Esposito1, L. Reyelt1, P. Natov1, L. Jorde1, P. Chouinard2, Q. Liu2, U. Anand2, J. Heuring3, W. Clifton3, N. K. Kapur1. 1CardioVascular Center for Research and Innovation, Tufts Medical Center, Boston, MA, 2Boston Scientific, Minneapolis, MN, 3Procyon, Houston, TX

(654) **A Prospective Comparison of Veno-Arterial Extra-Corporeal Membrane Oxygenation and a Percutaneous Ventricular Assist Device for Cardiogenic Shock Following Acute Myocardial Infarction:** A. R. Garan1, K. Takeda1, M. P. Salna2, V. K. Topkara1, S. Sreekanth1, J. Vandenberge3, M. Yuzefpolskaya1, Y. Naka1, P. C. Colombo1, D. Karmpaliotis1, D. Farrar4, A. Kirtane1, H. Takayama1, P. Kurlansky1. 1Columbia University New York, New York, NY, 2Stanford University, Stanford, CA, 3University of Vermont, Burlington, VT, 4Abbott, Abbott Park, IL

(655) **Early Experience of Durable Left Ventricular Assist Devices: Do We Need Bridge to Transplant Strategy in Korea?** J. Lee, Y. Cho, K. Sung, Y. Lee1, E. Jeon2, J. Choi2, G. Lee3. 1Thoracic and Cardiovascular Surgery, Samsung Medical Center, Seoul, Korea, Republic of, 2Cardiology, Samsung Medical Center, Seoul, Korea, Republic of

(656) **Testing Left Ventricular Assist Device in Argentina:** I. G. Berra1, A. Irusta2, A. Dilluch2, M. Berra3, M. Lewis2, G. Berra2. 1Hospital nacional de pediatria,1P. Garrahan, Buenos Aires, Argentina, 2LEW INSUMOS E INNOVACIONES, Buenos Aires, Argentina, 3Hospital nacional Posadas, Buenos Aires, Argentina, 4Catedra de Control, Facultad de ingenieria, Universidad de Buenos Aires, Buenos Aires, Argentina

(657) **Single-Center Experience with Prolonged Circulatory Support (≥5Years) with a Continuous-Flow Left Ventricular Assist Device:** A. Segura1, A. Nair2, A. Civitello2, J. Morgan3, O. Frazier1. 1Texas Heart Institute, Houston, TX, 2Baylor College of Medicine, Houston, TX
(658) Validity of a Novel Institutional Method to Display and Analyze HeartMate II Log Files: C. Holley1, C. Pierce2, A. Ambardekar3, L. A. Allen3, A. Briekte3, E. Benton3, J. C. Cleveland1, J. D. Pa1. 1Surgery, University of Colorado, Aurora, CO, 2University of Colorado Hospital, Aurora, CO, 3Medicine, University of Colorado, Aurora, CO

(659) Comparison of Hemocompatibility-Related Adverse Events in HVAD versus HeartMate II Device: P. Mehta1, T. Imamura2, A. Ambardekar3, J. Estep1, F. Russo1, C. Karmonik1, R. Hogg1, M. Al-Aatt1, S. Lim1, M. Zucker1, A. Ruhparwar1, C. Mariani1, G. Leggio1, J. Vilaro1, F. Musumeci2, A. Montalto2, C. Mariani1, J. Dalzell1, S. Martin Suarez1, M. Masetti1, P. Lilla Della Monica2, F. Schultheis2, C. Gidea2, M. Russo3, M. Zucker2, M. Camacho2, 1Internal Medicine, University of Colorado, Aurora, CO, 2Surgery, University of Colorado, Aurora, CO, 3Medicine, University of Colorado, Aurora, CO

(660) Extracorporeal Life Support in Patients with Primary Cardiogenic Shock: Predictors of Recovery and Survival: V. Tarzia1, L. Bagozzi1, G. Bortolussi2, E. Bellanti1, F. Zanella1, R. Bianco1, C. Guglielmi1, L. Testolin1, T. Bottio1, G. Gerosa1. 1Dept of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, 2University Hospitals Birmingham, Birmingham, United Kingdom

(661) Electrocardiogram-synchronized Rotational Speed Modulation System Can Reduce the Recirculation Due to Aortic Insufficiency in LVAD Support: K. Iizuka1, D. Akiyama1, Y. Takawa1, T. Tsukiya1, T. Mizuno1, N. Uriel2, E. Tatsumi1. 1Dept of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Dept of Cardiovascular Surgery, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan

(662) LVADs as Bridge to Candidacy in the UK: S. M. Shaw1, R. Venkateswaran1, S. N. Rushton2, R. Hogg2, N. Al-Aatt1, S. Lim1, S. Schueler3, J. Parameshwar3, N. Banner3. 1Heart and Lung Transplant, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2Statistics and Clinical Studies, NHSBT, Bristol, United Kingdom, 3Golden Jubilee National Hospital, Glasgow, United Kingdom, 4Queen Elizabeth Hospital, Birmingham, United Kingdom, 5Cardiothoracic Surgery, Freeman Hospital, Newcastle, United Kingdom, 6Papworth, Cambridge, United Kingdom, 7Harefield Hospital, London, United Kingdom

(663) Outcomes of Patients Bridged with LVAD to a Repeat Heart Transplant as Compared to Medical Management: Analysis of the UNOS Database: S. Fugar1, A. K. Okoh2, D. Eshun3, M. Schultheis3, C. Gidea2, M. Russo3, M. Zucker2, M. Camacho2. 1Internal Medicine, John H Stroger Hospital of Cook County, Chicago, IL, 2Cardiothoracic Surgery, RWJ Barnabas Health, Newark, NJ, 3Internal Medicine, Meharry Medical College, Nashville, TN

(664) IABP as a Bridge to Transplantation: Can we Identify Who May Benefit From a LVAD?: A. Guha1, A. Ali2, D. Nguyen1, B. Bruckner, B. Trachtenberg, E. A. Graviss, A. Bhimaraj, M. H. Park, I. Hussain, E. E. Suarez, G. Torre-Amione, J. Estep. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(665) Patient Survival and Therapeutic Outcomes in the UK Bridge to Heart Transplant Ventricular Assist Device Population: S. Rushton1, R. Hogg1, N. Banner2, A. Simon2, R. Venkateswaran3, S. Shaw1, N. Al-Aatt4, J. Dalzell4, S. Schueler5, G. MacGowan5, J. Mascaro5, L. Sern6, S. Tsui7, J. Parameshwar7. 1NHS Blood and Transplant, Bristol, United Kingdom, 2Harefield Hospital, London, United Kingdom, 3Wythenshawe Hospital, Manchester, United Kingdom, 4Golden Jubilee National Hospital, Glasgow, United Kingdom, 5Freeman Hospital, Newcastle, United Kingdom, 6Queen Elizabeth Hospital, Birmingham, United Kingdom, 7Papworth Hospital, Cambridge, United Kingdom

(666) Patterns of ED Utilization for LVAD Patients Compared to non-LVAD Patients: M. Al-Anii1, S. Gu1, B. Allen2, T. Beaver3, G. Arnaoutakis3, E. Jeng3, J. Vilaro1, J. Aranda, Jr1, M. Ahmed1. 1Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, 2Emergency Medicine, University of Florida, Gainesville, FL, 3Division of Thoracic and Cardiac Surgery, University of Florida, Gainesville, FL

(667) WITHDRAWN

(668) Outcomes of Extended Criteria Cardiac Transplantation versus Destination Left Ventricular Assist Device Therapy: A. Loforte1, A. Montalto2, C. Mariani1, S. Martin Suarez1, E. Pilato1, M. Masetti1, F. Sbaraglia1, P. Lilla Della Monica2, F. Grigioni1, F. Musumeci1, G. Marinelli1. 1Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy, 3Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(669) Computational Fluid Dynamics (CFD) - A Reliable Basis for Therapy and Surgical VAD Strategy?: J. Hochstuhl1, M. Kass2, S. Elia3, A. Ruhrparwar1, C. Karmonik3, S. Chang2. 1Dept of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, 2Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, 3MRI Core, Houston Methodist Research Institute, Houston, TX
(670) **BOLT Score - A New Prognostic Score for Predicting Survival to Transplant Among Patients on LVAD Support**: D. Yoeli, H. K. Lamba, F. H. Cheema, R. M. Delgado, L. Simpson, A. P. Nair, R. K. Ghanta, A. Rana, R. Civitello, T. Rosengart, O. Frazier, J. A. Morgan. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TN, 3Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX


(672) **Travel Time Does Not Adversely Effect Outcomes After Ventricular Assist Device**: J. Cullen, J. Mehallife, R. Hawkins, C. Fonner, I. L. Kron, J. A. Kern, A. Speir, J. Rich, M. Quader, A. I. Mawlawi, N. Teman, L. Yarboro. 1University of Virginia, Charlottesville, VA, 2Virginia Cardiovascular Surgery Quality Initiative, Falls Church, VA, 3INOVA Heart and Vascular Institute, Falls Church, VA, 4Virginia Commonwealth University, Richmond, VA

(673) **Anonymous Survey Reveals Low Controller Change Knowledge Among HeartMate II Patients and Caregivers**: M. A. Thompson, R. John, L. Hamann, J. Schultz, R. Cogswell. 1CV Specialty Nursing, University of Minnesota, Minneapolis, MN, 2Cardiovascular Surgery, University of Minnesota, Minneapolis, MN, 3Dept of Medicine, University of Minnesota, Minneapolis, MN, 4Cardiology, University of Minnesota, Minneapolis, MN

(674) **Prognostic Indicators in Extracorporeal Membrane Oxygenation for Cardiogenic Shock**: M. Guglin, A. Kolodziej, W. Handshoe, T. Triibble, H. Omar. 1Univ of Kentucky, Lexington, KY, 2Mercy Medical Center, Clinton, IA

(675) **Berlin Heart Excor as Bridge to Heart Transplantation. A Versatile Option in Patients Not Suitable for a Continuous Flow LVAD**: S. Bartl, G. Dellgren, P. Dahlberg, S. Hallhagen, B. Redfors, K. Karason. 1Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden, 2Cardiothoracic Surgery and Transplantation, Sahlgrenska University Hospital, Göteborg, Sweden, 3Pediatric Cardiothoracic Surgery, Queen Silvia Children’s Hospital, Sahlgrenska University Hospital, Göteborg, Sweden, 4Cardiothoracic anesthesia and intensive care, Sahlgrenska University Hospital, Göteborg, Sweden, 5Transplantation, Sahlgrenska University Hospital, Göteborg, Sweden

(676) **Continuous-flow Left Ventricular Assist Device Therapy in Adult Patients With Congenital Heart Disease**: T. Sugiuara, C. Kurihara, M. Kawabori, A. C. Critsinelis, G. Loor, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX


(678) **The Technical Supervising System Organization of Patients Supported by HVAD in Poland**: M. Gawlikowski, R. Kustosz, I. Copik, J. Pacholewicz, M. Zakliczynska, W. Wierzchicki, B. Kapelak, P. Siondalski. 1Artificial Heart Lab., Foundation of Cardiac Surgery Development, Zabrze, Poland, 2Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, 3Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland, 4Dept of Cardiac Surgery, Medical University of Gdansk, Gdansk, Poland

(679) **The World’s Longest-Supported HeartWare™ Ventricular Assist Device Patient 10 Years & Counting: The Western Australian Experience**: H. Hayes, J. Barber, L. Dembo, K. Lam, A. Shah, P. Dias, J. Lambert, R. Larbalestier, J. Baumwol. Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia

(680) **Heartmate 3 versus Heartmate 2: Is New Always Better?**: P. Ozturk, E. Demir, C. Sahutoglu, C. Engin, T. Yagdi, S. Nalbantgil, M. Ozbaran. 1Cardiovascular Surgery, Ege University, Izmir, Turkey, 2Cardiology, Ege University, Izmir, Turkey, 3Anesthesiology, Ege University, Izmir, Turkey

(681) **Differences in Fibrin Metabolism Among the Species for Preclinical Large Animal Models for Cardiovascular Device**: T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi. Dept. of Artificial organs, Nat’l Cerebral CV Ctr, Suita, Japan

(682) **Changes in Glycemic Control and Body Mass Index in Left Ventricular Assist Device Patients with Diabetes**: A. R. Vest, C. Chen, J. N. Upshaw, M. S. Kiernan, G. S. Couper, D. DeNofrio. Tufts Medical Center, Boston, MA
(683) **Body Composition Measurement Methods in Systolic Heart Failure Patients Receiving Left Ventricular Assist Devices**: A. R. Vest¹, W. W. Wong², C. Pellows¹, N. Yuen¹, A. DeNofrio¹, S. N. Meltzer¹, M. S. Kiernan¹, D. DeNofrio¹, G. S. Couper¹, E. Saltzman³. ¹Tufts Medical Center, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA

(684) **Inter-facility Collaboration to Decrease Acute Care Length of Stay Post LVAD Implantation**: D. Horstmanshof, S. George, M. Mendenhall, N. Chelikani, M. El Banayosy, C. Gibbs, T. Jacob, A. Patrick, M. Duke, C. Becker, T. Walter, K. Nelson. Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK

(685) **Predictive Value of I-CARS for LV Recovery in an Unselected cf-LVAD Cohort**: P. Jain, D. Robson, P. Jansz, C. Hayward. Heart failure and transplant unit, St. Vincent's Hospital, Sydney, Australia

(686) **Process Improvement for Education and Competency in First Responders Regarding Ventricular Assist Device Emergencies**: S. Stewart¹, C. Chinnici², B. Kim¹, A. Lucev¹, B. Sardanopoli-Heber¹, M. Welch¹, K. Satya¹, R. Berkowitz¹, ¹Heart Failure and Pulmonary Hypertension Program, Hackensack University Medical Center, Hackensack, NJ, ²Emergency Medical Services, Hackensack University Medical Center, Hackensack, NJ


(688) **Right Ventricular Failure After LVAD Implantation Occurs in a Pro-inflammatory Environment**: P. C. Tang¹, J. W. Haft¹, M. A. Romano¹, A. Assi¹, R. Hasan², M. Palardy², K. D. Aaronson², F. D. Pagani¹. ¹Cardiac Surgery, University of Michigan-Ann Arbor, Ann Arbor, MI, ²Internal Medicine, University of Michigan-Ann Arbor, Ann Arbor, MI


(690) **Right Heart Catheterization with Uninterrupted Anticoagulation via Brachial Vein Approach for Patients with Left Ventricular Assist Device**: T. Hasin¹, B. Ben-Avraham², T. Ben-Gal³. ¹Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Cardiology, Rabin Medical Center, Petach Tiqva, Israel

(691) **Mechanical Unloading Characteristics of the Impella 5.0 Axillary Pump Using a Hemodynamic-Echocardiographic Ramp Protocol**: E. K. Zern¹, A. W. Rottkamp², H. Holmlund², S. S. Mora², S. Sharma¹, N. Roy³, G. Cudemus³, K. Shelton¹, M. Villavicencio-Theodulo³, D. A. D' Alessandro³, S. S. Thomas³. ¹Dept of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Cardiology, Massachusetts General Hospital, Boston, MA, ³Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ⁴Dept of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, Boston, MA

(692) **Laparoscopic Sleeve Gastroectomy in Morbidly Obese Patients Undergoing Left Ventricular Assist Device Implantation**: I. D. Gregoric¹, R. Radovancevic¹, M. K. Patel¹, M. K. Jezovnik¹, S. S. Nathan¹, B. H. Akkanti¹, M. H. Akay¹, J. Dressel¹, B. Rodgers¹, S. Kumar¹, J. A. Patel¹, S. K. Shah², K. S. Bajwa², B. Kar¹. ¹The University of Texas Health Science Center at Houston, Center for Advanced Heart Failure, Houston, TX, ²The University of Texas Health Science Center at Houston, Advanced Gastrointestinal Surgery, Houston, TX

(693) **Impact of a Novel Shared Healthcare Delivery Model in Remotely Located Patients with Left Ventricular Assist Devices**: M. Yin¹, J. Strege¹, A. Elmer¹, E. Davis¹, E. M. Gilbert¹, S. McKellar², A. Koliopoulos², J. Nativi-Nicolau¹, J. Stellik¹, J. Pang¹, S. Drakos¹, C. Selzman², O. Wever-Pinzon¹. ¹Cardiology, University of Utah School of Medicine, Salt Lake City, UT, ²Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT

(694) **Change in Heart Rate from Pre-Implant to Discharge in Destination Therapy is Associated with Mortality and Admissions in LVAD Patients- A Substudy of the ENDURANCE trial**: E. Y. Birati¹, S. Shore¹, M. A. Acker¹, P. Atluri¹, J. J. Teuteberg², R. L. Kornos³, E. J. Birks³, C. Mah³, N. A. Mokadam³, F. D. Pagani³, J. G. Rogers⁷, T. A. Vassiliades⁸, J. E. Ramei¹. ¹University of Pennsylvania, Philadelphia, PA, ²Stanford University, Stanford, CA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Louisville, Louisville, KY, ⁵University of Washington, Seattle, WA, ⁶University of Michigan, Ann Arbor, MI, ⁷Duke University, Durham, NC, ⁸Medtronic, Framingham, MA
(695) The Ratio of Pulmonary Artery Diameter to Aortic Diameter Can Predict Right Heart Failure After Left Ventricular Assist Device Implantation; K. Nakamoto1, T. Ohtani1, M. Chimura1, F. Sera1, Y. Tsukamoto1, K. Toda2, S. Hikos1, O. Yamaguchi1, Y. Sawa2, Y. Sakata1. 1Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 2Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

(696) Sex Differences in Reverse Remodeling After Unloading by Contemporary Left Ventricular Assist Devices (LVADs); B. Kenigsberg1, D. T. Majure2, N. Afari-armah1, F. H. Sheikh1, M. R. Hofmeyer1, M. E. Rodrigo1, E. J. Molina1, S. W. Boyce1, S. S. Najjar1, S. F. Mohammed1. 1MedStar Washington Hospital Center, Washington, DC, 2Northwell Health Physician Partners, Manhasset, NY

(697) Impact of Creatinine Excretion Rate, a Maker of Sarcopenia, on Prediction of Mortality and Neurological Events in Advanced Heart Failure Patients With Left Ventricular Assist Device; K. Iwasaki1, Y. Kimura1, K. Toda1, N. Kikuchi1, Y. Kumai1, K. Kuroda1, O. Seguchi1, M. Yanase1, Y. Matsumoto2, T. Fujita2, J. Kobayashi2, N. Fukushima1. 1Dept of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Dept of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan


(699) Modification of Sleep Disordered Breathing after Increase in LVAD Pump Speed in HF Patients; N. Bonini1, C. Vignati1, A. Apostolo1, S. Paolillo1, F. Righini1, G. Gerosa2, T. Botti2, V. Tarzia2, J. Bejko2, P. Agostoni1. 1Centro Cardiologico Monzino, IRCCS, Milan, Italy, 2Cardiac Surgery Unit, Dept. of Cardiac, Thoracic & Vascular Sciences, University of Padua, Padua, Italy, 3Centro Cardiologico Monzino, IRCCS, Milano, Italy

(700) LVAD Pump Speed Increase is Associated With Increased Peak VO2 and Lower Cardiogenic Exercise Limitation; A. Apostolo1, C. Vignati1, N. Bonini1, S. Paolillo2, F. Righini1, J. Bejko2, V. Tarzia2, T. Bonini2, G. Gerosa2, P. Agostoni1. 1Centro Cardiologico Monzino, IRCCS, Milan, Italy, 2IRCCS SDN, Napoli, Italy, 3Cardiac Surgery Unit, Dept. of Cardiac, Thoracic & Vascular Sciences, Univ of Padua, Padua, Italy, 4Centro Cardiologico Monzino, IRCCS, Milano, Italy

(701) Left Ventricular Assist Device as Bridge-to-Transplant Therapy May Mitigate Elevated Pulmonary Vascular Resistance; J. J. Han1, S. Zaheer2, J. Chung2, C. Chen2, R. Kanade3, A. Gaffey2, J. E. Rame2, M. A. Acker1, P. Atluri1. 1Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Mayo Clinic School of Medicine, Rochester, MN, 4Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA

(702) Reducing Days in the Hospital with Cardiomesms Device in Patients with Left Ventricular Assist Device; A. C. Pandey1, K. Kheder2, M. Pellet2, A. V. Srivastava4, J. T. Heywood4, R. Mohan4. 1Division of Cardiology, Scripps Clinic/TSRI/STSI, La Jolla, CA, 2Medicine, Scripps Clinic, La Jolla, CA, 3Medicine, Scripps Clinic, La Jolla, CA, 4Division of Cardiology, Section of Heart Failure Research and Recovery, Scripps Clinic, La Jolla, CA

(703) Effects of Right Ventricle Optimization on Post-Operative Outcomes: A Retrospective Comparison; F. Sagebin1, B. Ayers1, B. Barrus1, S. Prasad1, H. Vidula2, E. Storozynsky2, S. Thomas2, L. Chen2, J. Alexis2, I. Gosev1. 1Div of Cardiac Surgery, Univ of Rochester, Rochester, NY, 2Div of Cardiology, Univ of Rochester, Rochester, NY

(704) HeartWare HVAD Log Files Provide Insight into Patient Behavior and Predicts Adverse Events; K. L. Kiehl1, R. Pedersen1, F. X. Downey2, J. D. Crouch2, N. Sulemanjee1, O. Cheema1, T. Hastings1, E. Roberts1, V. Thohan1. 1Tendick Center for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, 2Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI


(708) Does Increasing Experience in Implementing the Blood Pressure Management Protocol in the ENDURANCE Supplemental Trial Result in Better Outcomes?; C. Mahr1, J. J. Teuteberg2, J. D. Vega3, M. N. Walsh4, A. K. Ravichandran4, W. G. Cotts5, N. A. Mokadam1, T. A. Vassiliades4, J. G. Rogers1. 1University of Washington, Seattle, WA, 2Stanford University, Stanford, CA, 3Emory University, Atlanta, GA, 4St Vincent Heart Center, Indianapolis, IN, 5Advocate Heart Institute, Oak Lawn, IL, 6Medtronic, Framingham, MA, 7Duke University, Durham, NC

(709) Renal Function is Similar in LVAD Patients Regardless of Hemodynamic Status; M. N. Belkin, S. A. Besser, P. Mehta, B. Chung, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, G. Sayer, N. Uriel. University of Chicago, Chicago, IL


(712) Axial Flow Left Ventricular Assist Device is Associated with Progression of Aortic Valve Insufficiency; M. F. Masood1, I. Fischer1, K. Kotkar1, G. A. Ewald2, S. C. Silvestry2, K. R. Balsara1, A. Itch1. 1Surgery, Washington University School of Medicine, Saint Louis, MO, 2Medicine, Washington University School of Medicine, Saint Louis, MO, 3Surgery, Florida Hospital Transplant Institute, Orlando, FL

(713) Outcome of Centrimag Extracorporeal Mechanical Circulatory Support Use in Critical Cardiogenic Shock (INTERMACS 1 Patients); V. Mehta1, J. Hasan1, P. Callan2, S. Shaw2, S. Williams2, I. Dimarakis1, J. Barnard1, R. V. Venkateswaran2. 1Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2Cardiology, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 3Director of Transplantation, Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(714) VA-ECMO Cannulation Strategy and Influence on Cerebral Blood Flow Velocities; M. Cevasco, H. Ikegami, J. Willey, A. R. Garan, C. Chan, J. Han, P. Colombo, M. Yusefpolskaya, P. Kurlansky, Y. Naka, H. Takayama, K. Takeda. Columbia University Medical Center, New York, NY

(715) Outcomes and Risk Factor of Mechanical Circulatory Support by Periferal Veno-arterial Extrcortporal Membrane Oxygenation at Heart Transplant Candidates Needing Urgent Heart Transplantation; V. N. Poptsov, E. Spirina, S. Uschrenkov, V. Zacharevich, A. Dogonascheva. Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Russian Federation

(716) A Five-year Experience in Periferal Veno-Arterial Extracorporeal Membrane Oxygenation as a Method of Mechanical Circulatory Support in Heart Transplant Candidates; V. N. Poptsov, N. Koiloskova, E. Spirina, S. Uschrenkov, A. Dogonascheva, V. Zacharevich. Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Moscow, Russian Federation


(718) Cardiopulmonary Exercise Testing to Validate Pump Speed Optimization in Patients Implanted With HM 3; A. Montalto, V. Piazza, F. Albi, R. Gherli, F. Musumeci. San Camillo Hospital, Rome, Italy
(719) Exercise Capacity and Functional Performance in Patients With an HVAD Left Ventricular Assist Device (LVAD): Development 6 Month After Discharge From Cardiac Rehabilitation; T. Schmidt1, B. Bjarnason-Wehrens2, S. Mommertz1, A. Nitters-Daske1, C. Meyer genannt Potthoff1, S. Schulte-Eistrup1, N. Reiss1, Schüchtermann Klinik, Bad Rothenfelde, Germany, 2Institute for Cardiology and Sports Medicine, German Sports University, Cologne, Germany

(720) Can Routine Laboratory Values Predict 30-Day Survival of Patients after Cardiac Surgery Requiring ECMO-Support?; N. Neumann1, S. Zipfel1, N. Rübsamen2, M. Kubik3, M. J. Barten1, S. Kluge3, H. Reichenspurner1, A. Bernhardt1. Cardiac Surgery, Univ Heart Center Hamburg, Hamburg, Germany, 2Cardiology, Univ Heart Center Hamburg, Hamburg, Germany, 3Anesthesiology & Intensive Care Medicine, Univ Hospital Hamburg, Hamburg, Germany

(721) VV-ECMO as a Platform to Evaluate Bronchoscopic Saline Lavage and Surfactant Therapy in Severe ARDS; R. Qaqish1, L. Del Sorbo2, Y. Watanabe1, M. Galasso1, C. Summers1, A. Ali1, M. Takahashi1, A. Gazzalle1, S. Azad1, M. Liu1, S. Keshavjee1, M. Cypel1. Division of Thoracic Surgery, University of Toronto, Toronto, ON, Canada, 2InterDeprtment Critical Care Medicine, University of Toronto, Toronto, ON, Canada

(722) Digital Health Monitoring of Physical and Emotional Recovery After LVAD Placement; D. Banerjee1, D. Beiser2, F. Haddad3. 1Stanford, Palo Alto, CA, 2University of Chicago, Chicago, IL

(723) Successful Weaning and Explantation of the HeartMate3 Left Ventricular Assist Device Using a Pre-Designed Metal Plug; G. Faerber, H. Kirov, T. Sandhaus, T. Doenst. Univ Clinic Jena, Jena, Germany

(724) Association of Gene Polymorphisms with Thrombosis and Bleeding in Patients with Mechanical Circulatory System; M. Bekbossynova1, M. Zhalbinova2, S. Rakhimova2, A. Akilzhanova3, S. Andossova1. 1National Research Center for Cardiac surgery, Astana, Kazakhstan, 2National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan

(725) Prognostic Implications of Intermediate Hemolysis in Continuous Flow Left Ventricular Assist Device Patients; H. Rosenblum1, A. Pinsino1, M. Gavalas2, A. Zuver1, K. Parikh1, G. Parkis1, M. Flannery1, M. Mabasa1, E. A. Royzman1, A. Gaudig1, A. R. Garan1, V. K. Topkara1, H. Takayama1, K. Takeda1, Y. Naka1, M. Yuzefpolskaya1, P. C. Colombo1. 1Columbia University, New York, NY, 2Mount Sinai, New York, NY

(726) Does the Type of Mechanical Circulatory Support as a Bridge to Heart Transplant Affect Outcome after Transplant?; F. Esmailian, F. Arabia, L. Czer, M. Kittleson, D. Geft, R. Cole, G. Esmailian, M. Rafiei, E. Passano, H. Barone, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA

(727) Bridging to Heart Transplantation (BTT) in Seputagenarians with LVADs; A. Salimbangon, D. Vucicevic, M. Kwon, M. Deng, A. Chang, M. Moore, M. Kamath, A. Iyengar, S. Shah, R. Mequerdijian, E. Depasquale. UCLA, Los Angeles, CA


(729) Impaired Kidney Function and Impact on Survival After Left Ventricular Assist Device Implantation as a Bridge to Transplantation; D. Vucicevic1, A. Chang2, A. Salimbangon2, M. Kamath2, E. Moreno2, A. Iyengar2, S. Shah2, M. Cadeiras2, A. Ardehali3, M. Deng2, E. Depasquale2. 1Newark Beth Israel Medical Center, Newark, NJ, 2UCLA, Los Angeles, CA


(731) Long-Term Follow up and Predicting Factors of de Novo Aortic Regurgitation after LVAD Implantation; G. Benedetti1, P. Mohite1, H. Smail1, D. Garcia Saez1, N. P. Pati2, M. Husain1, A. Jothidasan1, M. Monteagudo-Vela1, H. A. Hassan3, F. Riesgo Gil1, O. Dar1, B. Mahesh1, N. R. Banner1, A. R. Simon1. 1Transplant Unit, Harefield Hospital, Harefield, United Kingdom, 2Liverpool Heart And Chest Hospital, Liverpool, United Kingdom, 3Menoufia University Hospital, Shbin El Kom, Egypt
(732) Trends and Associations of Serial NT-proBNP Measured After Ventricular Assist Device Implantation: J. M. Camuso1, C. Dunlap1, D. McGrath1, B. Nisraiyi2, S. Kilmarx1, K. Milley1, K. Stettner1, M. Villavicencio-Theoduloz1, S. Thomas2, G. Lewis2, D. D’Alessandro1, E. E. Cogliansani2, 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Cardiology, Massachusetts General Hospital, Boston, MA

(733) Safety of Centrifugal Left Ventricular Assist Device Implantation in Patients With Severe Left Ventricular Dysfunction and Secondary Mitral Valve Regurgitation Treated With Mitral Clips: E. Ammirati1, F. Musca1, C. M. Van de Heyning2, E. Perna1, M. Cipriani2, A. Cannata1, L. D’Angelo1, F. Milazzo1, A. Moreo1, D. De Bock3, C. F. Russo1, M. Frigerio1, 1De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy, 2Dept of Cardiology, Antwerp University Hospital, Edegem, Belgium, 3Dept of Cardiovascular Surgery, Antwerp University Hospital, Edegem, Belgium

(734) Association between Multidimensional Molecular Biomarkers and Functional Recovery Potential in Advanced Heart Failure: T. Bao1, R. Togashi1, M. Cadeiras1, J. Schaenman2, L. Masukawa1, J. Hai1, D. Chu1, E. Chang1, S. Kupiec-Weginski1, V. Groversberg2, A. Le1, R. Dod1, C. Kahn1, E. Oh1, J. Do1, C. Lumintang1, T. Grogan2, J. Meltzer2, M. Kwon2, M. Rossetti2, D. Elashoff2, E. Reed2, P. Ping2, G. Bondar1, M. C. Deng1, 1Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3Cornell University, Ithaca, NY

(735) Heart Failure in Rheumatoid Arthritis Patients: Trend of Admissions and Use of Advanced Heart Failure Therapies: V. Blumer1, G. A. Hernandez2, K. Corbitt1, M. Ortiz3, S. Chaparro1. 1University of Miami, Miami, FL, 2Vanderbilt University, Nashville, TN, 3Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of Venezuela

(736) Two Year Outcomes in Patients Successfully Explanted from Durable Left Ventricular Assist Device Support: K. Hrynewicz, C. Weaver, M. Samara, K. Mudy, B. Sun. Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN

(737) Implementation of a Multidisciplinary CODE SHOCK Strategy for Cardiogenic Shock: H. A. Garuba1, M. Boodhwan1, M. Rue1, E. Stadnick1, R. A. Davies1, M. Le May1, B. Bowes3, L. M. Mielniczuk1, S. Chih1. 1Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada, 2Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada, 3Dept of Clinical Services, University of Ottawa Heart Institute, Ottawa, ON, Canada

(738) Implantation Strategies and Outcomes of Patients Treated with Left Ventricular Assist Devices Awaiting for Heart Transplant in Europe and United States: Data from the TransAtlantic Registry on VAD and Transplant (TRAVIATA): M. Brambatti1, O. O. Braun1, E. Ammirati2, P. Shah3, L. Klein4, E. Perna2, C. Van de Heyning5, M. Cikes6, G. Gjesdal7, Y. K. Gernhofer1, J. Minto2, N. Jakus3, C. F. Russo2, M. Kassemos4, C. Partida4, B. Quan1, D. Milicic6, M. Cipriani2, L. J. Boga2, D. De Bock3, V. Pretorius1, J. Nilsson7, M. Frigerio2, E. Adler1. 1University of California San Diego, La Jolla, CA, 2De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy, 3Inova Heart and Vascular Institute, Falls Church, VA, 4University of California San Francisco, San Francisco, CA, 5Antwerp University Hospital, Edegem, Belgium, 6University of Zagreb School of Medicine, Zagreb, Croatia, 7Skane University Hospital, Lund, Sweden

(739) Sleep and Life Quality with Left Ventricular Assist Devices or Transplanted Heart: Results from a Multi-Center Observational Study: T. Botti1, J. Bejko1, H. Ocaqli1, M. Carrozzini1, C. Pagnin1, V. Tarzia1, P. Agostoni2, D. Bacich3, H. Ortis4, U. Livi5, M. Maiani6, A. Apostolo6, G. Di Gianmarco6, C. Lanera1, D. Gregori1, G. Gerosa1, 1Dept of Cardiologic Thoracic and Vascular Sciences, Univ of Padua, Padova, Italy, 2Univ of Milano, Padova, Italy, 3Univ Of Padova, Padova, Italy, 4Univ of Udine, Padova, Italy, 5Univ of Udine, Udine, Italy, 6Univ of Chieti, Padova, Italy

NURSING, HEALTH SCIENCES, ALLIED HEALTH
(Gallieni 1-2)

Poster Discussants: Susan Chernenko (Canada), Pamela Combs (USA), Helen Gibbs (New Zealand), J. Eric Hobson (USA), Christiane Kugler (Germany)

(740) Alleviation of VAD Coordinator Time Burden and Empowermentof HVAD Patients in Order to Improve Outcomes: T. Schöglohofer1, M. Blood2, J. Pietropaolo3, J. Lantz4, 1Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Dept of Mechanical Circulatory Support, University of Alabama at Birmingham Hospital, Birmingham, AL, 3Medtronic Inc., Mounds View, MN, 4Children’s Health, Dallas, TX
(741) Vocal Cord Paralysis and Aspiration Post Ventricular Assist Device Implantation; N. Patel, A. Reed, O. Dar, A. Simon. 1Speech & Language Therapy, Royal Brompton and Harefield NHS Trust, London, United Kingdom, 2Transplant Medicine, Royal Brompton and Harefield NHS Trust, London, United Kingdom, 3Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust, London, United Kingdom

(742) The Use of a Bed Bike for Patients Bedbound on Mechanical Circulatory Support: A Case Study; R. Marschieder, F. Nolan. Rehabilitation, Golden Jubilee National Hospital, Glasgow, United Kingdom

(743) Medication Adherence: Use of the Beliefs About Medication Questionnaire in Heart and Lung Transplant Patients; L. Painter, I. Fontanilla. Transplant Psychology, Auckland City Hospital, Auckland, New Zealand

(744) Predictors for Health Related Quality of Life in De Novo Heart Transplant Recipients; K. Rolli, A. K. Andreassen, M. Yardley, E. Bjørkelund, A. R. Authen, I. Grov, E. Gude, L. Gullestad, K. Nytraen. Dept of Cardiology, Oslo University Hospital, Oslo, Norway

(745) The Relationship Between Peak Cough Flow and Respiratory Function Testing (Spirometry), and the Factors That Influence This, Post Bilateral Sequential Single Lung Transplantation: A Cross-sectional Feasibility Study at a Single Centre Cardiothoracic Transplantation Unit; A. M. Roberts, C. L. Pereira, M. R. Carby, A. R. Simon, N. S. Drey, A. K. Reed. 1Royal Brompton and Harefield NHS Foundation Trust, Middlesex, United Kingdom, 2City, University of London, London, United Kingdom


(747) Assessment of Need for Quality Improvement in Transitional Care; H. M. Lim, E. Estes, M. Zamberlan, K. R. Schumacher, M. K. Cousino. C.S. Mott Children’s Hospital, Congenital Heart Center, Univ of Michigan, Ann Arbor, MI

(748) Exploring the Relationship Between BMI and Obesogenic Factors Including Nutritional Knowledge, Intake, Psychological Behaviours, Physical Activity and Quality of Life in a Post Heart Transplant Population: A Cross Sectional Study; R. Patel, C. Pereira, O. Dar, N. Banner, A. Simon, S. Hirani. 1Royal Brompton and Harefield Hospital, Middlesex, United Kingdom, 2City, University of London, London, United Kingdom

(749) Trajectories of Plasma sST2 by Different Metrics of Clinical Response After Left Ventricular Assist Device Placement; Q. Denfeld, J. O. Mudd, J. M. Gelow, S. O. Hiatt, S. Florig, B. A. Habeker, C. S. Lee. 1School of Nursing, Oregon Health & Science University, Portland, OR, 2Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 3Physiology & Pharmacology, Oregon Health & Science University, Portland, OR

(750) An International Survey of LVAD Hygiene Practices; A. Kaan, B. Cagliostro. 1Acute Heart Failure Program, St. Paul's Hospital, Vancouver, BC, Canada, 2Bi Campus Mechanical Circulatory Support Program, New York-Presbyterian Hospital, New York, NY

(751) Parallel Improvements in Physical Symptoms and Depression in Response to Left Ventricular Assist Device Implantation; C. S. Lee, K. L. Grady, J. M. Gelow, C. V. Chien, S. O. Hiatt, J. O. Mudd. 1School of Nursing, Oregon Health & Science Univ, Portland, OR, 2Feinberg Sch of Med, Northwestern Univ, Evanston, IL, 3Knight Cardiovascular Institute, Oregon Health & Science Univ, Portland, OR, 4REX Healthcare, Univ of North Carolina, Raleigh, NC

(752) Using Adherence Agreements in Heart Transplant Candidates: What’s Important?; A. Kaan, E. Johansson, W. Chiu, C. Cannon, Q. Young, K. Brownjohn. Acute Heart Failure Program, St. Paul's Hospital, Vancouver, BC, Canada


(754) Comparison of Different HRQOL Measures Waitlisted Patients for Lung Transplantation; J. Tokuno, T. F. Chen-Yoshikawa, T. Oga, T. Oto, T. Okawa, Y. Okada, M. Akiba, D. Nakajima, M. Hamaji, H. Motoyama, A. Aoyama, M. Isomi, H. Date. 1Dept of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan, 2Dept of Respiratory Care and Sleep Control Medicine, Kyoto University Hospital, Kyoto, Japan, 3Organ Transplant Center, Okayama University Hospital, Okayama, Japan, 4Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, 5Division of Organ Transplantation, Tohoku University Hospital, Sendai, Japan
(755) The Effect of Everolimus vs Calcineurin Inhibitors on Quality of Life During 5-6 Years Follow-up After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE); A. Relbo Authen1, I. Grov1, K. Karason2, F. Gustafsson3, H. Eiskjær4, G. Rådegran5, E. Gude1, K. Jansson6, D. Solbu7, S. Arora1, G. Dellgren8, A. K. Andreassen1, L. Gullestad9. 1Dept of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Dept of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Dept of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, 4Dept of Cardiology, Skejby University Hospital, Aarhus, Denmark, 5The Section for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, 6Dept of Cardiology County Hospital, Linkoping University, Linkoping, Sweden, 7Novartis employee., Novartis Norway AS, Oslo, Norway, 8Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, 9Dept of Cardiology K.G.Jebesen Cardiac Research Centre and Center for Heart Failure Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

(756) Providers Perspectives on Palliative Care Integration in Advanced Heart Failure Care; Y. Quiaoit, M. Molina. Cardiology- Heart failure/transplant, Hospital of the University of Pennsylvania, Philadelphia, PA

(757) WITHDRAWN

(758) Is the VAS Quality of Life Assessment Tool Sensitive to Both Male and Female MCSD Patients?; B. Coleman, R. Levine, F. Arabia, E. Passano, S. Dimbil, H. Barone, C. Runyan, N. Huie, J. Hajj, M. Lindsay, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(759) WITHDRAWN

(760) Adherence to Self-care Behaviors After Left Ventricular Assist Device Implantation; T. Ben Gal1, N. P. Kato2, B. Ben Avraham1, V. Yaari1, M. Abu-Hazeira1, D. Golobov1, A. Strömberg3, T. Jaarsma2. 1Heart Failure Unit, Cardiology Dept, Rabin Medical Center, Petah Tikva, Israel, 2Dept of social and Welfare studies, Linköping University, Linköping, Sweden, 3Dept of Health Sciences, Linköping University, Linköping, Sweden

(761) Negative Pressure Wound Therapy Applied to Groin Cannulation Incisions Decrease the Incidence and Severity of Seroma Formation; L. J. Bogar1, L. Cantwell2, M. Fregoso3, J. Chun3, R. Singh1. 1Cardiac Surgery, INOVA Fairfax Hospital, Falls Church, VA, 2Advanced Heart Failure, INOVA Fairfax Hospital, Falls Church, VA, 3Advanced Lung Center, INOVA Fairfax Hospital, Falls Church, VA

(762) Impact of Massage Therapy in Lung Transplant Recipients; H. Gauchez1, M. Taharo2, A. Sénéchal2, C. Cousty3, A. Tiberghien2, J. Monnex4, P. Boulinguez5. 1Univ Lyon 1, Lyon, France, 2Hospices Civils de Lyon, Lyon, France, 3Hospices Civils de Lyon, Lyon, France, 4Univ Lyon 1 & Hospices Civils de Lyon, Lyon, France, 5CNRS, Lyon, France


PATHOLOGY
(Agora 2)

Poster Discussants: Brandon Larsen (USA), Anja Roden (USA)

(764) Vasculitis in Post-Heart Transplant Endomyocardial Biopsy: Possible Relationship with Mixed Rejection, Circulating Donor Specific Antibodies and Worse Outcome; M. Fedrigo1, A. Romano1, T. Bottio2, G. Toscano2, A. Di Francesco1, G. Feltrin2, C. Castellani1, F. Zanco1, A. P. Fraiese4, A. Veronesi3, G. De Silvestro3, A. Nocco4, E. Benazzi4, G. Gerosa2, G. Thiene1, A. Angelini1. 1Cardiac Thoracic and Vascular Sciences, Pathology, Padua, Italy, 2Cardiac Thoracic and Vascular Sciences, Cardiosurgery, Padua, Italy, 3Regional Laboratory of Transplant, Transfusion Medicine, Camposampiero, Italy, 4Fondazione IRCCS Ca granda, Ospedale Maggiore, Milan, Italy

(766) Histologic and Molecular Microscope Determinants of Graft Survival in the INTERHEART Study: The Greater Importance of T Cell-mediated Rejection vs. Antibody-mediated Rejection in Graft Loss; J. Reeve1, D. H. Kim2, M. G. Crespo-Leiro3, J. Kobashigawa4, L. Potena5, M. Deng6, M. Cadeiras7, E. C. Depasquale8, P. Bruneval9, A. Loupy10, P. Macdonald11, A. Zuckermann12, A. Z. Aliabadi13, J. Goekler14, P. F. Halloran1. 1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2Univ of Alberta, Edmonton, AB, Canada, 3Complexo Hospitalario Univ A Coruña, A Coruña, Spain, 4Cedars-Sinai Heart Institute, Beverly Hills, CA, 5Univ of Bologna, Bologna, Italy, 6Ronald Reagan UCLA Medical Center, Los Angeles, CA, 7Hôpital Européen Georges Pompidou, Paris, France, 8Hôpital Necker, Paris, France, 9The Victor Chang Cardiac Research Institute, Sydney, Australia, 10Medical Univ of Vienna, Vienna, Austria

(767) Validating the INTERHEART Classifiers for Molecular Diagnosis of Rejection in 558 New Endomyocardial Biopsies; J. Reeve1, D. H. Kim2, M. G. Crespo-Leiro3, J. Kobashigawa4, L. Potena5, M. Deng6, M. Cadeiras7, E. C. Depasquale8, P. Bruneval9, A. Loupy10, P. Macdonald11, A. Zuckermann12, A. Z. Aliabadi13, J. Goekler14, P. F. Halloran1. 1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2Univ of Alberta, Edmonton, AB, Canada, 3Complexo Hospitalario Univ A Coruña, A Coruña, Spain, 4Cedars-Sinai Heart Institute, Beverly Hills, CA, 5Univ of Bologna, Bologna, Italy, 6Ronald Reagan UCLA Medical Center, Los Angeles, CA, 7Hôpital Européen Georges Pompidou, Paris, France, 8Hôpital Necker, Paris, France, 9The Victor Chang Cardiac Research Institute, Sydney, Australia, 10Medical Univ of Vienna, Vienna, Austria

(768) Improving the Diagnosis of Rejection by Molecular Phenotype of Endomyocardial Biopsies: Single Center Insights from the Interheart Study; L. Borgese1, L. Potena1, O. Leone2, V. Agostini2, J. Reeve3, M. Masetti4, A. Russo5, F. Grigioni6, P. Halloran7. 1Cardiology, University of Bologna, Bologna, Italy, 2Pathology, University of Bologna, Bologna, Italy, 3University of Alberta, Edmonton, AB, Canada

(769) NK Cells in Endomyocardial Biopsies From Cardiac Allografts: Detection, Quantification, and Precise Localization Using Multiplex Immunofluorescence; M. Terada1, M. Rabant2, C. Lesaffre1, J. Duong Van Huyen1, P. Bruneval1. 1INSERM U970, Paris, France, 2INSERM U1151, Paris, France

(770) The Interleukin-33/ST2 Pathway is Expressed in the Failing Human Heart and Associated with Pro-Fibrotic Remodeling of the Myocardium; M. M. Huibers1, C. C. Tseng2, J. van Kuik3, R. A. de Weger1, A. Vink1, N. de Jonge2. 1Pathology, UMC Utrecht, Utrecht, Netherlands, 2Cardiology, UMC Utrecht, Utrecht, Netherlands

(771) Pathological Correlation Between Apical Core Biopsies at the Time of Left Ventricular Assist Device Implantation and Excised Heart at Time of Transplant or Autopsy; M. Alhussein1, L. Battioni1, K. Runeckles1, J. Duero Posada1, Y. Moayed1, J. Lombardi1, H. J. Ross1, F. Billia1, V. Rao1, J. Butany1, M. McDonald1. 1Division of Cardiology, University Health Network, Toronto, ON, Canada, 2Division of Pathology, Univ Health Network, Toronto, ON, Canada

(772) Characterizing the Airway Inflammatory Milieu in Post-Transplantation Lung Biopsies of Cystic Fibrosis Patients: A Single Institution Study of Acute Cellular Rejection; A. J. McHenry1, A. Husain2, M. Ivanovic3, E. Lowery4, D. Dilling4, V. Ananthanarayanan5. 1Stritch School of Medicine, Loyola Univ Chicago, Maywood, IL, 2Dept of Pathology, Univ of Chicago, Chicago, IL, 3Dept of Pathology, Univ of Iowa, Iowa City, IA, 4Pulmonary and Critical Care Medicine, Loyola Univ Medical Center, Maywood, IL, 5Dept of Pathology, Loyola Univ Medical Center, Maywood, IL

(773) miRNA Dysregulation in Chronic Lung Allograft Rejection. A Computational, Quantitative and In Situ Analysis; F. Meloni1, E. Rossi2, S. Inghilleri3, M. Porzio4, M. Zorzetto3, R. Kessler5, P. Morbini2. 1Internal Medicine, University of Pavia and IRCCS S.Matteo, Pavia, Italy, 2Molecular medicine, University of Pavia and IRCCS S.Matteo, Pavia, Italy, 3Respiratory Diseases, IRCCS S.Matteo, Pavia, Italy, 4Hôpital Civil - Nouvel Hôpital Civil, Strasbourg, France, 5PU-PH, NHC, Hôpitaux universitaires de Strasbourg, Nouvel Hôpital Civil, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France

PHARMACY AND PHARMACOLOGY
(Agora 2)

Poster Discussants: Fay Burrows (Australia), Adam Cochrane (USA), Patricia Ging (Ireland)

(775) Association Between Tacrolimus Concentration/Dose Ratio and Renal Function Following Cardiac Transplant; L. M. Lourenco1, Z. Truman1, C. Murks2, T. Riley2, J. Powers2, M. Reilly2, S. Kalantar9, J. Raikherkar2, N. Sarzwat2, G. Kim2, G. Sayer2, N. Uriel3. 1Pharmacy Services, University of Chicago Medicine, Chicago, IL, 2Cardiology, University of Chicago Medicine, Chicago, IL

(776) Use of Oral Milrinone in Ventricular Assist Device Patient with Chronic Right Ventricular Failure: A Single Centre Experience; H. Lyster1, E. Zambon1, L. L.Seuthe@rbht.nhs.uk1, K. Habibi-Parker1, P. Ly1, R. Betmouni1, N. Leaver2, F. Riesgo-Gil3, O. Dar1, N. Banner1. 1Cardiothoracic transplantation, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, 2Immunosuppression Monitoring Service, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom

(777) Keeping Tacrolimus Levels Therapeutic: Step-Wise Protocol for Itraconazole Discontinuation; J. Stephen1, S. Al-Saleh2, L. LeMond3, J. Rosenthal3, D. Steidle3. 1Pharmacy, Mayo Clinic, Phoenix, AZ, 2Transplant Nursing, Mayo Clinic, Phoenix, AZ, 3Cardiology, Mayo Clinic, Phoenix, AZ

(778) Safety and Tolerability of High Intensity Statin Therapy in Heart Transplant Patients Receiving Immunosuppression with Tacrolimus; S. L. Tjugum, S. A. Heeney, M. E. Corkish, I. B. Hollis. University of North Carolina Medical Center, Chapel Hill, NC

(779) Optimizing Weight-based Enoxaparin Dosing for Lung Transplant Recipients; T. M. Veasey1, M. D. Lahey1, V. Scheuble2, J. E. Nelson1, S. Chandrashekar2. 1Dept of Pharmacy, UF Health Shands Hospital, Gainesville, FL, 2Dept of Medicine, University of Florida, Gainesville, FL

(780) Conversion to Extended Release Tacrolimus in Early Post Lung Transplantation Period - A Pilot Study; L. Morlacchi1, V. Rossetti1, L. Rosso2, A. Palleschi2, S. Aliberti1, R. Carrinola2, M. Montoli2, M. Nosotti2, P. Tarsia1. 1Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 2Thoracic and Lung Transplantation Surgery, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy


(782) Conversion from Advagraf/Prograf to Envarsus in Stable Lung Transplant Patients; G. Murakoezy1, A. Benazzo1, S. Schwarz1, S. O. Obermair-Ramp1, T. Stork2, W. Klepetko1, P. Jaksch1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Thoracic Surgery, Medical University of Vienna, Wien, Austria

(783) INR Remote Monitoring is Associated with Improved Time in Therapeutic Range Following Left Ventricular Assist Device Implantation; V. N. Nguyen1, M. Smith2, M. Belyk2, M. Brambatti3, O. O. Braun3, E. D. Adler2, V. G2, M. Mariski1, C. Stevens1, A. Feist1. 1Pharmacy, UC San Diego Health, San Diego, CA, 2Surgery, UC San Diego Health, San Diego, CA, 3Cardiology, UC San Diego Health, San Diego, CA

(784) Institution-based, Pharmacist-managed Anticoagulation in Patients with a Left Ventricular Assist Device; T. J. Bibb1, L. C. Halder1, D. L. McDanel1, A. Briasoulis2, P. A. Alvarez2, K. E. Horner1, J. K. Bhamra3, S. B. Larson3. 1Dept of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Cardiovascular Medicine, Dept of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 3Division of Cardiothoracic Surgery, Dept of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA

(785) Reduced Readmissions with Enoxaparin Bridging for Subtherapeutic INR in MCS; T. Khuu1, E. DePasquale2, A. Salimbangon1, A. Chang1, E. Moreno1, D. Rourke4, J. Creaser3, E. Vandenbogaart3, M. H. Kwon4, A. Ardehali4, A. Nsair2. 1Transplant Services, UCLA, Los Angeles, CA, 2Medicine - Cardiology, UCLA, Los Angeles, CA, 3Cardiomyopathy, UCLA, Los Angeles, CA, 4Surgery - CardioThoracic, UCLA, Los Angeles, CA

(786) Variability in Anticoagulation Practices With the Impella Percutaneous Ventricular Assist Device: A Survey of High-volume Centers; B. N. Reed1, R. J. DiDomenico2, J. E. Allender2, J. C. Coons4, J. F. Cox5, J. D. Moretz6, C. S. Oliphant7, D. L. Jennings8. 1Pharmacy Practice and Science, Univ of Maryland School of Pharmacy, Baltimore, MD, 2Univ of Illinois Chicago, Chicago, IL, 3WakeMed Health & Hospitals, Raleigh, NC, 4Univ of Pittsburgh Medical Center, Pittsburgh, PA, 5Palmetto Health, Columbia, SC, 6Vanderbilt Univ Medical Center, Nashville, TN, 7Methodist Le Bonheur Healthcare, Memphis, TN, 8New York-Presbyterian Hospital, Columbia Univ Irving Medical Center, New York City, NY
HEART FAILURE

(Muses)

Poster Discussants: Sharon Chih (Canada), Savitri Fedson (USA), Pascal Leprince (France), Guy MacGowan (United Kingdom), Alanna Morris (USA), Florian Wagner (Germany)

(787) Gender and Diastolic Dysfunction May be the Driver of Failure of Myocardial Recovery Following LVAD Implantation; K. StawiarSKI1, C. Zogg2, J. Park2, D. Jacoby2, L. Bellumkonda2, M. Chen2, T. Ahmad2, J. Testani2, G. McCloskey2, L. Sugeng2, P. Bonde2. 1Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, 2Yale School of Medicine, New Haven, CT

(788) Which "Roadmap" in Patients With Advanced or Refractory Heart Failure, Eligible for LVAD and Heart Transplantation?: L. F. Bertoldi1, E. Perna1, A. F. Giglio1, E. Ammirati1, M. G. Cipriani1, A. Garascia1, F. Macera1, L. D'Angelo1, M. Varrenti1, A. Costetti1, S. Nonini1, M. P. Gagliardone1, C. Russo1, P. G. Camici2, M. Frigerio1. 1DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy, 2Cardiothoracic Dept, San Raffaele Hospital, Milan, Italy

(789) Clinical and Humoral Determinants of Congestion-prone Advanced Heart Failure Phenotype; V. Melenovsky1, J. Benes1, M. Kotrc1, A. Jabor1, J. Kautzner1, J. Kovar1, P. Jarolim2. 1Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic, 2Brigham and Women's Hospital, Harvard University, Boston, MA

(790) Outcomes of Long-term Inotrope Therapy as a Bridge to Heart Transplant; E. C. Lee1, J. Martens1, J. Alexis1, I. Gosev2, H. Vidula1. 1Division of Cardiovascular Medicine, University of Rochester, Rochester, NY, 2Division of Cardiac Surgery, University of Rochester, Rochester, NY

(791) Refusal of Blood Products Should not be a Contraindication to LVAD Therapy; R. Salaba1t, C. LaBuhn1, D. Onsager1, T. Ota1, G. Sayer2, G. Kim2, G. Kim3, N. Uriel2, V. Jeevanandam1. 1Cardiothoracic Surgery, University of Chicago, Chicago, IL, 2Medicine, University of Chicago, Chicago, IL

(792) The Significance of NT-proBNP in Patients Assessed for Heart Transplant or LVAD; E. Wolsk, T. Deis, K. Rossing, F. Gustafsson. Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark

(793) The Benefits of Ambulatory Pulmonary Artery Pressure Monitoring in Patients With Heart Failure; H. Patel, S. Phillips. Carillon Clinic - Virginia Tech, Roanoke, VA

(794) Acute Reduction in Pulmonary Artery Pressures with Sacubitril-Valsartan Measured by the CardioMEMS HF Device; L. M. Raj1, J. McLeod2, O. Havakuk1, A. Wolfson1, H. Kwong1, A. Yoon1, M. Fong1, D. Shavelle1, L. Goldstein1. 1Division of Cardiology, USC, Los Angeles, CA, 2Dept of Medicine, USC, Los Angeles, CA

(795) “There’s Always Another Treatment” – The Promise of Cardiac Devices as Barrier to Advance Care Planning in Heart Failure; R. Hadler1, L. Allen2, D. Bekelman3, R. Arnold4, N. Goldstein5, D. Kavalieratos4. 1Dept of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Dept of Medicine, Division of Cardiology, University of Colorado, Denver, CO, 3Dept of Medicine, Division of Geriatrics, University of Colorado, Denver, CO, 4Dept of Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Dept of Medicine, Mount Sinai School of Medicine, New York, NY

(796) WITHDRAWN

(797) Mobile Integrated Healthcare - Community Paramedicine: An Integrated and Novel Approach to Caring for Heart Failure Patients; G. Reynolds1, M. Robinson2, M. Jernigan2, J. Webster2, A. Yehya2. 1CV Services, Piedmont Heart, Atlanta, GA, 2Advanced Heart Failure, Piedmont Heart, Atlanta, GA

(798) Transitional Care Service Slashes 30-day Readmission and Mortality Rates: A Single Center Experience; J. N. Patel1, D. Lewandowski2, C. Bhardwaj1, K. Berkovitz2, B. S. Clemson1. 1Cardiology (Medicine), University of Illinois College of Medicine - Peoria, Peoria, IL, 2Cardiology (Medicine), OSF St. Francis Medical Center, Peoria, IL
(799) Hospital Pathways Within One Year Before Cardiac Transplantation: A French Nationwide Study; C. Cantrelle1, R. Dorent1, O. Bastien1, T. Damy2, C. Legeai1, P. Tuppin3. 1Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, 2Cardiology, Assistance Publique Hôpitaux de Paris - Henri Mondor hospital, Créteil, France, 3Medical & Scientific, Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France

(800) Which Advanced Heart Failure Therapy Strategy is Optimal for Patients Over 60 Years Old?; Y. K. Gernhofer1, O. O. Braun2, M. Brambatti2, Q. M. Bu2, J. Silva Enciso2, B. H. Greenberg2, E. Adler2, V. Pretorius1. 1Cardiothoracic Surgery, UC San Diego, San Diego, CA, 2Cardiology, UC San Diego, San Diego, CA

(801) Utility of Intermacs Risk Classification at the Time of Assessment for Advanced Therapies; F. Foroutan1, E. Friesen1, J. Krakovsky2, S. Chih3, H. J. Ross1, C. Alba1. 1Cardiology, Toronto General Hospital, Toronto, ON, Canada, 2Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada, 3Cardiology, Ottawa Heart Institute, Toronto, ON, Canada

(802) The Association of Global Longitudinal Strain With Clinical Outcomes in Heart Failure Patients With Severe Left Ventricular Systolic Dysfunction; H. Lee1, J. Sin1, M. Kim2, N. Jeong3, S. Oh3, S. Lee1, S. Song4, S. Kim4, M. Kim4. 1Cardiology Dept, Pusan National University Hospital, Busan, Korea, Republic of, 2Dept of Pharmacy, Pusan National University Hospital, Busan, Korea, Republic of, 3Organ Transplantation Center, Pusan National University Hospital, Busan, Korea, Republic of, 4Dept of Thoracic Surgery, Pusan National University Hospital, Busan, Korea, Republic of

(803) Feasibility and Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock: Preliminary Results; I. Taleb, A. Koliopoulou, A. Tandar, S. McKellar, J. Nativi1, W. Abraham1. 1Cardiology, University of Chicago Medical Center, Chicago, IL, 2Advanced Heart Failure and Transplantation, Brigham and Women's Hospital, Boston, MA, 3Institute of Clinical and Experimental Medicine, Prague, Czech Republic, 4Institute for Informatics, Univ in St. Louis, Missouri, 5Division of Biostatistics, Azusa Pacific Univ, Azusa, CA, 6Division of Cardiovascular Medicine, University of Wisconsin, Madison, WI, 7Columbia University, Dept of Pharmacy, Pusan National University Hospital, Busan, Korea, Republic of

(804) Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education; K. Breathett1, S. Maffett2, R. Foraker3, R. Sturdivant4, K. Moon5, A. Hasan6, V. Franco6, S. Smith6, B. Lampert6, S. Emani6, G. Haas6, R. Kahwash6, R. Hershberger6, P. Binkley6, L. Helmink6, K. Colborn7, P. Peterson8, N. Sweitzer9, W. Abraham9. 1Division of Cardiovascular Medicine, Univ of Arizona, Tuscon, AZ, 2Division of Cardiovascular Medicine, Ohio State Wexner Medical Center, Columbus, OH, 3Institute for Informatics, Univ in St. Louis School of Medicine, St. Louis, MO, 4Division of Biostatistics, Azusa Pacific Univ, Azusa, CA, 5Division of Cardiovascular Medicine, Univ of Wisconsin, Madison, WI, 6Division of Cardiovascular Medicine, Ohio State Univ Wexner Medical Center, Columbus, OH, 7Univ of Colorado Adult and Child Consortium for Health Outcomes Research and Delivery Science, Aurora, CO, 8Division of Cardiovascular Medicine, Univ of Colorado, Aurora, CO

(805) Quality of Clinical Outcomes and Effectiveness of Heart Failure Exacerbation Management in Emergency Room Observation Unit Versus Coronary Care Unit; F. Al-Saffar1, S. Ibrahim2, P. Patel2, J. Ruiz-Morales2, J. Sabato2, A. Miller2. 1Mayo Clinic, Scottsdale, AZ, 2University of Florida, Jacksonville, FL

(806) Prediction of Mortality in Decompensated Heart Failure by Invasive Hemodynamics Compared to Clinical Assessment; N. Narang1, B. Chung1, A. Nguyen1, D. Rodgers1, T. Imamura1, S. Kalantari1, J. Raikhelkar1, N. Sarswat1, G. Kim1, V. Jeevanandam2, G. T. Sayer1, N. Uriel1. 1Cardiology, University of Chicago Medical Center, Chicago, IL, 2Cardiac Surgery, University of Chicago Medical Center, Chicago, IL

(807) Stroke Patterns and Implications for Ventricular Functional Remodeling in Left Ventricular Assists; D. F. Snipelisky1, P. Ivak2, G. Stewart1, M. Givertz1, M. Pfeffer1, J. Groarke1, S. Singh1, I. Netuka3, M. Mehra1. 1Advanced Heart Failure and Transplantation, Brigham and Women's Hospital, Boston, MA, 2Institute of Clinical and Experimental Medicine, Prague, Czech Republic, 3Institute for Clinical and Experimental Medicine, Prague, Czech Republic

(808) Incidence of Heart Failure in Patients with Cardiac Tumor Surgical Resection: A Single Center Experience; S. H. Ibara-Cortez, M. J. Reardon. Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

(809) Mitral Regurgitation Due to Ischemic Cardiomyopathy: Insights Using Computational, Robotics Mitral-Papillary-Ventricular Complex; J. Park, P. Bonde. Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT

(810) The Dilemma After CRT Device Removal: A Bi-ventricular Bridging Solution is Needed; L. Castro1, S. Pecha1, J. Vogler2, N. Gosau2, S. Willem2, H. Reichenspurner1, S. Hakmi2. 1Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2Dept of Cardiology, Electrophysiology, University Heart Center Hamburg, Hamburg, Germany
(811) Neutrophil to Lymphocyte Ratio at the Time of LVAD Implant Predicts 30-day Readmission; N. Ahmed1, H. Gandhi1, Y. Kim1, O. Saeed2, S. Patel2, S. Murthy2, J. Shin2, S. Forrest3, D. J. Goldstein3, U. P. Jorde2, D. B. Sims2. 1Dept of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, 2Division of Cardiology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, 3Division of Cardiothoracic Surgery, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

(812) Poscardiomyotomy Cardiogenic Shock: Characteristics, Management and Prognostic in a Contemporary Cohort; J. Vázquez López-Ibor1, F. Hernández Pérez1, J. Goirigolzarri1, M. Gómez Bueno1, J. García Suárez2, C. Martín López3, L. Alonso-Pulpón4, J. Segovia Cubero1. 1Cardiology, Hospital Puerta de Hierro, Madrid, Spain, 2anesthesiology, Hospital Puerta de Hierro, Madrid, Spain, 3Cardiac surgery, Hospital Puerta de Hierro, Madrid, Spain


(814) Comparison of Survival and Readmission Rates in Patients 65 and Older Undergoing Heart Transplantation or LVAD Implantation; T. Imamura1, C. Murks1, T. Riley1, J. Powers1, B. Chung1, A. Nguyen1, D. Rodgers1, J. Raikhelkar1, S. Kalantari1, M. R. Costanzo2, U. Jorde3, T. Ota1, T. Song1, D. Onsager1, C. Juricek1, V. Jeevanandam1, G. Kim1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Advocate Heart Institute, Naperville, IL, 3Montefiore Medical Center, New York, NY

(815) PAPi Shows a Stronger Correlation With RAP versus RVSWI in Both HFrEF and HFpEF; N. Nair1, S. Yang2, C. Marzbani1, L. Truong2, E. Gongora2. 1Division of Cardiology, Dept of Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX, 2Dept of Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX, 3Cardiothoracic Surgery, MCVI, Hollywood, FL


(817) Genetic Epidemiology of Ventricular Tachycardia in Patients with Cardiomyopathy in Kazakhstan: ATargeted Sequencing Study; M. Bekbossynova1, A. Akilzhanova2, C. Guelly3, Z. Aibilova2, A. Akhmetova1, U. Kairov4, O. Nuralinov1, G. Rashbayeva1, S. Trajanoski1, B. Abdirova1, Z. Zhumadilov2. 1National Research Center for Cardiac surgery, Astana, Kazakhstan, 2National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, 3Center of Medical Research, Medical University of Graz, Graz, Austria, 4Laboratory of Bioinformatics and Computational Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan

(818) Zinc Deficiency and Heart Failure: A Systematic Review of the Literature; H. R. Rosenblum, J. Wessler, A. Gupta, B. Bikdeli. Columbia University Medical Center, New York, NY

(819) Ischemic but not Dilative Cardiomyopathy Impairs the Thioredoxinsystem in the Myocardium; M. Dieterlen, S. Neidhardt, F. Emrich, K. Klaeske, K. Jawad, S. Lehmann, A. Meyer, M. Borger, J. Garbade. Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany

(820) IVC Assessment by Ultrasound in Acute and Ambulatory Heart Failure Patients Predictive of Mortality and Readmissions: A Systematic Review; T. Rahman, O. Sheyin, R. Bagur, S. Smith, S. De, R. Davey, R. M. McKelvie. Cardiology, University of Western Ontario, London, ON, Canada

(821) The Impact of Hospital Teaching Status on Inpatient Outcomes of Acute Heart Failure Patients in the United States; A. Albaeni1, M. Sharma1, S. Raslan2, G. A. Al-Dossari3, K. Chatlai2, W. I. Khalife2. 1Medicine, Heart Failure and Transplant, Univ of Texas Medical Branch, Galveston, TX, 2Medicine, Cardiovascular Medicine, Univ of Texas Medical Branch, Galveston, TX, 3Cardiovascular and Thoracic Surgery, Univ of Texas Medical Branch, Galveston, TX

HEART TRANSPLANTATION
(Muses)

Poster Discussants: Amal Alotaibi (USA), David Baran (USA), Lavanya Bellumkonda (USA), Alejandro Bertolotti (Argentina), Agnieszka Ciarka (Belgium), Maria Crespo-Leiro (Spain), Sung-Ho Jung (South Korea), Karl Lemstrom (Finland), Marco Masetti (Italy), Ravi Kumar Ratnagiri (India), Marian Urban (United Kingdom), Rajamyer Venkateswaran (United Kingdom), Andrae Wasler (Austria)
(822) Donor-recipient Ethnic Matching Impacts Short and Long-term Results of Heart Transplantation; Y. Peled1, R. Loewenthal1, E. Raichlin2, I. Gueta1, A. Younis2, Y. Kassif1, Y. Har-Zahav1, E. Nachum1, D. Freimark1, I. Goldenberg1, J. Lavee1. 1Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, 2Loyola University Medical Center, Maywood, IL

(823) Recurrent Acute Cellular Rejection Graded ISHLT 1R Early After Heart Transplantation Negatively Affects Long-term Outcomes; Y. Peled1, E. Raichlin2, I. Gueta1, I. Mazin1, Y. Kassif1, Y. Har-Zahav1, E. Nachum1, D. Freimark1, I. Goldenberg1, J. Lavee1. 1Sheba Med Ctr Tel Hashomer, Ramat Gan, Israel, 2Loyola Univ Med Ctr, Maywood, IL

(824) Improved Long Term Outcomes after Heart Transplantation Utilizing Donors with Traumatic Mode of Brain Death; Y. Peled1, Y. Kassif1, E. Raichlin2, A. Kogan1, Y. Har-Zahav1, E. Nachum1, D. Freimark1, J. Lavee1. 1Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel, 2Loyola University Medical Center, Maywood, IL

(825) The Role of Loss-of-Function Mutations on Development of Rejection After Heart Transplantation; J. van Setten1, N. de Jonge1, B. S. Cole2, B. Chang3, M. V. Holmes2, C. C. Baan3, O. C. Manintveld2, A. M. Peeters3, F. Dominguez4, K. K. Kush5, P. Garcia-Pavia4, J. W. Rossano2, R. A. de Weger1, J. H. Moore2, B. Keating2, F. W. Asselbergs1. 1Univ Medical Center Utrecht, Utrecht, Netherlands, 2Univ of Pennsylvania, Philadelphia, PA, 3Erasmus MC, Rotterdam, Netherlands, 4Puerta de Hierro Univ Hospital, Madrid, Spain, 5Stanford Univ, Stanford, CA

(826) Donor-derived Cell-free DNA Investigated by Digital PCR After Targeted Pre-Amplification: A Prospective Clinical Study of Heart-transplant Patients; J. Boehmer1, A. Ricksten2, K. Karason2, D. Andersson4, A. Stalberg1, H. Wahlander1, J. Asp2, C. Wasslavl2, J. Sunnegardh1, G. Dellgren5, 1Pediatric Cardiology, The Queen Silvia Children's Hospital, Gothenburg, Sweden, 2Gene Analysis, Laboratory for Clinical Chemistry, Gothenburg, Sweden, 3Dept of Cardiology, Sahlgrenska Univ Hospital, Gothenburg, Sweden, 4Sahlgrenska Cancer Center, Dept of Pathology, Gothenburg, Sweden, 5Transplant Institute, Sahlgrenska Univ Hospital, Gothenburg, Sweden

(827) Ways of Optimizing the Estimation of Results of Endomyocardial Biopsy in the Rejection of the Heart Transplant; T. V. Stavenchuk1, E. D. Kosmachova4, I. A. Shelestova3, A. A. Slavinsky4, E. A. Terman5, A. A. Verevkina6, K. O. Barbuhaty7,8,9, V. A. Porhanova10, 1Ultrasound Diagnostic, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, 2Therapy Dept № 1 FQI and PST "Kuban State medical university", Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, 3cardiology and cardiosurgery FQI and PST "Kuban state medical university", Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, 4Pathological anatomy, Kuban State Medical University, Krasnodar, Russian Federation, 5Pathomorphology Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, 6Pathological anatomy, Kuban State Medical Akademy, Krasnodar, Russian Federation, 7Cardiosurgery Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, 8Pathological anatomy, Kuban State Medical Akademy, Krasnodar, Russian Federation, 9Pathological anatomy, Kuban State Medical Akademy, Krasnodar, Russian Federation, 10Thoracic Surgery Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation

(828) De Novo DonorSpecific Antibodies as a Risk Marker for Early Antibody Mediated Rejection; D. B. Letchford, S. M. Offen, N. Watson, P. Jain, A. Jabbour, A. Keogh, E. Koltyar, C. S. Hayward, K. Muthiah, P. MacDonald. Heart failure / transplant, St Vincent’s Hospital, Darlinghurst, Australia


(830) Elevated Red Cell Distribution Width is Associated with Increased Incidence of Late Allograft Rejection after Heart Transplantation; G. Pogljajen, A. Cear, S. Frljak, G. Zemljic, M. Jaklic, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia

(831) Safety and Efficacy of Extended Release Tacrolimus After Heart Transplantation; G. Pogljajen, S. Frljak, A. Cear, G. Zemljic, R. Okrajsek, M. Šebeštjen, V. Andročec, M. Jaklic, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia
(832) Recipient Age and Acute Cellular Rejection - Implications for Targeted Surveillance After Heart Transplantation: V. Jernyd1, J. Wohlfahrt1, J. Ede1, G. J. Smith2, I. Haugen Lofman2, B. Andersson2, J. Nilsson1. 1Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 2Clinical Sciences Lund, Cardiology, Lund University and Skane University Hospital, Lund, Sweden, 3Medicine, Section of Cardiology, Huddinge, Karolinska Institutet, Karolinska Universitetssjukhuset, Stockholm, Sweden, 4Surgery, Lund University and Skane University Hospital, Lund, Sweden

(833) Long Term Graft Survival and Immediate Post-Operative Complications Between Patients with Ischemic and Idiopathic Dilated Cardiomyopathy Undergoing Cardiac Transplantation; A. K. OKOH, D. Chauhan, M. Schultheis, R. Karanam, C. Gidea, M. Camacho, M. Zucker, M. Russo. RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ

(834) The Use of Cardiac MRI to Detect Myocardial Fibrosis and Development of Restrictive Cardiac Physiology After HTx; D. Leong, J. Patel, B. Tamarappoo, L. Thomson, M. Kittleson, L. Czer, R. Levine, S. Dimbili, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA


(837) Post-Transplant Outcomes of Patients Initially Receiving Left Ventricular Assist Device as Either Bridge to Candidacy or Destination Therapy; J. Han1, M. Ando1, A. R. Garan2, M. Farr2, P. C. Colombo2, H. Takayama1, Y. Naka1, K. Takeda1. 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Division of Cardiology, Columbia University Medical Center, New York, NY

(838) Survival in Women after Heart Transplant: Do We Really Know How They Perform?; A. E. Morgan1, E. Dewey1, J. Mudd2, J. Gelow2, J. Davis2, H. K. Song3, F. A. Tibayan3, C. M. Bhamidipati3. 1Surgery, OHSU, Portland, OR, 2Cardiology, OHSU, Portland, OR, 3Cardiac Surgery, OHSU, Portland, OR

(839) Prognostic Value of Invasive Resting and Exercise Hemodynamics in Long-term Heart-transplanted Patients; T. S. Clemmensen, H. Eiskjær, B. B. Logstrup, S. H. Poulsen. Dept of Cardiology, Aarhus University Hospital, Aarhus, Denmark

(840) Myocardial Perfusion and the Relation to Central Hemodynamics in the Acute Phase After Heart Transplantation; T. S. Clemmensen1, S. H. Poulsen1, B. B. Logstrup1, L. P. Torbod2, H. J. Harms2, J. Frökiær2, H. Eiskjær1. 1Dept of Cardiology, Aarhus University Hospital, Aarhus, Denmark, 2Dept of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, Denmark


(842) Characterization of Circulating Donor Heart Specific Exosomes in Clinical Heart Transplantation; L. Korutla1, A. Habertheuer1, R. Hu1, P. Zielinski1, S. Reddy1, A. Naji2, P. VallabhaJosyula1. 1Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

(843) Assessment of Myocardial Strain Using Speckle Tracking Echocardiography Within the First 12 Months After Orthotopic Heart Transplantation; K. Antończyk1, T. Niklewski1, R. Antończyk1, M. Zakliczyński1, M. Zembala1, T. Kukulska1. 1Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Center for Heart Diseases, Zabrze, Poland, 2Dept of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(844) **Salvage ECMO as Bridge to Heart Transplantation - Single Center Experience**; F. Wittmann, J. Riebandt, V. Paspalj, T. Haberl, A. Aliabadi-Zuckermann, G. Lauffer, A. Zuckermann. *Cardiac Surgery, Medical University of Vienna, Vienna, Austria*

1Baylor University Medical Center, Dallas, TX, 2Barnes Jewish Hospital, St. Louis, MO, 3Tampa General Hospital, Tampa, FL, 4Aurora St. Luke’s Medical Center, Milwaukee, WI, 5St. Luke’s - Mid-America Heart Institute, Kansas City, MO, 6CareDx, Inc, Brisbane, CA, 7Cedars-Sinai Medical Center, Los Angeles, CA

(846) **WITHDRAWN**


(848) **Contribution of Individual Genes to Longitudinal Variation of Gene Expression Profile Scores**; E. C. DePasquale1, M. Cadeiras1, D. Hiller2, R. N. Woodward2, M. Crespo-Leiro3, M. C. Deng1. 1UCLA, Los Angeles, CA, 2CareDx, Brisbane, CA, 3Hospital Universitario de A Coruña, La Coruña, Spain

(849) **Recipient Working Status is Independently Associated with Outcomes in Heart Transplantation**; A. Lyengar1, M. Caceres Polo2, B. Sowell2, O. Kwon2, E. Adams1, L. Reardon2, A. Ardehali2, E. DePasquale2. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2University of California - Los Angeles, Los Angeles, CA, 3Wake Forest University School of Medicine, Winston-Salem, NC

(850) **Higher Frequency of Surveillance Endomyocardial Biopsies not Associated with Improved Survival After Heart Transplantation: A 10-Year, Single-Center Experience in Thailand**; S. Sinphurmsukskul1, P. Ongharit2, S. Siwamogsatham1, S. Puwanant1, V. Benjacholamas2, A. Ariyachaipanich1. 1Division of Cardiovascular Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, 2Cardiovascular and Thoracic Surgery Dept, King Chulalongkorn Memorial Hospital, Bangkok, Thailand


(852) **Clinical Characteristics of Sleep Apnea Syndrome in Heart Transplant Recipients**; A. Afzal1, K. Tecson2, A. Jamil3, J. Feliac4, H. Qin5, P. Garcha1, S. A. Hall1, S. A. Carey1. 1Center for Advanced Heart and Lung Disease, Baylor Univ Medical Center, Dallas, TX, 2Baylor Heart and Vascular Inst, Baylor Scott and White Research Inst, Dallas, TX, 3Annette C. and Harold C. Simmons Transplant Inst, Baylor Scott and White Research Inst, Dallas, TX

(853) **Model for End-Stage Liver Disease (MELD) Stratification Identifies Two Distinct Cohorts of Arrhythmogenic Right Ventricular Cardiomyopathy Patients Undergoing Transplantation**; N. Reza1, N. Mahmud2, M. Molina3, R. McLean1, L. R. Goldberg1, M. A. Acker3, C. Bermudez4, A. Owens3. 1Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

(854) **Endocri prophile of Heart Transplant Recipients in an Early Post-transplant Period**; M. Jensterle1, M. Rakusa2, G. Poglagen3, A. Janez1, B. Vrtovec1. 1Dept of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Dept of Endocrinology and Diabetology, University Medical Centre Maribor, Maribor, Slovenia, 3Advanced Heart Failure and Transplantation Programme, Dept of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

(855) **Low AlloMap Ordinal and Variability Scores Are Associated with Increased Malignancy Post Heart Transplant**; v. cotarlan1, J. Franzwa2, C. Laxson2, R. Chawla3, Y. Nabeep1, F. Johnson2. 1University of Cincinnati, Cincinnati, OH, 2University of Iowa, Iowa City, IA, 3University of Iowa, Cincinnati, OH

(856) **Low AlloMap Variability Score Within the First 3 Years Post Heart Transplant is Associated with the Combined Endpoint of Death, Malignancy and Coronary Vasculopathy Post Heart Transplant**; V. Crotarlan1, C. Laxson2, J. Franzwa2, R. Chawla3, F. Johnson2. 1University of Cincinnati, Cincinnati, OH, 2University of Iowa, Iowa City, IA, 3University of Iowa, Iowa City, OH

(858) **Evaluating the Impact of Gene Expression Profiling on Tricuspid Regurgitation in Cardiac Transplant Patients:** N. Mehta¹, S. Mendelsohn², P. Sharedalal³, H. Eisen⁴. ¹Cardiovascular Diseases, Drexel University College of Medicine, Philadelphia, PA, ²Internal Medicine, Drexel University College of Medicine, Philadelphia, PA

(859) **Risk Factors Associated with Sensitization and Its Correlation with Outcome in Korean Heart Transplantation Patients:** G. Oh¹, H. Cho¹, S. Kang², E. Jeon³, J. Kim⁴, H. Lee⁴. ¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Severance Hospital, Seoul, Korea, Republic of, ³Samsung Medical Center, Seoul, Korea, Republic of, ⁴Asan Medical Center, Seoul, Korea, Republic of

(860) **Donor Mechanism of Death (MOD) and Interstitial Fibrin (INTFIB) as Predictors of Outcome After Heart Transplantation:** E. H. Hammond¹, M. P. Revele², D. V. Miller³, G. L. Snow⁴, J. Stehlik⁵, K. M. Molina⁶, R. A. Alharethi⁷, C. H. Selzman⁸, W. Caine⁹, S. G. Drakos⁹, K. Afshar¹⁰, C. Zollinger¹⁰, A. G. Kfoury¹⁰. ¹Intermountain Healthcare and University of Utah, Salt Lake City, UT, ²Pathology, University of Utah Medical Center, Salt Lake City, UT, ³Pathology, Intermountain Medical Center, Salt Lake City, UT, ⁴Statistical Data Center, Intermountain Medical Center, Salt Lake City, UT, ⁵Cardiology, University of Utah Medical Center, Salt Lake City, UT, ⁶Cardiology, Primary Childrens Medical Center, Salt Lake City, UT, ⁷Cardiology, Intermountain Medical Center, Salt Lake City, UT, ⁸Cardiovascular Surgery, University of Utah Medical School, Salt Lake City, UT, ⁹Cardiovascular Surgery, Intermountain Medical Center, Salt Lake City, UT, ¹⁰Intermountain Donor Services, Salt Lake City, UT

(861) **Donor Heart Selection: The Outcome of Cardiac Graft Received After at Least 6 Declines by a Candidate on Medical Grounds: A Single-Center Experience:** N. Fukushima¹, M. Yanase¹, O. Seguchi¹, T. Fujita², S. Fukushima², K. Kuroda¹, Y. Kumaï¹, J. Kobayashi¹. ¹Dept of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, ²Dept of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan

(862) **Time Dependent Changes in Thyroid Hormone Levels During Donor Management:** A. B. Van Bakel¹, S. A. Moore², D. Welker², M. R. Stroud³, M. L. Craig³, A. J. Crumbley³, R. M. Sade³. ¹Medicine/Cardiology, Med Univ of South Carolina, Charleston, SC, ²We Are Sharing Hope SC, Charleston, SC, ³Surgery/CT Surgery, Med Univ of South Carolina, Charleston, SC

(863) **Promoted to Mini Oral**

(864) **Too Big to Fail: Using Obese Donors for Heart Transplantation:** N. Rajagopalan, A. E. Shafii, M. E. Sekela. University of Kentucky, Lexington, KY

(865) **Gender Mismatch with Female Donor Hearts to Male Recipients: A Single Center Analysis:** N. Rajagopalan, A. E. Shafii, M. E. Sekela. University of Kentucky, Lexington, KY

(866) **Increased Use of Multi-organ Transplantation in Heart Transplantation–Time Will Tell:** C. Lui, C. D. Fraser III, X. Zhou, A. Suarez-Pierre, J. C. Grimm, R. S. Higgins, K. J. Zehr, A. Kilic. Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD

(867) **Biomarkers and Donor Selection in Heart Transplantation:** A. Vorlat¹, N. Dehou¹, A. Vervaecke¹, V. Van Hoof², I. Rodriguez³, T. Vermeulen¹, E. Van Craenenbroeck¹, H. Heidbuchel¹, L. Van Aelst⁴, A. Ancion⁵, M. Claeyss⁶. ¹Cardiology, University Hospital of Antwerp, Edegem, Belgium, ²Clinical Biology, University Hospital of Antwerp, Edegem, Belgium, ³Cardiac Surgery, University Hospital of Antwerp, Edegem, Belgium, ⁴Cardiology, University Hospital of Leuven, Leuven, Belgium, ⁵Cardiology, University Hospital Sart Tilman, Liege, Belgium


(869) **Protocol Development for DCD Heart Transplantation:** J. W. Smith¹, D. Helterline², A. Stempien-Otero³. ¹Cardiothoracic Surgery, University of Washington, Seattle, WA, ²Division of Cardiology, University of Washington, Seattle, WA, ³Cardiology, University of Washington, Seattle, WA

(871) Variability in Donor Heart Acceptance Across the United States; K. Khush, R. Ball. Stanford University, Stanford, CA

(872) Potential Transplant Recipient Sequence Numbers Do Not Correlate with Worse Patient Outcomes; C. W. Chen1, J. J. Chung1, M. Daniel1, C. Pietras1, C. Bermudez1, R. McLean2, M. Acker1, P. Atluri1. 1Dept of Surgery, University of Pennsylvania, Philadelphia, PA, 2Dept of Medicine, University of Pennsylvania, Philadelphia, PA

(873) Analyzing Geographic Disparities in the US Heart Allocation System: A. Rivard1, F. Karami2, M. Gentili2, M. Nayebpour3, N. Koizumi3. 1Dept of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates, 2Industrial Engineering, University of Louisville, Louisville, KY, 3Schar School of Policy and Government, George Mason University, Arlington, VA

(874) A Randomized Comparison of T3 vs. T4 for Management of Hemodynamically Unstable Brain-dead Organ Donors: R. Dhar1, G. Marklin2. 1Neurology, Washington University in St. Louis School of Medicine, St Louis, MO, 2Mid-America Transplant, St Louis, MO

(875) New Heart Allocation System to Rescue the Patients With Severe Biventricular Failure: S. Saito, K. Toda, S. Miyagawa, Y. Yoshikawa, H. Hata, K. Domae, R. Matsuura, T. Ueno, T. Kuratani, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan


(878) Longer Waitlist Time Places Blood Group O Patients at Greater Risk of Experiencing a Major CF LVAD Related Complication; O. Saeed1, S. Cohen1, E. Borukhov1, S. Madan1, S. Rangasamy1, S. R. Patel1, J. Shin1, D. B. Sims1, D. J. Goldstein2, U. P. Jorde1. 1Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, 2Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY


(880) Heart Transplantation from Donors with Low Left Ventricle Systolic Function: V. N. Poptsov, N. Koloskova, E. Spirina, V. Zacharevich, A. Dogonascheva, V. Chatutskij. Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Russian Federation


(882) Influence of Donor Sex and Mechanism of Death on Cardiac Transplant Recipient Early pAMR Incidence and Cardiovascular Death; M. B. Hammond1, A. Vedic2, G. L. Snow3, C. Zollinger4, R. A. Alharethi5, K. M. Molina6, J. Stehlik7, C. H. Selzman8, B. B. Reid9, S. G. Drakos10, A. G. Kloufy11, E. H. Hammond11. 1Waterford High School, Salt Lake City, UT, 2Cardiology, Florida Hospital, Orlando, FL, 3Statistical Data Center, Intermountain Medical Center, Salt Lake City, UT, 4Intermountain Donor Services, Salt Lake City, UT, 5Cardiology, Intermountain Medical Center, Salt Lake City, UT, 6Cardiology, Primary Childrens Medical Center, Salt Lake City, UT, 7Cardiology, University of Utah Medical Center, Salt Lake City, UT, 8Cardiovascular Surgery, University of Utah Medical Center, Salt Lake City, UT, 9Cardiovascular Surgery, Waterford High School, Salt Lake City, UT, 10Cardiology, University of Utah School of Medicine, Salt Lake City, UT, 11Intermountain Healthcare and University of Utah, Salt Lake City, UT
(883) Kinetics of Regulatory CD4 T Cells in Heart Recipients Under Induction Therapy With One-single Dose versus Two-dose Basiliximab; S. Garcia1, J. Carbone1, I. Sousa2, A. Karinina2, E. Zatarain2, P. Navas2, A. Gallego1, L. Calahorra1, R. Lerma1, E. Sarmiento1. 1Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

(884) Predictors of Early and Late Mortality after Heart Transplantation in Patients Bridged with the Total Artificial Heart; E. J. Sawey1, J. T. Owens1, I. Tchoukina1, R. H. Cooke1, M. A. Quader2, R. R. Markley3, M. C. Smallfield1, D. G. Tang2, K. Desai2, K. K. Rao1, M. P. Flattery1, P. A. Usher1, V. Kasirajan2, K. B. Shah1. 1Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 2Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 3Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

(885) Cardiac Allograft Survival Stratified by Preservation Solution: A Multi-Institutional Analysis; C. Pietras1, A. Thomasson2, J. Gordon3, C. Chen1, J. Chung1, R. McLean2, M. Acker1, P. Atur1. 1Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 2Division of Cardiovascular Surgery, University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA

(886) PROMOTED TO MINI ORAL

(887) Salvage of Severe Primary Graft Dysfunction Following Cardiac Transplantation with Extracorporeal Life Support; S. Jacob1, B. Lima2, G. V. Gonzalez-Stawinski2, P. Patel3, E. V. Belli4, M. M. El-Sayed Ahmed1, I. A. Makey1, M. Thomas1, K. Landolfo1, J. Leoni-Moreno3, D. Yip5, S. M. Pham1. 1Cardio-thoracic Surgery, Mayo Clinic, Jacksonville, FL, 2Cardio-thoracic Surgery, Baylor University Medical Center, Dallas, TX, 3Transplant, Mayo Clinic, Jacksonville, FL

(888) Extra Corporeal Membrane Oxygenation (ECMO) for Primary Graft Dysfunction Following Heart Transplantation: A Single Centre Experience; V. Mehta1, J. Hasan1, P. Callan2, S. Shaw2, S. Williams2, I. Dimarakis1, J. Barnard1, R. Venkateswaran1. 1Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2Cardiology, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 3Director of Transplantation, Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(889) Heterotopic Cardiac Transplantation: Time for Another Look?; G. V. Letso1, F. Musfee1, F. H. Cheema1, A. Lee2, G. Loo1, J. Morgan1, T. Rosengart1, O. H. Frazier1. 1Surgery, Baylor College of Med, Houston, TX, 2Baylor College of Med, Houston, TX


(892) Donor Right Ventricular Stroke Work Index (RVSWI) is a Poor Predictor of Primary Graft Dysfunction (PGD) After Heart Transplantation; S. Das De1, S. Avtaar Singh1, J. Dalzell2, H. Doshi3, P. Curry2, N. Al-Attar2, S. Nair2. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(893) Does a Redo Heart Transplant Decrease the Chance for Primary Graft Dysfunction?; R. Levine1, J. Patel1, M. Kittleson1, L. Czer1, D. Chang1, E. Kransdorf1, S. Dimbil2, B. Kearney1, D. Ramzy1, F. Esmailian1, J. A. Kobashigawa1. 1Cedars-Sinai Heart Institute, Los Angeles, CA, 2Cedars-Sinai Heart Institute, Beverly Hills, CA

(894) Is Depression After Heart Transplantation HTX) Associated With Impaired Survival During Long-term Follow-up?; B. S. Bürker1, L. Gullestad1, E. Gude2, O. E. Havik3, I. Grov2, A. Relbo Authen2, A. K. Andreassen2, I. R. Hebold Haraldsen2, A. E. Fiane1, M. A. Dew4, S. Andersson5, U. F. Malt1. 1University of Oslo and Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3University of Bergen, Bergen, Norway, 4University of Pittsburgh School of Medicine, Pittsburgh, PA, 5University of Oslo, Oslo, Norway

(896) Relationship Between Patient-Perceived Treatment Burden and Health-Related Quality of Life in Heart Transplant Recipients: K. M. Deininger¹, J. D. Hirsch², S. A. Graveline², A. Feist², S. M. Smith³, J. A. Reich⁴, J. LaFleur⁵, A. V. Ambardekar⁶, J. Lindenfeld⁷, C. L. Aquilante¹. ¹Dept of Pharmaceutical Sciences, University of Colorado, Aurora, CO, ²Division of Clinical Pharmacy, University of California San Diego, La Jolla, CA, ³Dept of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, ⁴Dept of Sociology, University of Colorado, Denver, CO, ⁵Dept of Pharmacotherapy, University of Utah, Salt Lake City, UT, ⁶Division of Cardiology, University of Colorado, Aurora, CO, ⁷Advanced Heart Failure and Cardiac Transplant Program, Vanderbilt University, Nashville, TN

(897) Outcomes of Heart Transplant Recipients with LVAD Implantation as Destination Therapy versus Bridge to Transplantation: K. Ahmad¹, P. Combs², J. Munro³, K. Meehan³, K. Jennings⁴, C. Kabir⁵, G. Macaluso¹, S. Pauwaa¹, G. Bhat², A. Tatoles³, P. Pappas³, A. Andrade², W. Cotts³. ¹UIC/ Advocate Christ Medical Center, Chicago, IL, ²Advocate Christ Medical Center, Chicago, IL


(899) Burden and Consequences of Retained Cardiovascular Implantable Electronic Device Lead Fragments After Heart Transplantation: P. Alvarez¹, B. W. Sperry², A. L. Perez², M. Tong², A. A. Hussein², D. O. Taylor². ¹University of Iowa, Iowa City, IA, ²Cleveland Clinic, Cleveland, OH

(900) Factors Influencing Heart Rate Control After Heart Transplantation: A. H. Christensen¹, S. I. Nygaard¹, K. Rolid², K. Nytnoen², L. Gullestad², A. Fiane³, E. Thaulow¹, G. Dohlen¹, V. B. Wyller². ¹Pediatric Cardiology, Oslo Univ Hospital, Rikshospitalet, Oslo, Norway, ²Cardiology, University of Oslo, Rikshospitalet, Oslo, Norway, ³Thoracic Surgery, Oslo Univ Hospital, Rikshospitalet, Oslo, Norway, ⁴Pediatric Cardiology, Akershus Univ Hospital, Oslo, Norway


(902) Predictors and Outcomes of Readmission After Heart Transplantation: An Analysis of UNOS/OPTN Data From 2000 to 2015: R. C. Givens¹, V. K. Topkara¹, D. Edmondson¹, S. W. Restaino¹, P. C. Colombo¹, F. Latifi¹, D. Jennings¹, Y. Naka², H. Takayama², K. Takeda², M. A. Farr¹. ¹Medicine, Columbia University Medical Center, New York, NY, ²Surgery, Columbia University Medical Center, New York, NY

(903) The Effect of Dual Renin-angiotensin System Blockade Compared to Conventional Antihypertensive Combination on Blood Pressure and Renal Function After Heart Transplantation: A Randomized Controlled Trial: L. Hoskova¹, I. Malek¹, V. Melenovsky¹, J. Kautzner¹, I. Netuka¹, J. Franekova², A. Jabor². ¹Heart Center, IKEM, Prague, Czech Republic, ²Dept of Laboratory Methods, IKEM, Prague, Czech Republic

INFECTIOUS DISEASES

(Gallieni 1-2/Mikonos)

Poster Discussants: Saima Aslam (USA), Orla Morrissey (Australia), Stephanie Pouch (USA), Mace Schuurmans (Switzerland), Amparo Sole (Spain)

(904) High Prevalence of BK Virus in Heart Transplant Patients and Effect on Outcomes: A. Nguyen¹, T. Imamura¹, B. Chung¹, C. Murks¹, J. Powers¹, T. Riley¹, D. Onsager¹, T. Song¹, T. Ota¹, S. Kalantari¹, J. Raikhelkar³, N. Sarswat¹, G. Kim¹, M. Costanzo², U. Jorde¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Advocate Medical Group, Chicago, IL, ³Montefiore Medical Center, New York, NY

(905) Impact of Late Onset CMV Replication After Heart Transplant: L. Ponz de Antonio¹, A. Rodriguez Chaverri¹, M. Garcia Cosio¹, C. Ortiz Bautista², L. Moran Fernandez³, J. de Juan Baguda³, F. Lopez Medrano³, A. Garcia Reynes³, F. Arribas Ynsaurriaga³, J. Delgado Jiménez³. ¹Cardiology, University Hospital Doce de Octubre CIBERCV, Madrid, Spain, ²Cardiology, Hospital Universitario Gregorio Marañon, Madrid, Spain, ³Cardiology, University Hospital Doce de Octubre, Madrid, Spain, ⁴Internal Medicine, University Hospital Doce de Octubre, Madrid, Spain, ⁵Cardiology, University 12 de Octubre CIBERCV, Madrid, Spain
1Hospital Doce de Octubre, CIBERCV, Madrid, Spain, 2Hospital Doce de Octubre, Madrid, Spain, 3University Hospital Doce de Octubre, CIBERCV, Madrid, Spain


(910) Rates of CMV Reactivation in Non Mismatched Heart Transplant Patients; S. Often, D. Letchford, L. Carlos, F. Burrows, A. Jabbour, E. Kotlyar, A. Keogh, C. Hayward, K. Muthiah, P. Macdonald. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia

(911) Measuring EBV in Lung Transplant Patients - Lessons of 16 Years of Follow Up; E. J. Gore1, W. van der Bij2, C. C. Leer1, M. E. Erasmus3, C. Gan4, E. A. Verschuuren5. 1Medical Microbiology and Virology, University Medical Centre Groningen, Groningen, Netherlands, 2Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands, 3Cardiothoracic Surgery, University Medical Centre Groningen, Groningen, Netherlands, 4Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands, 5University Medical Centre Groningen, Groningen, Netherlands

(912) Better Survival Post Lung Transplantation in Cystic Fibrosis Despite Multidrug Antibiotic Resistance in Patients with Previous Achromobacter Colonization; S. Colin de Verdière1, D. Grenet2, S. De Miranda2, C. Picard2, H. Abdul2, M. Stern2, M. Le Guen3, E. Sage4, A. Roux5. 1Pneumology, Adult CF Center and Lung Transplantation, Hôpital Foch, Suresnes, France, 2Pneumology, Adult CF Center and Lung Transplantation, Foch Hospital, Suresnes, France, 3Anaesthesiology, Foch Hospital, Suresnes, France, 4Thoracic Surgery, Foch Hospital, Suresnes, France

(913) Impact of Candida Colonization on Lung Transplantation; J. S. Green1, R. Brown2, T. Umeda3, K. Rudser2, S. Elde4, J. M. Roberts4, M. I. Hertz5, J. H. Young1, R. Tomic5. 1Medicine, Infectious Diseases, University of Minnesota, Minneapolis, MN, 2Division of Biostatistics, University of Minnesota, Minneapolis, MN, 3Medicine, Pulmonary and Critical Care Medicine, University of Minnesota, Minneapolis, MN, 4Medicine, University of Minnesota, Minneapolis, MN

(914) Epidemiology and Risk Factors of Post Operative Pneumonias After Heart Transplantation; C. Vidal, R. Pasqualotto, A. James, A. Bouglé, G. Lebreton, S. Varnous, P. Leprince, J. Amour. Institut de cardiologie, Hôpital Pitié Salpêtrière, Paris, France

(915) Brincidofovir - Finally an Option for PML?; J. A. Schneider, T. A. Arbogast, C. R. Wolfe. Duke University Medical Center, Durham, NC


(918) Impact of Donor Lung Pathogenic Bacteria on Patient Outcomes in the Immediate Post-transplant Period; O. Ahmad, A. Shafii, D. Mannino, R. Choate, M. Baz. University of Kentucky, Lexington, KY

(919) Mucormycosis in Lung Transplant Recipients: A Systematic Review; O. Wand1, A. Unterman1, O. Shtraichman1, S. Izhakian1, L. Fridel2, M. R. Kramer1. 1Pulmonary Medicine, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 2Pathology Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
(920) Lung Transplantation in Cystic Fibrosis Patients Infected With B.Cepacia Complex: A Single Center Experience; N. Nechaev1, S. Golovinskii1, M. Simonova1, S. Krasovskyi2, V. Poptsov1, S. Gautier1. 1Federal State Budgetary Institution “Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs”, Ministry of Health of the Russian Federation, Moscow, Russian Federation, 2Federal State Budgetary Institution "Research Institution of Pulmonology" Federal Medical and Biological Agency of the Russian Federation, Moscow, Russian Federation

(921) Ureaplasma spp. and Mycoplasma hominis PCR in Respiratory Samples from Lung Transplant Recipients with Hyperammonemia Syndrome and Cerebral Edema; G. Aguilar1, W. Gohri1, J. Tikkanen2, L. Del Sorbo3, C. Chaparro2, T. Mazzulli4, A. Humar1, D. Kumar1, M. Cypek2, L. G. Singer2, S. Keshavjee2, S. Husain1. 1Transplant Infectious Diseases, Univ Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, Univ Health Network, Toronto, ON, Canada, 3Interdepartmental Division of Critical Care Medicine, Univ Health Network, Toronto, ON, Canada, 4Dept of Laboratory Medicine & Pathobiology, Mount Sinai Hospital/ Univ Health Network, Toronto, ON, Canada

(922) The Role of Infections in the Development of de Novo Donor-Specific Antibodies after Lung Transplantation; Y. Verplancke1, S. Husain2, K. Tinckham3, L. Singer4, S. Keshavjee4, J. Tikkanen5. 1Toronto General Hospital, Toronto, ON, Canada, 2Transplant Infectious Disease, Toronto General Hospital, Toronto, ON, Canada, 3Medicine/Nephrology, Toronto General Hospital, Toronto, ON, Canada, 4Lung transplantation, Toronto General Hospital, Toronto, ON, Canada, 5Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada

(923) Efficacy of Ribavirin in the Treatment of Respiratory Syncytial Virus Infections in Lung-Transplant Recipients; D. Voet1, J. M. Kwakkel-van Erp2, H. D. Luijk3, E. A. van de Graaf3, F. M. Verduyn Lunel1. 1Dept. of Medical Microbiology, Utrecht University Medical Center, Utrecht, Netherlands, 2Dept. of Pulmonology, Utrecht University Medical Center, Utrecht, Netherlands

(924) The Role of Gallium Scans in the Diagnosis of Clinically Suspected Left Ventricular Assist Device Infections in Western Australia; M. Asokendaran1, Z. AL-Ogaili1, F. Njue2, J. Barber2, H. Hayes2, K. Lam2. 1Nuclear Medicine Dept, Fiona Stanley Hospital, Perth, Australia, 2Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Perth, Australia

(925) Incidence and Impact of Severe LVAD-related Infections Requiring Surgical Treatment in Obesity Patients on Long-term HeartMate II and HeartWare Support; C. Kurihara1, M. Kawabori1, A. Critsinelis1, T. Sugiura1, A. B. Civitello1, L. Simpson1, J. K. George1, R. M. Delgado2, A. P. Nair1, G. Loor1, T. K. Rosengart1, O. H. Frazier2, J. A. Morgan. Texas Heart Institute/ Baylor College of Medicine, Texas Heart Institute/ Baylor College of Medicine, Houston, TX

(926) Comparative Infection Related Outcomes Between Recipients of an Axial Continuous-flow and an Intraoperative Centrifugal Continuous-flow Left Ventricular Assist Device: A Single Center Experience; J. Rind1, A. Faisal1, J. de Sanctis2, S. Lee3, R. Lampen4, P. Egele5. 1Internal Medicine, Spectrum Health/Michigan State University Internal Medicine Residency, Grand Rapids, MI, 2Infectious Disease, Spectrum Health Medical Group Division of Infectious Disease, Grand Rapids, MI, 3Advanced Heart Failure Cardiology, Spectrum Health Medical Group Advanced Heart Failure Cardiology, Grand Rapids, MI, 4Infectious Disease, Spectrum Health Medical Group Division of Infectious Disease, Grand Rapids, MI, 5Biositistics, Spectrum Health Bioinformatics Core, Grand Rapids, MI

(927) Conservative Treatment of Driveline Infections: A Single Centre Experience; A. Giacomini1, T. Nisi1, E. Lapenna1, F. Pappalardo1, M. Calabrese1, O. Forma1, A. Castiglioni1, O. Alfieri1, M. De Bonis1. 1Cardio-Thoracic and Vascular Surgery, San Raffaele Scientific Institute, Milan, Italy, 2Cardiovascular Anesthesia and Intensive Care, San Raffaele Scientific Institute, Milan, Italy, 3Wound Care Unit, San Raffaele Scientific Institute, Milan, Italy

(928) Infection Predisposes to Thrombosis During Long Term VAD Support; J. Castrodeza1, O. Gonzalez2, A. Woods2, D. Dobarro1, M. Urban2, N. Robinson-Smith2, S. Tovey2, A. Koshy3, D. Jakovljevic4, J. Samuel5, J. Jungschleger2, M. Carrasco-Moraleja1, G. Parry5, S. Schueler2, G. MacGowan5. 1Cardiology, Hospital Clinico Universitario Valladolid, Valladolid, Spain, 2Cardiothoracic Services, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 3Academic Fellow, Newcastle University, Newcastle Upon Tyne, United Kingdom, 4Senior Lecturer, Newcastle University, Newcastle Upon Tyne, United Kingdom, 5Microbiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 6Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(929) Incidence and Management of Device-related Infections With the Jarvik 2000 Axial Flow Pump; M. Gaillard1, E. M. Fletcher2, R. Ramadan1, A. Azmoun1, Y. Lepers1, C. Chabanne2, R. Nottin1, A. Anselmi2, P. Deleuze1, J. Guihaire1. 1Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, 2Thoracic and Cardiovascular Surgery, Pochtaillou Hospital, University of Rennes 1, Rennes, France
(930) Favorable Outcomes With Ventricular Assist Device Exchange for Refractory Infections: M. M. Carroll1, M. Bochan2, C. Salerno3, A. Ravichandran3. 1Indiana University School of Medicine, Evansville, IN, 2Infectious Disease of Indiana and St. Vincent Hospital, Indianapolis, IN, 3St. Vincent Heart Center, Indianapolis, IN


(932) Cytomegalovirus (CMV) Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis: G. Nance1, A. Serluco1, S. R. Deshpande2, R. Garro3, R. P. George3, M. S. Kellem4, R. Liverman5. 1Children's Healthcare of Atlanta, Atlanta, GA, 2Pediatric Cardiology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, 3Pediatric Nephrology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, 4Emory University, Atlanta, GA

JUNIOR FACULTY CLINICAL CASE REPORTS (Agora 3)

Poster Discussants: Dipanjan Banerjee (USA), Gerard Boyle (USA), Jennifer Conway (Canada), Sitaramesh Emami (USA), Feras Khalilieh (Saudi Arabia), Ashwin Ravichandran (USA), Elena Sandoval (Spain), Stephan Schub (Germany), Palak Shah (USA), Aleem Siddique (USA), Thenappan Thenappan (USA)


(1366) Successful LVAD Implantation in a Patient With Hemophilia A: A Case Report and Literature Review: S. Adhikari1, G. Murtaza1, W. G. Cotts2, G. Gavrilos3, P. S. Pappas1, A. Taooles4, A. A. Andrade1. 1University of Illinois at Chicago-Advocate Christ Medical Center, Oak Lawn, IL, 2Advocate Christ Medical Center, Oak Lawn, IL

(1367) Pumpless Extracorporeal Lung Assist as a Bridge to Medical Therapy in a Teenager With Severe Pulmonary Arterial Hypertension and Partial Anomalous Pulmonary Venous Return: S. Hascoet1, A. Boet1, L. Savale2, O. Sitbon2, X. Jais2, M. Humbert2, O. Mercier3, L. Houyel1, J. Horer1, E. Fadel3. 1Congenital Heart Diseases, Hopital Marie Lannelongue, Plessis-Robinson, France, 2Pulmonary Hypertension, Hopital Kremlin Bicetre, Kremlin Bicetre, France, 3Thoracic Surgery, Hopital Marie Lannelongue, Plessis-Robinson, France


(1369) Durable Biventricular Assist Device in a Transplanted Heart: E. Oliveros1, T. Suboc1, R. Paliga2, A. Tatooles2, S. Pauwa2, G. Macaluso2, D. Muhayddeen2, P. Pappas2, I. Balanlayos2, K. Ahmad2, G. Bhat2, A. Andrade3, W. Cotts2. 1Rush University Medical Center, Chicago, IL, 2Advocate Christ Medical Center, Chicago, IL

(1370) Bridge-to-Candidacy With Concomitant Total Artificial Heart and Pulmonary Thromboendarterectomy: A. Mohammed, D. Joyce, N. Gaglianello, D. Ishizawar, G. Dagar, K. Presberg, M. Saltzberg, L. Joyce. Med College of Wisconsin, Milwaukee, WI

(1371) Continuous Flow LVAD Implantation in Patients With Marfan's Syndrome: A. Critsinelis1, M. Kim1, C. Kurihara1, H. Lamba1, F. H. Cheema1, M. Kawabori1, T. Sugiyama1, R. Delgado1, L. Simpson2, J. George2, A. Nair2, A. Civitello2, T. Rosengart3, O. H. Frazier4, J. Morgan5. 1Division of Cardiothoracic Transplantation and Circulatory Support, Baylor College of Medicine, Houston, TX, 2Division of Cardiology, Baylor College of Medicine, Houston, TX, 3Department of Surgery, Baylor College of Medicine, Houston, TX

Poster Session 2 – Thursday, April 12 Infectious Diseases / Junior Faculty Clinical Case Reports
(1375) **Minimally Invasive HeartMate 3™ LVAD Implantation in Redo Cases on Impella CP Support**: R. Antończyk, K. Antończyk, K. Filipiak, J. Waszak, I. Copik, P. Przybyłowski, M. Zakliczyński, M. Zembala, M. O. Zembala. Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, SMDZ in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, Zabrze, Poland

(1376) **Acute Pump Failure of Jarvik 2000 LVAD With Development of Cardiogenic Shock Requiring LVAD Exchange - A Novel Approach**; K. A. Sell-Dottin¹, B. Haithcock². ¹Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, ²Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC

(1377) **Pump Washout Procedure in a Child With Centrifugal-Flow Ventricular Assist Device Support**; S. Choudhry, A. Liou, A. Jeewa, B. A. Elias, I. Adachi. Texas Children's Hospital, Baylor College of Medicine, Houston, TX

(1378) **Concomitant Surgical Cryoablation for Refractory Ventricular Tachycardia During Left Ventricular Assist Device Implantation for Ischemic Cardiomyopathy**; G. Sunagawa, M. Mitchell, A. Basil, S. Brann, S. Keshavamurthy, J. Gomez-Abraham, M. Kashem, N. Shigemura, K. Minakata, Y. Toyoda. Temple Heart and Vascular Institute, Temple University Hospital, Philadelphia, PA

(1379) WITHDRAWN

(1380) **Refractory Traumatic Bronchopleural Fistula: Is Extracorporeal Membrane Oxygenation the New Gold Standard?**; A. A. Grant¹, V. J. Hart², E. B. Lineen², A. Patel³, A. Badiye⁴, M. Loeba⁴, A. Ghodsizad⁵. ¹Dept of Surgery, Jackson Health System, Miami, FL, ²Dept of Surgery, University of Miami, Miami, FL, ³Dept of Cardiothoracic Surgery, University of Miami, Miami, FL, ⁴Dept of Cardiology, University of Miami, Miami, FL, ⁵Dept of Cardiothoracic Surgery, University of Miami, Miami, FL


(1383) **Implantation of Left Ventricular Assist Device in the Setting of a Heavily Calcified Left Ventricular Apex by Using the Apex Preserving/Telescope/Cerclage Technique (APTC)**; I. A. Salas de Armas, J. A. Patel, M. H. Akay, M. K. Jezovnik, R. Radovancevic, B. Kar, I. D. Gregoric. The University of Texas Health Science Center at Houston, Center for Advanced Heart Failure, Houston, TX

(1384) WITHDRAWN

(1385) **Transcatheter Aortic Valve Replacement as a Bridge to Left Ventricular Device Implantation**; A. Elmously¹, B. Worku¹, S. Wong², A. Salemi¹. ¹Cardiothoracic Surgery, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, ²Cardiology, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY

(1386) **Percutaneous Deactivation of HeartWare VAD in a Patient Presenting with Significant Pump Thrombosis**; A. Albulushi, M. Hyden, J. Delaney. Cardiology, University of Nebraska Medical Center, Omaha, NE

(1387) **Unusual Presentation of Pheochromocytoma in Patient Requiring Ventricular Assist Device Support**; A. Albulushi¹, N. Abdulazim¹, J. Sullivan², D. Stoller¹. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE, ²Anesthesiology, University of Nebraska Medical Center, Omaha, NE


(1389) **Risk of VAD Thrombosis Due to Left Ventricular Recovery**; D. D. Song¹, A. Lucev², S. Stewart², B. Kim². ¹Dept of Medicine, Rutgers New Jersey Medical School, Jersey City, NJ, ²Division of Heart Failure and Pulmonary Hypertension, Hackensack University Medical Center, Hackensack, NJ

(1390) **Management of Patients With Heparin-Induced Thrombocytopenia Scheduled to Receive a Continuous Flow Left Ventricular Assist Device**; S. R. Maffei, H. Lamba, A. Bracey, F. H. Cheema, A. Civitello, R. Delgado, L.
(1391) **Ventricular VADicardias**: C. Rueda1, G. Hernandez1, H. Keshmiri2, K. Patricia3, J. Lindenfeld1, 1Vanderbilt University, Nashville, TN, 2Advocate Illinois Masonic Medical Center, Chicago, IL, 3Montana Heart Center, Missoula, IL

(1392) **Outflow Graft Compression in a Patient With HeartMate II Left Ventricular Assist Device**: P. Pirzamarsla1, V. Rakita1, A. LaLa-Trindade1, S. Pinney1, D. Mancini1, M. Barghash1, M. Trivieri1, A. Anyanwu2, A. Pawale2, N. Moss3, S. S. Mitter1, 1Advanced Heart Failure and Cardiac Transplant, Mount Sinai Hospital, New York, NY, 2Cardiovascular Surgery, Mount Sinai Hospital, New York, NY

(1393) **LVAD Masking a Subclavian-Coronary Steal Syndrome**: A. Addas1, M. Kühl2, J. Fischer1, M. Borger1, J. Garbade1, 1Dept of Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany, 2Dept of Electrophysiology, Leipzig Heart Centre, Leipzig, Germany

(1394) **Recurrent Left Ventricular Assist Device Thromboses**: T. Artzner, T. Hoang Minh, M. Cristinar, S. Marguerite, G. Ajob, J. Mazzucotelli, A. Ruimy, S. Mebaouj, P. Mertes, M. Kindo. Strasbourg University Hospital, Strasbourg, France

(1395) **Successful Heart Transplantation After 1 Year of Continuous Vacuum Assisted Therapy in a Case of Severe BIVAD Infection**: J. Kremer1, U. Tochtermann1, B. Schmack1, A. Ruhipwar1, A. Heininger2, 1Cardiac Surgery, Univ Hospital Heidelberg, Heidelberg, Germany, 2Infectious Diseases, Univ Hospital Heidelberg, Heidelberg, Germany

(1396) **Extracorporeal Membrane Oxygenation in the Management of Tracheal Tears**: J. Tang1, J. Chen2, G. Dincheva2, K. Rajalingam3, J. Kratz2, M. Brzezinski4, J. Kukreja2, 1Chicago Medical School, Rosalind Franklin University, Chicago, IL, 2Surgery, Univ of California, San Francisco, CA, 3Undergraduate, Univ of California, Berkeley, CA, 4Anesthesia, Univ of California, San Francisco, CA

(1397) **Patient With a Left Ventricular Assist Device and Hypertensive Blood Pressure Response to Activity- Role of Invasive Exercise Hemodynamic Assessment**: M. Alhama Belotto, A. Bitar, R. Mohan, J. Heywood, A. Srivastava. Scripps Clinic, San Diego, CA

(1398) **Left Ventricular Assist Device Inflow Cannula Obstruction Without Hemolysis- Two Cases**: K. Mudy, E. Duncanson, T. Knickelbine, J. Lesser, B. Sun, P. Eckman. Abbott Northwestern Hospital, Minneapolis, MN

(1399) **Unusual Cause of Pneumomediastinum in an LVAD Patient**: T. Sugiuira, M. Kawabori, C. Kurihara, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX

(1400) **A Case of Suspected Reversible Cerebral Vasocostriction Syndrome Occurred in a Patient With a Continuous-flow Left Ventricular Assist Device**: T. Fujiio1, H. Deguchi2, T. Higo3, K. Ohtani2, K. Hiasa4, T. Ushijima3, Y. Tanoue3, H. Tsutsu2, A. Shiose3, 1Dept of Advanced Cardiopulmonary Failure, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2Dept of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 3Dept of Cardiovascular Surgery, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

(1401) **“Chronic Ventricular Fibrillation” in a Patient with a Biventricular Assist Device**: B. Koell1, B. Alexander1, S. Blankenberg2, H. Reichspunser1, H. Grahn2, 1Dept of Cardiac Surgery, University Heart Center, Hamburg, Germany, 2Dept of General and Interventional Cardiology, University Heart Center, Hamburg, Germany

(1402) **HeartMate II Implantation Through Mini-Sternotomy in a Low BSA Patient**: T. Ushijima1, Y. Tanoue2, K. Hirayama1, T. Fujiio2, T. Higo3, H. Tsutsu3, A. Shiose3, 1Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan, 2Advanced Cardiopulmonary Failure, Kyushu University Hospital, Fukuoka, Japan, 3Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

(1403) **Cyclophosphamide Myopericarditis: Progression to Cardiac Standstill**: E. K. Zern1, A. J. Coromilas1, N. Mihatov2, J. Mojica3, R. Malhotra2, M. Chung4, B. R. Dey5, S. V. Tsiaras2, N. Roy6, 1Dept of Medicine, Massachusetts General Hospital, Boston, MA, 2Division of Cardiology, Massachusetts General Hospital, Boston, MA, 3Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, MA, 4Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, 5Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, 6Dept of Surgery, Div of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(1405) Awake Veno-Arterial ECMO (VAECMO) Without Mechanical Ventilation as a Bridge to Advanced HF Therapies; S. M. Rodriguez, V. Luzania, M. Kwan, C. Kunavarapu. Advanced Heart Failure and Transplant Program, Methodist Hospital, San Antonio, TX


(1407) WITHDRAWN

(1408) Dramatic Consequences of Water Pipe Use Following Lung Transplantation; C. A. Robinson1, B. Vrugt2, M. M. Schuurmans3, C. Benden4, S. Benussi3, I. Inci3, W. Weder3, I. Opitz3. 1Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, 3Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, 4Division of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland

(1409) Middle Aortic Syndrome Unmasked After Placement of Berlin LVAD for Dilated Cardiomyopathy; T. T. Bradford1, P. Shivaram2, E. A. Frazier2, X. Garcia3, K. R. Knecht3. 1Arkansas Children's Hospital, Little Rock, AR, 2Dept of Pediatrics, Arkansas Children's Hospital, Little Rock, AR

(1410) Combined Heart and Kidney Transplantation in a 9 Kilogram Child; J. J. Parent1, D. L. Morales2, C. Chin2, D. Hooper3, T. D. Ryan2. 1Pediatric Cardiology, Riley Hospital at Indiana University Health, Indianapolis, IN, 2The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH


(1412) Acute Humoral Rejection in an Infant After Heart Transplantation: Uncommon But Possible; J. Marcano1, R. Zea-Vera2, H. Tunuguntla3, D. L. Kearney4, Z. M. Binsalamah2. 1Cardiothoracic Surgery, Texas Heart Institute - Baylor College of Medicine, Houston, TX, 2Congenital Heart Surgery, Texas Children's Hospital - Baylor College of Medicine, Houston, TX, 3Pediatric Cardiology, Texas Childrens Hospital - Baylor College of Medicine, Houston, TX, 4Pathology & Immunology, Texas Children's Hospital - Baylor College of Medicine, Houston, TX

(1413) Radiation-Induced Pulmonary Fibrosis After Therapy of Papillary Thyroid Carcinoma With Pulmonary Metastases; I. Saba, M. Loebe, D. Fertel, S. Shafazand, A. Ghodsizad, N. Brozzi. University of Miami, Miami, FL

(1414) Successful Single Lung Transplant Following Pneumonecnectomy in a Pediatric Patient With Cystic Fibrosis; T. Brand, B. E. Haithcock. Dept of Surgery, University North Carolina, Chapel Hill, NC

(1415) Successful Pediatric Heart Transplant in a Patient with Loey's-Dietz Syndrome; M. S. Ploutz1, A. Colon1, S. Grohall1, S. Pophali2, C. F. Lagerstrom2, D. A. Velez2, S. Zangwill5. 1Cardiology, Phoenix Children's Hospital, Phoenix, AZ, 2Cardiovascular Surgery, Phoenix Children's Hospital, Phoenix, AZ

(1416) ST Elevation Myocardial Infarction (STEMI) Early After Pediatric Heart Transplantation; M. Bang1, V. V. Dimas1, R. Butts1, M. Luna2, R. Jaquiss3, D. Sutcliffe4, T. Pirollo5, R. Morrow4, R. Kirk1. 1Pediatric Cardiology, UT Southwestern, Dallas, TX, 2Interventional Cardiology, UT Southwestern, Dallas, TX, 3Pediatric Cardiothoracic Surgery, UT Southwestern, Dallas, TX

(1417) Arrhythmogenic Cardiomyopathy: Children Don't Always Follow the Rules!: H. P. Tunuguntla1, A. Landstrom1, D. L. Kearney2, C. Gates1, S. Choudhry1, A. G. Cabrera2, J. F. Price2, I. Adachi3, W. J. Dreyer1, S. W. Denfield1. 1Pediatric Cardiology, Texas Children's Hospital, Houston, TX, 2Pathology, Texas Children's Hospital, Houston, TX, 3Congenital Heart Surgery, Texas Children's Hospital, Houston, TX
(1418) Bivalrudin, Dialysis, and Biventricular Assist Devices: A Pathway to Heart-Kidney Transplant in a HITT Positive Patient; E. R. Griffiths1, L. May2, K. Molina2, A. Lai2, A. W. Eckhauser1. 1Surgery, University of Utah Primary Children’s Hospital, Salt Lake City, UT, 2Pediatrics, University of Utah Primary Children’s Hospital, Salt Lake City, UT

(1419) Successful Bridge to Transplant in the Smallest Pediatric Patient To-Date Using the 50 cc SynCardia® Total Artificial Heart; G. S. Beasley1, K. Allen2, L. Jackson3, E. Pahl1, O. Eltayeb4, C. L. Backer4, M. Monge4, P. T. Thrush1. 1Pediatric Cardiology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL, 2Pediatric Cardiology and Critical Care Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL, 3Critical Care Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 4Cardiovascular-Thoracic Surgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL

(1420) Acute Coronary Thrombosis in a Child with Kawasaki’s Disease and Giant Coronary Aneurysms: BiVAD as a Bridge to Transplantation; R. A. Murthy1, G. Vaughn2, S. Haldean2, H. El-Said2, E. Yeh2, J. A. Lamberti1, J. Nigro1. 1Cardiothoracic Surgery, Rady Children’s Hospital, University of California San Diego, San Diego, CA, 2Pediatric Cardiology, Rady Children’s Hospital, University of California San Diego, San Diego, CA


(1422) High Pulmonary Vascular Resistance and Heart Transplantation; C. E. Ciccotello1, K. Kanter2, W. T. Mahle3, S. R. Deshpande3. 1Pediatric Cardiology, Emory University, Atlanta, GA, 2Dept of Cardiothoracic Surgery, Emory University, Atlanta, GA, 3Pediatric Cardiology, Emory University / Children’s Healthcare of Atlanta, Atlanta, GA

(1423) Negative Pressure Wound Therapy Prevents Infection and Allows for Rehabilitation in a Child on Long-Term Mechanical Circulatory Support; C. S. Jenkins1, D. J. Kozik1, A. Lorimer2. 1Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 2Pediatric Cardiovascular Surgery, Norton Healthcare, Louisville, KY

(1424) Stable Heart Regraft Function in the Presence of a High Titer Donor Specific Anti-HLA DQA Antibody; J. A. Spinner1, P. T. Jindra2, R. H. Kerman3, W. J. Dreyer4. 1Section of Pediatric Cardiology, Dept of Pediatrics, Baylor College of Medicine, Houston, TX, 2Section of Pediatric Cardiology, Dept of Pediatrics, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiovascular and Thoracic Surgery, University of British Columbia, Vancouver, BC, Canada

(1425) Isolated Pulmonary Artery Vasculitis Leading to Pulmonary Artery Aneurysm Formation; N. Moghaddam1, B. Moghaddam1, N. S. Dehghan2, M. T. Janusz3, N. W. Brunner4. 1Dept of Medicine, University of British Columbia, Vancouver, BC, Canada, 2Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiovascular and Thoracic Surgery, University of British Columbia, Vancouver, BC, Canada

(1426) Long Duration PA to LA Pumpless Interventional Lung Assist Device Bridge to Lung Transplantation in a Child with IPAH; M. Vayvada1, A. Yeginus1, A. E. Tasci1, S. S. Caner1, A. Erkilic2, E. Gurcu2, B. Ozbek3, A. Yildirim4. 1Thoracic Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, 2Anesthesiology, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, 3Pediatric Cardiovascular Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, 4Pediatric Cardiology, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey


(1429) Successful Bilateral Lung Transplant for Pulmonary Alveolar Microlithiasis at a Tertiary Care Hospital in India; A. Jindal1, V. Rahulan1, S. Attawar2, G. Balasubramani3, P. Dutta4. 1Pulmonary, Critical Care & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 2Cardiac Sciences, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 3Cardio-Thoracic Organ Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India
MECHANICAL CIRCULATORY SUPPORT

Poster Discussants: Pavan Atluri (USA), Katherine Fan (Hong Kong), Doug Horstmannhof (USA), Michael Kiernan (USA), Robert Kormos (USA), Sangjin Lee (USA), H. Todd Massey (USA), Christopher Salerno (USA), Thomas Schlöghofer (Austria), Garrick Stewart (USA), Andre Vincentelli (France)

(933) Clinical Experience With Argatroban as a Therapeutic Option for LVAD Associated Device Thrombosis: M. J. Ruiz-Cano, V. Launroth, E. Prashovikj, E. Ljajikj, M. Schoenbrodt, J. Boergermann, L. Paluszkiewicz, J. Gummert, M. Morschuis. Thorax- und Cardiovascular Surgery, Hersz- und Diabeteszentrum NRW, Bad Oeynhausen, Bad Oeynhausen, Germany


(935) Are Elevated Serum Hemolysis Markers a Harbinger of Thromboembolic Events in Heartmate II Patients?: R. Zayat, M. A. Khattab, U. Ahmad, C. Stoppe, L. Tewarie, A. Moza, A. Goetzenich, R. Autschbach. Dept of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, Dept of Intensive Care Medicine, RWTH University Hospital, Aachen, Germany


(937) Platelet Function, von Willebrand Factor and Hemocompatibility-related Adverse Events in Heartmate 3 and Heartmate II Patients: A Propensity Score Matched Study: R. Zayat, A. Goetzenich, O. Grottke, C. Stoppe, U. Ahmad, M. A. Khattab, L. Tewarie, A. Moza, R. Autschbach. Dept of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, Dept of Anesthesiology, RWTH University Hospital, Aachen, Germany, Dept of Intensive Care Medicine, RWTH University Hospital, Aachen, Germany


(941) Clinical Experience and Outcomes of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience of 24 Cases: R. Agarwal, A. Kyvernitakis, B. Soleimani, C. A. Milano, J. Kennedy, R. L. Benza, S. Muriali, S. H. Bailey. Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA, Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, Cardiothoracic Surgery, Penn State Hershey Heart and Vascular Institute, Hershey, PA, Cardiothoracic Surgery, Duke Univ Medical Center, Durham, NC, Cardiovascular Disease, Univ of Virginia Health System, Charlottesville, VA, Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

(942) Age-Related Risk of Adverse Events after Left Ventricular Assist Device Implantation: A Device-Specific Comparison: S. Poddi, V. Tchantchaleishvili, R. C. Daly, S. M. Dunlay, S. Maltais, J. M. Stulak. Cardiovascular Surgery, Mayo Clinic, Rochester, MN, Cardiovascular Diseases, Mayo Clinic, Rochester, MN
(943) Implication of Pre-Operative Pulmonary Function Testing on Gastrointestinal Bleeding After Continuous Flow LVAD; W. Askar1, M. Rappelt1, R. Pedersen2, N. Sulemanjee2, T. Hastings2, O. Cheema2, E. Roberts2, F. X. Downey3, J. Crouch4, V. Thohan2. 1Aurora Research Institute, Aurora Health Care, Milwaukee, WI, 2Tendick Clinic for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, 3Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI


(945) WITHDRAWN

(946) Incidence of Early and Late Pump Thrombosis on HeartMate II LVAD Support; J. Schultz1, A. K. Ho2, R. John3, K. Goodwin4, A. Kluis5, M. Pritzker2, E. Missov2, K. Liao3, R. Cogswell3. 1Dept of Medicine, University of Minnesota, Minneapolis, MN, 2Dept of Cardiology, University of Minnesota, Minneapolis, MN, 3Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, 4Dept of Surgery, University of Minnesota, Minneapolis, MN, 5University of Minnesota Medical School, University of Minnesota, Minneapolis, MN

(947) WITHDRAWN

(948) Early Postoperative Heparinization is Crucial for Prevention of Cerebral Vascular Accident in Patients with HeartMate II; Y. Matsumoto, T. Fujita, S. Fukushima, Y. Shimahara, Y. Kume, K. Yamashita, N. Kawamoto, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

(949) Impact of Late Aortic Regurgitation in Patients with HeartMate II; Y. Matsumoto, T. Fujita, S. Fukushima, Y. Shimahara, Y. Kume, K. Yamashita, N. Kawamoto, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

(950) A Novel Risk Model to Predict Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device Implantation; A. Loforte1, A. Montalto2, F. Musumeci2, C. Mariani2, V. Polizzi3, P. Lilla Della Monica2, F. Grigioni1, G. Marinelli1. 1Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(951) Hemocompatibility Related Adverse Events and Competitive Outcomes of Different Generation of Left Ventricular Assist Devices; A. Loforte1, A. Montalto2, C. Mariani2, V. Polizzi3, M. Masetti2, P. Lilla Della Monica2, F. Grigioni1, G. Marinelli1, F. Musumeci2. 1Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(952) Results of Unplanned Right Ventricular Assist Device for Severe Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device Insertion; A. Loforte1, A. Montalto2, C. Mariani2, S. Martin Suarez1, E. Pilato1, P. Lilla Della Monica2, F. Grigioni1, G. Marinelli1, F. Musumeci2. 1Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(953) Durability of Medical Therapy for Heartware LVAD Thrombosis; J. W. Wald1, C. Justice2, D. Guarracino2, J. Marble2, E. Laverty-Wilson2, E. Birati3, C. Bermudez2, P. Alturi4, M. Acker2, E. Rame3. 1Univ of Pennsylvania Hospital, Philadelphia, PA, 2Cardiothoracic Surgery, Univ of Pennsylvania Hospital, Philadelphia, PA, 3Cardiology, Univ of Pennsylvania Hospital, Philadelphia, PA, 4Cardiothoracic Surgery, Univ of Pennsylvania Hospital, Philadelphia, PA

(954) Utility of Hypercoagulable Work-Up in Predicting Post-Operative Complications in Total Artificial Heart (TAH) Implant Patients; L. S. Czer1, B. Coleman2, L. D. Lam3, M. Pollack4, D. Collier4, R. Lee4, D. Mochizuki4, L. S. Czer1, J. Moriguchi1, J. A. Kobashigawa1, F. A. Arabia5. 1Cedars Sinai Heart Inst, Cedars Sinai Med Ctr, Los Angeles, CA, 2Biomedical Sciences and Medicine, Cedars Sinai Med Ctr, Los Angeles, CA, 3Cedars Sinai Comprehensive Transplant Center, Cedars Sinai Med Ctr, Los Angeles, CA, 4UCSF School of Pharmacy, San Francisco, CA, 5CSHI Center for Surgical Device Management of Advanced Heart Disease, Cedars Sinai Med Ctr, Los Angeles, CA

(955) Low Serum TNF-α in a European Cohort Implanted with the HeartMate3 Left Ventricular Assist Device; I. Netuka1, G. Kim2, P. Ivák1, Z. Tucanova1, G. Sayer2, J. Raikhelkar2, S. Kalantari2, N. Sarswat3, N. Uriel5. 1Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2University of Chicago, Chicago, IL
(957) Pump Thrombosis in HeartWare HVAD Left Ventricular Assist Devices: Single Center Experience: E. Demir1, S. Nalbantgil2, P. Öztürk2, C. Sahutoglu3, Ç. Engin2, T. Yagdi2, M. Özbaran2. 1Cardiology, Ege University Medicine Faculty, İzmir, Turkey, 2Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey, 3Anesthesiology, Ege University Medicine Faculty, İzmir, Turkey
(958) Pulmonary Artery Pulsatility Index Predicts Right Ventricular Failure Post-LVAD Implantation in Ischemic Cardiomyopathy: S. Kumar1, J. S. Josephs1, K. Kumar2, O. Saeed3, S. Patel4, S. Murthy5, J. J. Shin5, S. Forest6, D. J. Goldstein4, U. P. Jorde3, D. B. Sims4. 1Dept of Medicine, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY, 2Dept of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, 3Division of Cardiology, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY, 4Division of Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY
(959) Optimizing Hemodynamics Does Not Improve the Pulmonary Artery Pulsatility Index’s Post-LVAD Right Ventricular Failure Predictive Value: S. Kumar1, S. A. Smith2, J. S. Josephs1, K. Kumar3, S. Murthy4, S. Patel4, O. Saeed4, J. J. Shin5, S. Forest5, D. J. Goldstein5, U. P. Jorde4, D. B. Sims4. 1Dept of Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, 2Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 3Dept of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, 4Division of Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, 5Division of Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY
(961) Temporal Relationship of Early versus Late Right Heart Failure in Patients with Continuous Flow LVADs: W. F. Stendardi1, O. O. Braun2, M. Brambatti2, V. Pretorius3, P. Kim2, H. Tran2, B. Greenberg2, E. Adler2, J. Silva Enciso2. 1Medicine, UCSD, San Diego, CA, 2Cardiology, UCSD, San Diego, CA, 3Surgery, UCSD, San Diego, CA
(962) Predictors for Early and Late Right Heart Failure After Left Ventricular Assist Device Implantation: W. F. Stendardi1, O. O. Braun2, M. Brambatti2, P. Kim2, V. Pretorius3, H. Tran2, B. Greenberg2, E. Adler2, J. Silva Enciso2. 1Medicine, UCSD, San Diego, CA, 2Cardiology, UCSD, San Diego, CA, 3Surgery, UCSD, San Diego, CA
(963) Impact of Continuous Flow Left Ventricular Assist Device on Graft Rejection and Donor-specific Antibodies Development After Heart Transplant: M. Garrozzini, J. Bejko, M. Comisso, F. Toto, G. Toscano, V. Tarzia, A. Gambino, E. Cozzi, D. Gregori, T. Bottio, G. Gerosa. Cardiac, Thoracic and Vascular Sciences, University of Padova, Cardiac Surgery Unit, Padova, Italy
(964) Administration of Beta-Blockers Early After LVAD Implantation is Not Associated with Early Right Ventricular Failure or Increased Mortality: M. H. Derbala1, B. Lee1, M. Alghothani1, A. McDavid2, B. Lampert1, B. Whitson2, R. Hasson2, S. Emani1, A. Hasan1, A. Kilic2, M. Donneyong3, S. A. Smith1. 1Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 2Dept of Cardiothoracic Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University College of Pharmacy, Columbus, OH
(965) Predictors of Respiratory Failure in Patients Supported with Continuous Flow Ventricular Assist Devices and the Effect on Survival: F. Sagebin1, B. Ayers1, B. Barrus1, S. Prasad1, H. Vidula2, E. Storoynsky2, S. Thomas2, L. Chen2, J. Alexis1, I. Gosev1. 1Division of Cardiac Surgery, University of Rochester, Rochester, NY, 2Division of Cardiology, University of Rochester, Rochester, NY
(966) Results of Concomitant Percutaneous Temporary RVAD Support Using the Cardiac Assist TandemHeart With ProtekDuo Cannula in LVAD Patients: B. Schmack1, J. Kremer1, A. Breic2, L. Grossekettler3, R. Goldwasser1, R. Arif1, M. Farag1, H. Schmidt1, M. Kreussler3, P. W. Raake3, M. Karck1, A. Ruhiparwar1. 1Dept of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, 2Dept of Anaesthesiology, University Hospital Heidelberg, Heidelberg, Germany, 3Dept of Cardiology, University Hospital Heidelberg, Heidelberg, Germany
(967) Impella 5.0 as a Bridge-To Bridge Option after Extracorporeal Life Support. Lessons Learned from the First 15 Cases: S. Zipfel1, S. Hakmi1, B. Reiter1, M. J. Barten1, M. Rybczinski2, M. Kubik2, S. Kluge4, H. Reichenspurner1, A. M. Bernhardt1. 1Dept of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Dept of General and
(968) Hemodynamic Determinants of Decline in Renal Function During Left Ventricular Assist Device Support; A. Pinsino1, A. Masoumi1, J. Radhakrishnan1, E. A. Royzman1, M. Mabasa1, F. Castagna2, A. M. Zuver1, M. Nasiri1, A. R. Garan1, V. K. Topkara1, H. Takayama1, K. Takeda1, Y. Naka1, R. T. Demmer1, P. C. Colombo1, M. Yuzelipskaya1. 1Columbia University, New York, NY; 2Columbia University, Yale Bridgeport Hospital, New York, NY; 3University of Minnesota, Columbia University, New York, NY

(969) Creatinine versus Cystatin C Based Equations for Estimation of Renal Function in Left Ventricular Assist Device Patients; A. Pinsino1, A. Masoumi1, J. Radhakrishnan1, R. T. Demmer2, E. A. Royzman1, M. Mabasa1, D. L. Brunjes1, A. M. Clemons1, B. Cagliostro1, A. R. Garan1, V. K. Topkara1, K. Takeda1, H. Takayama1, N. Yoshifumi1, P. C. Colombo1, M. Yuzelipskaya1. 1Columbia University, New York, NY; 2Columbia University, Columbia Univ, New York, NY; 3University of Minnesota, Columbia University, New York, NY

(970) LVAD versus BiVAD-mediated Allosensitization in Bridge-to-transplant Patients; A. Chaidaroglou1, M. Bonios2, A. Gkouziouta2, E. Leontiadis3, M. Pantou1, P. Gourzi1, A. Kapsalis1, N. Kogerakis3, G. Stavridis3, S. Adamopoulos3, D. Degiannis1. 1Molecular Immunopathology and Histocompatibility, Onassis Cardiac Surgery Center, Kallithea, Greece; 2Cardiology, Onassis Cardiac Surgery Center, Kallithea, Greece; 3Cardiothoracic Surgery, Onassis Cardiac Surgery Center, Kallithea, Greece

(971) The Ebb and Flow of Right Heart Failure in INTERMACS: Does Right Heart Failure Get Better or Worse Over Time?; J. Teuteberg1, G. Studdard2, F. Pagani3, M. Kiernan4, G. Oliveria5, E. Rame6, P. Alturi6, A. Gaffey7, E. Grandin7, J. Kirklin8, S. Myers8, C. Collum8, R. L. Kormos9. 1Stanford Univ, Stanford, CA; 2Univ of Alabama, Birmingham, Birmingham, AL; 3Univ of Michigan, Ann Arbor, MI; 4Tufts Univ, Boston, MA; 5Case Western Univ, Cleveland, OH; 6Univ of Pennsylvania, Philadelphia, PA; 7Beth Israel Deaconess, Boston, MA; 8Univ of Pittsburgh, Pittsburgh, PA

(972) Post-cardiomytomy as indication comes with its own predictors of mortality in Veno Arterial Extra Corporal Life Support; A. G. Proudfoot1, M. Leacche2, N. K. Manandhar Shresta1, T. A. Timek2, C. W. Villekese3, E. T. Murphy2, J. S. Fanning2, S. Jovinge3, T. J. Boeve2. 1Fredrik Meijer Heart and Vascular Institute, Saint Bartholomew’s Hospital, Grand Rapids, United Kingdom; 2Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI; 3Fredrik Meijer Heart and Vascular Institute, Saint Bartholomew’s Hospital, Grand Rapids, MI

(973) Temporal Predictors of Late Right Heart Failure After LVAD Implantation; H. Vidula, S. McNitt, M. Wang, V. Kutyifa, I. Gosev, J. Alexis. Univ of Rochester, Rochester, NY


(975) Correlation of High Molecular Weight Von Willebrand Factor Multimer loss and Rotational Speed During Short Term Mechanical Circulatory Support; L. S. Czer1, L. Lam1, R. Hays1, F. Baiesc1, A. Kuo1, S. Harii1, J. Moriguchi1, F. Arabia1, O. Volod2. 1 Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; 2Pathology, Cedars-Sinai Medical Center, Los Angeles, CA

(976) Cause of Death Among Bridge to Transplant and Destination Therapy LVAD Patients in a Large, Single Center Cohort; J. N. Schultz1, R. John2, C. Martin3, J. Misiakle3, R. Gogspwel3. 1Dept of Medicine, University of Minnesota, Minneapolis, MN; 2Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; 3Dean of Cardiology, University of Minnesota, Minneapolis, MN

(977) Atrial Fibrillation Increases Risk of Recurrent Heart Failure Readmissions in LVAD Patients; R. M. Wehbe1, A. Tibrewala1, A. S. Anderson1, K. Ghaforian1, I. Okwuosa1, E. Vorovich1, J. E. Wilcox1, C. Yancy1, D. T. Pham2, J. D. Rich1. 1Division of Cardiology, Dept of Medicine, Northwestern University, Chicago, IL; 2Division of Cardiac Surgery, Dept of Surgery, Northwestern University, Chicago, IL

(978) Low Incidence of Right Heart Failure During Left Ventricular Assist Device Implantation; G. Faerber, H. Kirov, T. Sandhaus, T. Doenst. Univ Clinic Jena, Jena, Germany

(979) Predicting Acute and Chronic Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Device Implant: The Importance of Right Atrial Strain and Regional Deformation of the Right Ventricular Free Wall; A. Iacovoni1, D. Bellavita2, C. Coronnello2, M. Simon3, C. Link3, C. Falletta2, G. Romano2, S. Sciacca2, G. Di Gesaro2, J. Malouf4, M. Pilato2, J. Gorcsan Ill5, A. Terzi1, F. Clemenza2. 1ASST Papa Giovanni XIXII, Bergamo, Italy; 2ISMETT,
(980) Accurate Quantitative Evaluation of Aortic Insufficiency During LVAD Support by Thermodilution Analysis; D. Akiyama1, T. Nishimura2, K. Iizuka1, T. Mizuno1, T. Tsukiyama1, Y. Takewa1, M. Ono3, E. Tatsumi1. 1Dept of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, 2Dept of Cardiovascular Surgery, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 3Dept of Cardiovascular Surgery, The Univ of Tokyo Hospital, Tokyo, Japan

(981) Pattern Discovery of Most Common Sequential Adverse Events after Left Ventricular Assist Device (LVAD) Implant; F. Movahedi1, L. Lohmueller2, L. Sees3, Y. Zhang4, M. Kanwar5, S. Murali5, R. Kormos6, R. Padman5, J. Antaki7. 1Electrical Engineering Dept, Univ of Pittsburgh, Pittsburgh, PA, 2Bioengineering Engineering Dept, Univ of Pittsburgh, Pittsburgh, PA, 3Heart and Vascular Institute, Univ of Pittsburgh Medical Center, Pittsburgh, PA, 4Weill Cornell Medicine, Cornell Univ, New York, NY, 5The Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA, 6Heinz College, Carnegie Mellon Univ, Pittsburgh, PA, 7Bioengineering Dept, Carnegie Mellon Univ, Pittsburgh, PA

(982) Barriers to Adherence with Early Postoperative Bridging Anticoagulation Protocols Following LVAS Implantation; K. A. Frankel1, D. M. Nemer2, J. Rimsans3, K. W. Sylvester1, E. N. Lyons1, M. Pfeffer3, M. Puligandla4, D. S. Neuberg5, M. M. Givertz1, J. M. Connors5, G. C. Stewart1. 1Brigham & Women’s Hospital, Boston, MA, 2Cleveland Clinic Foundation, Cleveland, OH, 3Dartmouth Hitchcock Medical Center, Lebanon, NH, 4Dana Farber Cancer Institute, Boston, MA, 5Brigham and Women’s Hospital, Boston, MA


(984) Echocardiographic Evaluation of Right Ventricular Function during Ex Vivo Heart Perfusion; G. Ruggeri1, R. Vanin Pinto Ribeiro2, B. Gellner3, J. Qua Hiansen1, M. Badiwala2, M. Meineri1. 1Dept of Anesthesia, Toronto General Hosp, Univ Health Network, Toronto, ON, Canada, 2Dept of Cardiovascular Surgery, Toronto General Hosp, Univ Health Network, Toronto, ON, Canada, 3Dept of Mechanical & Industrial Engineering, Univ of Toronto, Toronto, ON, Canada

(985) The Obesity Paradox is Lost After LVAD Implant; A. S. Cruz-Solbes, D. Nguyen, E. Graviss, B. Trachtenberg, I. Hussain, A. Bhimaraj, G. Torregroza1, M. Badiwala, S. Blankenberg, M. Kubik, S. Kluge, H. Reichenspurner, A. Bernhardt. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(986) Impact of Severe Tricuspid Valve Insufficiency on the Performance of Left Ventricular Assist Device; N. Sadat1, C. Torregroza1, J. von der Beek2, D. Scheiber2, I. J. Knor2, M. Sager2, P. Akhyari1, A. Lichtenberg1, D. Saeed1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Dept of Animal Research and Protection Task, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 3Cardiology, Angiology and Pulmology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(987) Gender Differences in Cardiac Reverse Remodeling in Mechanically Unloaded Hearts; S. Westhofen, A. Bernhardt, H. Reichenspurner, M. Barten. Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany


(990) Impact of Hepatic Fibrosis on Outcomes in Patients Undergoing Continuous-Flow LVAD Implantation; H. K. Lamba, M. Kim, C. Kurihara, M. Kawabori, T. Sugiura, A. Alnajar, F. H. Cheema, A. B. Civitello, R. Civitello, L. Simpson, A. P. Nair, T. Rosengart, O. Frazier, J. A. Morgan. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX


(993) Use of Advanced Heart Failure Therapies in Duchenne Muscular Dystrophy: C. A. Wittlieb-Weber, C. R. Villa, J. Conway, M. J. Bock, K. E. Gambetta, J. N. Johnson, A. K. Lal, K. R. Schumacher, S. P. Law, S. R. Deshpande, S. C. West, J. M. Friedland-Little, I. D. Lytrivi, M. A. McCulloch, R. J. Butts, D. R. Weber, K. R. Knecht. 1Pulmonary Medicine, Univ of Rochester Medical Center, Rochester, NY, 2Univ of Cincinnati, Cincinnati, OH, 3Univ of Alberta, Edmonton, AB, Canada, 4Loma Linda Univ Health, Loma Linda, CA, 5Northwestern Univ Feinberg School of Medicine, Chicago, IL, 6Mayo Clinic, Rochester, MN, 7Univ of Utah, Salt Lake City, UT, 8Univ of Michigan, Ann Arbor, MI, 9Columbia Univ Medical Center, New York, NY, 10Emory Univ School of Medicine, Atlanta, GA, 11Univ of Pittsburgh School of Medicine, Pittsburgh, PA, 12Seattle Children’s Hospital, Seattle, WA, 13Ichsan School of Medicine at Mount Sinai, New York, NY, 14Univ of Virginia Health System, Charlottesville, VA, 15Univ of Texas Southwestern Medical Center, Dallas, TX, 16Univ of Arkansas for Medical Sciences, Little Rock, AR


(995) Using Label-free Proteomics to Elucidate Affected Pathways in Pediatric Heart Transplant Rejection: S. R. Deshpande, T. Nguyen, A. K. Bhatia, K. O. Maher, D. M. Duong. 1Pediatric Cardiology, Emory University, Children’s Healthcare of Atlanta, Atlanta, GA, 2Emory University, Atlanta, GA, 3Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA, 4Integrated Proteomics Core, Emory University, Atlanta, GA

(996) Duchenne Muscular Dystrophy-Related Acute Heart Failure: Multicenter Study of Hospitalizations and Outcomes: S. R. Deshpande, C. A. Wittlieb-Weber, K. E. Gambetta, M. J. Bock, A. K. Lal, J. L. Conway, C. R. Villa, J. N. Johnson, K. R. Schumacher, S. C. West, J. M. Friedland-Little, I. D. Lytrivi, M. A. McCulloch, R. J. Butts, K. R. Knecht, S. Law. 1Pediatric Cardiology, Emory Univ, Children's Healthcare of Atlanta, Atlanta, GA, 2Pediatric Cardiology, Univ of Rochester Medical Center, Rochester, NY, 3Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Pediatric Cardiology, Loma Linda Univ, Loma Linda, CA, 5Pediatric Cardiology, Primary Children’s Hospital, Univ of Utah, Salt Lake City, UT, 6Pediatric Cardiology, Stollery Children's Hospital, Univ of Alberta, Edmonton, AB, Canada, 7Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Pediatric Cardiology, Mayo Clinic, Rochester, MN, 9Pediatric Cardiology, C.S. Mott Children's Hospital / Univ of Michigan, Ann Arbor, MI, 10Pediatric Cardiology, Univ of Pittsburgh, Pittsburgh, PA, 11Pediatric Cardiology, Seattle Children’s Hospital, Seattle, WA, 12Pediatric Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, 13Pediatric Cardiology, Univ of Virginia, Charlottesville, VA, 14Pediatric Cardiology, UT Southwestern, Dallas, TX, 15Pediatric Cardiology, Univ of Arkansas, Little Rock, AR, 16Pediatric Cardiology, Morgan Stanley Children's Hospital, Columbia Univ, New York, NY

(997) Evaluation of Prophylactic Valganciclovir for Cytomegalovirus (CMV) in Pediatric Heart Transplant Recipients: G. Nance, A. Serluco, R. S. Liverman, M. S. Kelleman, S. R. Deshpande. 1Children's Healthcare of Atlanta, Atlanta, GA, 2Emory University, Atlanta, GA, 3Pediatric Cardiology, Emory University / Children's Healthcare of Atlanta, Atlanta, GA

(998) Dynamic Myocardial Response to Exercise in Children with Isolated Non-compaction of the Left Ventricular Myocardium: C. Chen, B. Cifra, C. Slorach, S. Fan, C. Manhio, B. W. Mcrindle, A. Dragulescu, M. K. Friedberg, L. L. Mertens, A. N. Redington. 1Cardiology Service, Dept of Paediatric Subspecialties, KK Women’s and Children’s Hospital, Singapore, Singapore, 2Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Cardiology, Dept of Pediatrics, Cincinnati Children’s Hospital, Cincinnati, OH

(Agora 3)

**Poster Discussants:** Joshua Blatter (USA), Malcolm Brodlie (United Kingdom), Anne Dipchand (Canada), Samuel Goldfarb (USA), Mariska Kemna (USA), Ernestina Melicoff-Portillo (USA), David Morales (USA), Bart Rottier (Netherlands), Rakesh Singh (USA), Tajinder Singh (USA)

(1000) **Use of Isosorbide Dinitrate/Hydralazine Combination in Pediatric Patients with Heart Failure;** N. Musa¹, Y. Law², N. Richardson³, E. Albers¹, M. Kemna¹, J. Friedland-Little¹, B. Hong¹, R. Mazor⁴. ¹Dept of Pediatrics, Seattle Childrens Hospital/University of Washington, Seattle, WA, ²Dept of Pediatrics, Seattle Children’s Hospital/ University of Washington, Seattle, WA, ³Seattle Children’s Hospital, Seattle, WA

(1001) **Utilization of Cardiac MRI in Patients with Duchenne Muscular Dystrophy: A Contemporary Multi-Center Cohort;** S. C. West¹, C. A. Wittlieb-Weber², C. R. Villa³, C. Cunningham⁴, M. J. Bock⁵, K. E. Gambetta⁶, J. N. Johnson⁷, A. K. Lal⁸, K. R. Schumacher⁹, S. P. Law¹⁰, S. Deshpande¹¹, J. M. Friedland-Little¹², M. A. McCulloch¹³, R. J. Butts¹⁴, K. R. Knecht¹⁵, I. D. Lytrivi¹⁶. ¹Pediatric Cardiology, Children's Hosp of Pittsburgh, Pittsburgh, PA, ²Pediatric Cardiology, Univ of Rochester Medical Center, Rochester, NY, ³Pediatric Cardiology, Cincinnati Children’s Hosp, Cincinnati, OH, ⁴Pediatric Cardiology, Stollery Children's Hosp, Edmonton, ON, Canada, ⁵Pediatric Cardiology, Loma Linda Univ Medical Center, Loma Linda, CA, ⁶Pediatric Cardiology, Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, ⁷Pediatric Cardiology, Mayo Clinic, Rochester, MN, ⁸Pediatric Cardiology, Primary Children's Hosp, Salt Lake City, UT, ⁹Pediatric Cardiology, CS Mott Children's Hosp, Ann Arbor, MI, ¹⁰Pediatric Cardiology, New York-Presbyterian Morgan Stanley Children's Hosp, New York, NY, ¹¹Pediatric Cardiology, Children’s Hosp of Atlanta, Atlanta, GA, ¹²Pediatric Cardiology, Seattle Children's Hosp, Seattle, WA, ¹³Pediatric Cardiology, Univ of Virginia Children’s Hosp, Charlottesville, VA, ¹⁴Pediatric Cardiology, Univ of Texas Southwestern Children’s Medical Center, Dallas, TX, ¹⁵Pediatric Cardiology, Arkansas Children's Hosp, Little Rock, AR, ¹⁶Pediatric Cardiology, Mount Sinai Kravis Children's Hosp, New York, NY

(1002) **Echocardiographic Recovery of Function and Survival in Patients with Significant Cardiac Dysfunction from Anthracycline Induced Cardiomyopathy;** A. M. Khan¹, A. R. Punnoose², T. Zielke³, N. DeMarais⁴, A. Kuang¹, J. Reichek¹, K. Gambetta¹, E. Pahl¹. ¹Ann and Robert H. Lurie Children's Hospital, Chicago, IL, ²Cardiology, Children’s Hospital of Wisconsin, Milwaukee, WI, ³Carroll University, Waukesha, WI, ⁴Rosealind Franklin University of Medicine and Science, Chicago, IL

(1003) **Risk Factors for Poor Outcomes in Children Hospitalized With Acute Decompensated Heart Failure;** B. Hong¹, J. Friedland-Little¹, E. Albers¹, N. Jorgensen², R. Mazor³, N. Musa³, M. Kemna¹, Y. Law¹. ¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ²Dept of Biostatistics, University of Washington, Seattle, WA, ³Pediatric Critical Care, Seattle Children's Hospital, Seattle, WA

(1004) **Long-term Outcomes of Adult Survivors of Pediatric Heart Transplantation;** B. Hong¹, N. Jorgensen², E. Albers¹, J. Friedland-Little¹, M. Kemna¹, Y. Law¹. ¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ²Biostatistics, University of Washington, Seattle, WA

(1005) **Time and Age Specific Nomogram for Post Transplant Hemodynamics in Children;** M. F. Mils¹, J. Long², F. Qin², C. S. Almond¹, D. N. Rosenthal¹, S. Hollander¹. ¹Pediatric Cardiology, Stanford Children’s Health - Lucile Packard Children's Hospital, Palo Alto, CA, ²Dept of Medicine, Quantitative Sciences Unit, Stanford University, Palo Alto, CA

(1006) **WITHDRAWN**

(1007) **A New Prediction Model for Quantifying Mortality Risk in Congenital Heart Disease(CHD) Patients after Heart Transplant HTX;** L. J. Burchill¹, B. Mueller², C. Fan², C. Manhio², H. J. Ross³, A. Alba³. ¹Knight Cardiovascular Institute Adult Congenital Heart Program, Oregon Health Science University, Portland, OR, ²CV Data Management Centre, Hospital for Sick Children, Toronto, ON, Canada, ³Ted Rogers Center of Excellence in Heart Function, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada
(1008) Pediatric Heart Transplantation: Transitioning to Adult Care TRANSIT: E. Pahl1, A. Andrei2, K. Vant Hof1, M. Liu3, T. Shankel4, R. Chinnock5, S. Miyamoto5, A. V. Ambardkar6, A. Anderson2, L. J. Addonizio7, F. Latifi7, D. Lefkowitz8, L. Goldberg9, S. Hollander10, M. Pham10, J. Weissberg-Benchel11, N. Cool12, C. Yancy13, K. L. Grady13. 1Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Cardiology, Northwestern Univ Feinberg School of Medicine, Chicago, IL, 3Cardiology, Bluhm Cardiovascular Institute, Chicago, IL, 4Cardiology, Loma Linda Univ, Loma Linda, CA, 5Pediatric Cardiology, Univ of Colorado, Denver, CO, 6Cardiology, Univ of Colorado, Denver, CO, 7Cardiology, Columbus Univ, New York, NY, 8Children's Hospital of Philadelphia, Philadelphia, PA, 9University of Pennsylvania, Philadelphia, PA, 10Stanford Univ, Palo Alto, CA, 11Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 12Bluhm Cardiovascular Institute, Chicago, IL, 13Northwestern Univ Feinberg School of Medicine, Chicago, IL.

(1009) Practice Variation in Detection of Coronary Allograft Vasculopathy (CAV) in Children: A Pediatric Heart Transplant Study: E. Pahl1, D. Nandi1, J. Vo3, K. Schumacher4, M. Fenton5, R. Singh6, K. Lin7, J. Conway8, E. Pruitt3, S. Dahl9, J. M. Lamour10, J. Kirklin3, C. Chin11. 1Cardiology, Ann & Robert H. Lurie Children's Hosp of Chicago, Northwestern, Chicago, IL, 2Cardiology, Nationwide Children's Hosp, Columbus, OH, 3Cardiology, Univ of Alabama at Birmingham, Birmingham, AL, 4Cardiology, Univ of Michigan, CS Mott Children's Hosp, Ann Arbor, MI, 5Cardiology, Great Ormond Street Hosp for Children, London, United Kingdom, 6Cardiology, UC San Diego, Rady Children's Hosp, San Diego, CA, 7Cardiology, Children's Hosp of Philadelphia, Philadelphia, PA, 8Cardiology, Univ of Alberta, Edmonton, AB, Canada, 9Cardiology, Mayo Clinic (MCR), Rochester, MN, 10Cardiology, Children's Hosp at Montefiore, Bronx, NY, 11Cardiology, Cincinnati Children's Hosp Medical Center, Cincinnati, OH.

(1010) Marijuana in Pediatric and Adult Congenital Heart Transplant Listing: A Survey of Provider Practices and Attitudes: K. A. Phillips1, P. T. Thrush2, A. K. La3, S. J. Kindel4, C. Castleberry5, J. Sparks6, K. P. Daly7, J. N. Johnson8. 1Mayo Clinic School of Medicine, Rochester, MN, 2Lurie Children's Hospital of Colorado, Chicago, IL, 3Primary Children's Hospital/University of Utah, Salt Lake City, UT, 4Children's Hospital of Wisconsin, Milwaukee, WI, 5St Louis Children's Hospital, St. Louis, MO, 6Norton Children's Hospital, Louisville, KY, 7Boston Children's Hospital, Boston, MA, 8Mayo Clinic, Rochester, MN.

(1011) Outcomes of Myocarditis in Patients with Normal Left Ventricular Systolic Function on Admission: S. B. Barfuss1, S. R. Deshpande2, R. J. Butts3, K. R. Knecht4, M. E. Richmond5, K. Gambetta6, A. K. Lal1. 1Pediatrics, Primary Children's Hospital, University of Utah, Salt Lake City, UT, 2Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, 3Pediatric Cardiology, Children's Hospital, UT Southwest Medical Center, Dallas, TX, 4Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, 5Pediatric Cardiology, Columbia University Medical Center, New York, NY, 6Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 7Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT.


(1013) Cerebrovascular Autoregulation is Altered During Pediatric cfVAD Support: J. A. Spinner1, I. Adachi2, K. Kibler1, C. Rusin1, S. Tume1, E. Mossad1, D. Andropoulos1, B. Elias3, H. Tunuguntla1, A. Cabrera1, J. Price1, S. Denfield1, W. J. Dreyer1, K. M. Brady1. 1Pediatrics, Baylor College of Medicine, Houston, TX, 2Surgery, Baylor College of Medicine, Houston, TX, 3Texas Children's Hospital, Houston, TX.

(1014) High Burden of Diarrhea and Abdominal Pain After Pediatric Heart Transplantation: J. A. Spinner1, W. J. Dreyer1, A. G. Cabrera1, H. Tunuguntla1, C. Bocchini1, S. Devaraj2, J. Price1, J. S. Heinle3, I. Adachi2, S. W. Denfield1. 1Pediatrics, Baylor College of Medicine, Houston, TX, 2Pathology & Immunology, Baylor College of Medicine, Houston, TX, 3Surgery, Baylor College of Medicine, Houston, TX.

(1015) Cystatin C as a Marker of Renal Injury in Pediatric Heart Transplant Recipients: J. F. Goldberg1, T. A. Street1, X. Yu2, J. Wang3, J. R. Strelsin4, U. S. Boston5, J. A. Towbin1. 1Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN, 2Epidemiology, University of Memphis, Memphis, TN, 3Preventative Medicine, University of Tennessee School of Health Sciences, Memphis, TN, 4Pediatric Cardiac Surgery, University of Tennessee School of Health Sciences, Memphis, TN.

(1016) Rituximab for the Treatment of Refractory EBV Viremia and Prevention of PTLD in Pediatric Heart Transplant Recipients: M. J. Bock1, C. Sierra2, R. Tan3, T. Shankel4, S. Nayak4, J. Fitts5, R. E. Chinnock4. 1Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, 2Pharmacy, Loma Linda University Children's Hospital, Loma Linda, CA, 3Pharmacy, Loma Linda University Medical Center, Loma Linda, CA, 4Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, 5Loma Linda University Transplant Institute, Loma Linda, CA.

Center Variation in Listing Parameters Among US Pediatric Heart Transplant Programs; L. M. Barkoff1, K. Maeda2, D. N. Rosenthal3, Y. Zhang4, S. A. Hollander5, J. C. Dykes3, S. Chen3, N. A. McDonald1, S. J. Wilkens3, C. S. Almond3. 1Lucile Packard Children's Hospital, Palo Alto, CA, 2Dept of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, 3Dept of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 4Heart Center Clinical and Translational Research Unit, Stanford University, Palo Alto, CA

Pediatric Heart Transplantation in Spain. Data From the National Registry; L. G. Guereta1, M. Camino2, M. Tejero3, D. Albert4, S. Marcos5, A. Cano6. 1Hospital Universitario De La Paz, Madrid, Spain, 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3Pediatric Cardiology, Hospital Universitario Reina Sofía, Cordoba, Spain, 4Pediatric cardiology, Hospital Vall d'Hebron, Barcelona, Spain, 5pediatric Cardiology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 6Pediatric Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Duration of ECMO Support Predicts Survival in Transplant Patients; J. Grijalva1, B. Keeshan1, J. Dentel2, J. Chen1, D. McMullan1. 1Seattle Children's Hospital, Seattle, WA, 2Surgery, Seattle Children's Hospital, Seattle, WA

The Utility of Right Atrial Strain to Evaluate for Transplant Co-morbidities in Pediatric Heart Transplant Recipients; K. Watanabe1, M. Schäfer2, C. Cassidy1, S. D. Miyamoto1, P. Jone1. 1School of Medicine, University of Colorado, Aurora, CO, 2Dept of Bioengineering, University of Colorado, Aurora, CO

Post-transplant Mortality and the Components of Donor Organ Ischemic Time in Pediatric Heart Transplantation; R. R. Davies1, T. J. Pirolli1, M. Bano2, R. J. Butts2, D. L. Sutcliffe2, R. Kirk2, R. D. Jaquiss1. 1Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX, 2Pediatric Cardiology, UT Southwestern - Children's Health Dallas, Dallas, TX

When Critically Ill: Broaden Your Horizons for Acceptable Weight; K. W. Riggs1, R. Rizwan1, C. M. Giannini2, A. Lorts3, C. Chih3, R. Bryant III1, D. L. Morales1, F. Zafar1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Univ of Cincinnati, Cincinnati, OH, 3Pediatric Cardiology, Cincinnati Children’s Hospital, Cincinnati, OH

The Effect of Inflammation and Severity of Cardiac Allograft Vasculopathy on Coronary Artery Distensibility After Paediatric Heart Transplantation; S. A. Rosen1, M. Burch2, M. Fenton2. 1University College London, London, United Kingdom, 2Great Ormond Street Hospital, London, United Kingdom


The Use of Virtual Heart Transplantation Will Allow for a Broader Donor Pool in Pediatric Heart Transplantation for Dilated Cardiomyopathy; N. Szugye1, A. Lorts1, M. Taylor1, F. Zafar2, D. Morales2, R. Bryant III2, J. Broderick1, R. Moore1. 1Cardiology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, 2Cardiothoracic Surgery, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

Supplemental Use of Blood Cardioplegia Before Graft Implantation in Pediatric Heart Transplantation; M. Ramaswamy1, A. Beeman1, S. Henwood1, A. Hawkyard1, A. Robertson1, D. Ridout2, A. Walker2, R. Patel2, J. Simmonds1, N. Muthialu1. 1Great Ormond Street Hospital for Children, London, United Kingdom, 2University College London, London, United Kingdom

Early Changes in Donor Fraction Cell-free DNA in Newly Transplanted Pediatric Heart Transplant Patients; S. Kindel1, W. Ragalie2, S. Zangwill3, R. Katz4, A. Tomita-Mitchell5, K. Stamm6, M. E. Mitchell7. 1Cardiology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, 2Surgery, Medical College of Wisconsin, Milwaukee, WI, 3Cardiology, Phoenix Children's Hospital, Phoenix, AZ, 4University of Washington, Seattle, WA, 5Medical College of Wisconsin, Milwaukee, WI, 6TAI Diagnostics, Wauwatosa, WI, 7Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

Pretransplant Amiodarone Use and Post-transplant Outcomes in Pediatric Heart Transplant: A Propensity Score Analysis of the ISHLT Transplant Registry; R. Butts1, A. Dipchand2, D. Sutcliffe1, M. Bano1, R. Morrow3, R. Kirk1. 1Pediactrics, University of Texas Southwestern, Dallas, TX, 2Pediactrics, SickKids Hospital of Toronto, Toronto, ON, Canada, 3Pediactrics, Children's Medical Center of Dallas, Dallas, TX
(1030) Fifty Years of Pediatric Heart Transplantation - The First Successful Case and Results of the Early Era; C. R. Kirk, R. J. Butts, A. I. Dipchand. 1Heart Center, UTSW Medical, Dallas, TX, 2Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

(1031) Preoperative Use of Amiodarone is Associated With Perioperative Morbidity, But Not Mortality in Pediatric Heart Transplant Recipients; S. M. Amdani, A. Dalal, K. Simpson, J. Scheel, P. Eghetsad, A. Abarbanell, C. Canter, C. Castleberry. 1Pediatric Cardiology, St. Louis Children’s Hospital, St. Louis, MO, 2Pediatric Cardiothoracic Surgery, St. Louis Children's Hospital, St. Louis, MO

(1032) The Outcome of Cardiac Transplantation in Patients With Down Syndrome; E. Khoshbin, Z. Reinhardt, R. Kirk, G. Parry, S. Schueler, A. Hasan. 1Dept of Cardiac Surgery and Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 2Dept of Paediatric Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 3Dept of Paediatric Cardiology, Childrens Medical Centre, Dallas, TX, 4Dept of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom


(1035) Description of Longitudinal Measurement of Donor Fraction of Cell-Free DNA Following Rejection Treatment and Correlation to Clinical Outcomes; W. Ragalie, S. Kindell, S. Zangwill, M. E. Mitchell. 1Surgery, Medical College of Wisconsin, Milwaukee, WI, 2Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 3Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, 4Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

(1036) Pediatric Donor-Recipient Size Matching - Seeing is Believing, Or is it?; J. Plasencia, J. R. Ryan, D. Velez, K. Lagerstrom, J. J. Nigro, T. Karamlou, Y. Kamarianakis, D. H. Frakes, S. G. Pophal, S. D. Zangwill. 1Arizona State University, Tempe, AZ, 2Phoenix Children's Hospital, Phoenix, AZ, 3Rady Children's Hospital, San Diego, CA

(1037) Hybrid Stage 1 Palliation as a Bridge to Cardiac Transplantation in Patients With High Risk Single Ventricle Physiology; B. H. Morray, E. L. Albers, T. K. Jones, M. S. Kemna, L. C. Permut, Y. M. Law. 1Pediatrics, Seattle Children's Hospital, Seattle, WA, 2Cardiothoracic Surgery, Seattle Children’s Hospital, Seattle, WA

(1038) Narrative Review of Ethical Considerations in Pediatric Heart Transplantation; S. J. Wilkens, P. Smith, A. Patel. 1Pediatric Cardiology, Stanford Univ, Lucile Packard Children's Hospital, Palo Alto, CA, 2Northwestern Univ, Chicago, IL, 3Pediatric Cardiology, Northwestern Univ, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

(1039) Intellectual Disability and Pediatric Lung Transplantation; A. Iyengar, A. Goel, M. Caceres Polo, O. Kwon, C. Eisenring, R. Biniwale, E. DePasquale, A. Ardehali. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2University of California - Los Angeles, Los Angeles, CA


(1041) Lung Transplantation in Children and Young Adults in Czech Republic: A Single Center Experience; T. Dousova, J. Havlin, J. Fila, J. Kolari, M. Svorcova, L. Valenta-Bartakova, J. Pozniak, J. Simonek, R. Lischke. 1Dept of Pediatric Pneumology, Motol University Hospital, Prague, Czech Republic, 23rd Dept of Surgery, Lung and Thoracic Division, Motol University Hospital, Prague, Czech Republic, 2Dept of Pneumology, Motol University Hospital, Prague, Czech Republic
(1042) Hospital Costs for Pediatric Patients With Temporary Ventricular Assist Devices: A Multicenter Study From the Pediatric Interagency Registry for Mechanically Assisted Circulatory Support (Pedimacs) and the Pediatric Health Information System (PHIS); J. W. Rossano¹, R. S. Cantor², D. Dai¹, P. Shamszad¹, Y. Huang¹, M. Hall³, K. Y. Lin¹, M. Zinn⁴, E. Edens⁵, E. Parrino⁶, J. K. Kerklin². ¹Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, ²Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Children’s Hospital Association, Lenexa, KS, ⁴Cardiology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, ⁵Cardiology, University of Iowa, Iowa City, IA, ⁶Oschner Medical Center, New Orleans, LA

(1043) Characteristics and Outcomes of Pediatric Patients Supported with Ventricular Assist Device - A Multi-institutional Analysis; K. Puri¹, J. C. Causey², S. C. Tume², B. S. Moffett³, M. Anders². ¹Cardiology, Texas Children’s Hospital, Houston, TX, ²Critical Care Medicine, Texas Children’s Hospital, Houston, TX, ³Pain Medicine, Texas Children’s Hospital, Houston, TX

(1044) Iron Deficiency is Associated with Adverse Outcomes in Pediatric Heart Failure; K. Puri¹, J. A. Spinner¹, M. D. Shah¹, J. M. Powers³, S. W. Denfield⁴, A. G. Cabrera¹, H. P. Tunuguntla¹, W. J. Dreyer¹, J. F. Price¹. ¹Cardiology, Texas Children’s Hospital, Houston, TX, ²Hematology-Oncology, Texas Children’s Hospital, Houston, TX

(1045) BMI and Association with Outcomes in Pediatric Patients on Durable Ventricular Assist Device Support; K. Puri¹, A. Jimenez Gomez², I. Adachi³, S. W. Denfield¹, A. G. Cabrera¹, B. A. Elias³, J. F. Price¹, W. J. Dreyer¹, S. Choudhry⁴, H. P. Tunuguntla¹. ¹Cardiology, Texas Children’s Hospital, Houston, TX, ²Neurology, Texas Children’s Hospital, Houston, TX, ³Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX


(1047) Quality Improvement for VA ECMO in Pediatric Hospitals- A 20-Year Analysis of Neonatal and Pediatric VA ECMO Complications in North America; A. Kiankhooy, W. H. Gray, C. J. Baker, S. R. Kumar, V. A. Starnes, A. E. Hackmann. Division of Cardiac Surgery, Dept of Surgery, Keck School of Medicine of University of Southern California; The Heart Institute, Children’s Hospital of Los Angeles, Los Angeles, CA

(1048) Quality of Outpatient INR Control in Children Supported on a Ventricular Assist Device; J. Murray¹, S. Chen¹, J. Lee¹, J. Dykes¹, S. Wilkens¹, D. Rosenthal¹, A. Shin², C. S. Almond². ¹Lucile Packard Children’s Hospital, Palo Alto, CA, ²Dept of Pediatrics Stanford University, Lucile Packard Children’s Hospital Stanford, Palo Alto, CA

(1049) Ex vivo Effects of a Pediatric Extracorporeal Membrane Oxygenation (ECMO) Circuit on the Sequestration of Mycophenolate Mofetil and Tacrolimus; C. S. Heith¹, J. R. Hume², L. Hansen³, R. M. Bakken⁴, S. L. Ritter⁵, L. Zhang⁶, B. R. Long⁷, M. E. Steiner⁶, G. A. Fischer¹. ¹Pediatric Critical Care, Univ of Minnesota, Minneapolis, MN, ²Pediatric Critical Care, Univ of Minnesota, Minneapolis, MN, ³Pharmacy, Univ of Minnesota, Minneapolis, MN, ⁴Cardiopulmonary and ECMO Services, Fairview- Univ Medical Center, Minneapolis, MN, ⁵Cardiopulmonary and ECMO Services, Univ of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ⁶Clinical Translational and Science Institute, Univ of Minnesota, Minneapolis, MN

(1050) Quantification and Distribution of Thrombus Burden in Berlin Heart Pumps; S. Shea¹, K. Spitzer², M. Carroll³, D. N. Ku⁴, S. R. Deshpande⁵. ¹Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Perfusion Services, Children’s Healthcare of Atlanta, Atlanta, GA, ³VAD Program, Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Institute of Bioengineering and Biotechnology, Georgia Institute of Technology, Atlanta, GA, ⁵Pediatric Cardiology, Emory University / Children’s Healthcare of Atlanta, Atlanta, GA


(1052) Is Low-rpm a Risk Factor for Pump Thrombosis in Pediatric Patients with HeartWare HVAD?; Ş. Kocabeyoglu¹, U. Kervan¹, D. Sert¹, E. Aygun¹, A. Pac², D. Eris³, A. Temizhan³, U. Unal¹, M. Pac¹. ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Pediatric Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ³Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey

Poster Session 2 – Thursday, April 12
Pediatric Transplantation
(1053) **Survival and Neurological Outcome after Extracorporeal Cardiopulmonary Resuscitation in Children**; P. Kramer, A. Mommsen, F. Berger, K. R. Schmitt. Congenital Heart Disease, Deutsches Herzzentrum Berlin, Berlin, Germany

(1054) **Long Term Results of Mechanical Circulatory Support as Bridge to Transplant in Severe Heart Failure Pediatric Patients**; M. Taira, T. Ueno, T. Kido, T. Kanaya, N. Okuda, Y. Matsunaga, K. Toda, T. Kuratani, Y. Sawa. Dept of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan

(1055) **Prolonged but Successful Weaning from Berlin Heart EXCOR After a Long-term Mechanical Unloading in Infantile DCM**; J. Narita¹, S. Kogaki¹, S. Ishigaki¹, F. Torigoe¹, R. Ishii¹, H. Ishida¹, K. Ozono¹, M. Taira², T. Ueno², Y. Sawa². ¹Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan, ²Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

(1056) **Long-term Results of Berlin Heart EXCOR Pediatric Implantation in Japan**; M. Ono¹, Y. Sawa², N. Fukushima³, H. Ichikawa⁴, M. Ueno², Y. Hirata¹, K. Sakamoto⁵, T. Suzuki², Y. Kaneko⁷. ¹Dept. of Cardiac Surg., Univ. of Tokyo Hospital, Tokyo, Japan, ²Dept. of Cardiovascular Surg., Osaka Univ. Hospital, Osaka, Japan, ³Dept. of Organ Transplantation, National Cerebral and Cardiovascular Research Center, Osaka, Japan, ⁴Dept. of Pediatric Cardiac Surg., National Cerebral and Cardiovascular Research Center, Osaka, Japan, ⁵Dept. of Cardiovascular Surg., Mt. Fuji Shizuoka Children’s Hospital, Shizuoka, Japan, ⁶Dept. of Pediatric Cardiac Surg., Saitama International Medical Center, Saitama, Japan, ⁷Division of Cardiovascular Surg., National Medical Center for Children and Mothers, Tokyo, Japan

(1057) **Intra-corporeal Biventricular Assist Devices Using the HVAD in Children**; M. Schweiger¹, C. Mascio², K. Kanter³, S. Marasco⁴, P. Eghtesady⁵, M. Hübler⁴, M. Kavarana⁶. ¹Dept of Congenital Pediatric Surgery, Children’s Hospital Zurich, Zurich, Switzerland, ²Pediatric Cardiothoracic Surgery, Children’s Hospital of Philadelphia, Philadelphia, PA, ³Emory University School of Medicine, Children’s Healthcare of Atlanta Pediatric Cardiac Surgery, Atlanta, GA, ⁴Cardiothoracic Surgical Unit, The Alfred, Melbourne, Australia, ⁵Pediatric Cardiothoracic Surgery, Washington University in St. Louis and St. Louis Children’s Hospital, St.Louis, MO, ⁶Division of Pediatric Cardiothoracic Surgery, Charleston, SC
HEART TRANSPLANTATION

Muses

Poster Discussants: Alexander Bernhardt (Germany), Eric Epailly (France), Marta Farrero Torres (Spain), Livia Goldraich (Brazil), Manon Huibers (Netherlands), Jama Jahanyar (USA), Nandkishore Kapadia (India), Ivan Knezevic (Slovenia), Jose Luis Lambert (Spain), Clive Lewis (United Kingdom), Javier Segovia (Spain), Jorge Silva Enciso (USA)


(1059) Heart Preservation With the Organ Care System in Germany - Revival in High Risk Recipients; F. Ius1, M. Berchtold-Herz2, S. V. Rojas1, T. Kaufeld1, J. Scheumann2, M. Avsar1, J. Salman1, C. Bara1, F. Beyersdorf2, A. Haverich1, M. Siepe2, G. Warnecke1. 1Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Thoracic and Cardiovascular Surgery, University of Freiburg, Freiburg, Germany

(1060) Does Ex Vivo Perfusion Lead to More or Less Intimal Thickening in the First-year Post-Heart Transplantation; T. Sato1, B. Azarbal1, R. Cheng1, F. Esmailian1, J. Patel1, M. Kittleson1, L. Czer1, R. Levine1, S. Dimbil1, T. Khaya1, J. A. Kobashigawa1. 1Cedars-Sinai Heart Institute, Los Angeles, CA, 2Transmedics, Andover, MA


(1062) Heart Transplantation Using the Normothermic Ex-Vivo Perfusion Device Organ Care System for Donor Heart Preservation - Long-term Outcomes; B. Fujita, A. Sievert, J. Sunavsky, J. Börgemann, U. Fuchs, J. Gummert, U. Schulz, S. Ensminger. Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany


(1064) Baseline and 1-year Follow-up Serial Optical Coherence Tomography Evaluation of Coronary Plaques in Heart Transplant Recipients; Y. Tsukamoto1, T. Ohtani1, T. Shiraki1, Y. Ichibori1, S. Saito2, S. Hikoso1, K. Toda2, O. Yamaguchi1, Y. Sawa2, Y. Sakata1. 1Dept of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 2Dept of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan

(1065) Short Term Clinical Outcomes of Percutaneous Coronary Intervention in Heart Transplant Recipients in the US - Result from Largest Inpatient Registry (2005-2014); P. Patel1, A. Kaneria1, E. Koman2, J. Hoosain2, H. Patel3, F. Hasni2, G. Ledley2, A. Badheka4, S. Hankins3, H. Eisen2. 1Dept of Internal Medicine, Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia, PA, 2Dept of Cardiology, Drexel University College of Medicine, Philadelphia, PA, 3Pramukhswami Medical College, Anand, India, 4Dept of Cardiology, The Everett Clinic, Everett, WA

(1067) Biomarker Discovery in Cardiac Allograft Vasculopathy: Novel Aptamer Proteomic and MicroRNA Profiling; A. Almufleh1, K. Rayner2, L. Zhang3, L. Susser2, L. Milenicziuk1, E. Stadnick1, R. Davies1, P. Liu1, S. Chih1. 1Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada, 2Cardiometabolic microRNA Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada, 3Cardiac Function Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada

(1068) The Presence of Microchannel in Optical Coherence Tomography is Associated With the Plaque Volume of Cardiac Allograft Vasculopathy After Heart Transplantation; D. Nitta1, K. Kinugawa2, J. Yokota3, M. Endo4, M. Tsuji1, A. Saito1, S. Minatsuki2, E. Amiya1, M. Hatano2, M. Ono4, I. Komuro1. 1Dept of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan, 2Dept of Internal Medicine 2, The University of Toyama Hospital, Toyama, Japan, 3Dept of Medical Engineering, The University of Tokyo Hospital, Tokyo, Japan, 4Dept of Organ transplantation, The University of Tokyo Hospital, Tokyo, Japan, 5Dept of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital, Tokyo, Japan, 6Dept of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan

(1069) Impact of Coronary Artery Calcification on the Donor Heart on Transmitted Coronary Artery Disease in Heart Transplant Recipients; M. Al-Sultan1, C. Summer, A. Dhanekula, C. Williams, H. Nemeh, D. Lanfear. Cardiothoracic Surgery, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, 2Department of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY


(1071) Immunosuppression Impact in Heart Transplant Recipients with Chagas' Disease in the Development of Cardiac Allograft Vasculopathy Data of an Argentine Center; M. A. Pereadejordi, L. Favaloro, D. Absi, M. Lopez Rosetti, R. Ratto, M. F. Renedo, E. Giordanino, P. Morejon, R. R. Favaloro, A. Bertolotti. Intrathoracic Transplantation and Heart Failure Division, Favaloro Foundation - University Hospital, Buenos Aires, Argentina

(1072) Pre-Transplant Neutrophil to Lymphocyte Ratio Predicts 30-day Readmission for Patients Undergoing Cardiac Transplantation; N. Ahmed1, Y. Kim1, H. Gandhi1, O. Saeed2, S. Patel3, S. Murthy2, J. Shin2, S. Forrest3, D. J. Goldstein3, U. P. Jorde2, D. B. Sims3. 1Dept of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, 2Division of Cardiology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, 3Division of Cardiothoracic Surgery, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

(1073) Precision Medicine for Tacrolimus Dosing in Heart Transplant Recipients; Y. Yang, N. Sulejmani, A. Jantz, B. Summers, A. Dhanekula, C. Williams, H. Nemeh, D. Lanfear. Henry Ford Hospital, Detroit, MI

(1074) The Effect of Everolimus vs Calcineurin Inhibitors on Left Ventricular Mass in De Novo Heart Transplant Recipients After 3 Years Follow-Up - Results From the Randomized Controlled SCHEDULE Trial; K. Murbraeck1, R. Massey1, K. Karason2, F. Gustafsson3, H. Eiskjær4, G. Rådegran5, D. Solbu6, K. Broch6, E. Gude1, A. Andreassen1, L. Gullestad1. 1Cardiology, Oslo Univ Hospital, Oslo, Norway, 2Cardiology, Sahlgrenska Univ Hospital, Gothenburg, Sweden, 3Cardiology, Copenhagen Univ Hospital, Copenhagen, Denmark, 4Cardiology, Skejby Univ Hospital, Aarhus, Denmark, 5Clinic for Heart Failure and Valvular Disease, Skåne Univ Hospital, Lund, Sweden, 6Novartis, Oslo, Norway

(1075) Dynamic Phenomapping and HLA Class I and II Antibodies for Heart Transplant Outcomes; M. Bakir1, N. Jackson2, S. Han2, E. Chang1, C. Tseng2, T. Khuu1, A. Bu1, J. Zhang2, E. Reed2, M. Deng1, M. Cadeiras1. 1Cardiology, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, CA

(1076) Initial Experience with Bosentan for the Management of Pulmonary Hypertension after Heart Transplantation; E. Santiago1, M. Farrero1, J. Ivey-Miranda2, M. Castel1, A. Garcia-Álvarez1, F. Perez-Villa1. 1Heart Failure and Heart Transplantation Program, Hospital Clinic, Barcelona, Spain, 2Hospital de Cardiología, Centro Medico Nacional Siglo XXI, Mexico city, Mexico

(1077) Longitudinal Development in Left Ventricular Volume, Mass and Function in Heart Transplant Recipients - Results From the NOCTET Trial; K. Broch, R. J. Massey, K. Murbraeck, E. Gude, A. K. Andreassen, L. Gullestad. Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway

(1078) Questioning the Tacrolimus Dogma: Does Early Dose Control Matter?; W. L. Baker1, S. Steiger2, S. Martin2, N. Patel2, J. Radojevic2, K. Darsaklis2, L. O'Bara2, H. Kutzler2, J. Dougherty2, A. Feingold2, J. Hammond2, D. Fusco2, J. A. Gluck2. 1University of Connecticut, Storrs, CT, 2Hartford Hospital, Hartford, CT

(1080) Low-dose Prothrombin Complex Concentrates for Warfarin Reversal Prior to Heart Transplantation: M. R. Wanek1, K. Hodges2, R. Persaud3, N. Moazami4. 1Dept of Pharmacy, Cleveland Clinic, Cleveland, OH, 2Dept of Thoaris & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 3Dept of Pharmacy, Florida Hospitals, Orlando, FL, 4Dept of Cardiothoracic Surgery, New York University Langone Health, New York, NY

(1081) Phosphodiesterase-type 5 Inhibition for Refractory Pre-capillary PH in Advanced Heart Failure is Associated with Increased Early Mortality Post Heart Transplant: M. Ayers1, K. A. Clark2, J. A. Mazurek3, P. Zamani4, A. Fox5, R. Forde-McLean4, J. E. Rame4. 1Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 2Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

(1082) High Variability in Tacrolimus Trough Levels is Associated With Rejections After Heart Transplantation: L. Gueta1, N. Markovits1, H. Blavsky-Yarden1, E. Raichlin2, I. Mazin1, D. Freimark1, J. Lavee1, R. Leobstein1, Y. Peled1. 1Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, 2Loyola University Medical Center, Maywood, IL

(1083) Giant-cell Myocarditis: A Case Series from the Perspective of a United Kingdom Cardiac Transplantation Centre: N. Okonkwo, H. Enab, A. Tindale, O. Dar. Royal Brompton & Harefield NHS Trust, London, United Kingdom


(1085) Average Daily Dose of Mycophenolate Mofetil in the First Post-transplant Year and Long Term Clinical Outcomes: A Single Center Retrospective Study: K. WONG1, N. Pereira2, S. Kushwaha1. 1Dept of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Dept of Cardiovascular Diseases; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN

(1086) One Tac Trial: Renal Function After Conversion from Twice Daily to Extended Release Tacrolimus: D. A. Baran1, E. Menchavez2, M. J. Zucker2, C. Gidea3, M. Camacho4. 1Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, 2Heart Failure and Transplant, Newark Beth Israel Medical Center, Newark, NJ, 3Newark Beth Israel Medical Center, Newark, NJ


(1089) Variability in Trust in the Heart Transplant Team Internationally and Its Relation to Patient and Center Level Factors in Heart Transplant Centers: The International Cross-Sectional BRIGHT Study: X. Luta1, K. Iglesias2, I. Peytemann-Bridevaux2, R. Helmy1, K. Denhaerynck3, F. Dobbels4, C. Russell5, S. De Geest6. 1Institute of Nursing Science, Dept of Public Health, University of Basel, Basel, Switzerland, 2School of Health Sciences (HEdS-FR), University of Applied Sciences and Arts of Western Switzerland (HES-SO), Fribourg, Switzerland, 3Institute of Social and Preventive Medicine, University Hospital Lausanne, Switzerland, 4Academic Centre for Nursing and Midwifery, Dept of Public Health and Primary Care, Katholieke Universiteit Leuven, Leuven, Belgium, 5School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO

(1090) Discrepancy Between Heart Rate Response and Indices of Autonomic Cardiovascular Control One Year After Heart Transplantation: S. I. Nygaard1, A. H. Christensen1, K. Rolid1, K. Nytroen1, L. Gullestad2, A. Fiane1, E. Thaulow1, G. Dohlen1, V. B. Wyller2. 1Oslo Univ Hospital, Oslo, Norway, 2Akershus Univ Hospital, Lørenskog, Norway

(1091) Comparison of Heart Transplantation Outcomes Between Adult Congenital Heart Disease and Matched Adult Cardiac Patients in a Single Quaternary Reference Centre: A. Kinssella1, J. S. Alvarez1, R. V. Ribeiro1, F. Yu1, J. Heggie2, M. Badiwala1, V. Rao1. 1Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Anaesthetics, Toronto General Hospital, Toronto, ON, Canada
(1092) Cardiac Transplantation and Mechanical Circulatory Support in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC); S. Madan1, J. Cress2, D. B. Sims1, S. R. Patel1, O. Saeed1, S. Forest3, W. Jakobleff3, S. Murthy1, J. J. Shin1, D. J. Goldstein3, U. P. Jorde1. 1Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.


(1094) Effect of Different Treatment Modalities for End-stage Renal Disease After Heart Transplantation; S. Roest1, D. A. Hesselink2, I. Kardys1, K. Caliskan1, J. J. Brugts1, A. P. Maat3, A. A. Constantinescu1, O. C. Manttied1. 1Dept of Cardiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 2Dept of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 3Dept of Cardiothoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

(1095) WITHDRAWN

(1096) Risk of Post-Transplant De Novo Donor Specific Antibodies in Patients Receiving Transusions Perioperatively; I. Mahoney1, A. Young1, N. Shekildaze2, A. Morris3, D. Gupta3, K. Bhatt3, S. Laskar4, A. Smith3, J. Vega4, R. T. Cole5. 1Emory Univ Sch of Med, Atlanta, GA, 2Memorial Hospital, Savannah, GA, 3Cardiology, Emory Univ Sch of Med, Atlanta, GA, 4Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA.


(1098) Transplant Center Volume Impacts Survival Among ACHD Patients Undergoing Heart Transplantation - An Analysis of the UNOS Registry; J. N. Menachem1, J. Lindenfeld1, K. Schlendorf1, A. S. Shah1, D. P. Bichelli2, W. Book2, D. Brinkley1, M. Danter1, B. Frischhertz1, M. Keebler1, B. Kogon3, B. Mettler1, J. Rossano4, S. Brown Sacks1, T. Young5, M. Wigger1, S. Zalawadiya1. 1Vanderbilt Univ Med Ctr, Nashville, TN, 2Emory Univ, Atlanta, GA, 3Univ of Mississippi, Jackson, MS, 4Children's Hospital of Philadelphia, Philadelphia, PA, 5Ochsner Health System, New Orleans, LA.

(1099) Novel Technique to Reduce Warm Ischemic Time During Cardiac Implantation; K. Morcos1, S. Singh1, S. Das De1, H. AliHaidri1, Y. Hegazy1, J. Dalzell2, S. Nair1, H. Doshi1, N. Al-Attar1, P. Curry1. 1Cardiac Surgery and Transplant, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom.

(1100) Combined Heart and Lung Transplant: Improved Survival After Implementation of Exclusion and Inclusion Criteria; A. S. Cruz-Solbes1, I. Hussain, B. Trachtenberg, A. Bhimaraj, A. Guha, M. Park, G. Torre-Amione, T. Kaleekal, J. Estep. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX.

(1101) Improving Utility of MELD-XI Prognostic in Heart Transplant; R. Meguerdijian1, A. Chang1, E. Moreno1, A. Salimbangon1, M. Kamath1, T. Khuu1, M. Kwon1, M. Moore1, A. Nsair1, K. Pandya1, D. Vucicevic1, A. Ardehali1, M. C. Deng1, E. C. Depasquale2. 1UCLA, Los Angeles, CA, 2David Geffen School of Medicine, Los Angeles, CA.


(1103) Simultaneous Heart-Liver Transplant is Associated with Excellent Outcomes Independent of MELD Score; R. Araujo-Gutierrez, J. Gardner, B. Trachtenberg, A. Bhimaraj, I. Hussain, M. Park, G. Ashrith, E. E. Suarez, B. Bruckner, J. Estep. DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, TX.

(1104) Trends in Heart Transplantation in Patients with History of Prior Malignancy; M. S. Panhwar1, S. Al-Kindi2, M. Ginwalla1, G. Oliveira2. 1Internal Medicine, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH, 2Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH.

(1105) Effect of Donor Renal Function on Heart Transplant Outcomes; M. S. Panhwar, M. Ginwalla. Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH.

Poster Session 3 – Friday, April 13

Heart Transplantation
(1106) Relation of Age to Risk of Major Rejections, Allograft Vasculopathy, and Long-term Mortality in a Contemporary Cohort of Patients Undergoing Heart Transplantation; Y. Peled1, J. Lavee1, M. Arad1, E. Raichlin2, N. Shlomo1, Y. Har-Zahav1, Y. Kassif1, E. Nachum1, D. Freimark1, I. Goldenberg1, I. Mazin1. 1Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel, 2Loyola University Medical Center, Maywood, IL

(1107) Long Term Survival Outcomes Following Heart Transplantation are Significantly Impacted by Recipient Smoking Status; D. Yoeli1, H. Lambr1, F. H. Cheema1, R. M. Delgado1, L. Simpson1, A. B. Civitello2, A. Nair1, T. K. Rosengart1, O. Frazier1, J. Morgan1. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, VA

(1108) Implementing the Index for Mortality Prediction After Cardiac Transplantation Risk Scores to Optimize Resources; E. I. Jeng1, P. Lipori2, D. J. Hall1, L. Duce3, M. M. Ahmed4, J. Vilaro4, J. M. Aranda4, T. M. Beaver1, G. J. Arnaoutakis1. 1Surgery, University of Florida, Gainesville, FL, 2Finance, University of Florida, Gainesville, FL, 3Anesthesiology, University of Florida, Gainesville, FL, 4Medicine, University of Florida, Gainesville, FL

(1109) Ex-situ Intra-vascularultrasound (IVUS) May Allow Safe Access to Extended Criteria DCD Heart Donors; S. Messer1, A. Page1, M. Berman1, S. Tsui1, S. Large1, S. Hoole2. 1Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, 2Cardiology, Papworth Hospital, Cambridgeshire, United Kingdom

(1110) Survival post Heart Transplant by Era in Recipients -- = 65; M. Moore1, S. Fraschilla2, A. Chang2, A. Salimbangon2, M. Kamath2, A. Nsair1, L. Sweet2, E. DePasquale3. 1Heart and Lung Transplant, UCLA, Venice, CA, 2Heart and Lung Transplant, UCLA, Los Angeles, CA, 3Dept of Medicine, Division of Cardiology, UCLA, Los Angeles, CA

(1111) Benefit of Modified Bicaval Anastomosis Technique for Orthotopic Heart Transplantation From Size-mismatch Marginal Donor; T. Kakuta1, T. Fujita, S. Fukushima, N. Kawamoto, Y. Matsumoto, K. Yamashita, Y. Kume, Y. Shimahara, N. Fukushima, S. Kitamura, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Research Center, Suita, Japan

(1112) Perioperative Ischemic Reperfusion Injury, Aggravated by Prolonged Cardiac Ischemic Time, May Cause Temporary Deterioration of Allograft Function; Y. Nakamun, S. Saito, S. Miyagawa, Y. Yoshikawa, K. Domae, R. Matsuura, K. Toda, Y. Sawa. Cardiovascular Surgery, Osaka University, Suita, Japan

(1113) Redo Heart Transplantation: The Comparison of Survival Based on the Time Interval Between Transplants; D. Vucicevic1, A. Salimbangon2, A. Chang2, E. Moreno2, M. Kamath2, A. Iyengar2, S. Shah2, M. Deng2, A. Ardehali2, M. Cadeiras2, E. DePasquale2. 1Newark Beth Israel Medical Center, Newark, NJ, 2UCLA, Los Angeles, CA

(1114) The Comparison of Survival in Patients with Redo Heart Transplantation by Era; D. Vucicevic1, A. Chang2, A. Salimbangon2, E. Moreno2, M. Kamath2, S. Shah2, A. Iyengar2, M. Cadeiras2, A. Ardehali2, M. Deng2, E. DePasquale2. 1Newark Beth Israel Medical Center, Newark, NJ, 2UCLA, Los Angeles, CA

(1115) Advanced Heart Failure Therapies in Patients Aged ≥65 Years: Ventricular Assist Device vs. Heart Transplantation; D. M. Harmon1, K. M. Tecson2, A. K. Jamil3, H. Qin1, J. Felius1, B. Lima1, G. V. Gonzalez-Stawinski1, S. M. Joseph1, S. A. Hall1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Heart and Vascular Institute, Dallas, TX

(1116) Combined Heart-Kidney Transplantations: Is it necessary?; O. Konukoglu1, Y. Saltan2, G. Tellioglu2, D. Mansuroglu1, M. Balkanay1. 1Cardiovascular Surgery, Gaziosmanpasa Hospital, Istanbul, Turkey, 2Cardiology, Gaziosmanpasa Hospital, Istanbul, Turkey, 3Kidney Transplantation, General Surgery, Gaziosmanpasa Hospital, Istanbul, Turkey

(1117) Incidence and Outcomes of Cardiac Surgery After Orthotopic Heart Transplantation; M. T. Simpson1, H. Takayama1, J. Han1, P. Kuriansky1, A. R. Garan2, M. A. Farr2, P. C. Colombo2, Y. Naka1, K. Takeda1. 1Dept of Surgery, Columbia Univ Med Center, New York, NY, 2Dept of Medicine, Columbia Univ Medical Center, New York, NY

(1118) Outcome of Cardiac Retransplantation for Late Allograft Failure: A Fifteen-Year Single Center Experience; M. T. Simpson1, H. Takayama1, J. Han1, P. Kuriansky1, A. R. Garan2, M. A. Farr2, P. C. Colombo2, Y. Naka1, K. Takeda1. 1Dept of Surgery, Columbia University College of Physicians & Surgeons, New York, NY, 2Dept of Medicine, Columbia University College of Physicians & Surgeons, New York, NY
(1119) **Mechanical Circulatory Support for Late Cardiac Allograft Failure**; M. T. Simpson¹, H. Takayama¹, J. Han¹, M. Ando¹, M. Cevasco¹, P. Kurlansky¹, A. R. Garan², M. A. Farr², P. C. Colombo², Y. Naka¹, K. Takeda. ¹Dept of Surgery, Columbia University College of Physicians & Surgeons, New York, NY, ²Dept of Medicine, Columbia University College of Physicians & Surgeons, New York, NY


(1121) **Thoracic Organ Transplantation in Patients With Congenitally Corrected Transposition of the Great Arteries**; D. Schibliisky¹, M. Rafiqi¹, L. Kenny², C. Lewis¹, C. Burd³, J. Dunning¹, C. Sudarshan¹, A. Hasan², D. Crossland², L. Coats², S. Tsui¹, J. Parameshwar¹, M. Berman¹. ¹Dept of Transplantation, Papworth NHS Trust, Papworth Everard, Cambridge, United Kingdom, ²Adult Congenital and Children’s Heart Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Dept of Anaesthesia, Papworth NHS Trust, Papworth Everard, Cambridge, United Kingdom


(1123) **Transplant Outcomes in Destination Therapy vs Bridge to Transplant LVAD Patients**; R. J. Miller¹, Y. Moyaedi¹, A. Sharma¹, S. Zarafshari¹, B. Var°, F. Haddad¹, W. Hiesinger¹, D. Banerjee¹. ¹Stanford, Palo Alto, CA, ²Kaiser Permanente, Santa Clara, CA

(1124) **The Effect of Preoperative use of Mechanical Circulatory Support on Survival After Heart Transplantation in Finland**; K. B. Lestrom¹, A. Nykänen², C. Stark², K. Lestrom². ¹Cardiac Surgery, Helsinki University Hospital, Helsinki, Finland, ²Helsinki University Hospital, Helsinki, Finland

(1125) **Low Volume Centers have Inferior Post-Heart Transplant Survival**; H. K. Lamba¹, D. Yoeli¹, F. H. Cheema¹, R. Delgado¹, L. Simpson¹, A. Nair¹, A. B. Civitello¹, A. Rana², T. Rosengart¹, O. Frazier¹, J. A. Morgan¹. ¹Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, ²Division of Abdominal Transplantation, Texas Heart Institute at Baylor College of Medicine, Houston, TX

(1126) **Recipient Cardiac Enzymes: An Early Indicator of Primary Graft Dysfunction**; J. J. Martinez, M. Peltz, J. E. Pruszynski, L. C. Huffman, P. Bajona, M. A. Wait, J. S. Murala, M. E. Jessen, W. S. Ring. Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX

(1127) **The Impact of Gender Mismatch on Survival After Heart Transplantation**; S. Avtaar Singh¹, S. Das De¹, C. Berry², N. Banner³, N. Al-Attar³. ¹Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ³Cardiology and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, ⁴Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(1128) **Center Characteristics Play a Leading Role in Geographic Disparities in Access to Heart Transplantation in France**; C. Cantrelle¹, R. Dorent¹, E. Savoye¹, P. Tuppin², G. Lebreton³, C. Legelai¹, O. Bastien¹. ¹Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, ²Medical & Scientific, Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France, ³Medical & Scientific, Assistance Publique Hôpitaux de Paris - Hôpital de la Pitié Salpêtrière, Paris, France

(1129) **Ideal Body Weight May Be A Better Comparative Variable than Actual Body Weight for Donor-Recipient Matching in Orthotopic Heart Transplantation**; B. Hoemann, M. Cevasco, H. Takayama, J. Han, P. Kurlansky, P. Colombo, M. Farr, Y. Naka, K. Takeda. Columbia University College of Physicians and Surgeons, New York City, NY

(1130) **Survival in Re-Do Heart Transplant: Does Dual Organ Allocation Make a Difference?**; M. Y. Kamath, N. Bassi, J. Wilson, N. Bellam, T. Khuu, A. Iyengar, D. Vucicevic, M. Deng, A. Ardehali, E. Depasquale. UCLA, Los Angeles, CA


(1133) **Is the Luminex 1:8 Dilution Truly the Poor Man's C1q for Patients Awaiting Heart Transplantation?**; M. Kittleson, J. Patel, L. Czer, D. H. Chang, S. Dimbil, R. Levine, R. Bleiker, E. Kransdorf, F. Esmaillian, X. Zhang, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA


(1138) **In Sensitized Pre-Transplant Patients, Does IVIG after Heart Transplant Have any Benefit?**; J. Patel, M. Kittleson, L. Czer, D. Geft, S. Dimbil, R. Levine, B. Kearney, E. Kransdorf, F. Esmaillian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**LUNG TRANSPLANTATION**

*(Euterpe)*

**Poster Discussants:** Clemens Aigner (Germany), Michael Durheim (USA), Are Holm (Norway), Tereza Martinu (Canada), Josh Mooney (USA), Pali Shah (USA), Aida Venado (USA), Erik Verschuuren (Netherlands), Keith Wille (USA)

(1139) **Long Distance Relationships - Does the Geographic Distance From the Transplant Centre Affect Lung Transplant Outcomes?**; E. Khoshbin, J. Battle, H. Muse, K. Wallace, G. Ditchburn, G. Parry, S. Clark. 1Dept of Cardiac Surgery and Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 2Dept of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 3IAS Medical, London, United Kingdom


(1141) **Hyaluronan in Acute Rejection After Lung Transplantation**; J. L. Todd, M. L. Neely, C. Brinkley, F. L. Kelly, C. W. Frankel, J. Kirchner, J. A. Belperio, M. Budev, P. D. Shah, L. G. Singer, J. M. Reynolds, S. M. Palmer. 1Duke Univ Med Ctr, Durham, NC, 2University of California Los Angeles, Los Angeles, CA, 3Cleveland Clinic, Cleveland, OH, 4Johns Hopkins University, Baltimore, MD, 5University of Toronto, Toronto, ON, Canada

(1142) **Early Acute Cellular Rejection in Lung Transplant Recipients is Associated with Greater Variation in the Lung Allograft Microbiome**; C. J. Iasella, C. R. Ensor, A. Morris, B. Methé, J. F. McDyer. 1Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA

(1143) **Untreated Subclinical Minimal Acute Rejection Does Not Increase the Risk for Chronic Lung Allograft Dysfunction and Death After Lung Transplantation**; L. Levy, W. Klement, E. Husztí, M. Ahmed, J. Tikkakanen, R. Zamel, S. Azad, P. Fiset, D. Hwang, G. Tomlinson, S. Keshavjee, L. Singer, S. Juvet, T. Martinu. 1Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada, 3Dept of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
(1144) Risks and Benefits of Surveillance Transbronchial Biopsy after Lung Transplantation: A Single Center Experience; D. Tosi, R. Carrinola, L. Morlacchi, P. Tarsia, S. Sarzana, F. Damiano, M. Cattaneo, A. Palleschi, M. Nosotti. Fondazione Ca’ Granda IRCCS Policlinico Milan, Milano, Italy

(1145) Selection of Lung Transplant Candidates: A Look Behind the Scene; A. Lenoir, C. Perez-Valdes, J. D. Aubert. Service de Pneumologie, Lausanne University Hospital, Lausanne, Switzerland

(1146) Presence of de Novo Donor-Specific Antibodies to HLA-DQ in Lung Transplant Recipients Predicts Poor Survival; E. A. Belloli, L. Fitzgerald, D. Lyu, O. Moussa, K. Chan. Internal Medicine, Michigan Medicine, Ann Arbor, MI. Pharmacy, Michigan Medicine, Ann Arbor, MI. Pathology, Michigan Medicine, Ann Arbor, MI

(1147) HLA Donor Specific Antibody and HLA Antigen Bias are Independent Risk Factors for Chronic Lung Allograft Dysfunction; T. K. Roberts, M. Steele, D. Nunley. Dept of Pathology, University of Louisville, Louisville, KY. Trager Transplant Center, KentuckyOne Jewish Hospital, Louisville, KY. Dept of Internal Medicine, Lung Transplantation, University of Louisville, Louisville, KY


(1149) Early Detection of Chronic Lung Allograft Dysfunction After Bilateral Living Donor Lobar Lung Transplantation by Computed Tomographic Scanning Scoring Method; E. Niman, K. Miyoshi, S. Namura, T. Kurosaki, S. Ohtani, S. Sugimoto, M. Yamane, S. Toyooka, T. Oto. Dept of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama city, Japan

(1150) High Circulating CD4⁺CD25⁺FOXP3⁺ T Cell Subpopulation Early After Lung Transplantation is Associated With Development of Bronchiolitis Obliterans Syndrome; M. Durand, P. Lacoste, R. Danger, A. Tissot, C. Brosseau, N. Degauque, A. Magnan, S. Bourd, INSERM UMR 1064, Centre de Recherche en Transplantation et Immunologie, Nantes, France. INSERM UMR 1087, Institut du Thorax, Nantes, France


(1152) The Incidence of Chronic Lung Allograft Dysfunction After Cadaveric Lobar Lung Transplantation is Comparable to Conventional Lung Transplantation; I. Inci, M. Schuurmans, I. Iskender, S. Hillinger, I. Opitz, D. Schneider, C. Caviezel, C. Benden, W. Weder. Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. Pulmonology, University Hospital Zurich, Zurich, Switzerland

(1153) Circulating CD9⁺ B Cells: Biomarker of Long-term BOS-free Survival After Lung Transplantation; A. Tissot, M. Durand, E. Durand, A. Foureau, R. Danger, A. Magnan, S. Bourd, INSERM UMR1064, Centre de Recherche en Transplantation et Immunologie, Nantes, France. INSERM UMR1087, Institut du Thorax, Nantes, France

(1154) Bronchiolitis Obliterans Syndrome in Lung Transplantation: A Predictive Model; A. Khurshudyan, A. Iyengar, O. Kwon, M. Caceres, E. Eisenring, D. Ross, A. Ardehali. University of Illinois College of Medicine, Chicago, IL. David Geffen School of Medicine at UCLA, Los Angeles, CA


(1156) Predictors of Long Term Survival in Patients With Cystic Fibrosis Following Lung Transplantation; C. A. Robinson, A. Deibel, M. M. Schuurmans, I. Inci, C. Benden. Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland. Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

(1157) Standardizing and Improving the Classification for Causes of Death Post Lung Transplantation; K. Levin, M. Paraskeva, G. Westall, B. Levvey, G. Snell. Dept of General Respiratory and Lung Transplantation, The Alfred Hospital, Melbourne, Australia
(1158) Psoas Muscle Mass Predicts Early Postoperative Outcomes and Survival in Lung Transplantation; J. Suh, J. Lee, H. Paik, K. Narm, M. Park, S. Kim. 1Thoracic surgery, Yonsei University college of medicine, seoul, Korea, Republic of, 2Internal medicine, Yonsei University college of medicine, seoul, Korea, Republic of


(1160) “My Best Spirometry Numbers- What Do They Mean?”; M. R. Mohanka, R. Kanade, H. Garcia, J. Mullins, S. Bollineni, V. Kaza, F. Torres, A. Banga. UT Southwestern Medical Center, Dallas, TX

(1161) Air Trapping on Lung Scintigraphy After Lung Transplantation: Predictors and Association with Survival; H. Garcia, R. Kanade, L. D. Mahan, S. Castillo, D. Pinho, V. Kaza, M. Mohanka, D. Mathews, F. Torres, A. Banga. UT Southwestern Medical Center, Dallas, TX


(1166) Incidence and Outcomes of Post-lymphoproliferative Disorder in Lung Transplant Recipients. Analysis of the ISHLT Registry; L. Zaffiri, M. Neely, W. Cherikh, J. Stehlik, L. Snyder. 1Pulmonary and Critical Care, Duke University, Durham, NC, 2Biostatistics & Bioinformatics, Duke University, Durham, NC, 3UNOS, Richmond, VA, 4University of Utah, Salt Lake City, UT

(1167) Low Correlation Between PCWP and LVEDP in Patients With End-Stage Lung Disease; A. Kafi, B. Lindgren, G. Chaux, J. Mirocha, W. Cheng, D. Ramzy, J. Falk. 1Pulmonary and Critical Care, Cedars Sinai Medical Center, Los angeles, CA, 2Biostatistics and Bioinformatics, Cedars Sinai Medical Center, Los angeles, CA, 3Cardiothoracic Surgery, Cedars Sinai Medical Center, Los angeles, CA

(1168) Role for Assessment of Diaphragm Function Prior to Lung Transplant; S. E. Cohen, D. S. Tabari, N. Patel, G. E. Chaux. 1Pulmonary and Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, 2Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

(1169) Single and Double Lung Transplantation in Idiopathic Pulmonary Fibrosis: A Review of Pulmonary Artery Mean Pressure; M. A. Kashem, S. Keshavamurthy, J. Gomez-Abraham, Y. Toyoda. Cardiovascular Surgery, Temple University, Philadelphia, PA

(1170) Prevalence and Predictors of Coronary Artery Disease in Patients Evaluated for Lung Transplantation; H. Fernando, S. Noaman, G. Snell, A. Dart, J. Shaw, W. Chan. 1Cardiology, Alfred Hospital, Prahran, Australia, 2Lung Transplant, Alfred Hospital, Prahran, Australia

(1171) Prevalence of Post-transplant Diabetes Mellitus (PTDM) and Cardiovascular (CV) Risk Factors After Lung Transplantation; J. M. Leung, B. Paty, M. Almehthel, N. Partovi, J. Yee, R. D. Levy. 1Dept of Medicine, Division of Endocrinology, The University of British Columbia, Vancouver, BC, Canada, 2Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, 3Dept of Surgery, Division of Thoracic Surgery, The University of British Columbia, Vancouver, BC, Canada, 4Dept of Medicine, Division of Respirology, The University of British Columbia, Vancouver, BC, Canada
(1172) Diagnostic Value of Peripheral and Bronchoalveolar Leukocyte Profile in Lung Transplant Recipients After Alemtuzumab Induction Therapy. A Single Center Experience: Z. Á. Kováts¹, A. Bohacs¹, Z. I. Komlosi¹, A. Bikov¹, Z. Süttő¹, G. Lang², G. Losonczy¹, V. Müller¹. ¹Dept of Pulmonology, Semmelweis University, Budapest, Hungary, ²Dept of Thoracic Surgery, Semmelweis University, Budapest, Hungary

(1173) Short Term Outcomes After Lung Transplantation: Sternotomy Offers Advantages Over Clamshell Approach: G. N. Mody¹, D. Larios Chavez¹, D. Varon², C. Kerwin¹, A. Coppolino¹, R. Madathil¹, S. Singh¹, P. Camp¹, H. Goldberg³, H. R. Mallidi¹. ¹Surgery, Brigham and Women's Hospital, Boston, MA, ²Medical School, University of Michigan, Ann Arbor, MI, ³Medicine, Brigham and Women's Hospital, Boston, MA

(1174) Sternal Closure by Rigid Plate Fixation versus Traditional Technique After Clamshell Incision for Bilateral Lung Transplantation: M. N. Samano¹, H. F. Costa¹, L. M. Fernandes¹, L. Abdalla¹, O. Gomes Jr.¹, D. C. Mondadori¹, S. V. Campos², R. M. Carraro², P. M. Pego-Fernandes¹. ¹Thoracic Surgery Division, Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pulmonology Division, Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

(1175) Cardiopulmonary Bypass Use Does Not Affect Outcomes in Single Lung Transplantation: A. Iyengar¹, A. Khurshudyan², O. Kwon², M. Caceres Polo³, C. Eisenring³, R. Biniwale², D. Ross³, A. Ardehali³. ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of Illinois College of Medicine, Chicago, IL, ³University of California - Los Angeles, Los Angeles, CA

(1176) Recipient Working Status is Independently Associated with Outcomes in Lung Transplantation: A. Iyengar¹, M. Caceres Polo², O. Kwon², N. Faqi¹, R. Biniwale², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

(1177) Single vs. Double Lung Transplantation in Patients over Age 65: A. Iyengar¹, M. Caceres Polo², O. Kwon², J. Schenaanm², R. Biniwale², D. Ross², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA


(1179) Desensitization in Lung Transplant Recipients with a Positive Virtual Crossmatch: S. Hammad, B. Ravichandran, J. Kim, D. KuKuruga, M. McLenon, Z. Kon. University of Maryland Medical Center, Baltimore, MD

(1180) Effect of Rabbit Anti-Thymocyte Globulin Induction Therapy on the Incidence of Acute Cellular Rejection and Infection Complications After Lung Transplantation: J. Havlin¹, D. Pauksch¹, T. Dousova², J. Kolarik¹, M. Svorcova¹, L. Valenova-Bartakova³, J. Pozniak¹, J. Simonek¹, R. Lischke¹. ¹3rd Dept of Surgery, Motol University Hospital, Prague 5, Czech Republic, ²Dept of Pediatric Pneumology, Motol University Hospital, Prague 5, Czech Republic, ³Dept of Pneumology, Motol University Hospital, Prague 5, Czech Republic

(1181) The Impact of Azithromycin on the Post Lung Transplant Microbiome: S. E. Verleden¹, C. Spence², G. Einarsson², E. Johnston², A. J. Lee³, B. Vanaudenaerde¹, S. Elborn², D. Gilpin², R. Vos¹, M. Tunney². ¹KU Leuven, Leuven, Belgium, ²Queen’s University, Belfast, United Kingdom, ³Queen’s University, Belfast, Ireland

(1182) Safety of Early Sirolimus Immunosuppression in Lung Transplantation: J. Wojarski, S. Zeglen, M. Ochman, W. Karolak. Dept of Cardiac Surgery and Transplantology, Silesian Center for Heart Disease, Zabrze, Poland


(1184) Single Lung Transplantation in Patients with Severe Secondary Pulmonary Hypertension: B. S. Nasir, M. S. Mulvihill, M. Bishawi, M. L. Cox, D. J. Megna, J. C. Haney, J. A. Klapper, M. A. Daneshmand, M. G. Hartwig. Duke University Medical Center, Durham, NC
(1185) Does Center Volume Affect Failure to Rescue Rates in Lung Transplantation? A U.S. Nationwide Analysis; A. A. Osho1, M. Bishawi2, S. Hirji3, M. Mulvihill4, A. Axtell1, S. Melnitchouk5, D. D'Alessandro5, T. Astor5, M. Hartwig2, M. Villavicencio5, 1Dept of General Surgery, Massachusetts General Hospital, Boston, MA, 2Dept of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC, 3Dept of General Surgery, Brigham and Women's Hospital, Boston, MA, 4Dept of General Surgery, Duke University School of Medicine, Durham, NC, 5Dept of Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA

(1186) Outcomes Following Use of a Novel Treatment Protocol for Antibody Mediated Rejection After Lung Transplantation; V. Rusinov1, K. M. Willie1, N. S. Sharma2, C. B. Baker3, A. H. Johnson4, S. B. Pruitt5, N. J. Bush5, B. Wei5, C. W. Hoopes6, S. R. Duncan7, V. G. Valentine7, 1Medicine, Univ of Alabama at Birmingham, Birmingham, AL, 2Medicine, Univ of South Florida, Tampa, FL, 3Pharmacy, Virginia Commonwealth University, Richmond, VA, 4Surgery, Univ of Alabama at Birmingham, Birmingham, AL, 5Univ of Alabama at Birmingham, Birmingham, AL

(1187) Use of Sirolimus in Patients with Lymphangioleiomyomatosis (LAM) on Waiting Lists for Lung Transplant LTX; D. F. Dilling1, A. Nair2, C. J. Gries3, L. E. Beard4, A. J. Fisher2, S. R. Johnson5, F. X. McCormack6, 1Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 2Institute of Transplantation, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 3Florida Hospital, Orlando, FL, 4Dept of Medicine, University of California San Francisco, San Francisco, CA, 5Division of Respiratory Medicine, The University of Nottingham, Nottingham, United Kingdom, 6Division of Pulmonary & Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, OH

(1188) Cardiovascular Autonomic Control in End Stage Lung Disease Before Lung Transplantation; L. Morlacchi1, A. Monti2, E. Tobaldini2, V. Rossetti1, S. Henchi1, I. Righi3, S. Aiberti1, P. Terrasi4, N. Montano5, 1Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 2Dept of Internal Medicine; Dept of Clinical Sciences and Community Health, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 3Thoracic and Lung Transplant Surgery, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(1189) Elevated Pre-transplant Left Ventricular End Diastolic Pressure is Associated With Increased Risk of Primary Graft Dysfunction in Lung Transplant Recipients; D. Li, J. Weinkauf, A. Kapasi, A. Hirji, J. Nagendra, D. Lien, J. Ezekowitz, K. Halloran, University of Alberta, Edmonton, AB, Canada

(1190) MiRNA’s Profiling and Primary Graft Dysfunction: Novel Non-invasive Biomarkers; A. Palleschi1, V. Vaira2, G. Gaudioso3, M. Formica4, V. Musso4, R. Carrinola1, L. Morlacchi3, P. Tarsia3, A. Terrasi2, L. Rossio1, S. Ferrero6, 1Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, 2Division of Pathology, Fondazione IRCCS Ca’Granda - Ospedale Maggiore Policlinico, Milan, Italy, 3Pneumology Unit, Fondazione IRCCS Ca’Granda - Ospedale Maggiore Policlinico, Milan, Italy

(1191) Impact of Ischemic Time on Primary Graft Dysfunction: A National Analysis; K. Anderson1, A. Rucker1, M. Mulvihill2, B. Yerokun3, M. Hartwig2, 1Duke University School of Medicine, Durham, NC, 2Surgery, Duke University Medical Center, Durham, NC

(1192) Negative Impact of Primary Graft Dysfunction Grade 3 within the Initial 72 Hours on Short and Long Term Clinical Outcomes in Standard Criteria Double Lung Transplants: Prospective Evidence from the OCS Lung INSPIRE International Trial Results; A. Ardehali1, D. Van Raemdonck2, J. Kukreja3, M. Smith4, G. Loor5, F. Rea6, G. Massard7, F. De Robertis8, J. Nagrendran9, J. Moradiellos10, K. Dhillon11, C. Knosalla12, C. Bermudez13, S. Tsui14, J. Madsen15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, I. Tudorache20, B. Wiegmann21, M. Schiavon22, F. Calabrese23, N. Santelmo24, O. Olland25, P. Falcoz26, A. Varela27, M. Hertz28, A. Simon29, H. Resichenspurner30, A. Haverich21, G. Warnecke21, 1UCLA Sch of Med, Los Angeles, CA, 2Leuven University Hospital, Leuven, Belgium, 3University of California San Francisco Medical Center (UCSF), San Francisco, CA, 4St. Joseph’s Medical Center, Phoenix, AZ, 5University of Minnesota Medical Center, Minneapolis, MN, 6University of Padua Hospital, Padua, Italy, 7University Hospital of Strasbourg, Strasbourg, France, 8Harefield Hospital, London, United Kingdom, 9University of Alberta Medical Center, Edmonton, AB, Canada, 10University Puerta de Hierro Hospital, Madrid, Spain, 11St. Vincent’s Hospital, Sydney, Australia, 12German Heart Institute, Berlin, Germany, 13University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 14Papworth Hospital, Cambridge, United Kingdom, 15Massachusetts General Hospital, Boston, MA, 16Indiana University Health Methodist Hospital, Indianapolis, IN, 17Cleveland Clinic Foundation, Cleveland, OH, 18University of Hamburg, Hamburg, Germany, 19University Hospitals of Marseille, Marseille, France, 20Hannover Medical School, Hannover, Germany, 21Hamburg University Hospital, Hamburg, Germany
(1193) The Use of Inhaled Nitric Oxide versus Inhaled Epoprostenol in High Risk Lung Transplant Recipients: A. Wexler1, M. Patel2, J. Rusinak1, E. Mancl1, S. Quddus2. 1Pharmacy, Loyola University Medical Center, Maywood, IL, 2Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

(1194) Prognostic Value of PaO2/FiO2 Ratio at the End of Double-Lung Transplantation; J. Thes1, J. Fessler1, R. Pirracchio2, A. Roux1, E. Sage1, C. Cerf1, M. Fischler1, M. Le Guen1. 1Foch Lung Transplant Team, Suresnes, France, 2Hopital European Georges Pompidou, Paris, France

(1195) Inhaled Nitric Oxide Dependency at the End of Double-Lung Transplantation: A Boosted Propensity Score Cohort Analysis; M. Godement1, J. Fessler1, E. Sage1, A. Roux1, C. Cerf1, R. Pirracchio2, M. Fischler1, M. Le Guen1. 1Foch Lung Transplant Team, Suresnes, France, 2Hopital European Georges Pompidou, Paris, France

(1196) Preoperative Epidural Use in Lung Transplantation: A New Frontier in Pain Management?; A. Krishnan1, J. Hsu1, N. Weltman2, J. Orens3, P. Shah3, R. S. Higgins1, S. R. Broderick1, C. A. Merlo3, M. N. Hanna2, E. L. Bush1. 1Surgery- Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 3Medicine- Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

(1197) Comparison of Extra Corporeal Membrane Oxygenation versus Cardiopulmonary Bypass Support for Lung Transplantation; V. Mehta1, J. Hasan1, J. Salaie1, E. Milser2, K. Santhanakrishnan3, M. Al-Abou3, I. Dimarakis1, J. Barnard1, R. Venkateswaran1. 1Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2Blood Transfusion Practitioner, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 3Respiratory/Transplant Physician, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(1198) Bile Acid Aspiration is Associated with Airway Infections: A Targeted Metabolomic Approach; A. Urso1, D. F. Briganti1, J. Costa1, R. Nandakumar2, H. Robbins1, L. Shah1, J. R. Sonett3, S. Cremer2, S. Arcasoy1, F. D'Ovidio1. 1Lung Transplant Program, Columbia Univ, New York, NY, 2Pathology, Columbia Univ Medical Center, New York, NY

MECHANICAL CIRCULATORY SUPPORT
(Agora 3)

Poster Discussants: Maya Guglin (USA), Maryl Johnson (USA), Minoru Ono (Japan), Nicola Robinson Smith (United Kingdom), Keyur Shah (USA), Cumara Sivathasan (Singapore), Mary Cristy Smith (USA), Benjamin Sun (USA), Veli Topkara (USA), Patricia Uber (USA), Richard Wampler (USA), Melana Yuzefpolskaya (USA)

(1199) Bridge to Cancer Therapy: Can LVAD Support Allow Advanced Heart Failure Patients to Survive Cancer Treatment?; J. Raikhelkar1, P. Ivak2, C. LaBuhn3, B. Chung1, A. Nguyen1, N. Narang1, S. Kalantari1, N. Sarwari1, G. Kim1, G. Sayer1, T. Song3, T. Ota1, V. Jeevanandam3, J. Maly1, I. Netuka2, N. Uriel1. 1Cardiology, University of Chicago, Chicago, IL, 2Cardiac Surgery, Institute for Clinical and Experimental Medicine(IKEM), Prague, Czech Republic, 3Cardiac Surgery, University of Chicago, Chicago, IL

(1200) A Risk Model Incorporating Pectoralis Muscle Measures More Accurately Risk Predicts Mortality after Left Ventricular Assist Device Implantation; L. M. Teigen1, C. P. Earthman1, J. Hodges2, J. Shultz3, C. Martin4, R. John5, R. Cogswell64. 1Food Science and Nutrition, University of Minnesota, St. Paul, MN, 2Dept of Biostatistics, University of Minnesota, Minneapolis, MN, 3Dept of Medicine, University of Minnesota, Minneapolis, MN, 4Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 5Dept of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

(1201) Predicting Post-LVAD Mortality Across a Diverse HF Population Using Bayesian Analysis; M. Kanwar1, L. Lohmuller2, S. Bailey1, C. McIlvennan3, R. Kormos4, S. Murali1, J. Antaki2. 1Allegheny General Hospital, Pittsburgh, PA, 2Carnegie Mellon University, Pittsburgh, PA, 3University of Colorado, Denver, CO, 4University of Pittsburgh, Pittsburgh, PA

(1203) After the Referral: How Patients Fare After Evaluation for Left Ventricular Assist Device Placement; S. N. Yu, M. Cevasco, J. Han, M. Flannery, P. C. Colombo, H. Takayama, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY

(1204) Preoperative Predictors of Early Right Ventricular Failure After Left Ventricular Assist Device Implantation for Stable Patients in Intermacs 3-5 Status; M. J. Ruiz-Gano, E. Ljajikj, L. Paluszkiwicz, J. Boergermann, M. Schoenbrodt, V. Lauenroth, E. Prashovjik, J. Gummert, M. Morhuis. Thorax- und Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Bad Oeynhausen, Germany

(1205) Blood Group O Heart Transplant Waitlist Mortality in the Ventricular Assist Device Era; J. Trivedi1, R. Vijayakrishnan2, M. Slaughter1, E. Birks3, D. Abramov4. 1Dept of Cardiovascular and Thoracic Surgery, Louisville Univ, Louisville, KY, 2Dept of Cardiology, Louisville Univ, Louisville, KY, 3Cardiology, Loma Linda Univ, Loma Linda, CA

(1206) Systems Biological Identification of an Age-related Predictor of Functional Recovery Potential in Advanced Heart Failure; G. Bondar5, T. Bao6, R. Manoharan7, R. Togashi1, N. Agrawal8, S. Ramachandrula9, J. Hai10, D. Chu11, L. Masukawa12, M. Cadeiras12, J. Schaeenman12, E. Chang1, A. Le13, R. Dod1, C. Kahn1, E. Oh1, J. Do1, C. Lumintang1, S. Kupiec-Weglinski5, V. Groyssberg5, T. Grogan4, M. Rossetti4, D. Elashoff4, E. Reed4, P. Ping4, M. Deng1. 1Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA, 2Strand NGS Avadis, Bangalore, India, 3Cornell University, Ithaca, NY, 4University of California Los Angeles, Los Angeles, CA

(1207) Heart Failure Clinicians Want to Revive the REVIVE-IT Study Following the Results of the MOMENTUM 3 and ENDURANCE Supplement Trials; G. Sayer1, A. Anderson2, E. Raichlin3, C. Gupta4, K. Kim5, J. Raikfeltkar1, E. Vorovich6, D. Pham5, V. Jeevanandam7, T. Song5, D. Onsager6, D. Rodgers5, N. Uriel1. 1Cardiology, University of Chicago, Chicago, IL, 2Cardiology, Northwestern University, Chicago, IL, 3Cardiology, Loyola University, Chicago, IL, 4Cardiology, NorthShore University HealthSystem, Chicago, IL, 5Cardiac Surgery, Northwestern University, Chicago, IL, 6Cardiac Surgery, University of Chicago, Chicago, IL

(1208) Early Postoperative Organ Function Recovery Score and Long-term Survival in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support; L. M. Masukawa1, T. Bao1, R. Dod1, R. Togashi1, M. Cadeiras1, J. Schaeenman1, J. Hai1, D. Chu1, E. Chang1, S. Kupiec-Weglinski5, V. Groyssberg5, A. Le1, C. Kahn1, E. Oh1, J. Do1, C. Lumintang1, T. Grogan1, J. Meltzer1, M. Kwon1, M. Rossetti1, D. Elashoff1, E. Reed1, P. Ping1, G. Bondar1, M. C. Deng1. 1Medicine/Cardiology, Univ of California, Los Angeles, Los Angeles, CA, 2Medicine/Cardiology, Cornell Univ, Ithaca, NY

(1209) Predictors of Survival to Discharge After VA-ECMO Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock; J. A. Fried1, K. Takeda2, K. Clerkin1, M. Ando2, A. Masumia2, V. Topkara2, D. Burkhoff1, M. Yuzefpoiskaya1, A. Kirtane1, D. Karmpaliotis1, P. C. Colombo1, Y. Naka2, H. Takayama2, A. Garan1. 1Medicine, Columbia University New York, New York, NY, 2Surgery, Columbia University, New York, NEW

(1210) A Comparison of Renal Outcomes in Patients With LVAD and Heart Transplantation; A. Arshad, E. Kew, N. Howell, A. Ranasinghe, J. Mascaro, S. Lim. University Hospital Birmingham, Birmingham, United Kingdom

(1211) Psoas Muscle Diameter in Patients Undergoing Left Ventricular Assist Device Implantation; G. Yost, G. Bhat, M. Nagarkatte, A. Bhan, B. Kyi, S. Asokan, P. Pappas, A. Tatooles. Heart Institute, Advocate Christ Medical Center, Chicago, IL

(1212) Pre-Operative Pectoralis Muscle Measures by Computed Tomography Predict Early Right Heart Failure Deaths After Left Ventricular Assist Device; R. Cogswell1, L. Teigen2, J. Schultz2, T. Thenapan2, L. Lin4, J. Kealhofer1, C. Martin1, R. John1. 1Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 2Food Science and Nutrition, University of Minnesota, Minneapolis, MN, 3Dept of Medicine, University of Minnesota, Minneapolis, MN, 4Dept of Medicine, University of Minnesota, Minneapolis, MN, 5Dept of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

(1213) Socioeconomic Status Influences Outcomes for Patients Undergoing Heart Transplantation But Not LVAD Implantation; A. C. Coniglio1, J. N. Katz2, R. Watkins3, S. B. Waters2, M. E. Andrews2, B. C. Jensen2, L. J. Rose-Jones2, P. P. Chang1. 1Internal Medicine, University of North Carolina, Durham, NC, 2Cardiology, University of North Carolina, Durham, NC, 3University of North Carolina, Durham, NC

(1214) Is Pre-Operative Colonoscopy Screening for LVAD Therapy Needed for Higher INTERMACS Profile Patients in the Current Era?; A. Bansal1, K. Marz2, S. Desai2, J. Bhama2. 1Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA, 2Heart Failure and Heart Transplant, Ochsner Clinic Foundation, New Orleans, LA, 3Cardiothoracic Surgery, University of Iowa Health Care, Iowa City, IA

(1216) **Predictors of Neurologic Outcomes After Extracorporeal Cardiopulmonary Resuscitation**: J. Han1, M. Ando1, M. Cevasco1, P. A. Kurliansky1, A. R. Garan2, P. C. Colombo2, H. Takayama1, Y. Naka1, K. Takeda1. 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; 2Division of Cardiology, Columbia University Medical Center, New York, NY

(1217) **Use of Veno-arterial ECMO as Salvage Treatment in Patients With Refractory Post-cardiotomy Shock**: Single Center Experience; K. Mudy1, H. Tavangar2, K. Hryniewicz1, K. Wilson2, R. Garberich2, B. Sun1. 1Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN; 2Minneapolis Heart Institute Foundation, Minneapolis, MN

(1218) **Outcomes After Left Ventricular Assist Device Implant in Patients Requiring Peri-operative Dialysis**: G. A. Hernandez, C. Rueda, J. Boone, J. Lindenfeld, M. A. Wigger. *Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN*

(1219) **Pre-implantation Hepatic Imaging as a Predictor of LVAD Morbidity**: C. J. van Niekerk1, A. C. Pandey2, J. T. Heywood3, A. V. Srivastava3, R. Mohan3. 1Medicine, Scripps Clinic, La Jolla, CA; 2Div of Cardiology, Scripps Clinic/TSRI/STSI, La Jolla, CA; 3Div of Cardiology, Section of Heart Failure Research and Recovery, Scripps Clinic, La Jolla, CA

(1220) **Mid-term Survival after Ventricular Assist Device Implantation in Patients ≥ 70 Years**: N. Pizanis1, H. Carstens1, A. Koch1, P. Luedike2, T. Rassaf2, M. Kamler3. 1Thoracic and Cardiovascular Surgery, West German Heart Center Essen, Essen, Germany; 2Cardiology, West German Heart Center Essen, Essen, Germany

(1221) **Sex-Related Differences in Patients Undergoing Left Ventricular Assist Device Implantation as Destination Therapy**: A Single Center Experience; A. K. OKOH, M. Schultheis, C. Gidea, M. Russo, M. Zucker, M. Camacho. *RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*

(1222) **WITHDRAWN**

(1223) **Time is on Your Side: A Comparison of OR Times with ECMO Survival in Post Cardiotomy Patients**: A. Luksan1, D. B. Berkheim2, T. Ryan2, E. Lyden3, J. Y. Um2, A. Siddique2, M. J. Moulton2, H. Merritt2. 1Anesthesiology, University of Nebraska Medical Center, Omaha, NE; 2Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE; 3University of Nebraska Medical Center, Omaha, NE

(1224) **Spousal Support Does Not Affect Outcomes in Patients with Continuous Flow Left Ventricular Assist Device**: A. Topoll1, A. Althouse, K. Lockard, E. Dunn, N. Kunz, M. Dew, A. Kilic, C. Sciortino, M. Mathier, M. Shullo, R. Kormos, G. Hickey. *HVI, UPMC Presbyterian Hospital, Pittsburgh, PA*

(1225) **SIPAT May Predict Clinical Outcomes in Patients With Left Ventricular Assist Device (LVAD)**: Q. M. Bui, O. O. Braun, M. Brambatti, Y. Ko, H. Hernandez, N. Wettersten, H. A. Tran, V. Pretorius, E. Adler. *University of California San Diego, La Jolla, CA*

(1226) **Unique Predictors of 12 Month Mortality in Ischemic and Non-Ischemic LVAD Patients**: C. Khoo1, M. Kanwar2, L. E. Lohmueller1, S. Murali2, J. Antaki1. 1Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA; 2Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA


(1228) **Left Ventricular Assist Devices in INTERMACS 1 Acute Cardiogenic Shock Patients**: C. Louis1, U. Daimee2, I. Gosev1, S. Prasad1, S. McNitt3, A. Papernov2, J. Alexis3, V. Kutyla2. 1Cardiothoracic Surgery, URMC, Rochester, NY; 2Heart Research Follow-up Program, URMC, Rochester, NY; 3Cardiology, URMC, Rochester, NY

(1229) **Impact of Contemporary Ventricular Assist Device Therapy on Renal Outcomes in End Stage Heart Failure**: P. Z. Xu1, S. Wu1, H. Tun1, G. Adenuga2, M. Fong2. 1LAC USC Medical Center, Los Angeles, CA; 2Keck Medical Center, Los Angeles, CA

(1231) PROMOTED TO MINI ORAL


(1233) Overall Satisfaction and Adjustment After LVAD Using the QOLVAD: M. Soni1, K. Sandau2, R. Garberich3, B. A. Hoglund3, J. Cowger4, E. Y. Birati4, 1Medicine, University of Pennsylvania, Philadelphia, PA, 2Nursing, Bethel Univ, St. Paul, MN, 3Cardiovascular Medicine, Minneapolis Heart Institute, Minneapolis, MN, 4Metropolitan State Univ, St. Paul, MN, 5St. Vincent, Indianapolis, IN, 6Cardiovascular Medicine, Univ of Pennsylvania, Philadelphia, PA

(1234) Stability of Patient Values in the Face of Invasive Therapies for Life-threatening Illness: Insights from the DECIDE-LVAD Trial; L. A. Allen1, C. E. Knoopke2, E. C. Leister2, J. S. Thompson2, C. K. McIlvennan1, A. V. Ambardekar1, R. M. Arnold3, D. D. Matlock2. 1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, 2Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, CO, 3University of Pittsburgh, Pittsburgh, PA

(1235) Impact of the Thoracotomy Untethered LVAD Implant Approach on Patient Self-Reported Quality of Life in the HVAD LATERAL Trial; A. Cheung1, M. R. Danter2, N. A. Mokadam3, C. Mahr3, M. S. Kiernan4, D. T. Pham5, T. Boeve6, S. S. Najjar7, T. A. Vassiliades8, E. McGee9, 1University of British Columbia, Vancouver, BC, Canada, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Washington, Seattle, WA, 4Tufts Medical Center, Boston, MA, 5Northwestern, Chicago, IL, 6Spectrum Health, Grand Rapids, MO, 7MedStar Health, Washington, DC, 8Medtronic, Framingham, MA, 9Loyola University Medical Center, Maywood, IL

(1236) Life During Long Term LVAD Support; C. J. LaBuhn, V. Jeevanandam, D. Rodgers, T. Ota, G. Sayer, G. Kim, N. Uriel. Cardiac Surgery, University of Chicago, Chicago, IL

(1237) Spiritual Well-Being in LVAD Recipients Measured by FACIT-Sp is Comparable to Patients with Malignancy; P. M. Eckman1, R. Garberich1, C. E. Weaver1, S. Joseph2, S. Carey2, S. Hall2, J. Cowger1, S. P. Chaudhry3, S. Schroeder4, E. Birati5, M. Soni6, J. Marble5, B. Hoglund4, K. E. Sandau7. 1Minneapolis Heart Institute, Minneapolis, MN, 2Baylor Univ Medical Center, Dallas, TX, 3St. Vincent Heart Center, Indianapolis, IN, 4Bryan Heart Center, Lincoln, NE, 5Univ of Pennsylvania, Philadelphia, PA, 6Metropolitan State Univ, Saint. Paul, MN, 7Bethel Univ, Saint Paul, MN

(1238) Restoring Quality of Life - Untethered LVAD Swimming; J. Webster, A. Krishnamoorthy, T. Hrobowski, A. Yehya, A. Darlington, C. Marti, D. Dean. Advanced Heart Failure, Piedmont Heart, Atlanta, GA

(1239) Quality of Life with a Ventricular Assist Device (QOLVAD) Questionnaire: Preliminary Psychometrics for a New Measure: K. E. Sandau1, B. Pozehl2, C. Y. Jurgens3, R. Garberich4, C. E. Weaver5, B. A. Hoglund6, S. Joseph7, S. Carey7, S. Hall7, J. Cowger8, S. P. Chaudhry8, S. Schroeder8, E. Y. Birati9, M. Soni10, J. Marble10, P. Eckman4, 1Baylor Univ/Allina Health, St. Paul, MN, 2College of Nursing, Univ of Nebraska Medical Center, Omaha, NE, 3School of Nursing, Stony Brook Univ, New York City, NY, 4Minneapolis Heart Institute, Minneapolis, MN, 5Abbott Northwestern Hospital/ Minneapolis Heart Institute, Minneapolis, MN, 6Metropolitan State Univ, St. Paul, MN, 7Baylor Univ Medical Center, Dallas, TX, 8St. Vincent Heart Ctr, Indianapolis, IN, 9Bryan Heart Center, Lincoln, NE, 10Univ of Pennsylvania, Philadelphia, PA

(1240) Interval Depression Screening and Quality of Life Relationships in Ventricular Assist Device Patients; S. E. Schroeder1, B. J. Pozehl2, K. E. Sandau3, A. T. Lundstrom4, 1MCS Nurse Practitioner and Program Coordinator, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE, 2Nursing/Cardiology, University of Nebraska Medical Center, Omaha, NE, 3Nursing, Bethel University, St. Paul, MN, 4MCS RN Coordinator, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE

(1241) Improvement of Quality of Life and Mental Recovery after Left Ventricular Assist Device Implantation compared to Heart Transplantation; M. J. Barten1, S. Gasser1, A. Bernhardt1, C. Buchholz1, M. Rybczynski2, H. Grahn2, H. Reichenspurner1. 1Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

(1243) Depressive Symptoms Among Women and Men After Left Ventricular Assist Device; J. Marble, R. Garberich, P. Eckman, C. E. Weaver, S. Joseph, S. Carey, S. Hall, J. Cowger, S. P. Chaudhry, S. Schroeder, E. Y. Birati, M. Soni, B. A. Hoglund, K. E. Sandau. 1University of Pennsylvania, Philadelphia, PA, 2Minneapolis Heart Institute, Minneapolis, MN, 3Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, 4Baylor University Medical Center, Dallas, TX, 5St. Vincent Heart Center, Indianapolis, IN, 6Bryan Heart Center, Lincoln, NE, 7Metropolitan State University, St. Paul, MN, 8Bethel University/Allina Health, St. Paul, MN

(1244) The HeartWare HVAD System for the Treatment of Advanced Biventricular Heart Failure; S. Marasco, A. R. Simon, S. Tsui, D. Mcgiffin, M. Pac, U. Kervan, A. E. Fiane, J. D. Schmitto. 1The Alfred Hospital, Melbourne, Australia, 2Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom, 3Papworth Hospital, Cambridge, United Kingdom, 4Turkiye Yuksek Ihtisas Education & Research Hospital, Ankara, Turkey, 5Oslo University Hospital, Oslo, Norway, 6Hannover Medical School, Hannover, Germany

(1245) A Novel Driveline Stabilisation Technique for VAD; S. Özcobanoglu, C. Kemaloglu, U. Koksel, O. Erbasan, I. Golbasi, C. Turky, O. Bayezid. Cardiovascular Surgery, Akdeniz University Faculty of Medicine, Antalya, Turkey

(1246) PROMOTED TO ORAL

(1247) Recovery Plug for HeartMate 3 Left Ventricular Assist Device; J. Mulzer, E. Potapov, F. Kaufmann, M. Müller. HTG, German Heart Institute, Berlin, Germany

(1248) Less Invasive Left Ventricular Assist Device Implantation; Single Center Experience; D. Saeed, A. Albert, R. Wieloch, L. Ghari, B. Sowinski, U. Boeken, R. Westenfeld, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany


(1254) Totally Implantable Ventricular Assist Devices: Wireless Powering over Sub-Meter Distances; J. Park, P. Bonde. Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT

(1255) A Co-Rhythmic, Isolable, Self-Maintenance, Assist (CoRISMA) Device for Class III Heart Failure; J. Park, P. Bonde. Yale School of Medicine, New Haven, CT

(1256) Recovery or Remission? Changes in Cardiac Function After LVAD Explantation; P. Chavez, O. Saeed, U. Jorde, D. Goldstein, S. Patel. 1Cardiology, Montefiore Medical Center, New York, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, NY
(1257) Differential Effects of Carvedilol vs. Metoprolol on Mortality and Adverse Events in Left Ventricular Assist Devices Patients: A. Pinsino1, D. L. Jennings1, J. Z. Willey1, E. A. Royzman1, M. Mabasa1, F. Castagna2, A. R. Garan1, K. Ross1, L. Effner1, V. K. Topkara1, Y. Naka1, H. Takayama1, K. Takeda1, B. J. McDonnell3, J. R. Cockroft3, P. C. Colombo1, M. Yuzefpolskaya1, 1Columbia University, New York, NY, 2Yale Bridgeport Hospital, Bridgeport, CT, 3Cardiff Metropolitan University, Cardiff, United Kingdom

(1258) Neurohormonal Blockade with Sacubitril/Valsartan in Left Ventricular Assist Device (LVAD) Patients: F. Niue1, K. Collins2, H. Hayes1, J. Barber1, K. Lam1. 1Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia, 2Cardiology, Fiona Stanley Hospital, Murdoch, Australia

(1259) Preoperative Patient Optimization Using Low Dose Levosimendan Improves Outcomes of Patients After Left Ventricular Assist Device Implantation: S. Kocabeyoglu1, M. Pac1, U. Kervan1, M. Karahan1, E. Aygun1, O. Beyaz1, U. Unal1, Y. Guray2, B. Demirkan2. 1Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, 2Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey


(1261) Decoupling Between Diastolic Pulmonary Artery and Pulmonary Capillary Wedge Pressures at Incremental LVAD Speeds is a Poor Prognostic Factor Following LVAD Implantation: T. Imamura1, D. Rodgers1, G. Kim1, J. Raikhelkar2, N. Sarswat3, S. Kalantari4, A. Nguyen1, B. Chung5, C. Juricek1, D. Burkhoff2, T. Song1, T. Ota1, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

(1262) Estimation of Central Venous Pressure by Pacemaker Lead Impedances in LVAD Patients: T. Imamura1, D. Rodgers1, G. Kim1, J. Raikhelkar2, N. Sarswat3, S. Kalantari4, A. Nguyen1, B. Chung5, C. Juricek1, D. Burkhoff2, T. Song1, T. Ota1, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

(1263) Optimal Hemodynamics During LVAD Support Are Associated With Reduced Readmission Rate: T. Imamura1, J. Raikhelkar2, N. Sarswat3, D. Rodgers1, S. Kalantari4, A. Nguyen1, B. Chung5, N. Narang1, G. Kim1, C. Juricek1, C. Murks1, T. Ota1, T. Song1, M. R. Costanzo2, D. Burkhoff2, U. Jorde4, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Advocate Heart Institute, Naperville, IL, 3Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, 4Montefiore Medical Center, Bronx, NY

PULMONARY HYPERTENSION AND CTEPH
(Gallieni 1-2)

Poster Discussants: Roberto Badagliacca (Italy), Marco Caccamo (USA), Elie Fadel (France), Stefan Soderberg (Sweden)

(1264) Impact of Right Ventricular Function and Pulmonary Hypertension Therapy on Graft Dysfunction and Death in Lung Transplant Recipients: M. Thornberg1, C. J. Isabella1, S. A. Esper1, C. A. Moore1, M. R. Morrell1, J. Hayanga2, N. Shigemura3, A. Zeevi4, J. F. McDyer1, C. R. Ersol1. 1University of Pittsburgh, Pittsburgh, PA, 2West Virginia University, Morgantown, WV, 3Temple University, Philadelphia, PA

(1265) The Pathology of Thromboendarterectomy Specimens from 50 Chronic Thromboembolic Pulmonary Hypertension Patients: E. R. Rodriguez1, N. G. Smedira2, G. A. Heres3, C. D. Tan1. 1Pathology, The Cleveland Clinic, Cleveland, OH, 2Heart and Vascular Institute, The Cleveland Clinic, Cleveland, OH, 3Respiratory Institute, The Cleveland Clinic, Cleveland, OH

(1266) A “Thrombo-Endarterectomy” Approach: Establishing a New Center for CTEPH Patients: Y. Toyoda1, M. A. Kashem1, G. Ramakrishnan1, A. Vaidya2, P. Foria2. 1Cardiovascular Surgery, Temple University, Philadelphia, PA, 2Cardiology, Temple University, Philadelphia, PA

(1267) Extracorporeal Life Support After Pulmonary Thromboendarterectomy: Single Institutions Outcome: J. R. Higgins1, V. G. Pretorius1, T. Fernandes1, N. H. Kim2, K. Kerr2, D. Poch2, D. Papamatheakis2, M. Madani1. 1Cardiothoracic Surgery, UCSD Medical Center, La Jolla, CA, 2Pulmonary Medicine, UCSD Medical Center, La Jolla, CA
(1268) Should Right Heart Hemodynamics be the Primary Guide for Operability for Pulmonary Thromboendarterectomy?; D. Joyce¹, R. Frantz², S. Kushwaha², B. Lahr³, L. Joyce⁴. ¹Medical College of Wisconsin, Milwaukee, WI, ²Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ³Surgery, Mayo Clinic, Rochester, MN, ⁴Surgery, Medical College of Wisconsin, Milwaukee, WI

(1269) WITHDRAWN

(1270) Influence of Age on Pulmonary Vascular Function in Systemic Sclerosis: A Case Controlled Study; A. Rimouche¹, S. Caravita², L. Dewachter², A. Bondue¹, J. Vachery¹. ¹Cardiology, Erasme, Brussels, Belgium, ²Cardiology, Ospedale S Luca IRCCS Istituto Auxologico Italiano, Milano, Italy

(1271) Simple Echocardiographic Parameters to Capture Acute Changes in Right Ventricle-Pulmonary Artery Coupling in a Large Animal Model of Pulmonary Hypertension; D. Boulate¹, M. Amsallem², G. Girardete³, B. Decante¹, E. Fadel¹, T. Kouznetsova⁴, F. Haddad², O. Mercier¹. ¹Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, ²Cardiovascular Institute, Stanford University, Palo Alto, CA, ³Cardiology, Institut de Cardiologie, Montreal, QC, Canada, ⁴Research Unit Hypertension and Cardiovascular Epidemiology, KULeuven, Leuven, Belgium

(1272) Moderate to Severe Right Ventricular Failure in the Setting of Pulmonary Hypertension Resolves in Most Patients After Lung Transplantation; M. M. El-Sayed Ahmed¹, M. Thomas¹, S. Jacob¹, E. Lesser², Z. Li², C. K. Landolfo³, I. A. Makey¹, E. V. Beller¹, K. P. Landolfo³, J. M. Mallea³, D. B. Erasmus⁴, F. Alvarez⁴, C. A. Keller⁴, T. Narula⁴, S. M. Pham¹. ¹Thoracic and Cardiovascular Surgery, Mayo Clinic, Jacksonville, FL, ²Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, ³Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL, ⁴Lung Transplant, Mayo Clinic, Jacksonville, FL

(1273) Predictors of Mortality in Acute Right Ventricular Failure in Severe Pre-capillary Pulmonary Hypertension Treated by Dobutamine; M. Rietz. Cardiology, Hôpital Universitaire Erasme, Univ Libre de Bruxelles, Brussels, Belgium

(1274) The Successful Transition from Injectable to Inhaled Prostacyclins in the Outpatient Setting for Patients with Pulmonary Arterial Hypertension; L. Kimmig¹, C. Liao², R. Bag¹. ¹Pulmonary and Critical Care Medicine, University of Chicago Medicine, Chicago, IL, ²University of Chicago, Chicago, IL

(1275) Cardiovascular Magnetic Resonance Imaging for Risk Assessment and Prediction of Clinical Worsening in Pulmonary Arterial Hypertension; C. Göransson, N. Veijstrup, J. Carl森. Dept of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

(1276) The Clinical Features of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease in Japan; H. Mak¹, M. Hatano², S. Minatsu¹, I. Komuro¹. ¹Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan, ²Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan

(1277) Clinical Classification and Prevalence of Pulmonary Hypertension in Rural; L. Mirfakhraie¹, T. Dirks², S. Ebnet¹, P. Eckman³, B. Cabuay³, R. Garberich², S. Reed², P. J. Stokman², E. R. Fenstad². ¹Minneapolis Heart Institute Foundation, Minneapolis, MN, ²Minneapolis Heart Institute, Baxter, MN, ³Minneapolis Heart Institute, Minneapolis, MN

(1278) Fluid Challenge During Right Heart Catheterization: An Experience From a Tertiary Pulmonary Hypertension Referral Centre; N. Moghaddam¹, J. Swiston², R. D. Levy², V. F. Huckell³, N. W. Brunner³. ¹Dept of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Respirology, University of British Columbia, Vancouver, BC, Canada, ³Division of Cardiology, University of British Columbia, Vancouver, BC, Canada

(1279) Characteristics of Cardiopulmonary Exercise Testing in Patients with Combined Post-capillary and Pre-capillary Pulmonary Hypertension (CPC-PH) Due to Left Heart Disease; A. Goda, K. Takeuchi, H. Kikuchi, T. Inami, T. Satoh, H. Yoshino. Kyorin University Hospital, Tokyo, Japan

(1280) Reversibility of Pulmonary Hypertension with LVAD Support; A Meta-Analysis of Published Reports; P. L. Tremblay, C. R. Herman, R. J. Baskett. Dept of Surgery, Dalhousie University, Halifax, NS, Canada

(1281) Long-Term Changes in Pulmonary Haemodynamics after Continuous-Flow Left Ventricular Assist Device Implantation in Advanced Heart Failure Patients; A. F. Giglio¹, L. F. Bertoldi², E. Perna¹, E. Ammirati¹, F. Macera¹, M. G. Cipriani¹, A. Garascia¹, F. Oliva¹, C. Russo¹, M. Frigerio¹. ¹ASST Niguarda, Milan, Italy, ²San Raffaele, Milan, Italy
(1282) **Double-Lung versus Heart-Lung Transplantation for Pulmonary Hypertension - A Single-Center Experience**; J. Brouckaert¹, S. Verleden², T. Verbelen³, P. De Leyn¹, W. Coosemans¹, H. Decaluwé¹, L. Depypere¹, P. Nafteux¹, H. Van Veer¹, B. Meyns³, F. Rega³, M. Van De Velde⁴, G. Poortmans⁴, S. Rex⁴, A. Neyrinck⁴, G. Van den Berghe⁵, M. Schetz⁵, D. Vlasselaers⁵, J. Van Cleemput⁶, W. Budts⁶, R. Vos⁷, C. Belge⁷, M. Delcroix⁷, G. M. Verleden⁷, D. E. Van Raemdonck¹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²Pneumology, Catholic University Leuven, Leuven, Belgium, ³Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, ⁴Anaesthesiology, University Hospitals Leuven, Leuven, Belgium, ⁵Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium, ⁶Cardiology, University Hospitals Leuven, Leuven, Belgium, ⁷Pneumology, University Hospitals Leuven, Leuven, Belgium

(1283) **Unexpected Autopsy Finding as a Cause of Fatal Pulmonary Hypertension Post Transplant**; X. Garcia¹, L. Gonzalez-Krellwitz², N. Gokden², E. Frazier¹. ¹Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, ²Pathology, University of Arkansas for Medical Sciences, Little Rock, AR

(1284) **Evaluation of the Prognostic Factor and the Treatment Efficacy of Inhaled Iloprost in Patients with Group 3 Pulmonary Hypertension**; P. Su, C. Hsu. National Cheng Kung University Hospital, Tainan, Taiwan

(1285) **Quality of Life in Children and Young Adults With Pulmonary Hypertension and Its Association With Clinical Features**; P. Chau¹, K. R. Schumacher¹, K. Uzark¹, R. G. Grifka¹, C. Miller¹, S. Yu¹, R. Lowery¹, J. M. Friedland-Little². ¹Pediatrics, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Washington, Seattle, WA

(1286) **Rapid Transition from Parenteral to Oral Treprostinil in Pulmonary Hypertension is Feasible and Safe: A Retrospective Cohort Study**; H. Jarrett¹, A. K. Jonnalagadda¹, S. D. Liu¹, A. J. Bagnola², D. Lewis³, O. A. Shlobin³, C. F. Barnett¹. ¹Heart and Vascular Institute, MedStar Washington Hospital Center / MedStar Georgetown University Hospital, Washington, DC, ²Division of Pharmacy, Inova Fairfax Hospital, Falls Church, VA, ³Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA

(1287) **Double Lung transplantation In Patients with End-Stage Pulmonary Arterial Hypertension or End-Stage Inoperable Chronic Thromboembolic Pulmonary Hypertension**; A. Rinaldi¹, A. Dell'Amore², S. Pastore³, A. Rocca³, D. Giunta³, M. Palazzini³, A. Manes³, F. Dardi¹, E. Gotti¹, N. Galiè¹. ¹Cardiology, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy, ²Thoracic Surgery, Bologna University Hospital, Bologna, Italy, ³Anesthesiology, Bologna University Hospital, Bologna, Italy, ⁴Pneumology, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy, ⁵Thoracic Surgery, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy
POSTER SESSION 2
THURSDAY, APRIL 12
AGORA 3
JFTC, PEDS
Poster Maps, Session 2

Thursday, April 12
Muses / Euterpe

HF, HTX, MCS
CORE COMPETENCIES IN
HEART FAILURE AND CARDIAC TRANSPLANTATION

Tuesday, April 10, 2018
7:55 AM – 5:30 PM
Mediterranee ABC

Scientific Program Committee
Chair: Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
Co-Chair: Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA
Co-Chair: Eric Epailly, MD, Les Hopitaux University, Strasbourg, France

Faculty
David Baran, MD, Newark Beth Israel Hospital, Newark, NJ, USA
Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
Eugene DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA, USA
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Maria Frigerio, MD, A.O. Niguarda-Ca'Granda, Milan, Italy
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA
Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FLA, USA
Jean Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
Andre Vincentelli, CHU Regional de Lille Hospital Cardiologique, Lille, France

Practice Gaps
Heart failure is a leading cause of morbidity and mortality world-wide, and significant advances have occurred that are still not consistently implemented in every day practice. Clinicians need to understand the principles of acute and chronic heart failure disease management, including advanced treatment options, in order to deliver optimal care to these complex patients.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for health care professionals who are in the early stages of their careers or who are in training, or who are part of a new program, or who desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the core competencies of heart failure, cardiac transplantation and mechanical circulatory support, rather than as a detailed update for those who are already proficient in the field.

Educational Need
This course is designed to meeting the practitioner’s education need for a targeted review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients with heart failure, cardiac transplantation, and mechanical circulatory support devices.

Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:
1. Understand the general concepts, definitions and management principles of patients with heart failure.
2. Understand the general concepts, indications, contraindications and management principles of patients who are evaluated for and receive cardiac transplant.
3. Understand the general concepts, indications, contraindications and management principles of patients who are evaluated for and receive mechanical circulatory support devices.

**Course Summary**
This course is designed for early career professionals with an interest in congestive heart failure, cardiac transplantation, and mechanical circulatory support. Each section is designed with focused, didactic lectures followed by Q&A. The first section will cover the general topics of heart failure – definitions, epidemiology, pathophysiology, etiology. It will then move to signs and symptoms, diagnostic process and management and treatment modalities, followed by a focus on the acute decompensated heart – challenges in recognition and treatment as well as new developments. The second section will review updates in the understanding and treatment of heart failure with preserved ejection fraction HFpEF, and pulmonary hypertension with an emphasis on its relationship with heart failure. The third section will encompass the cardiac transplant patient, from evaluation of the recipient candidate and donor, to perioperative management principles, immunology, immunosuppression, rejection, and common long-term challenges. The final section will review the history and development of mechanical circulatory support and management of common complications.

**Accreditation Statement**
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**
ISHLT designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ANCC Credit**
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This course is co-provided by AMEDCO and ISHLT. Maximum of 7.50 contact hours.

**Disclosure**
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Faculty/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
7:00 AM – 7:55 AM
REGISTRATION & MORNING COFFEE

7:55 AM – 8:00 AM
WELCOME AND OVERVIEW OF COURSE
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

8:00 AM – 9:00 AM
SESSION 1: HEART FAILURE: OVERVIEW AND EVALUATION
Chair: Shelley Hall, MD
8:00 AM *Heart Failure: General Overview and Concepts*
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
8:15 AM *Evaluation of Patients with Heart Failure*
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
8:30 AM *Heart Failure Tests*
Eugene DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA, USA
8:45 AM Q&A with Panel

9:00 AM – 10:00 AM
SESSION 2: MANAGEMENT OF PATIENTS WITH CHRONIC HFrEF
Chair: Eric Epailly, MD
9:00 AM *Non-Pharmacologic and Pharmacologic Management*
Lavanya Bellumkonda, MD, School of Medicine, New Haven, CT, USA
9:15 AM *Principles for Arrhythmia Management and Electrical Devices*
Maria Frigerio, MD, A.O. Niguarda-Ca’Granda, Milan, Italy
9:30 AM *Surgical Management of Heart Failure*
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA
9:45 AM Q&A with Panel

10:00 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:30 AM
SESSION 3: ACUTE DECOMPENSATED HEART FAILURE
Chair: Lavanya Bellumkonda, MD
10:30 AM *Epidemiology and Pharmacologic Management*
David Baran, MD, Newark Beth Israel Hospital, Newark, NJ, USA
10:45 AM *Cardiogenic Shock*
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
11:00 AM *Transitions of Care*
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
11:15 AM Q&A with Panel

11:30 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:00 PM
SESSION 4: HFpEF AND PULMONARY HYPERTENSION
Chair: Shelley Hall, MD

1:00 PM  **HFpEF**
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

1:20 PM  **Pulmonary Hypertension: PAH in Heart Failure**
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

1:40 PM  Q&A with Panel

2:00 PM – 3:00 PM
SESSION 5: HEART TRANSPLANTATION 101
Chair: Lavanya Bellumkonda, MD

2:00 PM  **Evaluation of the Transplant Candidate**
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

2:15 PM  **Perioperative Management**
Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA

2:30 PM  **Chronic Care of the Transplant Recipient**
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France

2:45 PM  Q&A with Panel

3:00 PM – 3:30 PM
COFFEE BREAK

3:30 PM – 4:30 PM
SESSION 6: MECHANICAL CIRCULATORY SUPPORT
Chair: Eric Epailly, MD

3:30 PM  **Current Devices and Outcomes**
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FLA, USA

3:50 PM  **Chronic Complications in MCS**
Andre Vincentelli, CHU Regional de Lille Hospital Cardiologique, Lille, France

4:10 PM  Q&A with panel

4:30 PM – 5:30 PM
SESSION 7: CASE PRESENTATIONS
Chairs: Shelley Hall MD; Lavanya Bellumkonda, MD; Eric Epailly MD

4:30 PM  **Cardiogenic Shock Case**
David Baran MD, Newark Beth Israel Hospital, NJ, USA

4:45 PM  **Transplant vs VAD Case**
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

5:00 PM  Q&A with Panel

5:15 PM – 5:30 PM
COURSE SUMMARY AND EVALUATION
Shelley Hall MD, Baylor University Medical Center, Dallas, TX, USA

5:30 PM
ADJORN
CORE COMPETENCIES IN LUNG TRANSPLANTATION

Tuesday, April 10, 2018
7:55 AM – 5:45 PM
Hermes

Scientific Program Committee
Chair: Lorriana Leard, MD, University of California San Francisco, CA, USA
Co-Chair: Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden
Co-Chair: Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, USA

Faculty
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden
Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, USA
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA
Matthew Hartwig, MD, Duke University, Durham, NC, USA
Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN, USA
David Hornmuth, MD, St. Mary’s Medical Group, Indianapolis, IN, USA
Lorriana Leard, MD, University of California San Francisco, CA, USA
Erika D. Lease, MD, University of Washington, Seattle, WA, USA
Lianne G. Singer, MD, FRCP, Toronto General Hospital, Toronto, Canada
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA
Sofya Tokman, MD, Norton Thoracic Institute, Phoenix, AZ, USA
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium

Practice Gaps
1. The technology available to support the clinical practice of lung transplantation has progressed significantly in the past 7 years with advanced innovations available to support patients undergoing lung transplantation, to evaluate donor lungs, and to support patients in the immediate post-operative period. This course will address the application of these technologies in clinical practice.
2. Advanced understanding of the presentations of both acute and chronic allograft dysfunction has led to improved description and recognition of antibody mediated rejection, obstructive chronic lung allograft dysfunction and restrictive allograft syndrome that all specialists caring for lung transplantation need to be able to recognize.
3. Clinicians involved in the care of lung transplant patients are seeking a comprehensive review of the available evidence and consensus opinion about the evaluation and management of lung transplant patients.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for health care professionals who are in the early stages of their careers or who are in training, or who are part of a new program, or who desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the core competencies of lung transplantation, rather than as a detailed update for those who are already proficient in the field.

Educational Need
This course meets the practitioner’s educational need for a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation.
Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Explain in detail how to evaluate and list potential candidates for lung transplantation.
2. Discuss perioperative management of the donor, lung procurement, and operative strategies including use of extracorporeal life support and ex vivo lung perfusion.
3. Recognize the most common post-transplant complications including immediate post-operative complications, acute and chronic allograft dysfunction, infections, and other systemic complications.
4. Describe the immunosuppressive and preventative medication regimens that utilized in lung transplant recipients, the rationale for their use, and their potential complications.

Course Summary
The Core Competency Course in Lung Transplantation will provided a detailed examination of the clinical practice of lung transplantation today. Through focused presentations with an emphasis on clinical practice, the course will provide a historical context, cover candidate selection, donor management and organ procurement, post-transplant management and complications.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by AMEDCO and ISHLT. Maximum of 7.25 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:55 AM
REGISTRATION AND MORNING COFFEE

7:55 AM – 8:00 AM
WELCOME AND OVERVIEW
Lorriana Leard, MD, University of California San Francisco, CA, USA

8:00 AM - 9:00 AM
SESSION 1: LUNG TRANSPLANTATION: GETTING FROM HERE TO THERE – HISTORY, CANDIDATE AND DONOR SELECTION
Chair: Lorriana Leard, MD

8:00 AM History of Lung Transplantation
Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN, USA

8:15 AM Lung Transplant Candidacy, Selection, and Listing, Including Allocation Systems
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia

8:30 AM Lung Allograft Donation and Procurement
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

8:45 AM Q&A with Panel

9:00 AM – 10:00 AM
SESSION 2: SURGICAL AND POST-OPERATIVE MANAGEMENT OF LUNG TRANSPLANT RECIPIENTS
Chair: Göran Dellgren, MD, PhD

9:00 AM Surgical Options and Procedural Issues in Lung Transplantation
David Hormuth, MD, St. Mary’s Medical Group, Indianapolis, IN, USA

9:15 AM The Role of ECMO - To ECMO or not the ECMO, that is the Question!
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, SWEDEN

9:30 AM Surgical Complications and Post-OP Management after Lung Transplantation
Matthew Hartwig, MD, Duke University, Durham, NC, USA

9:45 AM Q&A with Panel

10:00 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:30 AM
SESSION 3: DEALING WITH REJECTION
Chair: Daniel Dilling, MD

10:30 AM Acute Cellular Rejection (ACR)
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany

10:45 AM Antibody Mediated Rejection (AMR)
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

11:00 AM Chronic Lung Allograft Dysfunction (CLAD)
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:15 AM Q&A with Panel

11:30 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:00 PM
SESSION 4: MANAGING THE MEDS – IMMUNOSUPPRESSION AND THE SYSTEMIC EFFECTS
Chair: Lorriana Leard, MD

1:00 PM Induction and Maintenance Immunosuppression
Daniel Dilling, MD, Loyola University Medical Center, Maywood, Illinois, USA

1:15 PM Hematologic Disorders Following Lung Transplant
Lorriana Leard, MD, University of California San Francisco, CA, USA

1:30 PM Gastrointestinal Issues Post Lung Transplant
Matthew Hartwig, MD, Duke University, Durham, NC, USA

1:45 PM Q&A with Panel

2:00 PM – 3:00 PM
SESSION 5: BUGS AND THEIR DRUGS – PROPHYLAXIS, DIAGNOSIS AND MANAGEMENT OF INFECTIONS AFTER LUNG TRANSPLANT
Chair: Göran Dellgren, MD, PhD

2:00 PM Bacterial and Mycobacterial Infections in Lung Transplantation
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

2:15 PM Fungal Infections in Lung Transplant Recipients
Erika D. Lease, MD, University of Washington, Seattle, WA, USA

2:30 PM Viral Pathogens from A to V (Adenovirus, CMV, EBV, HSV, RSV, and VZV)
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

2:45 PM Q&A with Panel

3:00 PM – 3:30 PM
COFFEE BREAK

3:30 PM – 4:30 PM
SESSION 6 – MALEVOLENT MALIGNANCIES
Chair: Daniel Dilling, MD

3:30 PM Skin Cancer in Lung Transplant Recipients
Sofya Tokman, MD, Norton Thoracic Institute, Phoenix, AZ, USA

3:45 PM Post Transplant Lymphoproliferative Disease (PTLD) in Thoracic Transplantation
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

4:00 PM Lung Cancer and Other Malignancies in Lung Transplant Recipients
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

4:15 PM Q&A with Panel

4:30 PM – 5:30 PM
SESSION 7 – LIFE AFTER TRANSPLANT
Chair: Lorriana Leard, MD

4:30 PM Management of the Metabolic Complications – Diabetes, Hypertension, and Osteoporosis
Daniel Dilling, MD, Loyola University Medical Center, Maywood, Illinois, USA

4:45 PM Reproductive Health after Lung Transplantation – Contraception, Fertility, and Pregnancy
Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium
5:00 PM  This is My Life – Outcomes and Quality of Life Post Transplant
Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada

5:15 PM  Q&A with Panel

5:30 PM – 5:45 PM
COURSE SUMMARY AND ASSESSMENT
Lorriana Leard, MD, University of California San Francisco, CA, USA

5:45 PM
ADJORN
CORE COMPETENCIES IN
MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 10, 2018
8:00 AM – 5:30 PM
Athena

Scientific Program Committee
Chair: Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany
Co-Chair: Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
Co-Chair: Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA

Faculty
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA
Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA
Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA
Jens Garbade, University of Leipzig, Leipzig, Germany
Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA
Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA
Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX, USA
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna, Italy
Kavitha Muthiah, MBchB, St. Vincent's Hospital, Sydney, Australia
Samer Najjar, MD, Medstar Heart Institute, Washington, DC, USA
Evgenij Potapov, MD, PhD, Deutsches Herzcentrum, Berlin, Germany
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC, USA
Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany
Christopher Salerno, MD, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA.
Thomas Schloeghofer, BSc, Medical University of Vienna, Vienna, Austria
Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospital, Newcastle Upon Tyne, United Kingdom
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
Lynne Warner Stevenson, MD, Vanderbilt University, Nashville, TN, USA

Practice Gaps
The field of the mechanical circulatory support systems experienced steady growth during the last years. The management of these complex patients remains challenging and starts prior to the surgical procedures. There is still lack of adequate knowledge of proper patient selection, right ventricular assessment, and proper management of device-related complications. This Course will address all important aspects in the management of these patients starting from patient selection and preparation for the assist device implantation. Further, several alternative implantation approaches and surgical pitfalls are presented. Finally, issues related to the home transition and adequate state of art management strategies of assist device related complication management are addressed.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical support, rather than as a detailed update for those who are already proficient experts in the field.

Educational Need
This course is designed to meeting the practitioner's educational need for a targeted review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients with mechanical circulatory support devices.
Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Explain how to risk stratify patient with advanced heart failure in order to assess MCS surgical risk and optimally time mechanical circulatory support (MCS) implantation.
2. Discuss the medical and social factors which impact patient outcomes during short- and long-term MCS.
3. Recognize the various types of MCS support available for patients with advanced single or biventricular heart failure and the technological differences that may impact pump selection and patient/device management.
4. Identify MCS implantation techniques and patient/pump management during the index admission intensive care unit and inpatient general care periods.
5. Describe how to manage patients and the MCS during outpatient long-term support with an understanding of interventions that can reduce patient- and device-related adverse events during MCS.
6. Diagnose and manage common clinical dilemmas and adverse encountered after MCS.

Course Summary
The purpose of this Core Competency Course is to provide a concise review of clinical knowledge and outline of the essential professional skills for candidate assessment and longitudinal support for mechanical circulatory support patients. This Course should serve programs providing mechanical circulatory support with a tool to review their standards of care, develop protocols, and implement guidelines established in management of mechanical circulator support patients.

The Course consists of six plenary sessions; in the first session, the current state of mechanical circulatory support systems are reviewed, followed by the challenging task of adequate patient selection and preoperative preparation including proper assessment tools of right ventricular function. In the third session all surgical aspects and alternative approaches of assist device implantation are addressed, followed by immediate postoperative care related issues and management of right ventricular insufficiency. The fifth session addresses the preparation strategies for proper and safe patient transition to home. In the final session, adequate management of device related long term complications are presented.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by AMEDCO and ISHLT. Maximum of 8.00 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 8:00 AM  
MORNING COFFEE AND REGISTRATION

8:00 AM – 8:05 AM  
WELCOME AND OVERVIEW  
Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany

8:05 AM – 9:15 AM  
SESSION 1 – REVIEW OF THE CURRENT STATE OF MCS  
Chair:  
Diyar Saeed, MD, PhD

8:05 AM  
MCS Technology 101  
Evgenij Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

8:25 AM  
BTT and DT Outcome  
Lynne Warner Stevenson, MD, Vanderbilt University, Nashville, TN, USA

8:40 AM  
Short-term Support and Shock  
Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA

9:00 AM  
Q&A with panel

9:15 AM – 10:30 AM  
SESSION 2 – PATIENT SELECTION  
Chair:  
Palak Shah, MD, MS

9:15 AM  
When Should Patients be Referred: Warning Signs  
Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

9:35 AM  
Assessing and Optimizing RV Function Preoperatively  
Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC, USA

9:55 AM  
Quality of Life After VAD and the Impact of Frailty and Social Behaviors on VAD Success  
Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

10:15 AM  
Q&A with panel

10:30 AM – 10:45 AM  
COFFEE BREAK

10:45 AM – NOON  
SESSION 3: SURGICAL CONSIDERATIONS  
Chair:  
Diyar Saeed, MD, PhD

10:45 AM  
Key Surgical Aspects of Implantation  
Jens Garbade, University of Leipzig, Leipzig, Germany

11:05 AM  
How Much Else is Too Much?  
Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospital, Newcastle Upon Tyne, UK

11:25 AM  
Tailoring Pumps to Patients  
Diyar Saeed, MD, Heinrich-Heine University, Dusseldorf, Germany

11:45 AM  
Q&A with panel

NOON – 1:00 PM  
LUNCH BREAK
1:00 PM – 2:15 PM
SESSION 4: POSTOPERATIVE CARE
Chair: Jennifer Cook, MD

1:00 PM Managing the RV Postop
Christopher Salerno, MD. St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.

1:20 PM Anticoagulation and Antiplatelet Therapy
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

1:40 PM Pump Speed Optimization: The Role of Imaging and Hemodynamics
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, Virginia, USA

2:00 PM Q&A with panel

2:15 – 3:15 PM
SESSION 5: TRANSITION TO HOME
Chair: Jennifer Cook, MD

2:15 PM VAD Education: Patient/Caregiver Assessments and Strategies for Successful VAD Self-Care
Thomas Schloeglhofer, BSc, Medical University of Vienna, Vienna, Austria

2:30 PM Starting New: How to Start and Succeed in MCS
Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA

2:45 PM Optimal Outpatient Management of VAD Recipients
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna, Italy

3:00 PM Q&A with panel

3:15 PM – 3:30 PM
COFFEE BREAK

3:30 PM – 5:20 PM
SESSION 6: LONG TERM MANAGEMENT OF PATIENTS AND COMPLICATIONS
Chair: Palak Shah, MD, MS

3:30 PM LVAD Infections: Prevention, Diagnosis, and Management
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA

3:50 PM Stroke: Risk factors for Hemorrhagic and Embolic CNS Complications and Management Strategies
Samer Najjar MD, Medstar Heart Institute, Washington, DC, USA

4:10 PM Pump Thrombosis: Diagnostic Strategies and Management Algorithms
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, Virginia, USA

4:30 PM Aortic Insufficiency in LVAD Recipients: Incidence, Screening, and Management
Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA

4:50 PM GI Bleeding
Kavitha Muthiah, MBchB, St. Vincent's Hospital, Sydney, Australia

5:10 PM Q&A with panel

5:20 PM – 5:30 PM
COURSE SUMMARY AND ASSESSMENT
Palak Shah, MD, MS

5:30 PM
ADJORN
MASTER CLASS IN
MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 10, 2018
Clio, Thalie

Scientific Program Committee
Chair: Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA
Co-Chair: Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Faculty
Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA
Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA
JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA
Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium
Jerry Estep, MD, The Methodist Hospital, Houston, TX, USA
Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA
Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

Course Summary
The MCS Master Class is intended for members with higher levels of expertise (completed the core curriculum course on MCS and/or primary practice in MCS ≥ 5 years). The course setting will generate a highly interactive environment composed of a small group of individuals and designed to enhance individual expertise and network development. Utilizing the concept of “convergent discussion” and the technique of “audience response system”, faculty moderators will use complex situations and controversial statements during practical case presentations in order to lead the group through active audience participation, towards specific answers based on practice gaps and learning objectives. The MCS Master Class is arranged in advanced breakout sessions for every participant to take full advantage of an integrated curriculum and the exceptional networking opportunity. The specific topics are devised according to defined clinical practice gaps in this fast developing specialty.

Practice Gaps
1. The outcomes of cardiogenic shock have remained poor, large randomized trials are scarce and the management of these patients remains challenging. Comprehensive clinical expertise of advanced usage of evolving MCS options including patient and device selection and transition to next step therapies constitute currently major limitations in the care of these critically ill patients.

2. Structures to seamlessly communicate events occurring in and outside of the operating room to ensure optimal performance by providers in each setting are lacking. Surgeons, cardiologist, and critical care practitioner often lack in depth insight of decision algorithms employed by their counterparts before, during, and after device implant and explant procedures.

3. The outcome impact and preferred technique of ancillary procedures - such as valve repair / replacement or left atrial appendage occlusion - during LVAD implantation has not been established.

4. The diagnosis and management of complex and combined adverse events such as cerebrovascular hemorrhagic accidents, device thrombosis and gastrointestinal bleeding is challenging and practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events.

5. The diagnostic and therapeutic approaches for early and late right ventricular failure in MCS patients has been evolving with the introduction of new diagnostic criteria and new technologies/therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.
6. The use of extracorporeal membrane oxygenation is growing rapidly both as a bridge to decision tool before LVAD/HTX and as a rescue bridge to recovery tool in the setting of primary graft failure, yet outcomes of patients transitioned from ECMO to LVAD or HTX remain poor and MCS based PGF treatment strategies have not been developed.

Target Audience
The target audience for this class includes cardiothoracic surgeons and cardiologists with MCS experience, specialists in heart failure care, allied health professionals with involvement in MCS patients, VAD coordinators, transplant coordinators, critical care specialists, and heart transplant professionals.

Educational Need
Mechanical circulatory support is a relatively new and rapidly evolving therapy for advanced congestive heart failure. Multiple device technologies are now in use for short and long term support and patient outcomes are highly dependent on in-depth understanding of device-induced changes in physiology as well as device specific serious adverse events. Multidisciplinary teams are an essential part of modern day mechanical circulatory support management. This Class is designed to meet the target audience’s need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by specialists and developing experts in the field of MCS for treatment of heart failure patients.

Learning Objectives
Upon completion of the Master Class, participants will be able to:
1: Identify the challenges during the diagnosis and management of complex cardiogenic shock patients and the potential benefits of a multidisciplinary team approach
2: Explain how to appropriately select patients for long-term MCS options with particular consideration of the need for / utility of ancillary procedures
3: Enhance understanding of the bidirectional impact of surgical and medical technique and management approaches
4: Describe how to develop a systematic approach to diagnosis and therapy of complex and combined adverse events such as device thrombosis, recurrent gastrointestinal bleeding and stroke
5: Name the diagnostic and therapeutic challenges of early and late RV failure
6. Acquire in depth understanding of ECMO placement, management, and explant in combination with LVAD or heart transplantation

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by AMEDCO and ISHLT. Maximum of 4.25 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
MORNING SCIENTIFIC PROGRAM SCHEDULE

8:00 AM – 8:10 AM
WELCOME AND OVERVIEW
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA
Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

8:10 AM – 10:15 AM
SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR SHOCK
Moderator: Finn Gustafson, MD

CASE SCENARIO A1: IABP to non-ECMO percutaneous MCS transition
Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO A2: ECMO
Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium

SMALL GROUP INTERACTIVE DISCUSSION B: BLEEDING AND THROMBOSIS
Moderator: Jerry Estep, MD

CASE SCENARIO B1: Recurrent GI Bleeding and Pump Thrombosis
Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

CASE SCENARIO B2: Management of cerebrovascular hemorrhagic accidents
Jerry Estep, MD, The Methodist, Hospital, Houston, TX, USA

10:15 AM – 10:45 AM
COFFEE BREAK

10:45 AM – 12:50 PM
SMALL GROUP INTERACTIVE DISCUSSION C: ANCILLARY PROCEDURES IN LVAD
Moderator: Igor Gregoric, MD

CASE SCENARIO C1: A patient with atrial fibrillation and severe mitral regurgitation
Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA

CASE SCENARIO C2: A patient with prior sternotomy and severe tricuspid regurgitation
Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA

SMALL GROUP INTERACTIVE DISCUSSION D: BAILOUT STRATEGIES FOR ECMO / BYPASS WEANING FAILURE
Moderator: JoAnn Lindenfeld, MD

CASE SCENARIO D1: ECMO weaning failure – transition to durable device or “high risk organ”? JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

CASE SCENARIO D2: Primary graft failure – ECMO? Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

12:50 PM – 1:00 PM
COURSE SUMMARY AND ASSESSMENT
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA
Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

1:00 PM
ADJOURN
AFTERNOON SCIENTIFIC PROGRAM SCHEDULE

2:00 PM – 2:10 PM
WELCOME AND OVERVIEW
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA
Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

2:10 PM – 4:15 PM
SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR SHOCK
Moderator: Finn Gustafson, MD

CASE SCENARIO A1: IABP to non-ECMO percutaneous MCS transition
Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO A2: ECMO
Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium

SMALL GROUP INTERACTIVE DISCUSSION B: BLEEDING AND THROMBOSIS
Moderator: Jerry Estep, MD

CASE SCENARIO B1: Recurrent GI Bleeding and Pump Thrombosis
Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

CASE SCENARIO B2: Management of cerebrovascular hemorrhagic accidents
Jerry Estep, MD, The Methodist, Hospital, Houston, TX, USA

4:15 PM – 4:45 PM
COFFEE BREAK

4:45 PM – 6:50 PM
SMALL GROUP INTERACTIVE DISCUSSION C: ANCILLARY PROCEDURES IN LVAD
Moderator: Igor Gregoric, MD

CASE SCENARIO C1: A patient with atrial fibrillation and severe mitral regurgitation
Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA

CASE SCENARIO C2: A patient with prior sternotomy and severe tricuspid regurgitation
Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA

SMALL GROUP INTERACTIVE DISCUSSION D: BAILOUT STRATEGIES FOR ECMO / BYPASS WEANING FAILURE
Moderator: JoAnn Lindenfeld, MD

CASE SCENARIO D1: ECMO weaning failure – transition to durable device or “high risk organ”?-
JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

CASE SCENARIO D2: Primary graft failure – ECMO?
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

6:50 PM – 7:00 PM
COURSE SUMMARY AND ASSESSMENT
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA
Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

7:00 PM
ADJOURN
MASTER CLASS IN
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Tuesday, April 10, 2018
2:00 PM – 7:00 PM
Erato, Uranie

Scientific Program Committee
Chair: David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom
Co-Chair: Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

Faculty
William Auger, MD, UCSD Medical Center, San Diego, CA, USA
Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
John Cannon, FRCP, Papworth Hospital, Cambridge, United Kingdom
Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
Marion Delcroix, MD, PhD, University Hospital Leuven, Leuven, Belgium
Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada
Elie Fadel, MD, Hospital Marie Lannelongue, La Plessis-Robinson, France
Deepa Gopalan, MD, Papworth Hospital, Cambridge, United Kingdom
Irene Lang, MD, Medical University of Vienna, Vienna, Austria
Michael Madani, MD, University of California San Diego Medical Center, San Diego, CA, USA
Takeshi Ogo, National Cerebral and Cardiovascular Center, Osaka, Japan
Joanna Pepke-Zaba, PhD, Papworth Hospital NHS Trust, Cambridge, United Kingdom

Course Summary
The four topics covered in Class include: Diagnostic challenges/modalities utilized for CTEPH, management strategies of the complex CTEPH patient, interventional approaches, and mechanical support and surgery for CTEPH. The topics cover the major aspects of CTEPH and highlight the significant differences in the diagnosis and management of these entities. Utilizing the concept of “convergent discussion” and audience response system techniques, faculty moderators will use complex clinical situations and controversial statements during practical case presentations in order to direct active audience participation. The aim is to provide specific insights based on current practice gaps and achieve selected learning objectives.

Practice Gaps
1. The multidisciplinary team approach is needed to properly diagnose, assess, and determine operability for CTEPH. The correct interpretation of imaging to select patients who will get a good technical response is not always easy to determine. Therefore, clinical decisions and whether or not to provide operative interventions need to be made with a deep understanding of the pathophysiology of the disease. The established risks and potential benefits that CTEPH treatment may offer, including surgery in this setting are discussed.

2. The current evidence base regarding the use of vasodilator drugs in technically operable patients, instead of or in addition to surgery, is in evolution. The timing and use in general of these pharmaceutical agents is controversial. The criteria for decision making, including, clot burden, anatomy of obstruction, and the individual patients’ co-morbidities are controversial.

3. Although the interventionalists have improved their techniques and understanding of balloon pulmonary angioplasty (BPA) there is still uncertainty surrounding the selection of patients for surgery versus performing BPA versus medical therapy. There is uncertainty as to the best approach in “segmental CTEPH disease”. This is an area that warrants further studies and discussions by a multidisciplinary group of experts.
4. Surgical techniques for CETEPH patients have improved. Advanced endarterectomy techniques, however, may be utilized without a clear standardization of approach. A discussion of these techniques risk/benefit is required. Understanding these newer approaches will help the team determine the best approach medical, surgical, interventional or a hybrid approach. The peri-operative care techniques and coordination is integral to surgical success. This may not be usually standardized or discussed in detail. There is a clear need to focus on this aspect of the procedure.

**Target Audience**
The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Master Class is an ISHLT educational event intended for specialists with advanced levels of expertise. Ideally, participants will have completed the core competency course on Pulmonary Hypertension (PH) and/or have primary practice in thoracic, cardiothoracic surgery or medical treatment of PH ≥ 5 years) and will have managed patients with one or more of the topics intended for discussion. Pulmonologists/respirologists, cardiologists, thoracic surgeons, cardiothoracic surgeons, interventional radiologists, interventional cardiologists, nurses, physician assistants, and allied health professionals with experience in CTEPH. The course is mainly intended for health care whose primary practice includes care of CTEPH patients and providers who are developing programs for medical, surgical or interventional treatment in this field.

**Educational Need**
The field of chronic thromboembolic disease is a changing landscape with increasing evidence for new therapies. With improved diagnostic tools, surgical techniques, use of interventional approaches, and the approval of medical therapies, the disease requires a multi-disciplinary team approach and training to understand contemporary decision making. This Class is designed to meet the target audience’s need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by those caring for patients with CTEPH.

**Learning Objectives**
After completion of this Master Class, the participant will have improved competence and professional performance in their ability to:
1. understand the imaging features that indicate operability in CTEPH patients
2. differentiate low and high risk scenarios for CETEPH interventions
3. appreciate the evidence gaps relating to the use of vasodilator drugs in CTEPH
4. acknowledge the overlap in the use of BPA and PEA in patients with segmental CTEPH disease dependent on institutional experience and hence the uncertainty in the current guidelines
5. understand the advanced technical endarterectomy procedure and care of patients with perioperative complications

**Accreditation Statement**
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation Statement**
ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ANCC Credit**
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by AMEDCO and ISHLT. The maximum credit is 4.25 contact hours.

**Disclosure**
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

2:00 PM – 2:10 PM
WELCOME AND OVERVIEW
David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom
Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

2:10 PM – 4:15 PM
SMALL GROUP INTERACTIVE DISCUSSION A: DIAGNOSIS AND ASSESSMENT OF OPERABILITY IN CTEPH
Moderator: Raymond Benza, MD

CASE SCENARIO A1: ‘Proximal’ CTEPH with expected good response from PEA
Deepa Gopalan, MD, Papworth Hospital, Cambridge, United Kingdom

CASE SCENARIO A2: Mixed pattern CTEPH with likely residual PH after PEA
William Auger, MD, UCSD Medical Center, San Diego, CA, USA

SMALL GROUP INTERACTIVE DISCUSSION B: USE OF VASODILATOR DRUGS PRE-AND POST-PEA
Moderator: Joanna Pepke-Zaba, PhD

CASE SCENARIO B1: Patient with severe PH ‘bridged’ with vasodilators prior to PEA
Marion Delcroix, MD, PhD, University Hospital Leuven, Leuven, Belgium

CASE SCENARIO B2: Patient with residual PH post PEA
John Cannon, FRCP, Papworth Hospital, Cambridge, United Kingdom

4:15 PM – 4:45 PM
COFFEE BREAK

4:45 PM – 6:50 PM
SMALL GROUP INTERACTIVE DISCUSSION C: SELECTION OF PATIENTS TO BENEFIT FROM BPA
Moderator: Duane Davis, MD, MBA

CASE SCENARIO C1: Typical patient with sub-segmental disease with expected good outcome from BPA
Irene Lang, MD, Medical University of Vienna, Vienna, Austria

CASE SCENARIO C2: Higher risk patient with less predictable result from BPA
Takeshi Ogo, National Cerebral and Cardiovascular Center, Osaka, Japan

SMALL GROUP INTERACTIVE DISCUSSION D: ADVANCED PEA TECHNIQUES AND PERI-OPERATIVE CARE
Moderator: Michael Madani, MD

CASE SCENARIO D1: Successful surgery in a patient with segmental/sub segmental disease
Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

CASE SCENARIO D2: Complexities of post-operative care, dealing with complications and residual PH in the early post-operative period
Elie Fadel, MD, Hospital Marie Lannelongue, La Plessis-Robinson, France

6:50 PM – 7:00 PM
COURSE SUMMARY AND ASSESSMENT
David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom
Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

7:00 PM
ADJOURN
AFFILIATE EVENTS

Coming Soon...
CORPORATE EVENTS AND INDUSTRY THEATERS LISTINGS

The following approved Corporate Events and Industry Theaters are taking place during the ISHLT Annual Meeting. All events are taking place at the Acropolis Congrés Centre unless noted as off-site. The Industry Theaters will take place inside the Rhodes Exhibit Hall in the Risso 6 Room.

Coming Soon…
<table>
<thead>
<tr>
<th>Booth</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Abbott</td>
</tr>
<tr>
<td>48</td>
<td>Abiomed</td>
</tr>
<tr>
<td>31</td>
<td>ActiCare Health</td>
</tr>
<tr>
<td>33</td>
<td>Alere Home Monitoring</td>
</tr>
<tr>
<td>43, 44</td>
<td>Bayer AG</td>
</tr>
<tr>
<td>53</td>
<td>Bellerophon Therapeutics</td>
</tr>
<tr>
<td>37</td>
<td>Berlin Heart GMBH</td>
</tr>
<tr>
<td>49, 50, 51</td>
<td>Biotest AG</td>
</tr>
<tr>
<td>34</td>
<td>Bridge to Life (Europe) Ltd</td>
</tr>
<tr>
<td>41, 42</td>
<td>CareDx</td>
</tr>
<tr>
<td>5, 6</td>
<td>Carmat</td>
</tr>
<tr>
<td>32</td>
<td>Elsevier</td>
</tr>
<tr>
<td>7, 8</td>
<td>Evaheart, Inc.</td>
</tr>
<tr>
<td>15</td>
<td>Getinge</td>
</tr>
<tr>
<td>30</td>
<td>Hibernicor LLC.</td>
</tr>
<tr>
<td>4</td>
<td>ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)</td>
</tr>
<tr>
<td>12</td>
<td>Institut Georges Lopez</td>
</tr>
<tr>
<td>3</td>
<td>ISHLT Registries</td>
</tr>
<tr>
<td>10</td>
<td>Jarvik Heart, Inc.</td>
</tr>
<tr>
<td>39</td>
<td>Mallincrodt Pharmaceuticals/Therakos UK (Ltd)</td>
</tr>
<tr>
<td>38</td>
<td>Medtronic</td>
</tr>
<tr>
<td>29</td>
<td>Millar, Inc.</td>
</tr>
<tr>
<td>45, 46</td>
<td>One Lambda, A Thermo Fisher Scientific Brand</td>
</tr>
<tr>
<td>14</td>
<td>Paragonix Technologies</td>
</tr>
<tr>
<td>52</td>
<td>Pulmonary Hypertension Association</td>
</tr>
<tr>
<td>9</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>13</td>
<td>SynCardia Systems, LLC</td>
</tr>
<tr>
<td>11</td>
<td>TAI Diagnostics, Inc</td>
</tr>
<tr>
<td>35</td>
<td>Tandem Life</td>
</tr>
<tr>
<td>36</td>
<td>Transmedics, Inc.</td>
</tr>
<tr>
<td>47</td>
<td>XVIVO Perfusion AB</td>
</tr>
</tbody>
</table>
ABBOTT  Booth #40
Avenue Da Viniciaan 11
Zaychtem, Belgium B-1935
www.sjm.com

ABBOTT HAS LONG BEEN IN THE BUSINESS OF LIFE
At Abbott, we’re all about helping you live the best life you can through good health. We keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health. Every day and around the world, we’re discovering new ways to make life better.

ABIOMED  Booth #48
Neuenhofer Weg 26
Aachen, Germany 52074
www.abiomedi.com

Abiomed manufactures the Impella® family of the world’s smallest heart pumps that provide temporary circulatory support, enabling the heart to rest and potentially recover its native function. The Impella pumps both unload the heart and stabilize the patient’s hemodynamics before or during a percutaneous coronary intervention (PCI) procedure and during cardiogenic shock. With this minimally invasive intervention, Abiomed aims to change the standard of care for hemodynamic support by “Recovering hearts, saving lives™.”

Visit us at: www.abiomedi.com
Learn more about Protected PCI at: www.protectedpci.com | www.protectedpci.eu

ACTICARE HEALTH  Booth #31
6111 Southfront Road, Suite M
Livermore, CA 94551
http://acticarehealth.com

ActiCare Health (Booth #31) offers the first and only VAD, heart transplant and lung transplant tele-health and advanced monitoring platform with 24x7 support, empowering both patients and clinicians to achieve remarkable outcomes with reduced stress. In response to the immense administrative and operational challenges faced by VAD and transplant departments, we’ve designed a program to provide enhanced visibility into patients’ health status, modernize patient safety and communication, optimize discharge plan adherence, and minimize adverse clinical and financial events. Our program is designed to positively affect health outcomes and quality of life, enhance care coordination and staff efficiency, and reduce costs.

ALERE HOME MONITORING  Booth #33
6465 National Drive
Livermore, CA 94550

BAYER AG Booth #43, 44
Muellerstr. 178
13342 Berlin, Germany
www.bayer.com

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com.
BELLEROPHON THERAPEUTICS  Booth #53
184 Liberty Corner
Warren, NJ  07059
BERLIN HEART GMBH  Booth #37
Wiesenweg 10
Berlin, Germany 12247
www.berlinheart.de

Berlin Heart is the only company worldwide that develops, produces, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size. EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. INCOR® is an implantable axial-flow LVAD for adults. The Berlin Heart EXCOR® Pediatric Ventricular Assist Device is approved for use in the US. All other products are not FDA approved.

BIOTEST AG  Booth #49,50,51
Landsteinerstraße 5
63303 Dreieich, Germany
www.biotest.de

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies.

BRIDGE TO LIFE (EUROPE) LTD  Booth #34
LU311 The Light Bult, 1 Filament Walk
Wandsworth, United Kingdom SW18 4GQ

CAREDX, INC.  Booth #41, 42
3260 Bayshore Blvd.
Brisbane, CA
www.caredx.com

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

CARMAT  Booth #5, 6
36 Avenue De L’Europe – CS 40533
Vélizy-Villacoublay, France
www.carmatsa.com

CARMAT (contraction of founders’ names Professor Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart with its power supply and monitoring systems. Key differentiating features of this device are: use of bovine pericardium for most parts in contact with blood, which potentially reduces thromboembolic risks, and automatically adjustable pulsatile flow in response to patients’ physiological needs thanks to embedded sensors and electronics. CARMAT heart is an investigational device only and is not commercially available. The First-in-Man feasibility study was completed early in 2016. A CE MARK pivotal study is currently ongoing in Europe.
EVAHEART, Inc.  Booth #7, 8  
6655 TRAVIS ST. STE 590  
HOUSTON, TX 77030 USA  
www.evaheart-usa.com

The EVAHEART Left Ventricular Assist System (LVAS)™ is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010, and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is ongoing in the US.

GETINGE  Booth #15  
Kehlerst 31  
Rastatt, Germany 76437

The CARDIOHELP System is a compact heart-lung support system suitable for all indications requiring extracorporeal circulation for cardiopulmonary support. Although extracorporeal life support provided by the CARDIOHELP System is not a therapy itself, it acts as a bridge for recovery or transplantation, enabling caregivers to optimize the patient’s therapy. In cases of respiratory support, the extracorporeal circuit provided in a critical care unit enables the use of ultra-protective ventilation to optimize the therapy of acute respiratory distress syndromes (ARDS). The CARDIOHELP System can also act as cardiac support system until the myocardium recovers after an acute myocardial infarction.

HIBERNICOR LLC  Booth #30  
253 Ridge Drive  
Jackson, MS 39216  
769-257-6146  
www.hibernicor.com/asporto/

Right now, world-wide greater than 6000 patients with end-stage heart failure are waiting for a donated heart. Many donated hearts – about 20 percent – are not used. The hearts are deemed unusable because the current ice cooler method only allows 3-4 hours of transport time. The solution to this problem is Asporto; an microcomputer controlled lightweight device which pumps cardioplegic to the donor heart during hypothermic storage. It is designed to improve the quality of the donor heart; thus allowing a greater transport distance. Hibernicor is a startup company developing the Asporto device - currently in pre-clinical research and development. For more information: www.hibernicor.com

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY (IMACS)  Booth #4  
701 19TH Street South, LHRB 790  
Birmingham, AL 35294  
http://www.ishlt.org/registries/mcsdDatabase.asp

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.
The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

INSTITUT GEORGES LOPEZ  Booth #12
Parc Tertiaire du Bois Dieu
RN6 - 1 Allée des Chevreuils
Lissieu, France 69380
www.groupe-igl.com

Institut Georges Lopez consists of a network of subsidiaries located worldwide. This means we are never far from our customers. IGL design, manufacture, and market proprietary and equivalents products for organ preservation classified as drugs or medical devices. We represent a key player in the world of organ preservation, uniquely positioned by providing a comprehensive offer for the organ storage. We strive to be the worldwide reference in organ preservation technologies. Our work is inspired by our commitment to consistently meeting customer and regulatory requirements, to delivering quality products and to providing an innovative and comprehensive offer for organ preservation.”

ISHLT INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY  Booth #3
700 N 4th Street
Richmond, VA 23219
www.ishlt.org

The ISHLT International Pediatric Heart Failure Registry (iPHFR) is an international registry intended to enroll and follow pediatric patients with heart failure in the setting of either congenital or acquired heart disease in all countries and hospitals that wish to participate. The primary goal is to collect and analyze clinically relevant data on pediatric heart failure patients in order to better understand the natural history and response to current treatment regimens.

ISHLT INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION  Booth #3
700 N 4th Street
Richmond, VA 23219
www.ishlt.org

The ISHLT International Registry for Heart and Lung Transplantation was created for the purpose of providing on-going, current information on the worldwide thoracic organ transplantation experience. The collected data is made available to ISHLT members and the public via online quarterly data reports and annual data slides. The Annual ISHLT Registry Report includes survival data, risk factor data, and other outcome data in thoracic transplantation for a variety of demographic criteria.

JARVIK HEART, INC.  Booth #10
333 West 52nd St
New York, NY 10019
www.jarvikheart.com

Jarvik Heart, Inc. is a privately held, New York City based company that develops, manufactures and sells unique cardiac assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available* for the long-term treatment of Heart Failure. The New Jarvik 15mm VAD has been designed for pediatric and small patients and will enter clinical trials in the USA and EU in 2018.

*Jarvik 2000 available, in US, only in FDA clinical trial.
MALLINCKRODT PHARMACEUTICALS/THERAKOS UK (LTD)  Booth #39
3 Lotus Park, The Causeway
Staines-upon-Thames, Surrey, TW18 3AG, United Kingdom
www.therakos.co.uk

Mallinckrodt is focused on providing innovative therapeutic platforms and comprehensive support services to better enable healthcare professionals to deliver optimised ECP Immunomodulation to patients. The THERAKOS™ CELLEX™ Photopheresis system, the only integrated ECP platform, represents our latest advancement in ECP Immunomodulation technology.

THERAKOS ECP Immunomodulation™ employs the patient’s own immune cells to modulate dysregulated immune function. The therapy consists of extracorporeally treating a small fraction of the patient’s own leukocytes by exposing them to UVA light in the presence of a photosensitizing agent. This treatment induces apoptosis, which in turn initiates a cascade of immunomodulatory activities involving regulation of important immune cells and cytokines.

MEDTRONIC  Booth #38
710 Medtronic Parkway
Minneapolis, MN 55432-5604
www.medtronic.com

Patients are at the center of everything we do —and we believe medical technology can play an even greater role in improving people’s lives.

Medtronic Mechanical Circulatory Support is committed to continuous learning and innovation, to further advance the treatment of end-stage heart failure. We strive to improve patient outcomes and the clinical experience of your practice. Stop by the Medtronic booth to learn more and to see the latest HeartWare™ HVAD™ System enhancements.

Join us in our commitment to take healthcare Further, Together. Be inspired at medtronic.com.

MILLAR, INC.  Booth #29
6001-A Gulf Freeway
Houston, TX 77023
www.millar.com

Millar is committed to making the improbable possible in cardiovascular diagnostics and research by delivering products that enable a deeper understanding of hemodynamic function. From accurate, pressure waveforms with the Mikro-Cath™ pressure catheter to plotting the complete cardiac cycle with the Inca® PV Loop System, expert insight is within reach. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial. Millar OEM also serves the medical device and life sciences industries through our MEMS pressure sensors, ISO 13485 precision manufacturing and wireless power technology.

ONE LAMBDA, A THERMO FISHER SCIENTIFIC BRAND  Booth #45, 46
21001 Kittridge Street
Canoga Park, CA 91303
www.onelambda.com

One Lambda, a brand of Thermo Fisher Scientific, is the global leader in transplant diagnostics. For over 30 years we remain committed to the global scientific and transplant communities; improving the standard of care for transplant patients and their families worldwide. We offer a broad range of HLA typing and antibody detection products, laboratory instrumentation, software and reagents to support clinicians and laboratories in the management of transplant patients.
PARAGONIX TECHNOLOGIES  Booth #14
Paragonix Technologies, Inc.
c/o Vaughn & Associates
639 Granite Street
Braintree, MA 02184
www.paragonixtechnologies.com

PULMONARY HYPERTENSION ASSOCIATION  Booth #52
801 Roeder Road, Ste. 1000
Silver Spring, MD 20910
www.PHAssociation.org

SCANLAN INTERNATIONAL, INC.  Booth #9
One Scanlan Plaza
Saint Paul, MN 55107
info@scanlangroup.com
www.scanlaninternational.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, Scanlan® SUPER CUT™ and PREMIER Scissors. Full line of VATS / MIS Thoracoscopic instruments including the Chitwood Aortic Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps. Single-use products include: Scanlan® VASCU-STAT™ bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

SYNCARDIA SYSTEMS, LLC  Booth #13
1992 E. Silverlake Road
Tucson, AZ 85713
www.syncardia.com

The SynCardia temporary Total Artificial Heart (TAH-t), the world’s most used artificial heart, is now available in two sizes to serve more patients. The 70cc TAH-t is FDA, Health Canada and CE approved as a bridge to transplant for patients with end-stage biventricular failure. The smaller 50cc TAH-t, approved in Europe and Canada and undergoing an Investigational Device Exemption clinical study in the U.S., is designed for patients of smaller stature, including women and adolescents. Stable patients can be discharged to wait for a matching donor heart at home using the Freedom® portable driver. Visit our booth to learn more.

TAI DIAGNOSTICS, INC.  Booth #11
10101 Innovation Drive, Suite 600
Wauwatosa, WI, 53226
www.taidiagnostics.com

TAI Diagnostics, Inc. is a leading biotechnology company focused on providing non-invasive and highly sensitive diagnostic tests to monitor the health of transplanted organs in patients who have received solid organ transplants.

The myTAIheart™ test aids in identifying heart transplant recipients with a low probability of acute cellular rejection and can be used on patients as young as two months of age, and as early as one week post-transplant. myTAIheart is non-invasive, requiring only a small sample of blood with actionable results available the next business day.
TANDEM LIFE  Booth #35
240 Alpha Drive
Pittsburgh, PA 15238

One Pump. Massive Potential. TandemLife (formerly, CardiacAssist, Inc.) exists to deliver Life Support Simplified, with one small pump enabling any type of extracorporeal circulatory support your patients may need. The TandemHeart pump was the driving force behind the world’s first percutaneous left heart support system. We’ve added on to this legacy of innovation by developing three new product lines with the same reliability you’ve come to expect; TandemLife, TandemLung, and Protek Duo. Visit us to learn how we can empower your program to deliver breakthrough performance in extracorporeal support.

TRANSMEDICS, INC.  Booth #36
200 Minuteman Road, Suite 302
Andover, MA 01810
www.transmedics.com

TransMedics Inc. is a global leader in the field of ex-vivo physiologic organ preservation for lung, heart and liver transplantation using the Organ Care System (OCS™) technology. The OCS™ is the only portable multi-organ platform for ex-vivo preservation, optimization and assessment of donor organs for transplantation.

XVIVO PERFUSION AB  Booth #47
Box 53015
SE-400 14 Gothenburg, Sweden
www.xvivoperfusion.com

XVIVO Perfusion manufactures and markets solutions and systems for transplantation:
- Perfadex® and Perfadex® Plus for hypothermic flushing and preservation of donor lungs during transport
- STEEN Solution™ for normothermic ex vivo lung perfusion and evaluation
- XPS™ and LS™ platforms for warm perfusion and evaluation of lungs ex vivo, after donation and prior to transplantation

XPS™, disposables and the perfusates are CE-marked, approved in Canada, Australia and US. LS™ and disposables are approved in Europe, Canada and Australia.

XVIVO aims to increase the number of organs available for transplantation and transplantation success rates using new transplantation concepts and techniques.
FUTURE ANNUAL MEETINGS

2019
39th Annual Meeting and Scientific Sessions
Orlando, FL, USA
April 3-6 2019

2020
40th Annual Meeting and Scientific Sessions
Montreal, Canada
April 2020

2021
41st Annual Meeting and Scientific Sessions
Sydney, Australia
April 2021

International Society for Heart and Lung Transplantation
14673 Midway Road, Suite 200
Addison, TX 75001 USA
972-490-9495
www.isHLT.org